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A B S T R A C T
Background
The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide.
Whether diet, physical activity or both can prevent or delay T2DM and its associated complications in at-risk people is unknown.
Objectives
To assess the effects of diet, physical activity or both on the prevention or delay of T2DM and its associated complications in people
at increased risk of developing T2DM.
Search methods
This is an update of the Cochrane Review published in 2008. We searched the CENTRAL, MEDLINE, Embase, ClinicalTrials.gov,
ICTRP Search Portal and reference lists of systematic reviews, articles and health technology assessment reports. The date of the last
search of all databases was January 2017. We continuously used a MEDLINE email alert service to identify newly published studies
using the same search strategy as described for MEDLINE up to September 2017.
Selection criteria
We included randomised controlled trials (RCTs) with a duration of two years or more.
Data collection and analysis
Weused standard Cochrane methodology for data collection and analysis. We assessed the overall quality of the evidence using GRADE.
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Main results
We included 12 RCTs randomising 5238 people. One trial contributed 41% of all participants. The duration of the interventions
varied from two to six years. We judged none of the included trials at low risk of bias for all ’Risk of bias’ domains.
Eleven trials compared diet plus physical activity with standard or no treatment. Nine RCTs included participants with impaired glucose
tolerance (IGT), one RCT included participants with IGT, impaired fasting blood glucose (IFG) or both, and one RCT included people
with fasting glucose levels between 5.3 to 6.9 mmol/L. A total of 12 deaths occurred in 2049 participants in the diet plus physical
activity groups compared with 10 in 2050 participants in the comparator groups (RR 1.12, 95% CI 0.50 to 2.50; 95% prediction
interval 0.44 to 2.88; 4099 participants, 10 trials; very low-quality evidence). The definition of T2DM incidence varied among the
included trials. Altogether 315 of 2122 diet plus physical activity participants (14.8%) developed T2DM compared with 614 of 2389
comparator participants (25.7%) (RR 0.57, 95% CI 0.50 to 0.64; 95% prediction interval 0.50 to 0.65; 4511 participants, 11 trials;
moderate-quality evidence). Two trials reported serious adverse events. In one trial no adverse events occurred. In the other trial one of
51 diet plus physical activity participants compared with none of 51 comparator participants experienced a serious adverse event (low-
quality evidence). Cardiovascular mortality was rarely reported (four of 1626 diet plus physical activity participants and four of 1637
comparator participants (the RR ranged between 0.94 and 3.16; 3263 participants, 7 trials; very low-quality evidence). Only one trial
reported that no non-fatal myocardial infarction or non-fatal stroke had occurred (low-quality evidence). Two trials reported that none
of the participants had experienced hypoglycaemia. One trial investigated health-related quality of life in 2144 participants and noted
that a minimal important difference between intervention groups was not reached (very low-quality evidence). Three trials evaluated
costs of the interventions in 2755 participants. The largest trial of these reported an analysis of costs from the health system perspective
and society perspective reflecting USD 31,500 and USD 51,600 per quality-adjusted life year (QALY) with diet plus physical activity,
respectively (low-quality evidence). There were no data on blindness or end-stage renal disease.
One trial compared a diet-only intervention with a physical-activity intervention or standard treatment. The participants had IGT.
Three of 130 participants in the diet group compared with none of the 141 participants in the physical activity group died (very low-
quality evidence). None of the participants died because of cardiovascular disease (very low-quality evidence). Altogether 57 of 130
diet participants (43.8%) compared with 58 of 141 physical activity participants (41.1%) group developed T2DM (very low-quality
evidence). No adverse events were recorded (very low-quality evidence). There were no data on non-fatal myocardial infarction, non-
fatal stroke, blindness, end-stage renal disease, health-related quality of life or socioeconomic effects.
Two trials compared physical activity with standard treatment in 397 participants. One trial included participants with IGT, the other
trial included participants with IGT, IFG or both. One trial reported that none of the 141 physical activity participants compared
with three of 133 control participants died. The other trial reported that three of 84 physical activity participants and one of 39
control participants died (very low-quality evidence). In one trial T2DM developed in 58 of 141 physical activity participants (41.1%)
compared with 90 of 133 control participants (67.7%). In the other trial 10 of 84 physical activity participants (11.9%) compared with
seven of 39 control participants (18%) developed T2DM (very low-quality evidence). Serious adverse events were rarely reported (one
trial noted no events, one trial described events in three of 66 physical activity participants compared with one of 39 control participants
- very low-quality evidence). Only one trial reported on cardiovascular mortality (none of 274 participants died - very low-quality
evidence). Non-fatal myocardial infarction or stroke were rarely observed in the one trial randomising 123 participants (very low-quality
evidence). One trial reported that none of the participants in the trial experienced hypoglycaemia. One trial investigating health-related
quality of life in 123 participants showed no substantial differences between intervention groups (very low-quality evidence). There
were no data on blindness or socioeconomic effects.
Authors’ conclusions
There is no firm evidence that diet alone or physical activity alone compared to standard treatment influences the risk of T2DM and
especially its associated complications in people at increased risk of developing T2DM. However, diet plus physical activity reduces
or delays the incidence of T2DM in people with IGT. Data are lacking for the effect of diet plus physical activity for people with
intermediate hyperglycaemia defined by other glycaemic variables. Most RCTs did not investigate patient-important outcomes.
P L A I N L A N G U A G E S U M M A R Y
Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at
increased risk
Review question
2Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Are diet or physical activity, or both able to prevent or delay the development of type 2 diabetes and its associated complications in at-
risk people?
Background
People with moderately elevated blood glucose (often referred to as ’prediabetes’) are said to be at an increased risk of developing type 2
diabetes. It is currently recommended that all people with increased risk of developing type 2 diabetes should adjust their eating habits
and physical activity levels. We wanted to find out whether these changes in diet, physical activity or both could prevent or delay type
2 diabetes in people at increased risk. We also wanted to know the effects on patient-important outcomes, such as complications of
diabetes (e.g. kidney and eye disease, heart attack, stroke), death from any cause, health-related quality of life (a measure of a person’s
satisfaction with their life and health) and side-effects.
Study characteristics
Participants had to have blood glucose levels higher than considered normal, but below the glucose levels that are used to diagnose
type 2 diabetes mellitus. We found 12 randomised controlled trials (clinical studies where people are randomly put into one of two or
more treatment groups) with 5238 participants. The duration of the treatments varied from two years to six years. Most trials included
people defined as being at increased risk of type 2 diabetes based on glucose levels measured two hours after ingestion of 75 g of glucose
(i.e. ’impaired glucose tolerance’ (IGT) after an oral glucose tolerance test).
This evidence is up to date as of January 2017. We used a MEDLINE email alert service to identify newly published studies up to
September 2017.
Key results
One study compared diet only with physical activity only. Fifty-seven of 130 participants (44%) in the diet-only group compared with
58 of 141 participants (41%) in the physical activity-only group developed type 2 diabetes. Two studies compared physical activity with
standard treatment; in one study 58 of 141 participants (41%) in the physical activity group compared with 90 of 133 participants
(68%) in the control group developed type 2 diabetes; in the other study 10 of 84 participants (12%) in the physical activity group
compared with seven out of 39 participants (18%) in the control group developed type 2 diabetes. Eleven studies compared diet plus
physical activity with standard or no treatment. Diet plus physical activity decreased the risk of developing type 2 diabetes, which
occurred in 315 of 2122 participants (15%) in the diet plus physical activity group compared with 614 of 2389 participants (26%) in
the standard treatment group.
We detected neither an advantage nor a disadvantage of diet, physical activity or both with regard to heart attacks or strokes. Our
included studies did not report on complications of diabetes such as kidney or eye disease. The effects on health-related quality of life
were inconclusive. Very few participants died in the course of the studies and side-effects were also rare. Future long-term studies should
investigate more patient-important outcomes like complications of diabetes, because we do not know for sure whether ’prediabetes’ is
just a condition arbitrarily defined by a laboratory measurement or is, in fact, a real risk factor for type 2 diabetes mellitus and whether
treatment of this condition translates into better patient-important outcomes.
Quality of the evidence
All included trials had deficiencies in the way that they were conducted or how key items were reported. For diet plus physical activity
compared with standard treatment, we found rather good evidence that the development of new type 2 diabetes was reduced or delayed.
For the other comparisons the number of participants was small, resulting in a high risk of random errors (play of chance).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Diet plus physical activity versus standard treatment for prevention or delay of type 2 diabetes mellitus
Population: people at increased risk of developing type 2 diabetes mellitus
Settings: outpat ients
Intervention: diet plus physical act ivity
Comparison: standard treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Standard treatment Diet plus physical ac-
tivity
All- cause mortality
Follow-up: up to 6
years (mean durat ion 3.
6 years)
5 per 1000 5 per 1000 (2 to 12) RR 1.12 (0.50 to 2.50) 4099 (10) ⊕©©©
very lowa
The 95% predict ion in-
terval ranged f rom 0.44
to 2.88
TSA showed that 0.
61% of the diversity-ad-
justed information size
was accrued to detect
or reject a 10% RRR
Incidence of type 2 di-
abetes mellitus
Diagnost ic criteria:
• 3 trials applied the
WHO 1985 criteria
(FPG≥ 7.8 mmol/ L or
a 2-hour glucose ≥ 11.
1 mmol/ L af ter a 75 g
OGTT) (Da Qing 1997;
DPS 2001; Oldroyd
2005).
• 3 trials applied the
WHO 1999 criteria
(FPG≥ 7.0 mmol/ L
257 per 1000 146 per 1000 (129 to
164)
RR 0.57 (0.50 to 0.64) 4511 (11) ⊕⊕⊕©
moderateb
The 95% predict ion in-
terval ranged f rom 0.50
to 0.65
TSA showed f irm evi-
dence for a 10% RRR in
favour of diet plus phys-
ical act ivity
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and/ or a 2-hour
glucose ≥ 11.1 mmol/
L af ter a 75 g OGTT)
(EDIPS 2009; IDPP
2006; JDPP 2013).
• 1 trial with ADA
1997 criteria (FPG≥ 7.
0 mmol/ L or 2-hour
glucose ≥ 11.1 mmol/
L af ter a 75 g OGTT (i.
e. ident ical to WHO
1999 criteria) (DPP
2002).
• 1 trial with FPG >
7.0 mmol/ L (HELP PD
2011), 1 trial with FGP
> 7.8 mmol/ L (Kosaka
2005), 1 trial with 2-
hour PG≥ 11.1 mmol/
L af ter a 75 g OGTT
(PODOSA 2014).
• 4 trials also relied
on T2DM reported by
physicians or the use
of glucose-lowering
drugs (Da Qing 1997;
EDIPS 2009; HELP PD
2011; PODOSA 2014).
Follow-up: up to 6
years (mean durat ion 3.
8 years)
Serious adverse events
(SAE)
Follow-up: up to 6 years
See comment See comment See comment 250 (2) ⊕⊕©©
lowc
In 1 trial 1/ 51 part ici-
pants in the diet plus
physical act ivity group
compared with 0/ 51
part icipants in the stan-
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dard treatment group
experienced a SAE (
EDIPS 2009)
1 trial reported that no
adverse occurred (Da
Qing 1997).
In 4 other trials it was
clearly described that
SAE data had been col-
lected but data were not
presented (DPP 2002;
HELP PD 2011; IDPP
2006; JDPP 2013)
Cardiovascular mortal-
ity
Follow-up: up to 6
years (mean durat ion 3.
1 years)
2 per 1000 2 per 1000 (1 to 9) RR 0.94 (0.24 to 3.65) 3263 (7) ⊕©©©
very lowa
TSA showed that 0.
13% of the diversity-ad-
justed information size
was accrued to detect
or reject a 10% RRR
Non- fatal myocardial
infarction/stroke
Follow-up: 3.11 years
See comment See comment See comment 102 (1) ⊕©©©
lowd
1 trial reported that
none of the part icipants
experienced a non-fa-
tal myocardial infarc-
t ion or non-fatal stroke
(EDIPS 2009)
Health- related quality
of life
Descript ion: SF-36 to
evaluate the SF-6D,PCS
and MCS
MID was def ined as dif -
ference in scores be-
tween groups of at least
3%
Follow-up: 3.2 years
See comment See comment See comment 2144 (1) ⊕©©©
very lowe
SF-6D and PCS im-
proved in the diet plus
physical act ivity group
(DPP 2002), MID was
not achieved
MCS improved in the
placebo group (DPP
2002), MID was not
achieved
6
D
ie
t,
p
h
y
sic
a
l
a
c
tiv
ity
o
r
b
o
th
fo
r
p
re
v
e
n
tio
n
o
r
d
e
la
y
o
f
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
a
n
d
its
a
sso
c
ia
te
d
c
o
m
p
lic
a
tio
n
s
in
p
e
o
p
le
a
t
in
c
re
a
se
d
risk
o
f
d
e
v
e
lo
p
in
g
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Socioeconomic effects
Descript ion:
direct medical costs of
the intervent ions
Follow-up: up to 3 years
The mean direct medi-
cal costs of the inter-
vent ion ranged across
control groups f rom
USD 61 to USD 184
The mean direct med-
ical costs in the inter-
vent ion groups ranged
across diet plus physi-
cal act ivity group f rom
USD 225 to USD 3625
- 2775 (4) ⊕⊕©©
lowf
1 trial reported on the
health system/ society
perspect ive: USD 31,
500/ USD 51,600 per
QALY with diet plus
physical act ivity (DPP
2002)
1 trial reported to-
tal extra 3-year mean
costs for the diet plus
physical act ivity group
of GBP 1126, with
GBP 615 being diet it ian
costs, and more out-
pat ient visits in the in-
tervent ion group than
in the control group
cost ing GBP 327 more
(PODOSA 2014).
1 trial reported direct
medical costs for each
part icipant in the diet
plus physical act ivity
group of USD 850 com-
pared with USD 142 in
the control group; direct
costs of care outside
the trial were USD 5177
for the diet plus physi-
cal act ivity group com-
pared with USD7454 for
the control group (HELP
PD 2011)
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1 trial reported direct
medical costs of in-
tervent ions over the 3-
year trial period of USD
61 per part icipant in
the control group com-
pared with USD 225
in the diet plus physi-
cal act ivity group (IDPP
2006)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
ADA: American Diabetes Associat ion; CI: conf idence interval; DPP: Diabetes Prevent ion Program; FGL: f ast ing glucose levels; FPG: f ast ing plasma glucose; MCS: mental
component summaries; MID: minimal important dif f erence; OGTT: oral glucose tolerance test; PCS: physical component summaries;PG: plasma glucose; QUALY: quality-
adjusted lif e years; RR: risk rat io; RRR: relat ive risk reduct ion; SAE: serious adverse event; SF-36: 36-Item Short-Form; SF-6D: health ut ility index (SF-6D); T2DM: type 2
diabetes mellitus; TSA: t rial sequent ial analysis;WHO: World Health Organizat ion
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
∗Assumed risk was derived f rom the event rates in the comparator groups
aDowngraded by three levels because of risk of bias including possible publicat ion and other bias, inconsistency and
imprecision - see Appendix 14.
bDowngraded by one level because of other bias (early term inat ion of three trials due to benef it providing the majority of data)
- see Appendix 14.
cDowngraded by two levels because of report ing bias and imprecision - see Appendix 14.
dDowngraded by two levels because of serious imprecision (very sparse data) - see Appendix 14.
eDowngraded by three levels because of serious risk of bias (performance bias, detect ion bias, other bias) and imprecision -
see Appendix 14.
fDowngraded by two levels because of risk of bias (trial stopped early for benef it providing the majority of data) and
imprecision - see Appendix 14.
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B A C K G R O U N D
Description of the condition
’Prediabetes’, ’borderline diabetes’, the ’prediabetic stage’, ’high
risk of diabetes’ or ’intermediate hyperglycaemia’ (WHO/IDF
2006) are often characterised by various measurements of elevated
blood glucose concentrations (such as isolated impaired fasting
glucose (IFG), isolated impaired glucose tolerance (IGT), isolated
elevated glycosylated haemoglobin A1c (HbA1c) or combinations
thereof ). These elevated blood glucose levels indicating hypergly-
caemia are considered too high to be normal but below the diag-
nostic threshold for type 2 diabetes mellitus (T2DM). Therefore,
because of the continuous spectrum from the normal to the dia-
betic stage, a sound evidence base is needed to define thresholds for
conditions of ’sub-diabetes’. It is obvious that the different terms
used to describe various stages of hyperglycaemia might induce
different emotional reactions. For example, the term ’prediabetes’
may imply (at least for the lay person) that diabetes is unavoidable
whereas (high) risk of diabetes has the positive connotation that
the disease may be avoided altogether.We will use all of the above-
mentioned terms throughout this systematic review, however a we
will focus on ’prediabetes’ because many people associate this label
with dire consequences - despite the disputable construct of in-
termediate health states termed prediseases (Viera 2011). On the
other side, any diagnosis of ’prediabetes’ might be an opportunity
to review, for example, eating habits and physical activity levels,
thus enabling affected individuals to actively change their way of
life.
Themost commonly used criteria to define people with a high risk
of developing T2DM were established by the American Diabetes
Association (ADA) and the World Health Organization (WHO).
The first glycaemic measurement used to define the prediabetic
stage by the US National Diabetes Data Group was IGT (NDDG
1979). IGT is based on the measurement of plasma glucose two
hours after ingestion of 75 g glucose. The prediabetic range is de-
fined as a plasma glucose level between 7.8 to 11.1 mmol/L (140
to 200 mg/dL) two hours after the glucose load. Studies have indi-
cated that IGT is caused by insulin resistance and defective insulin
secretion (Abdul-Ghani 2006). In 1997 the ADA and later on the
WHO introduced the IFG concept to define ’prediabetes’ (ADA
1997; WHO 1999). The initial definition of IFG was 6.1 to 6.9
mmol/L (110 to125mg/dL). Later on, theADA reduced the lower
threshold for defining IFG to 5.6 mmol/L (100 mg/dL) (ADA
2003). However, this lower cut-off point for IFG to define ’predi-
abetes’ was not endorsed by the WHO (WHO/IDF 2006). IFG
seems to be associated with ß-cell dysfunction (impaired insulin
secretion) and an increase of the hepatic glucose output (DeFronzo
1989). More recently, HbA1c has been introduced for identify-
ing people with a high risk of developing T2DM. In 2009, the
International Expert Committee (IEC) suggested the HbA1c to
identify people with a high risk of T2DM. People with HbA1c
measurements between 6.0% to 6.4% fulfilled this criterion (IEC
2009). Shortly after, the ADA redefined this HbA1c level as 5.7%
to 6.4% to identify people with a high risk of developing T2DM
(ADA 2010). Unlike IFG and IGT, HbA1c reflects longer-term
glycaemic control, that is, how the blood glucose levels have been
during the previous two to three months (Inzucchi 2012).
In 2010, the International Diabetes Federation (IDF) estimated
the prevalence of IGT to be 343 million, and this number is
predicted to increase to 471 million by 2035 (IDF 2013). Stud-
ies have shown poor correlations between HbA1c and IFG/IGT
(Gosmanov 2014; Selvin 2011). Moreover, the various glycaemic
tests do not seem to identify the same people (Gosmanov 2014;
Selvin 2011). The risk of progression from ’prediabetes’ to T2DM
depends on the diagnostic criteria used to identify ’prediabetes’.
Some people diagnosed with ’prediabetes’ will never develop
T2DM, and some will return to normoglycaemia. IGT is often
accepted as the best glycaemic variable for ’prediabetes’ to predict
progression to T2DM. However, studies indicate that less than
half of the people defined as prediabetic by means of IGT will
develop T2DM in the following 10 years. IFG and HbA1c are
both thought to predict a different risk spectrum for developing
T2DM (Cheng 2006; Morris 2013). Most importantly, ’predia-
betes’ is commonly an asymptomatic condition, and naturally of-
ten remains ’undiagnosed’ (CDC 2015). Consequently, ’predia-
betes’ may exist before the diagnosis of T2DM is established.
Currently, ADA recommends reduced calorie intake and increased
physical activity for people with increased risk of T2DM (ADA
2017). It is still not clarified if any particular intervention, espe-
cially glucose-lowering drugs, should be recommended for peo-
ple with ’prediabetes’ (Yudkin 2014). Trials have indicated that
the progression from ’prediabetes’ to T2DM is reduced, or maybe
just delayed with ’lifestyle’ interventions (increased physical ac-
tivity, dietary changes or both) (Diabetes Prevention Program
2002; Diabetes Prevention Program FU 2009; Finnish Diabetes
Prevention StudyGroup 2001). A recent meta-analysis of 22 stud-
ies with behaviour-changing interventions in people at high risk
of T2DM concluded that the effect of lifestyle interventions on
longer-term diabetes prevention had not been clarified (Dunkley
2014).
The prescription of pharmacological glucose-lowering interven-
tions for the prevention of T2DM is not generally accepted among
international diabetes associations and clinicians. Several groups of
pharmacological glucose-lowering interventions have been investi-
gated in people with ’prediabetes’. Some findings indicate that the
progression from ’prediabetes’ to T2DM is reduced or maybe just
delayed (Diabetes Prevention Program 2002; Diabetes Prevention
Program FU 2009). However, the ADA recommends metformin
for people with ’prediabetes’ and a body mass index more than 35
kg/m², aged less than 60 years, and women with prior gestational
diabetes mellitus (ADA 2015).
9Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description of the intervention
Interventional as well as observational studies have shown a re-
duction in the incidence of T2DM with reduced calorie intake
and increased physical activity in people at risk of T2DM (Da
Qing 1997; DPP 2002; Helmrich 1991; Smith 2016). It has been
shown that diet plus physical activity reduces cardiovascular risk
factors, thereby indicating a potential beneficial effect on mortal-
ity and cardiovascular outcomes (Balk 2015).
Diet plus physical activity is recommended as an initial interven-
tion not only for people with intermediate hyperglycaemia but also
for people with T2DM (ADA 2017). However, one large-scale,
randomised, controlled trial in people overweight or obese people
with T2DM did not show a substantial effect on mortality and
cardiovascular outcomes with intensive diet plus physical activity
compared with control after 9.6 years (Look AHEAD 2013).
Nutritional advice usually consists of caloric restriction in over-
weight people, low total fat content (especially saturated fat) and
high (predominantly unrefined) carbohydrate content. Physical
activity advice usually consists of an intervention programme.
Adverse effects of the intervention
Physical activity or diet interventions are not generally considered
to be associated with any serious adverse event. However, physical
activity may cause traumatic injuries of variable severity depend-
ing on the type and intensity of physical activity. Additionally, ex-
ercising may produce adverse effects on the cardiovascular system
in those people with insufficient training or unfavourable cardio-
vascular fitness (even cardiovascular events and death may poten-
tially occur while exercising). Also, the implementation of dietary
measures may produce several deficiencies in nutritional status if
restrictive low-calorie diets are used. Further, dieting may reduce
quality of life of people under this treatment. Unfortunately, very
little information on these issues is available from randomised con-
trolled trials.
How the intervention might work
There are prospective cohort studies that have shown that in-
creased physical activity, independent of other risk factors, has a
protective effect against the development of T2DM (Helmrich
1991; Manson 1992). These epidemiological prospective studies
demonstrated that various levels of regular physical activity once
to several times a week were associated with a decreased incidence
of the disease at long-term follow-up (14 years and five years re-
spectively) (Helmrich 1991; Manson 1992).
Three large clinical trials in people with IGT have shown a relative
risk reduction of about 50% in the progression to T2DM with
restricted diet and increased physical activity (Da Qing 1997;
DPP 2002; DPS 2001). However, whether and how diet, physical
activity or both influence the risk of complications associated with
T2DM is still not clarified.
Why it is important to do this review
There has been an increased focus on the prevention or delay of
T2DMwith non-pharmacological interventions and glucose-low-
ering medications. Recently, several systematic reviews and health
technology assessment reports have been performed in people with
elevated risk of T2DM (Aguiar 2014; Ali 2012; Ashra 2015; Balk
2015; Cardona-Morrell 2010;Dunkley 2014;Gillett 2012;Gillies
2007; Glechner 2015; Gong 2015; Hopper 2011; ICER 2016;
Merlotti 2014a; Merlotti 2014b; Modesti 2016; Norris 2005;
Santaguida 2005; Schellenberg 2013; Selph 2015; Stevens 2015;
Yamaoka 2005; Yates 2007; Yoon 2013; Yuen 2010; Zhang 2017;
Zheng 2016).
Sixteen of these systematic reviews included exclusively people
with intermediate hyperglycaemia (Aguiar 2014; Gillett 2012;
Gillies 2007; Glechner 2015; Gong 2015; Hopper 2011; ICER
2016; Norris 2005; Santaguida 2005; Selph 2015; Stevens 2015;
Yamaoka 2005; Yates 2007; Yoon 2013; Yuen 2010; Zheng 2016);
10 systematic reviews included people with an increased risk of
T2DM defined by additional variables with intermediate hyper-
glycaemia being one risk factor only (e.g. obesity, metabolic risk
factors, family history of diabetes etc) (Ali 2012; Ashra 2015; Balk
2015; Cardona-Morrell 2010; Dunkley 2014; Merlotti 2014a;
Merlotti 2014b;Modesti 2016; Schellenberg 2013; Zhang 2017).
This review is an update of the Cochrane Review published in
2008 (Orozco 2008). In this update we have implemented new
methodology and changed the priority of outcomes, focusing on
patient-important outcomemeasures. Also, we have only included
trials where intermediate hyperglycaemiawas measured at baseline
as an indicator of increased risk for the development of T2DM.
O B J E C T I V E S
To assess the effects of diet, physical activity or both for the preven-
tion or delay of T2DM and its associated complications in people
at increased risk of developing T2DM.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled clinical trials (RCTs).
10Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of participants
Nondiabetic individuals at increased risk of developing T2DM,
that is, diagnosed with intermediate hyperglycaemia or ’predia-
betes’.
Diagnostic criteria for ’prediabetes’
Tobe consistentwith changes in the classification of anddiagnostic
criteria for ’prediabetes’ (impaired fasting glucose (IFG), impaired
glucose tolerance (IGT) and elevated glycosylated haemoglobin
A1c (HbA1c)) over the years, the diagnosis had to be established
using the standard criteria valid at the time of the trial commenc-
ing (for example ADA 1997; ADA 2010; NDDG 1979; WHO
1999). Ideally, the diagnostic criteria should have been described.
If necessary, we used the trial authors’ definition of ’prediabetes’
but contacted trial authors for additional information. Differences
of glycaemic measurements used to define ’prediabetes’ may in-
troduce substantial heterogeneity.We therefore planned to subject
diagnostic criteria to a subgroup analysis.
Types of interventions
We planned to investigate the following comparisons of interven-
tion versus comparator.
Intervention
• Diet
• Physical activity
• Diet plus physical activity
Comparator
• Standard treatment
• No intervention
Comparison of interventions
• Diet versus physical activity
Other concomitant interventions had to be the same in the inter-
vention and comparator groups to establish fair comparisons.
Minimum duration of intervention
We included trials with a minimum duration of intervention of
two years.
Summary of exclusion criteria
We excluded the following.
• Trials where the intervention or comparator group
comprised the administration of any pharmacological agent.
• People diagnosed with ’metabolic syndrome’ because this is
a special cohort of doubtful clinical usefulness and uncertain
distinct disease entity (a composite of risk indicators such as
elevated blood lipids, insulin resistance, obesity, high blood
pressure).
• Trials applying diet advice through single-food or
supplement dietary changes (e.g. zinc supplement).
• Trials with identical diet or physical activity interventions,
or both, applied with different approaches (e.g. same advice
applied by means of individual or group sessions).
We did not exclude trials because one or several of our primary
or secondary outcome measures were not reported in the publi-
cation. In case none of our primary or secondary outcomes were
reported, we included the trial and contacted the corresponding
author for supplementary data. If no additional data were available
we planned to provide some basic information in a supplementary
table.
Types of outcome measures
Primary outcomes
• All-cause mortality
• Incidence of T2DM
• Serious adverse events
Secondary outcomes
• Cardiovascular mortality
• Non-fatal myocardial infarction
• Non-fatal stroke
• Amputation of lower extremity
• Blindness or severe vision loss
• End-stage renal disease
• Non-serious adverse events
• Hypoglycaemia
• Health-related quality of life
• Time to progression to T2DM
• Measures of blood glucose control
• Socioeconomic effects
Method of outcome measurement
• All-cause mortality: defined as death from any cause
• Incidence of T2DM and time to progression to T2DM:
defined according to diagnostic criteria valid at the time the
diagnosis was established, using the standard criteria valid at the
time of the trial commencing (e.g. ADA 2008; WHO 1998). If
necessary, we used the trial authors’ definition of T2DM.
• Serious adverse events: defined according to the
International Conference on Harmonization Guidelines as any
event that led to death, that was life-threatening, required in-
patient hospitalisation or prolongation of existing
hospitalisation, resulted in persistent or significant disability, and
any important medical event that may have had jeopardised the
participant or required intervention to prevent it (ICH 1997) or
as reported in trials.
• Cardiovascular mortality, non-fatal myocardial infarction,
non-fatal stroke, amputation of lower extremity, blindness or
severe vision loss, hypoglycaemia (mild, moderate, severe/
serious): defined as reported in trials.
• End-stage renal disease: defined as dialysis, renal
transplantation or death due to renal disease.
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• Non-serious adverse events: defined as number of
participants with any untoward medical occurrence not
necessarily having a causal relationship with the intervention.
• Health-related quality of life: defined as mental and
physical health-related quality of life, separate and combined,
evaluated by a validated instrument such as Short-Form 36.
• Measures of blood glucose control: fasting blood glucose,
blood glucose two hours after ingestion of 75 g glucose and
HbA1c measurements.
• Socioeconomic effects: for example costs of the
intervention, absence from work, medication consumption.
Timing of outcome measurement
• Measured at the end of the intervention and the end of
follow-up: all-cause mortality, cardiovascular mortality, blindness
or severe vision loss, hypoglycaemia (mild, moderate, severe/
serious), end-stage renal disease, non-serious adverse events;
health-related quality of life, measures of blood glucose control,
socioeconomic effects
• Measured at the end of the intervention and the longest
reported end of follow-up: incidence of T2DM
• Measured at any time of the intervention and during
follow-up: serious adverse events
Search methods for identification of studies
Electronic searches
We based this review update on different search techniques.
First, we extracted the included trials of two systematic reviews
targeting people at increased risk for T2DM. The first review
was funded by the Agency for Healthcare Research and Qual-
ity (AHRQ) and evaluated lifestyle interventions (Schellenberg
2013). The second review was funded by the Centers for Dis-
ease Control and Prevention Community Preventive Services Task
Force and evaluated combined diet and physical activity programs
(Balk 2015). Both of these reviews included extensive and highly
sensitive search strategies conducted in several databases up to June
2013 (Schellenberg 2013) and up to February 2015 (Balk 2015).
In addition to evaluating these two systematic reviews, we checked
the reference lists of a further 28 systematic reviews and extracted
145 potentially relevant trials in total. This snowballing search
technique is reflected in the upper right part of the trial flow dia-
gram.
Second, we identified further trials using a revised search strategy
from 2014 to the specified date. We did not place restrictions on
the language of publication, and searched the following literature
databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via Cochrane Register of Studies Online (CRSO)
(searched 17 January 2017).
• MEDLINE Ovid (Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R)) (from 1946 to present, searched 17
January 2017).
• Embase Ovid (from 1974 to 2017 Week 3, searched 17
January 2017)
Additionally we searched the following trials registers from incep-
tion to the specified date.
• ClinicalTrials.gov (www.clinicaltrials.gov) (searched 17
January 2017).
• WHO International Clinical Trials Registry Platform
(ICTRP; apps.who.int/trialsearch/) searched 17 January 2017)
For detailed search strategies, see Appendix 1. We continuously
applied an email alert service for MEDLINE via OvidSP to iden-
tify newly published trials using the search strategy detailed in
Appendix 1 up to September 2017.
Searching other resources
We tried to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved, included
trials, (systematic) reviews, meta-analyses and health technology
assessment reports.
Data collection and analysis
Selection of studies
Two review authors (BH and BR) independently scanned the ab-
stract or title, or both, of every record we retrieved, to determine
which trials should be assessed further. We investigated the full-
text articles of all potentially relevant articles. We resolved discrep-
ancies through consensus or by recourse to a third review author
(MM). We prepared a flow diagram of the number of trials iden-
tified and excluded at each stage in accordance with the PRISMA
flow diagram of trial selection (Liberati 2009; Figure 1).
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Figure 1. Trial flow diagram
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Data extraction and management
For trials that fulfilled the inclusion criteria, two review authors
(BH and GG) independently extracted outcome data and assessed
the risk of bias. One review author (BH) extracted key character-
istics of participants and interventions and another (GG) checked
them. We reported data on efficacy outcomes and adverse events
using standard data extraction sheets from Cochrane Metabolic
and Endocrine Disorders. We resolved any disagreements by dis-
cussion or, if required, by consultation with a third review author
(BR) (for details, see Characteristics of included studies; Table 1;
Appendix 2; Appendix 3; Appendix 4; Appendix 5; Appendix 6;
Appendix 7; Appendix 8; Appendix 9; Appendix 10; Appendix 11;
Appendix 12; Appendix 13; Appendix 14; Appendix 15: Appendix
16; Appendix 17; Appendix 18; Appendix 19).
We provided information about potentially relevant ongoing tri-
als, including trial identifier, in the ’Characteristics of ongoing
studies’ table and in a joint appendix ’Matrix of study endpoints
(publications and trial documents)’ (Appendix 6). For each in-
cluded trial, we tried to retrieve the protocol and planned to report
primary, secondary and other outcomes in comparison with data
in publications in a joint appendix. If not available from the search
of the databases, reference screening or Internet searches, we asked
trial authors to provide a copy of the protocol.
We emailed all authors of the included trials to enquire whether
they would be willing to answer questions regarding their trials.
We presented the results of this survey in Appendix 13.We sought
relevant missing information on the trial from the primary au-
thor(s) of the article, if possible.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents, or
multiple reports of a primary trial, we maximised the information
yield by collating all available data, and we used themost complete
data set aggregated across all known publications. We listed du-
plicate publications, companion documents, multiple reports of a
primary trial, and trial documents of included trials (such as trial
registry information) as secondary references under the study ID
of the included trial. Furthermore, we also listed duplicate pub-
lications, companion documents, multiple reports of a trial, and
trial documents of excluded trials (such as trials registry informa-
tion) as secondary references under the study ID of the excluded
trial.
Data from clinical trials registers
If data from included trials were available as study results in clinical
trials registers, such as ClinicalTrials.gov or similar sources, we
made full use of this information and extracted the data. If there
was also a full publication of the trial, we collated and critically
appraised all available data. If an included trial was marked as
a completed study in a clinical trials register but no additional
information (study results, publication or both) was available, we
added this trial to the table ’Characteristics of studies awaiting
classification’.
Assessment of risk of bias in included studies
Two review authors (BH and GG) independently assessed the risk
of bias of each included trial. We resolved any disagreements by
consensus, or by consultation with a third review author (BR). If
adequate information was not available from the trial publication,
trial protocol or both, we contacted trial authors for missing data
on ’Risk of bias’ items.
We used the Cochrane ’Risk of bias’ assessment tool (Higgins
2011a) and judged risk of bias criteria as either low, high, or unclear
and evaluated individual bias items as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a)
where any of the specified criteria for a judgement on low, unclear
or high risk of bias justified the associated categorisation.
Random sequence generation
Selection bias due to inadequate generation of a randomised se-
quence - assessment at trial level
We described for each included trial the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing of lots, tossing a coin, shuffling cards or
envelopes, and throwing dice are adequate if performed by an
independent person not otherwise involved in the trial. Use of
the minimisation technique will be considered as equivalent to
being random.
• Unclear risk of bias: insufficient information about the
sequence generation process.
• High risk of bias: the sequence generation method was non-
random (e.g. sequence generated by odd or even date of birth;
sequence generated by some rule based on date (or day) of
admission; sequence generated by some rule based on hospital or
clinic record number; allocation by judgement of the clinician;
allocation by preference of the participant; allocation based on
the results of a laboratory test or a series of tests; allocation by
availability of the intervention). We excluded such trials.
Allocation concealment
Selection bias due to inadequate concealment of allocations prior
to assignment - assessment at trial level
We described for each included trial themethod used to conceal al-
location to interventions prior to assignment and assessed whether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment.
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• Low risk of bias: central allocation (including telephone,
interactive voice-recorder, web-based and pharmacy-controlled
randomisation); sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed
envelopes.
• Unclear risk of bias: insufficient information about the
allocation concealment.
• High risk of bias: using an open random allocation schedule
(e.g. a list of random numbers); using assignment envelopes
without appropriate safeguards; alternation or rotation; date of
birth; case record number; any other explicitly unconcealed
procedure. We excluded such trials.
Blinding of participants and study personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the trial - assessment at out-
come level
We evaluated the risk of performance bias separately for each out-
come (Hróbjartsson 2013).We notedwhether outcomeswere self-
reported, investigator-assessed or adjudicated outcome measures
(see below).
• Low risk of bias: blinding of participants and key study
personnel ensured, and unlikely that the blinding could have
been broken; no blinding or incomplete blinding, but the review
authors judged that the outcome was not likely to be influenced
by lack of blinding.
• Unclear risk of bias: insufficient information about the
blinding of participants and study personnel; the trial did not
address this outcome.
• High risk of bias: no blinding or incomplete blinding, and
the outcome was likely to be influenced by lack of blinding;
blinding of trial participants and key personnel attempted, but
likely that the blinding could have been broken, and the
outcome was likely to be influenced by lack of blinding.
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessment - assessment at outcome level
We evaluated the risk of detection bias separately for each out-
come (Hróbjartsson 2013).We notedwhether outcomeswere self-
reported, investigator-assessed or adjudicated outcome measures
(see below).
• Low risk of bias: blinding of outcome assessment ensured,
and unlikely that the blinding could have been broken; no
blinding of outcome assessment, but the review authors judged
that the outcome measurement was not likely to be influenced
by lack of blinding.
• Unclear risk of bias: insufficient information about the
blinding of outcome assessors; the trial did not address this
outcome.
• High risk of bias: no blinding of outcome assessment, and
the outcome measurement is likely to be influenced by lack of
blinding; blinding of outcome assessment, but likely that the
blinding could have been broken, and the outcome measurement
is likely to be influenced by lack of blinding.
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data - assessment at outcome level
We described for each included trial, and for each outcome, the
completeness of data including attrition and exclusions from the
analysis. We investigated whether attrition and exclusions were
reported and the number included in the analysis at each stage
(compared with the number of randomised participants per in-
tervention/comparator groups), if reasons for attrition or exclu-
sion were reported, and whethermissing data were balanced across
groups or were related to outcomes. We considered the implica-
tions of missing outcome data per outcome, such as high dropout
rates (e.g. above 15%) or disparate attrition rates (e.g. difference
of 10% or more between trial arms).
• Low risk of bias: no missing outcome data; reasons for
missing outcome data unlikely to be related to true outcome (for
survival data, censoring unlikely to be introducing bias); missing
outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate; for
continuous outcome data, plausible effect size (difference in
means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on
observed effect size; appropriate methods, such as multiple
imputation, were used to handle missing data.
• Unclear risk of bias: insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias; the trial did not
address this outcome.
• High risk of bias: reason for missing outcome data likely to
be related to true outcome, with either imbalance in numbers or
reasons for missing data across intervention groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically
relevant bias in intervention effect estimate; for continuous
outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size;
‘as-treated’ or similar analysis done with substantial departure of
the intervention received from that assigned at randomisation;
potentially inappropriate application of simple imputation.
Selective reporting
Reporting bias due to selective outcome reporting - assessment at
trial level
We assessed outcome reporting bias by integrating the results of
Appendix 6, ’Matrix of trial endpoints (publications and trial
documents)’ (Mathieu 2009), with those of Appendix 7 ’High
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risk of outcome reporting bias according to ORBIT classification’
(Kirkham 2010). This analysis formed the basis for the judgement
of selective reporting.
• Low risk of bias: the trial protocol was available and all of
the trial’s pre-specified (primary and secondary) outcomes that
were of interest in the review were reported in the pre-specified
way; the study protocol was not available but it was clear that the
published reports included all expected outcomes (ORBIT
classification).
• Unclear risk of bias: insufficient information about selective
reporting.
• High risk of bias: not all of the trial’s pre-specified primary
outcomes were reported; one or more primary outcomes was
reported using measurements, analysis methods or subsets of the
data (e.g. subscales) that had not been pre-specified; one or more
reported primary outcomes had not been pre-specified (unless
clear justification for their reporting was provided, such as an
unexpected adverse effect); one or more outcomes of interest in
the review were reported incompletely so that they could not be
entered in a meta-analysis; the trial report failed to include
results for a key outcome that would be expected to have been
reported for such a trial (ORBIT classification).
Other bias
Bias due to problems not covered elsewhere - assessment at trial
level
Other risk of bias reflects other circumstances that may threaten
the validity of the trials, for example, funding bias and academic
bias (Lundh 2012).
• Low risk of bias: the trial appeared to be free of other
sources of bias.
• Unclear risk of bias: insufficient information to assess
whether an important risk of bias existed; insufficient rationale
or evidence that an identified problem introduced bias.
• High risk of bias: had a potential source of bias related to
the specific trial design used; has been claimed to have been
fraudulent; had some other serious problem.
We presented a ’Risk of bias’ graph and a ’Risk of bias’ summary
figure.
We distinguished between self-reported, investigator-assessed and
adjudicated outcome measures.
We considered the following self-reported outcomes.
• Non-serious adverse events
• Hypoglycaemia, if reported by participants
• Health-related quality of life
• Blood glucose control, if measured by trial participants
We considered the following investigator-assessed outcomes
• All-cause mortality
• Incidence of T2DM
• Time to progression to T2DM
• Serious adverse events
• Cardiovascular mortality
• Non-fatal myocardial infarction
• Non-fatal stroke
• Amputation of lower extremity
• Blindness or severe vision loss
• End-stage renal disease
• Hypoglycaemia, if measured by trial personnel
• Blood glucose control, if measured by trial personnel
• Socioeconomic effects.
Summary assessment of risk of bias
Risk of bias for a trial across outcomes
Some risk of bias domains like selection bias (sequence genera-
tion and allocation sequence concealment) affected the risk of bias
across all outcome measures in a trial. Otherwise, we did not per-
form a summary assessment of the risk of bias across all outcomes
for a trial. In case of high risk of selection bias, we excluded the
trial.
Risk of bias for an outcome within a trial and across domains
We assessed the risk of bias for an outcomemeasure including all of
the entries relevant to that outcome, that is, both trial-level entries
and outcome-specific entries. Low risk of bias was defined as low
risk of bias for all key domains, unclear risk of bias as unclear risk
of bias for one or more key domains and high risk of bias as high
risk of bias for one or more key domains.
Risk of bias for an outcome across trials and across domains
These were our main summary assessments that were be incor-
porated in our judgements about the quality of evidence in the
’Summary of finding’ table(s). Low risk of bias was defined as most
information coming from trials at low risk of bias, unclear risk of
bias as most information coming from trials at low or unclear risk
of bias and high risk of bias as a sufficient proportion of informa-
tion coming from trials at high risk of bias.
Measures of treatment effect
When at least two trials were available for a comparison of a given
outcome we expressed dichotomous data as risk ratio (RR) with
95% confidence intervals (CIs) and with trial sequential analysis
(TSA)-adjusted CIs if the diversity-adjusted required information
size was not reached.We planned to calculate time-to-event data as
hazard ratio (HR) with 95% CI with the generic inverse variance
method. We planned to use unadjusted HRs for preference, as
adjustment could differ among the included trials.
We expressed continuous data reported on the same scale as mean
difference (MD) with 95% CIs and with TSA-adjusted CIs if the
diversity-adjusted required information size was not reached. For
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trials addressing the same outcome but using different outcome
measure scales we planned to use standardised mean differences
(SMD) with 95% CI. For outcomes meta-analysed as SMD and
the generic inverse variance method, we are presently unable to
conduct TSA and adjust the 95% CIs.
The scales measuring health-related quality of life (HRQoL) may
go in different directions. In some scales, values increase with im-
proved HRQoL, whereas in other scales, values decrease with im-
provedHRQoL. To adjust for the different directions of the scales,
we planned to multiply the scales that reported better HRQoL
with decreasing values by -1.
Unit of analysis issues
We took into account the level at which randomisation occurred,
such as cross-over trials, cluster-randomised trials and multiple
observations for the same outcome. If more than one compar-
ison from the same trial was eligible for inclusion in the same
meta-analysis, we either combined groups to create a single, pair-
wise comparison or appropriately reduced the sample size so that
the same participants did not contribute multiply (splitting the
’shared’ group into two or more groups). While the latter approach
offers some solution to adjusting the precision of the comparison,
it does not account for correlation arising from the same set of
participants being in multiple comparisons (Deeks 2011).
We planned to reanalyse cluster-randomised trials that did not
appropriately adjust for potential clustering of participants within
clusters in their analysis. The variance of the intervention effects
would have been inflated by a design effect (DEFF). Calculation of
a DEFF involves estimation of an intra-cluster correlation (ICC).
We planned to obtain estimates of ICCs through contact with
trial authors, or by imputing them using estimates from other
included studies that reported ICCs, or using external estimates
from empirical research (e.g. Bell 2013). We planned to examine
the impact of clustering using sensitivity analyses.
Dealing with missing data
We tried to obtain missing data from trial authors and carefully
evaluated important numerical data such as screened, randomly
assigned participants as well as intention-to-treat, and as-treated
and per-protocol populations.
We investigated attrition rates (e.g. dropouts, losses to follow-up,
withdrawals), and critically appraised issues concerning missing
data and imputation methods (e.g. last observation carried for-
ward).
Where means and standard deviations (SDs) for outcomes were
not reported and we could not get the information that we needed
from trial authors, we imputed these values by assuming the SDs
of the missing outcome to be the average of the SDs from those
trials in which this information was reported.
We planned to investigate the impact of imputation on meta-
analyses by performing sensitivity analyses.
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we planned not to report trial results as the pooled effect esti-
mate in a meta-analysis.
We identified heterogeneity (inconsistency) by visually inspecting
the forest plots and by using a standard Chi² test with a signifi-
cance level of α = 0.1. In view of the low power of this test, we
also considered the I² statistic (Higgins 2003), which quantifies
inconsistency across trials to assess the impact of heterogeneity on
the meta-analysis (Deeks 2011; Higgins 2002).
Assessment of reporting biases
If we included 10 ormore trials investigating a particular outcome,
we used funnel plots to assess small-trial effects. Several explana-
tions may account for funnel plot asymmetry, including true het-
erogeneity of effect with respect to trial size, poor methodological
design (and hence bias of small trials) and publication bias. We
therefore interpreted results carefully (Sterne 2011).
Data synthesis
We planned to undertake (or display) a meta-analysis only if we
judged participants, interventions, comparisons, and outcomes to
be sufficiently similar to ensure an answer that would be clini-
cally meaningful. Unless good evidence showed homogeneous ef-
fects across trials of different methodological quality, we primarily
summarised low risk of bias data using a random-effects model
(Wood 2008). We interpreted random-effects meta-analyses with
due consideration to the whole distribution of effects and pre-
sented a 95% prediction interval (Borenstein 2017a; Borenstein
2017b; Higgins 2009). A prediction interval needs at least three
trials to be calculated and specifies a predicted range for the true
treatment effect in an individual trial (Riley 2011). For rare events
such as event rates below 1%, we planned to use the Peto’s odds ra-
tio method, provided that there was no substantial imbalance be-
tween intervention and comparator group sizes and intervention
effects were not exceptionally large. In addition, we performed
statistical analyses according to the statistical guidelines presented
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011).
Trial sequential analyses
In a single trial, sparse data and interim analyses increase the risk
of type I and type II errors. To avoid type I errors, group sequential
monitoring boundaries are applied to decide whether a trial could
be terminated early because of a sufficiently small P value, that is
the cumulative Z-curve crosses the monitoring boundaries (Lan
1983). Likewise, before reaching the planned sample size of a trial,
the trial may be stopped due to futility if the cumulative Z-score
crosses the futility monitoring boundaries. Sequential monitoring
boundaries for benefit, harm, or futility can be applied to meta-
analyses as well, called trial sequential monitoring boundaries (
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Higgins 2010; Wetterslev 2008). In TSA, the addition of each
trial in a cumulative meta-analysis is regarded as an interim meta-
analysis and helps to clarify if significance or futility is reached or
whether additional trials are needed (Wetterslev 2008).
TSA combines a calculation of the diversity-adjusted required in-
formation size (cumulated meta-analysis sample size to detect or
reject a specific relative intervention effect) for meta-analysis with
the threshold of data associated with statistics. We planned to per-
form TSA on all outcomes included in the ’Summary of findings’
table (Brok 2009; Pogue 1997; Wetterslev 2008).
The idea in TSA is that if the cumulative Z-curve crosses the
boundary for benefit or harm before a diversity-adjusted required
information size is reached, a sufficient level of evidence for the
anticipated intervention effect has been reached with the assumed
type I error and no further trials may be needed. If the cumula-
tive Z-curve crosses the boundary for futility before a diversity-
adjusted required information size is reached, the assumed inter-
vention effect can be rejected with the assumed type II error and
no further trials may be needed. If the Z-curve does not cross any
boundary, then there is insufficient evidence to reach a conclu-
sion. To construct the trial sequential monitoring boundaries, the
required information size is needed and is calculated as the least
number of participants needed in a well-powered single trial and
subsequently adjusted for diversity among the included trials in
the meta-analysis (Brok 2009; Wetterslev 2008). We applied TSA
as it decreases the risk of type I and II errors due to sparse data and
multiple updating in a cumulative meta-analysis, and it provides
us with important information in order to estimate the risks of
imprecision when the required information size is not reached.
Additionally, TSA provides important information regarding the
need for additional trials and the required information size of such
trials (Wetterslev 2008).
We applied trial sequential monitoring boundaries according to
an estimated clinically important effect. We based the required
information size on an a priori effect corresponding to a 10% rel-
ative risk reduction (RRR) for beneficial effects of the interven-
tions and a 30% relative risk increase for harmful effects of the
interventions.
For continuous outcomes we performed TSA with MDs, by using
the trials applying the same scale to calculate the required sample
size. For continuous outcomes, we tested the evidence for the
achieved differences in the cumulative meta-analyses.
For adjustment of heterogeneity of the required information size
we used the diversity (D²) estimated in the meta-analyses of in-
cluded trials. When diversity was zero in a meta-analysis, we per-
formed a sensitivity analysis using an assumed diversity of 20%.
Subgroup analysis and investigation of heterogeneity
We expected the following characteristics to introduce clinical het-
erogeneity and performed subgroup analyses to investigate inter-
actions.
• Trials with a long duration (four years and longer) versus
trials with a short duration (less than four years).
• Diagnostic ’prediabetes’ criteria (IFG, IGT, HbA1c)
• Age, depending on data
• Sex
• Ethnicity, depending on data
• Comorbid conditions, such as hypertension or obesity
• Participants with previous gestational diabetes mellitus
Sensitivity analysis
We planned to perform sensitivity analyses to explore the influ-
ence of the following factors (when applicable) on effect sizes by
restricting the analysis to the following.
• Published trials.
• Taking into account risk of bias, as specified in the
’Assessment of risk of bias in included studies’ section.
• Trials using the following filters: imputation, language of
publication, source of funding (industry versus other), or
country.
We also planned to test the robustness of results by repeating
the analysis using different measures of effect size (RR, OR, etc.)
and different statistical models (fixed-effect and random-effects
models).
Quality of evidence
We presented the overall quality of the evidence for each outcome
according to the GRADE approach, which takes into account is-
sues relating not only to internal validity (risk of bias, inconsis-
tency, imprecision, publication bias) but also to external validity,
such as directness of results. Two review authors (BHandBR) rated
the quality of evidence for each outcome. We presented a sum-
mary of the evidence in ’Summary of findings’ tables ( Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3). These tables provide key information
about the best estimate of the magnitude of the effect of interven-
tions, in relative terms and as absolute differences, the numbers
of participants and trials addressing each important outcome, and
rate the overall confidence in effect estimates for each outcome.
We created the ’Summary of findings’ tables on the basis of meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Schünemann 2011) by means of the table editor in
Review Manager 5 (RevMan 2014), and included three appen-
dices (Appendix 14; Appendix 15; Appendix 16) providing check-
lists as guides to the consistency and reproducibility of GRADE
assessments (Meader 2014) to help with the standardisation of
the ’Summary of findings’ tables. Alternatively, we would have
used theGRADEproGDT software (GRADEproGDT 2015) and
would have presented evidence profile tables as an appendix. We
presented results for the outcomes as described in the Types of
outcome measures section. If meta-analysis was not possible, we
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presented the results in a narrative format in the ’Summary of
findings’ tables. We justified all decisions to downgrade the quality
of the evidence using footnotes, and we made comments to aid
the reader’s understanding of the review where necessary.
We presented a ’Summary of findings’ table to report the following
outcomes, listed according to priority.
• All-cause mortality
• Incidence of T2DM
• Serious adverse events
• Cardiovascular mortality
• Non-fatal myocardial infarction/stroke
• Health-related quality of life
• Socioeconomic effects
R E S U L T S
Description of studies
For a detailed description of studies, see the ’Characteristics of
included studies’, ’Characteristics of
excluded studies’, ’Characteristics of studies awaiting classification’
and ’Characteristics of ongoing studies’ sections.
Studies awaiting classification
We classified five trials in six references as studies awaiting classi-
fication (see ’Characteristics of studies awaiting classification’ ta-
ble).
Ongoing studies
We found three ongoing randomised controlled trials (RCTs) in
nine references (NCT01530165; PREVIEW; PROPELS). We es-
timate the ongoing trials to include 23,808 participants. The def-
inition of intermediate hyperglycaemia varied among the ongo-
ing trials; one trial included participants with impaired glucose
tolerance (IGT) (NCT01530165), one trial included participants
with IGT, impaired fasting glucose (IFG) or both (PREVIEW),
and one trial included participants with IFG or moderately el-
evated glycosylated haemoglobin A1c (HbA1c) (PROPELS). All
the ongoing trials assessed one or more outcomes of interest for
our review. Two of the ongoing trials’ predefined outcomes stated
that they would assess one of our primary outcomes (incidence
of T2DM) (NCT01530165; PREVIEW). Future updates will in-
clude all ongoing trials, if possible.
Results of the search
The original Cochrane Review published in 2008 included eight
RCTs. In this update we excluded two of these trials as they did
not have intermediate hyperglycaemia as an inclusion criterion
(Bo 2007; Wing 1998). Thus, six trials of the original review
remained (Da Qing 1997; DPP 2002; DPS 2001; IDPP 2006;
Kosaka 2005;Oldroyd 2005). The updated search of the databases
identified 2072 records after duplicates were removed (Figure 1).
We excluded most of the references on the basis of their titles and
abstracts because they clearly did not meet the inclusion criteria.
We evaluated 181 references further. In this updated search we
identified a total of 56 additional references for four of the already
included trials of the 2008 review (DaQing 1997;DPP2002;DPS
2001; IDPP 2006). After screening the full-texts and evaluating
the existing references from the 2008 review, 12 RCTs published
in 127 records met our inclusion criteria. We excluded a total of
62 references from the updated search after full-text evaluation.
Therefore, in addition to the six included trials of the Cochrane
Review published in 2008 we included six more trials (EDIPS
2009; Hellgren 2016; HELP PD 2011; JDPP 2013; PODOSA
2014; SLIM 2003).
We continuously used a MEDLINE email alert service to identify
newly published studies using the same search strategy as described
for MEDLINE up to September 2017.
Included studies
A detailed description of the characteristics of included studies
is presented elsewhere (see Characteristics of included studies;
Table 1 and Appendix 2; Appendix 3; Appendix 4; Appendix 5;
Appendix 6; Appendix 7; Appendix 8; Appendix 9; Appendix 10;
Appendix 11; Appendix 12). The following is a succinct overview:
Source of data
We contacted all trial authors or investigators through email (see
Appendix 13). When important information was lacking on on-
going studies and excluded studies, we contacted investigators for
clarification.
Overview of trial populations
Ten trials reported the number of participants screened (Da Qing
1997; DPP 2002; EDIPS 2009; Hellgren 2016; HELP PD 2011;
IDPP 2006; JDPP 2013; Oldroyd 2005; PODOSA 2014; SLIM
2003). Two trials did not report the number of participants ran-
domised to each intervention group upon trial initiation (DaQing
1997; Hellgren 2016). A total of 5238 participants were ran-
domised; 11 trials evaluated diet plus physical activity (Da Qing
1997; DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011;
IDPP 2006; JDPP 2013; Kosaka 2005; Oldroyd 2005; PODOSA
2014; SLIM 2003). The two trial randomising participants to
physical activity only in one of their treatment arms did not report
the number of participants randomised to the intervention groups
(Da Qing 1997; Hellgren 2016); the same was the case for the one
trial arm randomising to diet only (Da Qing 1997).
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Ten trials provided information about sample size and power
calculations (Da Qing 1997; DPP 2002; DPS 2001; EDIPS
2009; HELP PD 2011; IDPP 2006; JDPP 2013; Oldroyd 2005;
PODOSA 2014; SLIM 2003).
The proportion of participants finishing the trial varied from 48%
(SLIM 2003) to 98% (PODOSA 2014).
Trial design
Ten included trials were parallel RCTs and two trials had a cluster-
randomised design (DaQing 1997; PODOSA 2014). In DaQing
each clinic was randomised to carry out the intervention on each
of the eligible participants attending the clinic (Da Qing 1997). A
total of 33 health care clinics were included (Da Qing 1997). No
intra-cluster correlation (ICC) coefficient was reported. However,
we estimated it to be 0.05. The design effect was therefore esti-
mated to be 1+ (average cluster size - 1) x 0.05 = 1 + ((530/33) - 1)
x 0.05 = 1.75. For dichotomous data, we divided both the num-
ber of participants experiencing an event as well as the number
of participants by the design effect. For continuous data we only
adjusted the sample size for the design effect. Means and standard
deviations remained unchanged. In the PODOSA 2014 trial par-
ticipants constituted 156 family clusters that were randomised (78
families with 85 participants were allocated to the intervention
group and 78 families with 86 participants were allocated to the
control group). First degree relatives living in the same city were
not randomised separately. The ICC coefficient was assumed to
be zero.
The number of participants varied from 78 (Oldroyd 2005) to
2161 (DPP 2002). One trial contributed 41% of the total number
of all randomised participants (DPP 2002). Four trials were multi-
centre trials (Da Qing 1997; DPP 2002; DPS 2001; JDPP 2013),
four trials were single-centre trials (EDIPS 2009; Hellgren 2016;
HELP PD 2011; Oldroyd 2005), and four trials did not pro-
vide any centre description (IDPP 2006; Kosaka 2005; PODOSA
2014; SLIM 2003). All trials were performed in outpatient set-
tings.
None of the trials reported blinding of the participants and in-
vestigators. One trial had a run-in period of three weeks where
participants had to fill out a diary and take placebo pills (DPP
2002). The duration of the intervention in the included trials var-
ied from two to six years. Three trials had an extended follow-up
period after the intervention period had stopped (Da Qing 1997;
DPP 2002; DPS 2001). The extended follow-up period varied
from 5 to 17 years. One trial based the sample size calculation on
an anticipated incidence of T2DM during six years of follow-up.
Trial authors said that they had planned six years’ follow-up, but
only reported three years of follow-up (JDPP 2013). Another trial
originally planned a follow-up of three years, but was extended to
six years in the course of the trial (SLIM 2003).
Six trials were performed in European countries (DPS 2001;
EDIPS 2009; Hellgren 2016; Oldroyd 2005; PODOSA 2014;
SLIM 2003); two trials in the USA (DPP 2002; HELP PD 2011)
and four trials in Asian countries (Da Qing 1997; IDPP 2006;
JDPP 2013; Kosaka 2005).
Two trials included one ormore intervention armswithmetformin
(DPP 2002; IDPP 2006). Results from these intervention arms
will be reported elsewhere (Lü 2010). One of the trials originally
included a troglitazone arm, which was discontinued due to liver
toxicity of the drug (DPP 2002).
Three of the included trials stated that they had received grants
from a pharmaceutical company (DPP 2002; DPS 2001; IDPP
2006). Eight trials reported non-commercial funding (Da Qing
1997; EDIPS 2009;Hellgren 2016;HELP PD 2011; JDPP 2013;
Oldroyd 2005; PODOSA 2014; SLIM 2003). One trial did not
report the funding source (Kosaka 2005).
Three trials were terminated early due to beneficial effects in the
intervention group (DPP 2002; DPS 2001; IDPP 2006).
Participants
Four trials included only Asian people (Da Qing 1997; IDPP
2006; JDPP 2013; Kosaka 2005): two of these trials included
Japanese people (JDPP 2013; Kosaka 2005), one trial included
Asian Indians (IDPP 2006) and one trial included Chinese people
(Da Qing 1997). One trial performed in the UK only included
people of Indian or Pakistini origin (PODOSA 2014). Two trials
included only white people (Oldroyd 2005; SLIM 2003). Two
trials included people with different ethnicity (DPP 2002; HELP
PD 2011): in one of the trials more than 50% of the included
participants were white and about 20% African American (DPP
2002), the other trial reported about 75% were white and 25%
AfricanAmerican (HELPPD2011). Three trials did not report the
ethnicity of the participants (DPS 2001; EDIPS 2009; Hellgren
2016): two of the trials might have included mainly white partici-
pants as they were conducted in Sweden and Finland (DPS 2001;
Hellgren 2016).
All trial authors provided information on gender. One trial in-
cluded only men (Kosaka 2005), the remaining trials included
both men and women. All trials except one had a balanced dis-
tribution of women and men in the intervention and comparator
groups, this trial included 54% women in the intervention group
compared with 31% in the comparator group (Oldroyd 2005).
The age of the included participants varied from 45 to 63 years.
All trials except one reported fasting glucose values at baseline
(Hellgren 2016). Mean fasting glucose values at baseline varied
from 5.5 mmol/L to 6.2 mmol/L. Nine trials reported two-hour
glucose values after a glucose-load at baseline and ranged from
8.2 mmol/L to 9.2 mmol/L (Da Qing 1997; DPP 2002; DPS
2001; EDIPS 2009; IDPP 2006; JDPP 2013; Oldroyd 2005;
PODOSA 2014; SLIM 2003). Glycosylated haemoglobin A1c
(HbA1c) values were reported at baseline in six trials and ranged
from 5.7% to 6.2% (DPP 2002; DPS 2001; IDPP 2006; JDPP
2013; Oldroyd 2005; SLIM 2003). One trial did not report any
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glycaemic baseline values (Hellgren 2016).
All trials reported body mass index (BMI) at baseline. Three of the
included trials required a minimum BMI for all eligible partici-
pants (DPP 2002; EDIPS 2009; HELP PD 2011). In two trials
the mean BMI at baseline was less than 25 kg/m2 (JDPP 2013;
Kosaka 2005). Four trials had a mean BMI at baseline between 25
kg/m2 to 30 kg/m2 (Da Qing 1997; Hellgren 2016; IDPP 2006;
SLIM 2003). Six trials reported a mean BMI at baseline above 30
kg/m2 (DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011;
Oldroyd 2005; PODOSA 2014). None of the trials had a mean
BMI at baseline above 35 kg/m2. Most trials excluded participants
with other endocrine conditions, hepatic or kidney disease.
Diagnosis of intermediate hyperglycaemia
The diagnosis applied in the included trials for identifying in-
termediate hyperglycaemia varied. Three trials applied the World
Health Organization (WHO) 1985 diagnostic criteria for the def-
inition of IGT (fasting plasma glucose (FPG) < 7.8 mmol/L and
two-hour plasma glucose after oral glucose tolerance test (OGTT)
between ≥ 7.8 mmol/L and < 11.1 mmol/L) (Da Qing 1997;
DPS 2001; Oldroyd 2005). Three trials applied the WHO 1999
criteria for the definition of IGT (fasting plasma glucose (FPG) <
7.0 mmol/L and two-hour plasma glucose after OGTT between
≥ 7.8 mmol/L and < 11.1 mmol/L) (EDIPS 2009; IDPP 2006;
JDPP 2013). For one of these trials it was stated that the diagnosis
of IGT was based on the OGTT and trial authors did not clearly
describe any measurement of FPG (EDIPS 2009). In the main
publication it was described that intermediate hyperglycaemia was
defined according to the WHO 1999 criteria, but the reference
for the diagnostic criteria was the WHO 1985 reference (EDIPS
2009; WHO 1985). The investigators confirmed that the diagno-
sis of T2DM was established by FPG or two-hour plasma glucose
(EDIPS 2009). Therefore, plasma glucose must have been mea-
sured (EDIPS 2009). One trial applied the WHO 1999 criteria
for the definition of IFG (FPG ≥ 6.1 and < 7.8 mmol/L and two-
hour glucose < 7.8 mmol/L) and/or IGT (FPG < 7.0 mmol/L and
two-hour plasma glucose after OGTT between ≥ 7.8 mmol/L
and < 11.1 mmol/L) (PODOSA 2014). One trial included people
with IGT defined by FPG < 7.8 mmol/L and two-hour plasma
glucose after 100 g OGTT between 8.9 mmol/L and 13.3 mmol/
L, which roughly corresponds to 7.8 mmol/L to 11 mmol/L after
a 75 g OGTT (Kosaka 2005). Therefore, the criterion was almost
identical to the WHO 1980 criteria for IGT (FPG < 8.0 mmol/L
and two-hour plasma glucose after OGTT between≥ 8.0 mmol/
L and < 11.0 mmol/L) (WHO 1980). One trial included people
with fasting glucose levels between 5.3 mmol/L and 6.9 mmol/L
(HELP PD 2011). This definition did not adhere to the definition
by theWHO or American Diabetes Association (ADA), however,
the definition was very close to the glycaemic levels recommended
by ADA 2003 (FPG 5.6 mmol/L to 6.9 mmol/L) (ADA 2003).
One trial applied the diagnostic criteria for impaired glucose de-
fined by ADA 1997 (FPG 5.3 mmol/L to 6.9 mmol/L and two-
hour plasma glucose after OGTT between 7.8 and 11.0 mmol/
L) (ADA 1997) (DPP 2002). For the Native American Indian
clinics FPG less then 6.9 mmol/L with no lower limit applied.
Before June 1997, the criterion for FPG was 5.6 to 7.7 mmol/
L, or less than 7.7 mmol/L in the Native American Indian clinics
(DPP 2002). A total of 54 participants (total in all three interven-
tion groups) included in the Diabetes Prevention Program (DPP)
had FPG above 7.0 mmol/L at baseline (DPP 2002). Thirteen
percent of the participants included in the DPP had HbA1c ≥
6.5% at baseline (DPP 2002). One trial defined IGT by FPG <
7.8 mmol/L and two-hour plasma glucose after OGTT between
≥ 7.8 mmol/L and < 12.5 mmol/L (SLIM 2003). No medical as-
sociations recommend these limits to diagnose IGT (SLIM 2003).
Twenty-two participants of the initially randomised 147 partici-
pants had a two-hour glucose value above 11 mmol/L in this trial
(SLIM 2003). One trial defined IFG as FPG > 6.0 mmol/L to
< 7.0 mmol/L with two-hour plasma glucose after OGTT < 8.9
mmol/L, while IGT was defined as two-hour plasma glucose af-
ter OGTT between 8.8 mmol/L and < 12.2 mmol/L, and fasting
glucose < 7.0 mmol/L (Hellgren 2016).
Interventions
All the participants in the included trialswere treatment-naivewith
regard to pharmacological glucose-lowering interventions. Two of
the included trials had more than one intervention group of rel-
evance for this review (Da Qing 1997; Hellgren 2016). Hellgren
2016 initially analysed data from the two intervention groups sep-
arately. As the treatment effect was almost identical in both groups,
they analysed the two groups together and thereafter designated
them as the combined intervention group. Both the intervention
arms in Hellgren 2016 had a more intense physical activity strat-
egy than the comparator group. Diet advice was identical in both
intervention groups and the comparator group. Da Qing 1997
had four intervention arms: physical activity only, diet only, phys-
ical activity plus diet and control group. We combined data for
the physical activity only, diet only and physical activity plus diet
group as one intervention group in the post-intervention follow-
up period.
Ten trials aimed for weight reduction for all participants allocated
to the intervention groups or only for participants with a BMI
above a certain limit (this BMI limit varied among the included tri-
als) (Da Qing 1997; DPP 2002; DPS 2001; EDIPS 2009; HELP
PD 2011; JDPP 2013; Kosaka 2005; Oldroyd 2005; PODOSA
2014; SLIM 2003). Participants with BMI above 25 kg/m2 allo-
cated to the diet-only group in Da Qing 1997 were encouraged to
reduce their calorie intake, so they lost 0.5 kg to 1.0 kg per month
until they achieved a BMI of 23 kg/m2. For the other intervention
groups inDaQing 1997, the intervention intensity did not change
according to BMI. Three trials aimed for a BMI less than 25 kg/
m2 in the diet plus physical activity group (DPS 2001; EDIPS
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2009; Oldroyd 2005). One trial advised participants with a BMI
above 22 kg/m2 allocated to the diet plus physical activity group
to lose weight (Kosaka 2005). One trial recommended a weight
reduction of at least 7% in participants in the diet plus physical
activity group (DPP 2002); two trials recommended a weight loss
of 5% to 7% (HELP PD2011; SLIM2003); one trial aimed at 5%
weight reduction in obese or overweight participants allocated to
diet plus physical activity (JDPP 2013). One trial recommended
a weight loss goal of 2.5 kg more in the diet plus physical activity
group compared with the control group (PODOSA 2014).
The physical activity interventions differed largely among the tri-
als. Some trials did not aim for a certain amount of minutes of
activity, but just an increase in existing physical activity levels for
the participants in the intervention group (Da Qing 1997; DPS
2001; Hellgren 2016). Other trials recommended physical activ-
ity of different intensity with a minimum number of minutes per
day or week (DPP 2002; EDIPS 2009; HELP PD 2011; IDPP
2006; JDPP 2013; Kosaka 2005; Oldroyd 2005; PODOSA 2014;
SLIM 2003). Some defined physical activity levels in the inter-
vention groups, which corresponded to the physical activity rec-
ommended in the control groups in other trials. Some trials pro-
moted physical activity (Da Qing 1997; EDIPS 2009; HELP PD
2011; JDPP 2013 Kosaka 2005; Oldroyd 2005; PODOSA 2014)
and others offered physical activity programmes (DPP 2002; DPS
2001; Hellgren 2016; SLIM 2003). Most programmes included
walking and cycling.
Only one trial focused exclusively on physical activity interven-
tions for the prevention of T2DM (Hellgren 2016).
The diet interventions were mainly based on caloric restriction,
reduced fat intake and increased fibre intake (DaQing 1997; DPP
2002; DPS 2001; EDIPS 2009; HELP PD 2011; IDPP 2006;
JDPP 2013; Kosaka 2005; Oldroyd 2005; PODOSA 2014; SLIM
2003).
The number of contacts with the participants in the intervention
groups ranged from 3 to 46 (Hellgren 2016; IDPP 2006). The
intervention was applied to the participants in groups or on an in-
dividual basis. Nine of the trials applied both individual and group
sessions for the participants in the intervention group (Da Qing
1997; DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011;
IDPP 2006; JDPP 2013; PODOSA 2014; SLIM 2003); three
trials provided individual sessions only (Hellgren 2016; Kosaka
2005; Oldroyd 2005). In most of the trials the intervention facil-
itators were a physiotherapist, an exercise physiologist and a dieti-
tian.
In one of the included trials, the control group did not receive any
intervention (Oldroyd 2005). In the remaining included trials, the
control group received recommendations, advice or education on
how to increase physical activity and reduce calorie intake.
Three trials had an extended follow-up period after the interven-
tion period had stopped (Da Qing 1997; DPP 2002; DPS 2001).
In the DaQing 1997 and DPS 2001 follow-up studies, the partic-
ipants did not receive any kind of diet or physical activity advice
from the investigators. In theDPP2002 follow-up study (Diabetes
Prevention Program Outcome Study (DPPOS)) sessions on diet
plus physical activity were offered to all participants every third
month. The participants initially randomised to theDPP diet plus
exercise group were also offered sessions in order to reinvigorate
their self-management behaviours for weight loss (DPP 2002).
In the Da Qing 1997 the participants were re-examined after 20
years and 23 years of follow-up. In the DPP 2002 and DPS 2001
follow-up studies the participants were examined yearly.
Outcomes
All included trials reported one or more of the primary outcomes
for this review. All included trials, except one (Oldroyd 2005), ex-
plicitly specified the primary outcome.Nine trials predefined a pri-
mary outcome with interest for this review (Da Qing 1997; DPP
2002; DPS 2001; EDIPS 2009; HELP PD 2011; IDPP 2006;
JDPP 2013; Kosaka 2005; SLIM 2003). Six trials had registered a
protocol in a trials register (DPP 2002; DPS 2001; EDIPS 2009;
HELP PD2011; JDPP2013; PODOSA2014).One trial changed
its primary outcome from incidence of T2DM to weight change
during the trial in order to ensure statistical power (PODOSA
2014). Weight change had originally been defined as a secondary
outcome. Reporting on adverse events, macrovascular and mi-
crovascular complications was sparse.
Excluded studies
We excluded 41 trials after full-text evaluation (for details see
Characteristics of excluded studies). We excluded 16 trials pub-
lished in 26 references as the duration of the intervention was
less than two years (D-CLIP; DH!AAN; Hesselink 2013; Huang
2007; J-DOIT; Kawahara 2008; Kinmonth 2008; Lindahl 1999;
Marrero 2016; Page 1992; Ramachandran 2013; Sathish 2017;
Savoye 2007; Thompson 2008; Villareal 2006; Yates 2011). We
excluded 11 trials published in 12 references as they did not
have intermediate hyperglycaemia as an inclusion criterion or the
people with intermediate hyperglycaemia were analysed together
with people of another glycaemic status, and separate data were
not available (APHRODITE; Bo 2007; E-LITE; Eriksson 2006;
NCT02374788; Rosas 2016; Schmidt 2016; SHINE; The Fasting
Hyperglycaemia Study 1997a; Wing 1998; Yates 2012). We ex-
cluded three trials published in three references as they did not
allocate the participants to diet, physical activity or both by ran-
domisation (De la Rosa 2007; Eriksson 1991; Tao 2004). We ex-
cluded one trial due to inadequate description of the intervention
group (Sartor 1980).We excluded 10 trials in 18 references as they
did not compare the interventions of interest for this review (Grey
2004; Jarrett 1979; Let’s Prevent; Liao 2002; Nanditha 2014;
NCT02250066; PULSE; Saito 2011; Wein 1999; Wong 2013).
Of these, seven trials in 14 references compared the same inten-
sity of the diet plus physical activity intervention, but applied the
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advice differently (e.g. one visit per year versus four visits per year)
(Grey 2004; Let’s Prevent; Nanditha 2014; PULSE; Saito 2011;
Wein 1999;Wong 2013).We furthermore excluded 16 systematic
reviews (Aguiar 2014; Gillett 2012; Gillies 2007; Glechner 2015;
Gong 2015; Hopper 2011; ICER 2016; Norris 2005; Santaguida
2005; Selph2015; Stevens 2015; Yamaoka 2005; Yates 2007; Yoon
2013; Yuen 2010; Zheng 2016).
Risk of bias in included studies
For details on the risk of bias of the included trials see
Characteristics of included studies.
For an overview of review authors’ judgements about each risk of
bias item for individual trials and across all trials see Figure 2 and
Figure 3. No trial was free from risk of bias in all ’Risk of bias’
domains.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies (blank cells indicate that the particular outcome was not investigated in
some studies).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study (blank cells indicate that the study did not report that particular outcome).
Allocation
We judged eight of the trials to be at low risk of selection bias with
regard to themethodof randomisation and allocation concealment
(DPP 2002; DPS 2001; EDIPS 2009; Hellgren 2016; HELP PD
2011; JDPP 2013; Oldroyd 2005; PODOSA 2014).
The remaining trials reported that the participants were ran-
domised but provided no further description (Da Qing 1997;
IDPP 2006; Kosaka 2005; SLIM 2003).
We evaluated trial baseline data for our predefined prognostic
baseline variables. In one trial a significantly larger proportion of
control participants reported engaging in regular physical activ-
ity at least once a week compared with intervention participants
(53% versus 24%) and there were fewer women (10/32 (32%))
than men (22/32 (69%)) in the control group compared with the
diet plus physical activity group (Oldroyd 2005). Another trial
reported that physical activity was significantly higher at baseline
in the diet plus physical activity group than in the control group
(Da Qing 1997).
Blinding
Double-blindingwas not possible or practical in the included trials
due to the type of intervention.
One trial mentioned that an independent outcome committee
evaluated the incidence of T2DM (DPS 2001). None of the re-
maining trials reported that a blinded outcome committee was
instituted to assess outcomes during the intervention period.
Wheremeasured, all primary outcomes of this review were investi-
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gator assessed and we judged these to be at low risk of performance
and detection bias. All the included trials reported blood glucose
measurements performed by the investigators and we judged these
outcomes measures to be at low risk of performance and detec-
tion bias. Two trials explicitly stated that glycaemic measures were
masked for the investigators and participants until diabetes was
confirmed (DPP 2002; DPS 2001). Non-serious adverse events
and mild hypoglycaemia were partly or exclusively self-reported in
all trials. Overall, we considered the risk of performance bias and
detection bias to be low or unclear for our secondary outcomes.
Incomplete outcome data
We considered overall risk of attrition bias to be unclear for most
of our outcomes. Ten trials reported the number of participants
randomised and finishing the trial for each intervention group
(DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011; IDPP
2006; JDPP 2013; Kosaka 2005; Oldroyd 2005; PODOSA 2014;
SLIM 2003). Two trials did not describe how many participants
were initially randomised to each intervention group but reported
the number analysed (DaQing 1997;Hellgren 2016). Three trials
provided details on the participants not completing the trial (DPS
2001; JDPP 2013; PODOSA 2014).
Selective reporting
Six of the trials had a published protocol (DPP 2002; DPS 2001;
EDIPS 2009; HELP PD 2011; JDPP 2013; PODOSA 2014).
We judged one trial as low risk of selective outcome reporting bias
after the investigators provided additional information (Hellgren
2016). We judged eight of the included trials to be at high risk
of reporting bias on one or more of the outcomes of relevance
for our review (Da Qing 1997; DPP 2002; DPS 2001; EDIPS
2009; HELP PD 2011; IDPP 2006; JDPP 2013; Kosaka 2005).
Three trials had an unclear risk of selective outcome reporting
bias (Oldroyd 2005; PODOSA 2014; SLIM 2003). Two of the
judgments of unclear risk of selective outcome reporting bias were
based on lack of trial protocol (Oldroyd 2005; SLIM 2003) and
one trial because the primary outcomewas changedduring the trial
(PODOSA 2014). For more details see Appendix 6 and Appendix
7. One trial had a low risk of selective outcome reporting bias
(Hellgren 2016).
Other potential sources of bias
We judged five trials to be at low risk of other bias (EDIPS 2009;
Hellgren 2016; JDPP 2013; Oldroyd 2005; PODOSA 2014).
Three trials had an unclear risk of other bias (HELP PD 2011;
Kosaka 2005; SLIM 2003). We judged four trials to be at high
risk of other bias, either because the trial was terminated early
for benefit (DPP 2002; DPS 2001; IDPP 2006) or because trial
authors did not report an ICC coefficient in their cluster-RCT
making it necessary to estimate this coefficient (Da Qing 1997).
Four of the included trials had received grants from a pharma-
ceutical company and we judged these as unclear risk of other
bias (DPP 2002; DPS 2001; HELP PD 2011; IDPP 2006). One
trial did not report funding source (Kosaka 2005). It is known
that receiving funding or provision of free drugs or devices from
a pharmaceutical company leads to more favourable results and
conclusions than sponsorship from other sources (Lundh 2017).
One trial prolonged the intervention period without any explana-
tion (SLIM 2003).
Effects of interventions
See: Summary of findings for the main comparison Diet plus
physical activity versus standard treatment; Summary of findings
2 Diet versus physical activity or standard treatment; Summary
of findings 3 Physical activity versus standard treatment
Baseline characteristics
For details of baseline characteristics, see Appendix 3; Appendix 4
and Appendix 5.
Diet versus comparator
One trial compared diet with one or more comparators (Da Qing
1997). This trial had four intervention arms: diet only, physical
activity only, diet plus physical activity and standard treatment
(Da Qing 1997). The trial was cluster randomised. The trial had
an extended follow-up period of 17 years. No ICC coefficient
was reported. Based on an anticipated ICC coefficient of 0.05
we assumed a design effect of 1.75 (Higgins 2011). In the post-
interventional follow-up period the trialists combined the three
intervention groups into one composite intervention group. Data
for the extended follow-up period for the combined intervention
groups are described in the section ’Diet plus physical activity
versus standard treatment’.
Diet versus physical activity
Only one trial compared diet with physical activity in one of its
trial arms (Da Qing 1997). The overall quality of evidence was
very low because of risk of reporting and other bias and serious
imprecision (very sparse data)
Primary outcomes
All-cause mortality
Three out of 130 participants in the diet-only trial arm compared
with none out of 141 participants in the physical activity-only
trial arm died during the intervention period (when adjusting for
cluster-RCT design: 2/74 versus 0/81). None of the participants
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died due to cardiovascular disease. None of the participants who
died had developed T2DM before death.
Incidence of T2DM
The incidence of T2DM was the primary outcome. T2DM was
defined according to the WHO 1985 criteria (either a FPG ≥
140 mg/dL (7.8 mmol/L) or higher or a two-hour plasma glucose
≥ 200 mg/dL (11.1 mmol/L) after 75 g OGTT) and confirmed
with a repeated test 7 to 14 days after the first test or from a re-
port of physician-diagnosed diabetes with evidence in the medical
record of high glucose concentrations, or use of glucose-lowering
drugs. Fifty-seven out of 130 participants in the diet-only group
compared with 58 participants out of 141 in the physical activ-
ity only group developed T2DM during the intervention period
(when adjusting for cluster-RCTdesign: 33/74 versus 33/81). The
cumulative incidence of T2DM at six years was 43.8% (95% CI
35.3 to 52.3) in the diet only group compared with 41.1% (95%
CI 33.4 to 49.4) in the physical activity only group (not adjusted
for clustering). In the diet only group the incidence rate of T2DM
was 10.0/100 person years (95% CI 7.5 to 12.5) compared with
8.3/100 person years (95% CI 6.4 to 10.3) in the physical activ-
ity only group (not adjusted for clustering). When analysing the
incidence according to FPG 7.8 mmol/L or above, the rate was
3.7/100 person years (95% CI 2.1 to 5.3) in the diet only group
compared with 5.3/100 person years (95% CI 3.6 to 7.0) in the
physical activity only group (not adjusted for clustering).
Due to the differences in dietary advice according to BMI, Da
Qing 1997 evaluated separately the incidence of T2DM in those
who had a BMI at baseline less than 25 kg/m2 or 25 kg/m2 or
higher. Of the lean participants (BMI at baseline < 25 kg/m2), 21
(38.2%) out of 55 participants in the diet only compared with
15 (26.5%) out of 57 participants in the physical activity only
group developed T2DM during the intervention period (when
adjusting for clustering 12/31 versus 9/33). Of the overweight
participants (BMI at baseline ≥ 25 kg/m2), 36 (48%) out of 75
participants in the diet only compared with 43 (51.2%) out of
84 participants in the physical activity group developed T2DM
during the intervention period (when adjusting for clustering 21/
43 versus 26/46).
Of the 263 diabetes diagnoses made in all the intervention groups
during the six years of intervention, 55 (21%) diagnoses were ini-
tially made by local physicians and confirmed by the city hospital
with anOGTT; 208 (79%) were made as a result of the systematic
OGTT during the trial.
Serious adverse events
No (serious) adverse events occurred in both groups.
Secondary outcomes
Cardiovascular mortality
None of the participants in either group died of cardiovascular
reasons.
Non-fatal myocardial infarction
Not reported, however from a published abstract it was apparent
that cardiovascular events were collected during the trial.
Non-fatal stroke
Not reported, however from a published abstract it was apparent
that cardiovascular events were collected during the trial.
Amputation of lower extremity
Not reported.
Blindness or severe vision loss
DaQing 1997 reported the incidence of severe retinopathy among
the participants originally assigned to diet only (4.5/1000 person
years (95% CI 1.8 to 7.1)) compared with physical activity only
(5.3/1000 person years (95% CI 2.5 to 8.0)) after 20 years of fol-
low-up (i.e. 14 years after the end of intervention). This difference
was not statistically significant.
End-stage renal disease
Not reported.
Non-serious adverse events
No adverse events occurred in either group.
Hypoglycaemia
Not reported.
Health-related quality of life
Not reported.
Time to progression to T2DM
Not reported.
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Measures of blood glucose control
Fasting glucose
At the end of follow-up after six years of intervention, FPG in the
diet only group was 7.0 mmol/L (SD 4.4) based on 130 partic-
ipants (74 participants when adjusting for clustering) compared
with 6.8 mmol/L (SD 2.2) in 141 participants (81 participants
when adjusting for clustering) in the physical activity group.
Glucose two hours after an oral glucose load
At the end of follow-up after six years of intervention, two-hour
glucose after an oral glucose load in the diet only group was 10.5
mmol/L (SD 4.9) based on 130 participants (74 participants when
adjusting for clustering) compared with 10.5 mmol/L (SD 3.9) in
141 participants (81 participants when adjusting for clustering)
in the physical activity group.
HbA1c
Not reported.
Socioeconomic effects
Not reported.
Diet versus standard treatment
Only one trial compared diet with standard treatment in one of
its trial arms (Da Qing 1997). The overall quality of evidence was
very low because of risk of reporting and other bias and serious
imprecision (very sparse data)
Primary outcomes
All-cause mortality
Three out of 130 participants in the diet only group compared
with three participants out of 133 in the standard treatment group
died during the intervention period (when adjusting for cluster-
design: 2/74 versus 2/76). None of the participants died because
of cardiovascular disease. None of the participants who died had
developed T2DM before death. The HR (adjusted for age and
clustering) when combining diet only, physical activity only and
diet plus physical activity compared with standard treatment was
1.33 (95% CI 0.45 to 3.92) at the end of the intervention period.
Incidence of T2DM
Fifty-sevenout of 130participants in the diet only group compared
with 90 participants out of 133 in the standard treatment group
developed T2DM during the intervention period (when adjusting
for cluster design: 33/74 versus 51/76).
The cumulative incidence of T2DM at six years was 43.8% (95%
CI 35.3 to 52.3) in the diet only group compared with 67.7%
(95% CI 59.8 to 75.2) in the standard treatment group (not ad-
justed for clustering). In the diet only group, the incidence rate
of T2DM (defined according to WHO 1985) was 10.0/100 per-
son years (95% CI 7.5 to 12.5) compared with 15.7/100 person
years (95% CI 12.7 to 18.7) in the standard treatment group (not
adjusted for clustering). When analysing the incidence according
to FPG 7.8 mmol/L or higher, the rate was 3.7/100 person years
(95% CI 2.1 to 5.3) in the diet only group compared with 9.6/
100 person years (95% CI 7.2 to 12.0) in the standard treatment
group (not adjusted for clustering).
Due to the differences in dietary advice according to BMI, the
trialists evaluated separately incidence of T2DM in those who had
BMI at baseline less than 25 kg/m2 or 25 kg/m2 or higher. Of
the lean participants (BMI at baseline < 25 kg/m2) 21 (38.2%)
out of 55 participants in the diet only group compared with 30
(60%) out of 50 participants in the standard treatment group
developed T2DM during the intervention period (when adjusting
for clustering 12/31 versus 17/29). Of the obese participants (BMI
at baseline ≥ 25 kg/m2) 36 (48%) out of 75 participants in the
diet only group compared with 60 (72.3%) out of 83 participants
in the standard treatment group developed T2DM during the
intervention period (when adjusting for clustering 21/43 versus
34/47).
After 20 years of follow-up (i.e. 14 years after the intervention had
stopped) the HR (adjusted for age and clustering) for the diet only
group versus standard treatment group was 0.58 (95% CI 0.38 to
0.89).
Serious adverse events
No (serious) adverse events occurred in either group.
Secondary outcomes
Cardiovascular mortality
None of the participants in either group died of cardiovascular
reasons.
Non-fatal myocardial infarction
Not reported, however from a published abstract it was apparent
that cardiovascular events were collected during the trial.
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Non-fatal stroke
Not reported, however from a published abstract it was apparent
that cardiovascular events were collected during the trial.
Amputation of lower extremity
Not reported.
Blindness er severe vision loss
Not reported.
End-stage renal disease
Not reported.
Non-serious adverse events
No adverse events occurred in either group.
Hypoglycaemia
Not reported.
Health-related quality of life
Not reported.
Time to progression to T2DM
Not reported.
Measures of blood glucose control
Fasting glucose
FPG at the end of follow-up after six years of intervention in the
diet only group was 7.0 mmol/L (SD 4.4) based on 130 partic-
ipants (74 participants when adjusting for clustering) compared
with 7.6 mmol/L (SD 2.6) in 133 participants (76 participants
when adjusting for clustering) in the standard treatment group.
Glucose two hours after an oral glucose load
Glucose two hours after an oral glucose load at the end of follow-
up after six years of intervention in the diet only group was 10.5
mmol/L (SD 4.9) based on 130 participants (74 participants when
adjusting for clustering) compared with 12.4 mmol/L (SD 4.2) in
133 participants (76 participants when adjusting for clustering)
in the standard treatment group.
HbA1c
Not reported.
Socioeconomic effects
Not reported.
Physical activity versus standard treatment
Two trials compared physical activity with one or more controls
(Da Qing 1997; Hellgren 2016). Da Qing 1997 had four inter-
vention arms: diet only, physical activity only, diet plus physical
activity and standard treatment (Da Qing 1997). The trial was
cluster randomised. No ICC coefficient was reported. Based on an
anticipated ICC coefficient of 0.05 we assumed a design effect of
1.75 (Higgins 2011). In the post-interventional follow-up period,
Da Qing 1997 combined the three intervention groups into one
composite intervention group. Data for the extended follow-up
period for the combined intervention group are described in the
section ’Diet plus physical activity versus standard treatment’.
One trial had two physical activity groups (Hellgren 2016), and
initially analysed data from these two groups separately (Hellgren
2016). As the outcomes proved to be essentially the same in
both groups, they analysed the physical activity groups together
and thereafter designated them as the combined physical activ-
ity group. Both intervention arms in Hellgren 2016 had a more
intense physical activity strategy than the comparator group.The
diet advice was identical in the physical activity groups and the
standard treatment group.
The two trials comparing physical activity with standard treatment
varied according to several important prognostic baseline charac-
teristics (e.g. Da Qing 1997 included only Asian Chinese and the
average age of the participants was about 45 years compared with
Hellgren 2016 including presumably only white people with an
average age of participants of 63 years). Da Qing 1997 included
people with IGT according to the WHO 1985 criteria. Hellgren
2016 included participants with IGT, IFG or both. DaQing 1997
had a duration of the intervention of six years compared with three
years in Hellgren 2016.
The overall quality of evidence was very low mainly because of
risk of bias and imprecision (sparse data)
Primary outcomes
All-cause mortality
One trial reported that none of the 141 participants in the physical
activity only group compared with three participants out of 133 in
the standard treatment group died during the intervention period
(when adjusting for cluster-RCT design: 0/81 versus 2/76) (Da
Qing 1997). None of the participants who died had developed
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T2DM before death. The HR (adjusted for age and clustering)
when combining diet only, physical activity only and diet plus
physical activity comparedwith standard treatmentwas 1.33 (95%
CI 0.45 to 3.92) at the end of the intervention period (Da Qing
1997). The other trial reported that four participants died; three
out of 84 in the physical activity group and one out of 39 in the
standard treatment group. It was not possible to judge to which
group the deceased participants had originally been randomised,
however, the investigators provided this additional information
(Hellgren 2016) (Analysis 1.1).
Incidence of type 2 diabetes
Da Qing 1997’s primary outcome was the incidence of T2DM,
which they defined according to the WHO 1985 criteria (either
a FPG ≥ 7.8 mmol/L or higher or a two-hour plasma glucose
≥ 11.1 mmol/L after a 75 gram OGTT) and confirmed with a
repeat test 7 to 14 days after the first test or from a report of
physician-diagnosed diabetes with evidence in the medical record
of high glucose concentrations, or use of glucose-lowering drugs.
Fifty-eight out of 141 participants in the physical activity only
group compared with 90 participants out of 133 in the standard
treatment group developedT2DM during the intervention period
(when adjusting for cluster design: 33/84 versus 51/76) - Analysis
1.2.
The cumulative incidence of T2DM at six years was 41.1% (95%
CI 33.4 to 49.4) in the physical activity only group compared with
67.7% (95% CI 59.8 to 75.2) in the standard treatment group
(not adjusted for clustering). In the physical activity only group
the incidence of T2DM (defined according to WHO 1985) was
8.3/100 person years (95% CI 6.4 to 10.3) compared with 15.7/
100 person years (95% CI 12.7 to 18.7) in the standard treatment
group (not adjusted for clustering). When analysing the incidence
according to FPG 7.8 mmol/L or higher, the incidence of T2DM
was 5.3/100 person years (95% CI 3.6 to 7.0) in the physical
activity only group compared with 9.6/100 person years (95% CI
7.2 to 12.0) in the standard treatment group (not adjusted for
clustering) (Da Qing 1997).
Of the lean participants (BMI at baseline < 25 kg/m2), 15 (26.3%)
out of 57 participants in the physical activity only group com-
pared with 30 (60%) out of 50 in the standard treatment group
developed T2DM during the intervention period (when adjusting
for clustering 9/33 versus 17/29). Of the overweight participants
(BMI at baseline ≥ 25 kg/m2), 43 (51.2%) out of 84 participants
in the physical activity only group compared with 60 (72.3%)
out of 83 participants in the standard treatment group developed
T2DM during the intervention period (when adjusting for clus-
tering 25/48 versus 34/47) (Da Qing 1997).
For all the 263 diabetes diagnoses made in all the intervention
groups during the six years of intervention in Da Qing 1997,
55 diagnoses (21%) were initially made by local physicians and
confirmed by the city hospital with an OGTT; 208 (79%) were
made as a result of the systematic OGTT during the trial.
The other trial reporting T2DM defined the condition by FPG
more than 6.9 mmol/L and/or two-hour plasma glucose concen-
tration more than 12.1 mmol/L (Hellgren 2016). Ten (11.9%)
out of 84 participants in the physical activity group compared with
seven (17.9%) out of 39 participants in the standard treatment
group developed T2DM during the intervention period (Analysis
1.2).
In the physical activity group 32 participants had IGT only; 38
had IFG only and 11 had IGT and IFG combined. Of the 32
participants with IGT at baseline in the physical activity group,
seven (22%) developed T2DM; of the 38 with IFG at baseline,
three (7.8%) developed T2DM; of the 11 with combined IFG
and IGT, two (18.2%) developed T2DM. In the standard treat-
ment group 15 participants had IGT only; 21 had IFG only and
six had IGT and IFG combined. Of the 15 participants with IGT
at baseline in the standard treatment group five (33%) developed
T2DM; of the 21 with IFG at baseline, two (7.8%) developed
T2DM; of the six with combined IFG and IGT, four (66.7%) de-
veloped T2DM (Hellgren 2016). The number of the participants
included in the subgroups of different glycaemic definitions of in-
termediate hyperglycaemia did not add up to the total number of
participants developing T2DM provided by the investigators of
the trial (physical activity 81 versus 84 and standard treatment 32
versus 39) (Hellgren 2016). We contacted the investigators about
the participants who did not participate in the final follow-up and
asked if these people had developed T2DM (Hellgren 2016).
One trial had an extended follow-up period (Da Qing 1997). The
HR for the incidence of T2DM(adjusted for age and clustering) of
physical activity versus standard treatment after 20 years of follow-
up was 0.51 (95% CI 0.31 to 0.83) (Da Qing 1997).
Serious adverse events
One trial reported that they did not observe any adverse events.
However, this seems unlikely, because the publications indicated
that serious adverse events were experienced (e.g. cardiovascular
events) (Da Qing 1997). The other trial did not publish any data
on serious adverse events, but these were provided by the inves-
tigators (Hellgren 2016). No further definition of the outcome
was provided. Three (4.5%) out of 66 participants in the phys-
ical activity group versus one (2.6%) out of 39 participants in
the standard treatment group experienced a serious adverse event
(Hellgren 2016) (Analysis 1.3).
Secondary outcomes
Cardiovascular mortality
None of the participants in the groups died of cardiovascular rea-
sons.
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Non-fatal myocardial infarction
One trial reported that none of the 66 participants in the physical
activity group compared with three (9.7%) of 31 participants in
the standard treatment group experienced a non-fatal myocardial
infarction. No further definition of the outcome was provided.
These data were provided by the investigators (Hellgren 2016).
Non-fatal stroke
One trial reported that one (1.5%) out of 66 participants in the
physical activity group compared with one (3.2%) out of 31 par-
ticipants in the standard treatment group experienced a non-fatal
stroke. No further definition of the outcome was provided. These
data were provided by the investigators (Hellgren 2016).
Amputation of lower extremity
One trial reported that none of the participants in the trial experi-
enced an amputation of the lower extremity. No further definition
of the outcome was provided. These data were provided by the
investigators (Hellgren 2016).
Blindness or severe vision loss
Not reported
End-stage renal disease
Not reported.
Non-serious adverse events
One trial reported that no adverse event was observed (Da Qing
1997).
Hypoglycaemia
One trial reported that none of the participants in the trial expe-
rienced hypoglycaemia. No further definition of the outcome was
provided. These data were provided by the investigators (Hellgren
2016).
Health-related quality of life
One of the trials comparing physical activity with standard treat-
ment reported health-related quality of life (HrQoL) (Hellgren
2016). Information on this outcome was provided by the investi-
gators. It is unclear whether they assessed HrQoL with a validated
instrument. It was measured by two questions, where participants
graded their total physical and mental health from 1 to 7. Partici-
pants also graded their general health from 1 (best) to 5 (very bad).
There were questions about sleep and energy. The investigators
reported that 13 participants (27%) in the physical activity group
reported that HrQoL from baseline to end of follow-up worsened,
in 21 participants (43%) it was unchanged and in 14 participants
(29%) it increased - the total number of participants in the physi-
cal activity group included in the analyses was 48 participants. The
investigators reported that eight participants (35%) in the stan-
dard treatment group rated themselves worsened, 10 participants
(43%) remained unchanged and five participants (22%) improved
- the total number of participants in the standard treatment group
included in the analyses was 23 (Hellgren 2016). These data were
provided by the investigators.
Time to progression to type 2 diabetes
Not reported.
Measures of blood glucose control
Fasting glucose
FPG after six years of intervention in the physical activity group
was 6.8 mmol/L (SD 2.2) based on 141 participants (81 partici-
pants when adjusting for clustering) compared with 7.6 mmol/L
(SD 2.6) in 133 participants (76 participants when adjusting for
clustering) in the standard treatment group (Da Qing 1997). The
investigators of Hellgren 2016 provided data on change in fasting
plasma glucose on request (Analysis 1.4).
Glucose two hours after an oral glucose load
One trial reported glycaemic values after six years of intervention.
The two-hour glucose after an oral glucose load in the physical
activity group was 10.5 mmol/L (SD 3.9) based on 141 partic-
ipants (81 participants when adjusting for clustering) compared
with 12.4 mmol/L (SD 4.2) in 133 participants (76 participants
when adjusting for clustering) in the standard treatment group
(Da Qing 1997). The investigators of Hellgren 2016 provided
data on change in glucose two hours after an OGTT on request
(Analysis 1.5).
HbA1c
Not reported.
Socioeconomic effects
Not reported.
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Diet plus physical activity versus standard treatment
Eleven trials compared the combination of diet plus physical ac-
tivity with standard treatment or no intervention (Da Qing 1997;
DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011; IDPP
2006; JDPP 2013; Kosaka 2005; Oldroyd 2005; PODOSA 2014;
SLIM 2003).DaQing 1997 had four intervention arms: diet only,
physical activity only, diet plus physical activity and standard treat-
ment. The trial was cluster randomised. The authors reported that
HRs at 20 and 23 years of follow-up were adjusted for cluster-
ing, but no information of adjustment for clustering was provided
at the end of intervention. No ICC coefficient was reported (Da
Qing 1997). Based on an anticipated ICC coefficient of 0.05 we
assumed a design effect of 1.75 (Higgins 2011). In the post-inter-
vention follow-up period Da Qing 1997 combined the three in-
tervention groups (diet only, physical activity only, diet plus phys-
ical activity) into one intervention group. Two other trials also
reported data with relevance to this review after the intervention
had been stopped (DPP 2002; DPS 2001).
Da Qing 1997 included people with IGT according to theWHO
1985 criteria (two-hour plasma glucose≥ 6.7 mmol/L and < 11.0
mmol/L after an OGTT).
Nine trials exclusively included people with IGT (Da Qing 1997;
DPP 2002; DPS 2001; EDIPS 2009; IDPP 2006; JDPP 2013;
Kosaka 2005; Oldroyd 2005; SLIM 2003). One trial included
people with IGT, IFG or both (PODOSA 2014). One trial in-
cluded people with FPG levels between 5.3 to 6.9mmol/L (HELP
PD 2011).
Primary outcomes
All-cause mortality
Ten trials reported data on all-cause mortality (Da Qing 1997;
DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011; IDPP
2006; JDPP 2013; Oldroyd 2005; PODOSA 2014; SLIM 2003).
None of these trials had predefined all-cause mortality as a primary
outcome (see Appendix 6). In Da Qing 1997 five out of 126 par-
ticipants died in the diet plus physical activity group versus three
out of 133 participants in the standard treatment group (when
adjusted for clustering; diet plus physical activity three out of 72
participants versus standard treatment two out of 76 participants).
Most of the trials reporting death were from trials with low risk
of selection bias (DPP 2002; DPS 2001; EDIPS 2009; HELP PD
2011; JDPP 2013; Oldroyd 2005; PODOSA 2014).
A total of 12 deaths were reported in 2049 participants in the diet
plus physical activity group versus 10 out of 2050 participants in
the comparator group (RR 1.12, 95% CI 0.50 to 2.50; P = 0.86;
4099 participants, 10 trials; very low-quality evidence). Funnel
plot asymmetry was not present. The 95% prediction interval
ranged from 0.44 to 2.88 (Analysis 2.1).
Trial sequential analysis (TSA) showed that 0.61% of the diver-
sity-adjusted information size was accrued so far to detect or reject
a 10% relative risk reduction (RRR). Diversity was zero, but we
applied a diversity of 20% when calculating the diversity-required
information size, as heterogeneity is likely to increase when future
trials are included. As only a minor fraction of the diversity-ad-
justed required information size to detect or reject a 10% RRRwas
accrued, we could not calculate the TSA-adjusted 95% CIs with
diversity at 20%. If a diversity of 0% was applied, then 0.77% of
the diversity-adjusted information size was accrued to detect or
reject a 10% RRR. Still, we could not calculate the TSA-adjusted
95% CIs.
Subgroup analyses according to the duration of the intervention
((≥ 4 years) versus trials with short duration (< 4 years)), diag-
nostic criteria (IGT versus other); age (≥ 50 years versus < 50
years); ethnicity (Asian only versus other and mixed ethnicities);
morbidity (BMI ≥ 30 kg/m2 versus < 30 kg/m2) showed no sta-
tistical significant interactions (Appendix 18). We could not per-
form subgroup analyses according to sex and previous gestational
diabetes due to lack of data.
Sensitivity analyses including only trials with low risk of selection
bias (DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011;
JDPP 2013;Oldroyd2005; PODOSA2014) did not substantially
change the effect estimate (RR 1.14, 95% CI 0.42 to 3.12; P =
0.79).
One trial reported a HR (adjusted for age and clustering) when
combining diet only, physical activity only and diet plus physical
activity compared with control at the end of intervention (HR
1.33, 95% CI 0.45 to 3.92) (Da Qing 1997).
Three trials comparing diet plus physical activity had extended
follow-up periods (Da Qing 1997; DPP 2002; DPS 2001). Two
of these reported mortality data during the follow-up period (Da
Qing 1997; DPS 2001).
One trial reported that six out of 257 participants originally ran-
domised to diet plus physical activity group died compared with
10 out of 248 participants in the control arm after amedian follow-
up of 10.6 years (i.e. 6.6 years after the intervention had stopped)
(DPS 2001). Mortality in the former diet plus physical activity
group was 2.2/1000 person years (95% CI 1.0 to 0.35) compared
with 3.8/1000 person years (95%CI 2.0 to 7.0) in the former con-
trol group. The HR was 0.57 (95% CI 0.21 to 1.58) (unknown
adjusting) (DPS 2001).
One trial reported a HR (adjusted for age and clustering) when
combining diet only, physical activity only and diet plus physical
activity compared with control to be 0.96 (95% CI 0.65 to 1.41)
after 20 years of follow-up (i.e. 14 years after the intervention
had stopped) (Da Qing 1997). The same trial reported 23 years
of follow-up (i.e. 17 years after the intervention had stopped);
121 out of 430 participants (after cluster-adjustment: 69/246)
allocated to the former intervention group (combined diet only,
physical activity only and diet plus physical activity) versus 53
out of 138 (after cluster-adjustment 30/79) in the former control
group died (DaQing 1997). The cumulative incidence of all-cause
mortality was 28.1% (95% CI 23.9 to 32.4) in the combined
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former intervention group and 38.4% (95% CI 30.3 to 46.5) in
the former comparator group, with a HR (adjusted for cluster-
randomisation) of 0.71 (95% CI 0.51 to 0.99; P = 0.049). Deaths
per 1000 person years were 14.3 (95% CI 11.8 to 16.9) in the
combined former intervention group compared with 19.9 (95%
CI 14.5 to 25.2) in the former comparator group.
Post-hoc subgroup analyses after 23 years of follow-up showed
that, among women, the cumulative incidence of all-cause mor-
tality in the former comparator group was elevated compared with
the combined former intervention group (HR 0.46, 95% CI 0.24
to 0.87; P = 0.02). The number of deaths included in this post-
hoc analysis was 30 deaths in 200 women in the combined former
intervention group compared with 17 deaths out of 59 women
in the former comparator group (Da Qing 1997). For men the
intervention did not show statistically significant differences (91
deaths among 230 male participants in the combined former in-
tervention group compared with 36 deaths out of 79 participants
in the former comparator group; HR 0.97 (95% CI 0.97 to 1.46).
We performed multivariable analyses in order to test if different
baseline characteristics could explain the differences (e.g. smok-
ing, age), but the difference between men and women persisted.
However, when the time to onset of T2DM was included in the
multivariable models, then the intervention variable was no longer
significant (Da Qing 1997).
Incidence of type 2 diabetes
Eleven trials reported data on the incidence of T2DM. The defi-
nition of T2DM varied among the included trials. Three trials ap-
plied theWHO1985 diagnostic criteria (either FPG≥ 7.8mmol/
L or higher or a two-hour plasma glucose ≥ 11.1 mmol/L after a
75 g OGTT) (Da Qing 1997; DPS 2001; Oldroyd 2005); four
trials applied the WHO 1999 criteria to establish the diagnosis of
T2DM (either FPG≥ 7.0mmol/L and/or a two-hour plasma glu-
cose concentration ≥ 11.1 mmol/L after a 75 g OGTT) (EDIPS
2009; IDPP 2006; JDPP 2013; SLIM 2003).One trial established
the diagnosis of T2DM based on the ADA 1997 diagnostic cri-
teria (FPG ≥ 7.0 mmol/L or a two-hour plasma glucose ≥ 11.1
mmol/L after a 75 g OGTT (i.e. identical to WHO 1999 crite-
ria)) (DPP 2002). One trial applied FPG levels above 7.0 mmol/L
to establish the diagnosis of T2DM (HELP PD 2011). One trial
applied FPG levels above 7.8 mmol/L to establish the diagnosis
of T2DM (Kosaka 2005). One trial established the diagnosis of
T2DM based on two-hour plasma glucose of 11.1 mmol/L or
higher after a 75 g OGTT (PODOSA 2014). Furthermore, four
trials also defined the diagnosis of T2DM as reported by a physi-
cian or the use of glucose-lowering drugs (Da Qing 1997; EDIPS
2009; HELP PD 2011; PODOSA 2014).
A total of 315 out of 2122 participants developed T2DM in the
diet plus physical activity group versus 614 out of 2389 partici-
pants in the comparator group (RR 0.57, 95% CI 0.50 to 0.64;
P < 0.00001; 4511 participants, 11 trials; moderate quality evi-
dence). The 95% prediction interval ranged from 0.50 to 0.65.
TSA showed firm evidence for a 10% RRR in favour of diet plus
physical activity. Funnel plot asymmetry was not present (Analysis
2.8).
Of the 12 participants in PODOSA 2014 diagnosed with T2DM
in the diet plus physical activity group, only two participants were
diagnosed withOGTT at the third year of the trial. The remaining
10 participants who developed T2DM in the diet plus physical
activity groupduring the trial were diagnosed by a physician. In the
control group 10 participants were diagnosed with T2DM, based
on a physicians’ diagnosis and seven participants were diagnosed
with the OGTT at the third year of the trial (PODOSA 2014).
The incidence rate of T2DM in the Japan Diabetes Prevention
Program (JDPP 2013) trial was 2.7/100 person years in the diet
plus physical activity group compared with 5.1/100 person years
in the control group. The JDPP trial included both lean and obese
participants with a BMI ranging from 16.8 to 39.6 kg/m2. Addi-
tional analyses were made according to BMI at baseline. T2DM
developed in five out of 52 participants in the lowest quartile (two
from the control group and three from the intervention group)
during the three years. An effect of the behaviour-changing inter-
vention was therefore not apparent in this lowest BMI quartile.
However, the cut-off point for the lower quartile was not available
from the publication (JDPP 2013). Subgroup analysis for the par-
ticipants with BMI more than 22.5 kg/m2 revealed a significant
decrease in the cumulative incidence of T2DM with the interven-
tion (P = 0.027). The cumulative incidence of T2DM was sig-
nificantly lower in the diet plus physical activity group compared
with controls among participants with baseline HbA1c levels of
5.7% or higher, while this was not found among participants with
baseline HbA1c levels less than 5.7% (JDPP 2013).
The Indian Diabetes Prevention Programmes (IDPP 2006) trial
reported a cumulative incidence of T2DMat 39.3% (95%CI 30.4
to 48.5) in the diet plus physical activity group compared with
55.0% (95% CI 46 to 63.5) in the control group (IDPP 2006).
The number of participants needed to be treated to prevent one
T2DM case was 6.4. The HR for developing T2DM (adjusted
for sex, age, family history of diabetes, BMI, waist circumference,
baseline fasting and two-hour glucose and corresponding insulin
values, hypertension and smoking) for the diet plus physical ac-
tivity group compared with the control group was 0.62 (95% CI
0.23 to 1.02; P = 0.018) (IDPP 2006). Plasma glucose two-hour
after anOGTT, fasting and two-hour insulin showed independent
influence on the development of T2DM (IDPP 2006).
In Da Qing 1997 the incidence rate of T2DM in the diet plus
physical activity group was 9.6/100 person years (95% CI 7.2
to 12.0) compared with 15.7/100 person years (95% CI 12.7 to
18.7) in the control group (not adjusted for clustering). When
analysing the incidence rate of T2DM according to fasting plasma
glucose of 7.8 mmol/L or higher, the incidence rate of T2DM
was 5.5/100 person years (95% CI 3.7 to 7.3) in the diet plus
physical activity group compared with 9.6/100 person years (95%
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CI 7.2 to 12.0) in the control group (not adjusted for clustering)
(Da Qing 1997). The HR (adjusted for age and clustering) when
combining diet only, physical activity only and diet plus physical
activity compared with control was 0.49 (95% CI 0.33 to 0.73).
Of the lean participants (BMI at baseline < 25 kg/m2), 16 (34.8%)
out of 46 participants in the diet plus physical activity group com-
pared with 30 (60%) out of 50 in the control group developed
T2DM during the intervention period (when adjusting for clus-
tering 9/26 versus 17/29). Of the obese participants (BMI at base-
line ≥ 25 kg/m2), 42 (52.5%) out of 80 participants in the diet
plus physical activity group compared with 60 (72.3%) out of 83
in the control group developed T2DM during the intervention
period (when adjusting for clustering 24/46 versus 34/47) (Da
Qing 1997).
A total of 263 participants were diagnosed with T2DM during
the six years of intervention; 55 diagnoses (21%) were initially
made by local physicians and confirmed by the city hospital with
an OGTT; 208 (79%) were made as a result of the systematic
OGTTs during the trial (Da Qing 1997).
In DPS 2001 the incidence rate of T2DM after a median of four
years’ intervention was 4.2/100 person years in the diet plus phys-
ical activity group compared with 7.4/100 person years in the
control group. The HR (adjusted for sex, age, BMI, waist cir-
cumference, fasting and two-hour glucose, insulin, homeostatic
model assessment - insulin resistance (HOMA-IR), estimated risk
with The Finnish Diabetes Risk Score (FINDRISC)) was 0.54
(95% CI 0.37 to 0.78) in favour of the diet plus physical activity
group. Incidence and HRs were present for several baseline vari-
ables (sex, age, BMI, waist circumference; fasting plasma glucose;
two-hour glucose; fasting insulin; HOMA-IR and FINDRISC)
(Appendix 19). The interaction between age at baseline as a con-
tinuous variable and intervention effect was statistically significant
(P = 0.0130) (Appendix 19). Baseline glycaemic (fasting and two-
hour glucose) status was directly associatedwith diabetes incidence
in the diet plus physical activity group and the control group.
However, the effect of intervention was independent of glycaemic
status (Appendix 19).
The trial authors performed several subgroup analyses according
to different prognostic baseline variables in DPP 2002 (Appendix
19). Subgroup analyses found that treatment effects did not differ
substantially according to sex, race or ethnic group; however, the
effect of the behaviour-changing intervention was greater among
participants with lower baseline glucose concentrations two hours
after a glucose load.
One publication presented a composite analysis including three
of the included trials (DPS 2001; EDIPS 2009; SLIM 2003). A
total of 749 participants were included in the analyses with a mean
follow-up of 3.1 years (Penn 2013). The HR for the incidence of
T2DM was 0.42, (95% CI 0.29 to 0.60; P < 0.001) in favour of
diet plus physical activity. On average 7.4 people had to undergo
diet plus physical activity for a mean of 3.1 years to prevent one
case of T2DM(number needed to treat for an additional beneficial
outcome 22.9 for one year).
Subgroup analysis: analysing trials according to the duration of
the intervention and diagnostic criteria showed no interaction be-
tween the subgroups (P =0.88 andP= 0.42) (Analysis 2.9; Analysis
2.10) (Appendix 18). Subgroup analyses stratifying the included
trials according to age, ethnicity and obesity showed statistically
significant interactions (Appendix 18) (Analysis 2.11; Analysis
2.12; Analysis 2.13). However, the CIs in these analyses overlap to
a small degree. As a caveat, these observations should be regarded
as hypothesis-generating only. We could not perform subgroup
analyses according to sex and previous gestational diabetes due to
lack of data.
Sensitivity analysis: we could not perform sensitivity analysis ac-
cording to publication status (all included trials were published)
and language of publication (all included trials were published in
English). Sensitivity analysis restricted to only trials with low risk
of selection bias showed a RR of 0.50 (95% CI 0.44 to 0.58; P <
0.00001) (DPP 2002; DPS 2001; EDIPS 2009; HELP PD 2011;
JDPP 2013; Oldroyd 2005; PODOSA 2014), that is, it did not
show substantial differences to including all trials. Analysing trials
performed in Asia showed a RR of 0.67 (95% CI 0.56 to 0.82; P
<0.0001) (Da Qing 1997; IDPP2006; JDPP2013; Kosaka 2005);
for trials performed in Europe, the RR was 0.54 (95% CI 0.41
to 0.72; P < 0.0001) (DPS 2001; EDIPS 2009; Oldroyd 2005;
PODOSA 2014; SLIM 2003).
Three trials reported the incidence of T2DM after an extended
follow-up period (Da Qing 1997; DPP 2002; DPS 2001). One
trial reported the incidence of T2DM after nine years (i.e. five
years after the end of the intervention period). A total of 106 in the
diet plus physical activity group out of 265 participants versus 140
out of 257 participants in the control group were diagnosed with
T2DM (DPS 2001). The incidence of T2DM per 100 person
years was 4.5 (95% CI 3.8 to 5.5) in the diet plus physical activity
group versus 7.2 (95%CI 6.1 to 8.5) in the control group; theHR
(adjusted for sex, age, BMI and two-hour glucose) was 0.61 (95%
CI 0.48 to 0.79; P < 0.001) and the absolute risk reduction was
19%. The number needed to treat to prevent one case of T2DM
was 5.2. In the post-intervention follow-up (median seven years),
62 out of 200 participants in the former diet plus physical activity
group, compared with 68 out of 166 participants in the former
control group were newly diagnosed with T2DM. The incidence
of T2DM in the former diet plus physical activity group was 4.9
(95%CI 3.8 to 6.3) compared with 7.0 (95%CI 5.5 to 8.9) in the
control group (DPS 2001); the HR (adjusted for sex, age, BMI
and two-hour glucose) was 0.67 (95%CI 0.48 to 0.95; P = 0.023).
There was a 32% relative risk reduction and a 15% absolute risk
reduction during the post-intervention follow-up period in favour
of the former diet plus physical activity group (DPS 2001).
Da Qing 1997 reported the incidence of T2DM after 20 and 23
years of follow-up. The HR (adjusted for age and clustering) of
the former diet plus physical activity group (diet only, physical
activity only, diet plus physical activity) versus control after 20
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years of follow-up was 0.57 (95% CI 0.41 to 0.81). After 23
years of follow-up 312 out of 430 participants of the combined
former intervention group versus 124 out of 138 participants in
the former control group developed T2DM. The HR (adjusted
for clustering) was 0.55 (95% CI 0.40 to 0.76; P = 0.001). The
median delay to the onset of T2DM was 3.6 years after 20 years
of follow-up.
During the first seven years the incidence of T2DM in the Dia-
betes Prevention Program Outcomes Study (DPPOS) compared
with the incidence of T2DM in the Diabetes Prevention Program
(DPP) decreased in the control group (-42%) (HR 0.58, 95% CI
0.48 to 0.69) compared with the incidence in the former diet plus
physical activity group (31%) group (HR 1.31, 95% CI 1.07 to
1.61) (see DPP 2002). After 15 years of follow-up in the DPPOS
the incidence of T2DM was reduced by 27% in the former diet
plus physical activity group (HR 0.73, 95% CI 0.65 to 0.83; P <
0.0001) (DPP 2002). Over the 15 years of follow-up the average
annual T2DM incidence rate was 5.2% in the former diet plus
physical activity group and 7.0% in the former control group. At
year 15, the cumulative incidence of T2DM was 562 participants
(62%) in the former control group versus 480 participants (55%)
in the former diet plus physical activity group (DPP 2002). The
median delay to onset of T2DM after 10 years was about four
years by diet plus physical activity compared with control. After
10 years of follow-up (i.e. about seven years after the intervention
period had stopped) 23% in the former diet plus physical activity
group compared with 19% in the former control group had be-
come normoglycaemic (fasting glucose < 6.1 mmol/L, two-hour
glucose < 7.8mmol/L, and no previous diagnosis of T2DM) (DPP
2002). The annual incidence of T2DM in the diet plus physical
activity group rose slowly through year 4 after randomisation, then
declined to steady levels at year 7. The control group had the high-
est incidence of T2DM early in the DPP, with a relatively steady
decline through the end of the DPP and into the DPPOS, and
levelling late in the DPPOS. Post hoc analysis defining T2DM
by HbA1c at 6.5% or higher showed that the incidence rate was
reduced with diet plus physical activity compared with control
during the DPP (4.6 cases/100 person years versus 8.8 cases/100
person years) and at 10 years of follow-up (3.5 cases/100 person
years versus 5.0 cases/100 person years) (DPP 2002). Only par-
ticipants with HbA1c less than 6.5% at baseline were included
in this post hoc analysis (diet plus physical activity N = 932 at
baseline; control N = 922 at baseline) (DPP 2002). During the
total follow-up period there were differences among ethnic groups
in the incidence of diabetes defined as HbA1c 6.5% or higher or
FPG 7.0 mmol/L or higher and/or two-hour plasma glucose 11.1
mmol/L or higher (Appendix 19). Only 26% of the participants
diagnosed with T2DM according to FPG or glucose values after
an OGTT had previous or simultaneous HbA1 6.5% or higher.
On the other hand, 55% of those first attaining an HbA1c 6.5%
or higher had current or previous diagnosis of T2DM defined ac-
cording to FPG 7.0 mmol/L or higher and/or two-hour plasma
glucose 11.1 mmol/L or higher (DPP 2002).
Serious adverse events
Two trials reported serious adverse events (Da Qing 1997; EDIPS
2009). In one trial the investigators provided information that
one out of 51 participants in the diet plus physical activity group
compared with none out of 51 participants in the control group
experienced a serious adverse event (EDIPS 2009). The other trial
reported that no adverse events were experienced in the interven-
tion arms (low-quality evidence) (Da Qing 1997) (Analysis 2.29)).
Four other trials clearly described recording serious adverse events
but they did not present any data (DPP 2002; HELP PD 2011;
IDPP2006; JDPP2013). InDPP 2002 only serious adverse events
related to metformin were reported for each trial arm. We could
not perform any meta-analysis or subgroup analysis due to lack of
data.
Secondary outcomes
Cardiovascular mortality
Seven trials reported data on cardiovascular mortality (Da Qing
1997; DPP 2002; EDIPS 2009; HELP PD 2011; IDPP 2006;
JDPP 2013; Oldroyd 2005). Four of the trials reported that none
of the participants died due to cardiovascular disease (EDIPS
2009; HELP PD 2011; IDPP 2006; JDPP 2013). The number of
participants who died due to cardiovascular disease was low (four
out of 1626 participants in the diet plus physical activity group
compared with four out of 1637 participants in the control group)
(RR 0.94, 95% CI 0.24 to 3.65; P = 0.93; 3263 participants, 7
trials; very low-quality evidence). The 95% prediction interval was
not meaningful (Analysis 2.14).
TSA showed that 0.13% of the diversity-adjusted information size
was accrued to detect or reject a 10% RRR. Diversity was zero,
but we applied a diversity of 20% when calculating the diversity-
required information size as heterogeneity is likely to increasewhen
future trials are included. As only a minor fraction of the diversity-
adjusted required information size to detect or reject a 10% RRR
was accrued, we could not calculate the TSA-adjusted 95% CIs
with a diversity at 20%. Applying diversity at 0%, 0.16% of the
diversity-adjusted information size was accrued to detect or reject
a 10% RRR. Still, we could not calculate the TSA-adjusted 95%
CIs.
We did not perform subgroup or sensitivity analyses due to lack
of data.
One trial reported cardiovascular mortality after the intervention
period had stopped (Da Qing 1997). The trial reported the HR
(adjusted for age and clustering) after a total follow-up period of
20 years (i.e. 14 years after the intervention had stopped) for the
combined former diet only, physical activity only and diet plus
physical activity group versus former control to be 0.83 (95% CI
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0.48 to 1.05). After 23 years of follow-up 78 participants died
as a result of cardiovascular disease; 51 in the combined former
intervention groups versus 27 in the former control group (when
adjusting for clustering 29 versus 15). Cumulative incidences were
11.9% (95% CI 8.8 to 15.0) versus 19.6% (95% CI 12.9 to 26.3;
the HR (adjusted for age and clustering) was 0.59 (95% CI 0.36
to 0.96; P = 0.03). Post hoc analyses comparing women with men
after 23 years of follow-up showed a HR of 0.28 (95% CI to 0.11
to 0.71; P = 0.01) and 0.91 (95% CI 0.50 to 1.65), respectively
(Da Qing 1997).
Non-fatal myocardial infarction
None of the trials reported non-fatal myocardial infarction at the
end of the intervention period. However, the investigators of one
of the included trials reported that none of the participants in
the diet plus physical activity group or the standard treatment
group (51 participants in each intervention group) had a non-fatal
myocardial infarction (EDIPS 2009) - low quality evidence.
The DPP reported the total number of non-fatal cardiovascular
events at the end of the intervention. Non-fatal cardiovascular
events occurred in 24 out of 1079 participants (2.2%) (incidence
rate 9.7 events per 1000 patient-years) in the diet plus physical
activity group compared with 18 out of 1082 participants (1.7%)
with an incidence rate of 7.3 events per 1000 patient-years in the
control group. No substantial differences were seen in the diet plus
physical activity group compared with standard treatment (DPP
2002). The excess of events in the diet plus physical activity group
was due to hospitalisations because of cardiovascular disease and
revascularisation procedures (DPP 2002).
The IDPP also only reported the total number of cardiovascular
events with four (3.3%) out of 120 participants in the diet plus
physical activity group compared with two (1.5%) out of 133
participants in the control group (IDPP 2006).
Da Qing 1997 reported a cumulative incidence of any first cardio-
vascular event to be 5.2 (95% CI 3.0 to 7.3) in the combined in-
tervention group (diet only, physical activity only, diet plus phys-
ical activity) compared with 5.4 (95% CI 1.5 to 9.2) in the con-
trol group during the intervention period. The incidence rate per
100 person years was 0.9 (95% CI 0.2 to 1.6) in the interven-
tion group compared with 0.9 (95% CI 0.5 to 1.3) in the control
group during the intervention period. The HR adjusted for age
and clustering was 0.96 (95% CI 0.76 to 1.44).
From one trial it was apparent that cardiovascular event data were
collected during the interventionperiod, but nodatawere reported
(DPS 2001).
Two trials reported cardiovascular complications after the inter-
vention period had stopped (DaQing 1997; DPS 2001). One trial
reported composite cardiovascular morbidity after a total follow-
up of 10.6 years (i.e. about 6.6 years after the end of intervention);
57 cardiovascular events were reported in 257 participants of the
former diet plus physical activity group compared with 54 events
in 248 participants in the former control group (DPS 2001). The
incidence rate of cardiovascular morbidity was 22.9 in the former
diet plus physical activity group versus 22.0 per 1000 person years
in the former control group; the HR was 1.04( 95% CI 0.72 to
1.51). Men and women had the same incidence in the two inter-
vention groups (DPS 2001). Da Qing 1997 reported the cumu-
lative incidence of any first cardiovascular event to be 40.9 (95%
CI 36.0 to 45.9) in the combined former intervention group (diet
only, physical activity only, diet plus physical activity) compared
with 44.1 (95% CI 35.3 to 53.0) in the former control group after
a total follow-up period of 20 years (i.e. 14 years after the inter-
vention had stopped). The incidence rate per 100 person years
was 2.3 (95% CI 1.9 to 2.7) in the intervention group compared
with 2.5 (95% CI 1.9 to 3.2) in the control group after 20 years
of follow-up. The HR adjusted for age and clustering was 0.98
(95% CI 0.71 to 1.37) (Da Qing 1997).
Non-fatal stroke
None of the trials reported non-fatal stroke at the end of the inter-
vention period. However, the investigators of one of the included
trials reported that none of the participants in the diet plus phys-
ical activity or the control group (51 participants in each inter-
vention group) had a non-fatal stroke (EDIPS 2009) - low quality
evidence.
Several trials reported data on composite cardiovascular events (see
above) (DPP 2002; Da Qing 1997; IDPP 2006).
Amputation of lower extremity
None of the trials reported amputationof the lower extremity at the
end of the intervention period. However, the investigators of one
of the included trials reported that none of the participants in the
diet plus physical activity or the control group (51 participants in
each intervention group) had an amputationof the lower extremity
(EDIPS 2009).
Several trials reported data on composite cardiovascular events (see
above) (DPP 2002; Da Qing 1997; IDPP 2006).
Blindness or severe vision loss
We did not identify trials with data on blindness or severe vision
loss for this comparison.
One trial reported severe retinopathy after 20 years of follow-
up. Severe retinopathy occurred in 31 participants out of 238 in
the intervention group (cumulative incidence 9.2%) compared
with 17 out of 93 in the control group (cumulative incidence
16.2%) (Da Qing 1997). The HR (adjusted for clustering and
age) was 0.53 (95% CI 0.29 to 0.99; P = 0.048) in favour of
the intervention (Da Qing 1997). All participants with severe
retinopathy had developed T2DM by the time the retinopathy
was recognised (Da Qing 1997).
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One trial reported an aggregate outcome of microvascular disease
(nephropathy, retinopathy and neuropathy) after 15 years of fol-
low-up (DPP 2002). The prevalence of microvascular outcomes
after 15 years did not differ substantially between the interven-
tion and control group despite group differences in the incidence
of T2DM (former diet plus physical activity group 11.3% (95%
CI 10.1 to 12.7) compared with former control 12.4% (95% CI
11.1 to 13.8)). The women but not the men in the former diet
plus physical activity group experienced a reduction in microvas-
cular disease (RR 0.79, 95% CI 0.64 to 0.98) compared with the
former control group. There were no substantial differences in
the treatment effects on aggregate microvascular complications in
subgroups defined by age or ethnicity, except that Hispanic Amer-
icans had a lower microvascular disease prevalence in the former
diet plus physical activity group than in the former control group
(RR 0.43, 95% CI 0.20 to 0.91) (DPP 2002).
End-stage renal disease
None of the trials reported end-stage renal disease at the end of
the intervention period.
One trial reported renal replacement therapy or death due to kid-
ney failure after 20 years of follow-up (i.e. 14 years after the inter-
vention had stopped) . Seven out of 441 participants (when ad-
justing for clustering: 4 out of 252 participants) of the combined
former intervention group compared with two out of 136 partic-
ipants (when adjusting for clustering 1 out of 78 participants) in
the former control group developed end-stage renal disease (Da
Qing 1997).
Non-serious adverse events
One trial reported that nonon-serious adverse eventswere reported
(diet plus physical activity 0/126 (adjusted for clustering 0/72
versus control 0/76)) (DaQing 1997). Another trial reported three
(3.6%) out of 84 participants in the diet plus physical activity
group compared with four (4.8%) out of 83 participants in the
control group experienced a non-serious adverse event (PODOSA
2014).
Hypoglycaemia
Two trials reported that none of the participants experienced hy-
poglycaemia (IDPP 2006: diet plus physical activity 0/133 com-
pared with control 0/136; EDIPS 2009: diet plus physical activity
0/51 compared with control 0/51).
Health-related quality of life
TheDPP trial applied the 36-item Short-Form (SF-36) to evaluate
the health utility index (SF-6D), physical component summaries
(PCS) and mental component summaries (MCS). Minimal im-
portant difference (MID) was defined as a difference in scores be-
tween groups of at least 3% (DPP 2002). A total of 1070 partic-
ipants from the diet plus physical activity group and 1074 par-
ticipants from the standard treatment group were included (DPP
2002). In both the diet plus physical activity arm as well as the
control arm HrQoL summary scores worsened during the trial,
but the decline for SF-6D (P < 0.05) and PCS (P < 0.01) was
slower in diet plus physical activity participants compared to the
changes in the control group; however, none reached the MID of
3%. After a mean of 3.2 years of follow-up there were improve-
ments in the SF-6D (0.008; P = 0.04) in the diet plus physical ac-
tivity group compared with control, however, the MID of 3% be-
tween the intervention groups was not achieved. The PCS (1.57;
P < 0.0001) also improved in the diet plus physical activity group
compared with control (DPP 2002). Again, the MID between
the intervention groups was not achieved. MCS improved in the
placebo group compared with the diet plus physical activity group
during the intervention period with 0.28 (SD 0.32). No exact P-
value was provided, the value was more than 5%. The MID was
not achieved (DPP 2002). The overall quality of evidence for this
outcome measure was very low.
The investigators from the PODOSA 2014 reported that the par-
ticipants were asked how healthy they were during the trial. The
replies were not analysed at the end of the intervention.
One trial stated in the design article that HrQoL measured with
the SF-36 would be assessed. However, no data were available
(HELP PD 2011). One publication stated that HrQoL was mea-
sured, but no data were reported (EDIPS 2009). According to the
investigators HrQoL was not analysed (EDIPS 2009).
Time to progression to type 2 diabetes
One trial reported data on the time to progression to T2DM in
the post-interventional follow-up period (median of seven years).
Among the participants who developed T2DM the median time
to the onset of T2DM was 15 years (95% CI 13 to 17) in the
former intervention group compared with 10 years (95% CI 8
to 12 years) in the former control group (95% CI 8 to 12 years)
(DPS 2001).
Measures of blood glucose control
Fasting glucose
Ten trials reported FPG (Da Qing 1997; DPP 2002; DPS 2001;
EDIPS 2009; HELP PD 2011; IDPP 2006; JDPP 2013; Oldroyd
2005; PODOSA 2014; SLIM 2003). Effect-estimates in both ran-
dom-effects and fixed-effect models showed differences (random
MD -0.17 mmol/L, 95% CI -0.27 to -0.06; P = 0.003; fixed MD
-0.21 mmol/L, 95% CI -0.27 to -0.15; P < 0.00001; 10 trials;
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3530 participants; Analysis 2.18). The 95% prediction interval
ranged between -0.43 mmol/L to 0.09 mmol/L.
TSA showed that diversity-adjusted information size was accrued
to detect or reject a difference in fasting plasma glucose at -0.17
mmol/L in favour of the diet plus physical activity group.Diversity
was 70%.
Subgroup analyses: according to duration of the intervention ((≥
4 years) versus trials with short duration (< 4 years)), diagnostic
criteria of participants with IGT versus other; age (included par-
ticipants ≥ 50 years versus < 50 years); ethnicity (Asian versus
predominantly White); morbidity (BMI ≥ 30 kg/m2 versus < 30
kg/m2); showed no statistically significant interactions (Appendix
18). We could not perform subgroup analyses according to sex
and previous gestational diabetes due to lack of data.
Sensitivity analysis: we could not perform sensitivity analyses ac-
cording to publication status and language of publication as all
included trials were published in English. Sensitivity analysis re-
stricted to trials with low risk of selection bias showed a MD of
-0.14 mmol/L (95% CI -0.26 to -0.01; P = 0.03) (DPP 2002;
DPS 2001; EDIPS 2009;HELP PD 2011; JDPP 2013; Oldroyd
2005; PODOSA 2014). Analysing trials according to geographies
for trials performed in Asia showed a MD of -0.18 mmol/L (95%
CI -0.49 to 0.13; P = 0.15) (Da Qing 1997; IDPP 2006; JDPP
2013). Trials performed in Europe showed a MD of -0.08 mmol/
L (95% CI -0.80 to 0.08; P = 0.15) (DPS 2001; EDIPS 2009;
Oldroyd 2005; PODOSA 2014; SLIM 2003). One trial reported
FPG after 20 years of follow-up (Da Qing 1997). The mean FPG
was 7.9 (SD 3.2) in 260 participants (149 participants when ad-
justing for clustering) in the combined former intervention groups
compared with 8.7 (SD 3.1) in 80 participants (46 participants
when adjusting for clustering) in the former control group (Da
Qing 1997). Another trial reported FPG after 15 years of follow-
up. FPG was 6.8 mmol/L (SD 2.0) in 751 participants in the for-
mer diet plus physical activity group compared with 6.8 mmol/L
(SD 1.9) in 780 participants in the former control group (DPP
2002).
Glucose two hours after an oral glucose load
Nine trials reported glucose values two hours after an oral glucose
load (Da Qing 1997; DPP 2002; DPS 2001; EDIPS 2009; IDPP
2006; JDPP 2013; Oldroyd 2005; PODOSA 2014; SLIM 2003).
Two hours after an oral glucose load glucose values were higher
in the control group compared with the diet plus physical activity
group (random MD -0.46 mmol/L, 95% CI -0.79 to -0.12; P
= 0.008; fixed MD -0.29 mmol/L, 95% CI -0.44 to -0.15; P
< 0.00001; 9 trials; 3261 participants; Analysis 2.24). The 95%
prediction interval ranged between -1.41 mmol/L to 0.49 mmol/
L.
TSA showed that diversity-adjusted information size was accrued
to detect or reject a difference in two-hour plasma glucose at -
0.46 mmol/L in favour of the diet plus physical activity group.
Diversity was 82%.
Subgroup analyses: according to duration of the intervention ((≥
4 years) versus trials with short duration (< 4 years)), ethnicity
(Asian versus predominantly white); morbidity (BMI≥ 30 kg/m2
versus < 30 kg/m2); showed no statistically significant interactions
(Appendix 18). The subgroups of trials according to age (≥ 50
years versus < 50 years) showed significant interaction between
subgroups (P = 0.003). However, the CIs in these analyses overlap
to a small degree. As a caveat, these observations should be regarded
as hypothesis-generating only. We could not perform subgroup
analyses according to sex, diagnostic criteria of participants with
IGT versus other and previous gestational diabetes due to lack of
data.
Sensitivity analysis: we could not perform sensitivity analysis ac-
cording to publication status (all included trials were published)
and language of publication (all included trials were published in
English). Sensitivity analysis restricted to trials with low risk of
selection bias showed a MD of -0.14 mmol/L (95% CI -0.26 to -
0.01; P = 0.03) (DPP 2002;DPS 2001; EDIPS 2009; JDPP 2013;
Oldroyd 2005; PODOSA 2014). Analysing trials performed in
Asia showed a MD of -1.10 mmol/L (95% CI -2.3 to 0.11; P =
0.07) (Da Qing 1997; IDPP 2006; JDPP 2013). Trials performed
in Europe showed aMD of -0.35 mmol/L (95% CI -0.78 to 0.08;
P = 0.11) (DPS 2001; EDIPS 2009; Oldroyd 2005; PODOSA
2014).
One trial reported glucose values two hours after an OGTT after
20 years of follow-up (Da Qing 1997). The mean two-hour glu-
cose value was 11.5 mmol/L (SD 5.0) in 100 participants (57 par-
ticipants when adjusting for clustering) in the combined former
intervention groups compared with 13.8 mmol/L (SD 5.8) in 28
participants (16 participants when adjusting for clustering) in the
former control group (Da Qing 1997).
HbA1c
Four trials reported data on HbA1c (DPP 2002; DPS 2001;
EDIPS 2009; SLIM 2003).
In the random-effects model the MD was -0.11% (95% CI -0.23
to 0.02; P = 0.09; 4 trials; 2453 participants) (Analysis 2.31), in
the fixed-effect model the MD was -0.18%, 95% CI -0.23 to -
0.13; P < 0.00001). The 95% prediction interval ranged between
-1.64% and 1.42%.
TSA showed that 36.5% diversity-adjusted information size was
accrued to detect or reject a HbA1c difference of -0.11% between
the intervention groups. Alfa-spending-adjusted 95% CI was -
0.34 to 0.12. Diversity was 86%.
Subgroup analysis: analysing trials according to the duration of
the intervention (≥ 4 years) versus trials with short duration (<
4 years) showed no interaction between subgroups (P = 0.99) (
Analysis 2.34; Appendix 18). Analysing trials according to theBMI
≥ 30 kg/m2 versus < 30 kg/m2 showed no interaction between
37Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
subgroups (P = 0.10) (Analysis 2.35). All trials reporting HbA1c
included people with IGT, all included participants aged 50 years
or more, and all included only white or mainly white people (DPP
2002; DPS 2001; EDIPS 2009; SLIM 2003).
Sensitivity analysis: we could not perform sensitivity analysis ac-
cording to publication status (all included trials were published)
and language of publication (all included trials were published in
English). Sensitivity analysis restricted to only trials with low risk
of selection bias showed MD -0.15%, 95% CI -0.27 to -0.04; P
= 0.009 (DPP 2002; DPS 2001; EDIPS 2009). Analysing trials
according to geographies in trials performed in Europe showed
a MD of -0.02%, 95% CI -0.26 to 0.21; P = 0.84 (DPS 2001;
EDIPS 2009; SLIM 2003).
One trial reported theHbA1c after 20 years of follow-up (DaQing
1997). The mean HbA1c was 7.34% (SD 1.7) in 271 participants
(155 participants when adjusting for clustering) in the combined
former intervention group compared with 7.83% (SD 2.0) in 81
participants (46 participants when adjusting for clustering) in the
former control group (Da Qing 1997). Another trial reported
the HbA1c after 15 years of follow-up. The mean HbA1c was
6.2% (SD 1.2) in 751 participants in the former diet plus physical
activity group compared with 6.3% (SD 1.2) in 780 participants
in the former control group (DPP 2002).
Socioeconomic effects
During DPP 2002, the diet plus physical activity groups were sub-
stantially more expensive than the standard treatment interven-
tion. Direct medical costs of the interventions during the DPP
were estimated to be USD 3628 for the diet plus physical activity
group versus USD 184 for the control group. Direct medical costs
(hospital days, emergency room visits, urgent care visits, outpa-
tient visits, calls to providers, supplies, laboratory tests, and pre-
scription medications within the intervention groups) outside the
DPP were estimated to be USD 5182 for the diet plus physical
activity group compared with USD 5680 for the control group.
However, due to the high direct medical costs of T2DM, the diet
plus physical activity intervention was estimated to be cost-effec-
tive. The quality of evidence was low. From the perspective of the
health system (direct medical costs of the interventions plus direct
medical costs of care outside the trial) the cost was USD 31,500
per quality-adjusted life years (QALY) gained with diet plus phys-
ical activity compared with control. From the perspective of soci-
ety (direct medical costs plus non medical costs (expenditure on
medical treatment but not involving purchase of medical services
or products) plus indirect costs (costs to society due to morbidity
and mortality, e.g. absent from work due to medical treatment))
the cost was USD 51,600 perQALY gained with diet plus physical
activity compared with control.
PODOSA 2014 reported that the extra mean cost for the diet plus
physical activity group was GBP 1126 (95% CI -2414 to 4666)
after three years, with GBP 615 of the difference being dietitian
costs. Primary-care visits and costs did not differ between groups,
but there were more outpatient visits in the intervention group
(costing GBP 327 more than in the control group).
IDPP 2006 estimated directmedical costs of interventions over the
three-year trial period to be USD 61 per participant in the control
group compared with USD 225 in the diet plus physical activity
group. The cost-effectiveness to prevent one case of diabetes with
diet plus physical activity was USD 1052.
In HELP PD 2011, direct medical costs for each participant in the
diet plus physical activity group were USD 850 compared with
USD142 in the control group. Direct costs of care outside the trial
were USD 5177 for the diet plus physical activity group compared
with USD 7454 for the control group.
The overall quality of evidence was low for this outcome measure.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Diet versus physical activity or standard treatment for prevention or delay of type 2 diabetes mellitus
Population: people at increased risk of developing type 2 diabetes mellitus
Settings: outpat ients
Intervention: dietary intervent ion
Comparison: physical act ivity or standard treatment
Outcomes Physical activity Diet or standard treat-
ment
Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
All- cause mortality
Follow-up: 6 years
See comment See comment See comment 530 (1) ⊕©©©
very lowa
3/ 130 part icipants died
in the diet group vs 0/
141 part icipants in the
physical act ivity group
3/ 133 part icipants died
in the standard treat-
ment group
Incidence of type 2 di-
abetes mellitus
Def init ion: WHO 1985
criteria
Follow-up: 6 years
See comment See comment See comment 530 (1) ⊕©©©
very lowa
57/ 130 part icipants de-
veloped T2DM in the diet
group vs 58/ 141 part ici-
pants in the physical ac-
t ivity group
90/ 133 part icipants de-
vel-
oped T2DM in the stan-
dard treatment group
Serious adverse events
Follow-up: 6 years
See comment See comment See comment 530 (1) ⊕©©©
very lowa
No (serious) adverse
events occurred in any
group
Cardiovascular mortal-
ity
Follow-up: 6 years
See comment See comment See comment 530 (1) ⊕©©©
very lowa
No part icipants in any
group died of cardiovas-
cular reasons
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Non- fatal myocardial
infarction/stroke
Not reported
Health- related quality
of life
Not reported
Socioeconomic effects Not reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io; T2DM: type 2 diabetes mellitus; WHO: World Health Organizat ion
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
∗Assumed risk was derived f rom the event rates in the comparator groups
aDowngraded by three levels because of risk of report ing and other bias and serious imprecision (very sparse data) - see
Appendix 15
4
0
D
ie
t,
p
h
y
sic
a
l
a
c
tiv
ity
o
r
b
o
th
fo
r
p
re
v
e
n
tio
n
o
r
d
e
la
y
o
f
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
a
n
d
its
a
sso
c
ia
te
d
c
o
m
p
lic
a
tio
n
s
in
p
e
o
p
le
a
t
in
c
re
a
se
d
risk
o
f
d
e
v
e
lo
p
in
g
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Physical activity versus standard treatment for prevention or delay of type 2 diabetes mellitus
Population: people at increased risk of developing type 2 diabetes mellitus
Settings: outpat ients
Intervention: physical act ivity
Comparison: standard treatment
Outcomes Standard treatment Physical activity Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
All- cause mortality
Follow-up: 3 and 6 years
See comment See comment See comment 397 (2) ⊕©©©
very lowa
1 trial reported that 0/ 141
part icipants in the phys-
ical act ivity group com-
pared with 3/ 133 part ic-
ipants in the standard
treatment group died (Da
Qing 1997)
1 trial reported that 3/ 84
part icipants in the physi-
cal act ivity group and 1/
39 part icipants in the stan-
dard treatment group died
(Hellgren 2016 - data pro-
vided by trial authors)
Incidence of type 2 di-
abetes mellitus
Def init ion:
• 1 trial: FPG≥ 7.8
mmol/ L or a 2-hour
plasma glucose ≥ 11.1
mmol/ L af ter a 75 g
OGTT (Da Qing 1997).
• 1 trial FPG > 6.9
mmol/ L and/ or 2-hour
plasma glucose
concentrat ion > 12.1
See comment See comment See comment 397 (2) ⊕©©©
very lowa
1 trial reported that 58/
141 part icipants in the
physical act ivity group
compared with 90/ 133
part icipants in the stan-
dard treatment group de-
veloped T2DM (Da Qing
1997)
1 trial reported that 10/ 84
part icipants in the phys-
ical act ivity group com-
4
1
D
ie
t,
p
h
y
sic
a
l
a
c
tiv
ity
o
r
b
o
th
fo
r
p
re
v
e
n
tio
n
o
r
d
e
la
y
o
f
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
a
n
d
its
a
sso
c
ia
te
d
c
o
m
p
lic
a
tio
n
s
in
p
e
o
p
le
a
t
in
c
re
a
se
d
risk
o
f
d
e
v
e
lo
p
in
g
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
mmol/ L (Hellgren
2016)
Follow-up: 3 and 6 years
pared with 7/ 39 part ic-
ipants in the standard
treatment group devel-
oped T2DM (Hellgren
2016)
Serious adverse events
Follow-up: 3 and 6 years
See comment See comment See comment 397 (2) ⊕©©©
very lowa
1 trial reported no (seri-
ous) adverse events oc-
curred (Da Qing 1997).
1 trial reported that 3/ 66
part icipants in the phys-
ical act ivity group com-
pared with 1/ 39 part ic-
ipants in the standard
treatment group experi-
enced a serious adverse
event (Hellgren 2016 -
data provided by trial au-
thors)
Cardiovascular mortal-
ity
Follow-up: 6 years
See comment See comment See comment 274 (1) ⊕©©©
very lowa
No part icipants in any
group died of cardiovas-
cular reasons
Non- fatal myocardial
infarction/stroke
Descript ion: non-fatal
myocardial infarct ion/
stroke
Follow-up: 3 years
See comment See comment See comment 123 (1) ⊕©©©
very lowa
1 trial reported that 0/ 66
part icipants in the phys-
ical act ivity group com-
pared with 3/ 31 part ic-
ipants in the standard
treatment group experi-
enced a non-fatal myocar-
dial infarct ion (Hellgren
2016 - data provided by
trial authors)
1 trial reported that 1/ 66
part icipants in the phys-
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ical act ivity group com-
pared with 1/ 31 part ic-
ipants in the standard
treatment group experi-
enced a non-fatal stroke
(Hellgren 2016 - data pro-
vided by trial authors)
Health- related quality
of life
Def init ion: measured by
two quest ions (grading
total physical and men-
tal health f rom 1 to 7;
grading general health
f rom 1 (best) to 5 (very
bad))
Follow-up: 3 years
See comment See comment See comment 123 (1) ⊕©©©
very lowa
27%, 43% and 29% of
part icipants in the physi-
cal act ivity group experi-
enced worse, unchanged
and better health-related
quality of lif e, respect ively
(Hellgren 2016 - data pro-
vided by trial authors)
35%, 43% and 22% in
the standard treatment
group experienced worse,
unchanged and better
health-related quality of
lif e, respect ively (Hellgren
2016 - data provided by
trial authors)
Socioeconomic effects Not reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; FPG: f ast ing plasma glucose; OGTT: oral glucose tolerance test; RR: risk rat io; T2DM: type 2 diabetes mellitus
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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∗Assumed risk was derived f rom the event rates in the comparator groups
aDowngraded by three levels because of risk of report ing and other bias and serious imprecision (very sparse data) - see
Appendix 16
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This Cochrane Review investigated the effects of diet or physical
activity, or both in people at increased risk of developingT2DM.
We included 12 trials with a total of 5238 participants. We judged
all trials as at unclear or high risk of bias in one or more ’Risk of
bias’ domains. The amount of evidence on patient-important out-
comes was limited. The meta-analysis comparing diet plus physi-
cal activity with standard or no treatment showed moderate-qual-
ity evidence of a reduced incidence of T2DM after the end of the
intervention. The diversity-adjusted required information size of
TSA to confirm a 10% RRR was reached. The reporting on mor-
tality and macrovascular as well as microvascular diabetes compli-
cations was insufficient and we judged the quality of evidence for
these outcome measures as low or very low.
Overall completeness and applicability of
evidence
The diagnosis of intermediate hyperglycaemia varied among trials
and some trials used a definition that may have included partic-
ipants judged to be euglycaemic or having T2DM. However, all
trials except one had IGT as an inclusion criterion (HELP PD
2011). The results of this reviewmight therefore not be applicable
to people defined by other glycaemic categories of intermediate
hyperglycaemia.
Detailed information about the participants was lacking in most
trials. The included trials applied different intensities of diet and
physical activity. In our review, all programmes were conducted
in adults. Therefore, our results may not apply to children and
adolescents. A potential selection bias exists as more healthy and
motivated people may participate in a clinical trial. However, a
Cochrane Review observed that clinical outcomes in people par-
ticipating in RCTs are comparable to similar individuals outside
trials (Vist 2008). However, the implementation of diet and phys-
ical activity programmes outside a clinical trial often shows less
pronounced effects in surrogate markers (e.g. glycaemic measures)
(Ashra 2015).
Three of the included trials contributed about 70% of all data
(Da Qing 1997; DPP 2002; DPS 2001). Reporting of complica-
tions associated with T2DM during the intervention period was
lacking. However, after 23 years of follow-up, all-cause mortality
and cardiovascular mortality were reduced in one study (Da Qing
1997). This effect was only found in women. However, the trial
found a delay in the onset of T2DM of 3.6 years (Da Qing 1997).
The only data on microvascular complications were available after
an extended follow-up period. There was discrepancy in the long-
term effects of the diet plus physical activity intervention in the
DPP 2002 and the Da Qing 1997 follow-up. Da Qing 1997 re-
ported a reduction of severe retinopathy after 20 years of follow-up
in the former intervention group (HR 0.53, 95% CI 0.29 to 0.99;
P = 0.048). In DPP 2002 there was no influence on microvascular
outcomes after 15 years of follow-up.
The three major trials all included people with IGT. Unfortu-
nately, similar trials have not been performed in people with IFG
ormoderately elevatedHbA1c.One of the excluded trials included
379 overweight Japanese people with IFG only. However, the in-
tervention group and the control group received similar diet and
physical activity advice, but with less frequent visits in the control
group, and was consequently not included in this review (Saito
2011). The trial did not find an impact on the risk of T2DM
in participants with isolated IFG after 36 months of intervention
(HR 1.17, 95% CI 0.50 to 2.74) (Saito 2011). However, because
of the technical complexities of performing an OGTT compared
with measuring fasting glucose or HbA1c, most people with inter-
mediate hyperglycaemia are expected to be diagnosed with these
modalities (International Expert Committee 2009). It is therefore
unclear whether similar effects in reducing or delaying T2DM in-
cidence will be found in the majority of people with intermediate
hyperglycaemia.
The number of participants diagnosed with T2DM in the control
groups in the included trials was higher than that estimated from
observational studies (Cheng 2006; Morris 2013). This might be
explained by the regular glycaemic testing of people participating
in a RCT. Therefore, many of those diagnosed with T2DM in a
RCT may not be diagnosed in a ’real-world’ setting.
Most trials included participants aged above 50 years. In bothDPP
2002 and DPS 2001, diet plus physical activity was most effective
in reducing T2DM incidence in people aged 60 years or more. A
person aged 65 years or more with newly diagnosed T2DM with
a HbA1c of 7% has a theoretical life-time risk of blindness or end-
stage renal disease of less than 0.5% (Vijan 1997). The reason for
the lack of reliable data on diabetic complications T2DM in our
review might be explained by the low rate of these complications
in the people with the largest intervention effect and the time it
takes to develop these complications (Vijan 1997).
In all trials reporting the direct costs of the diet and physical activ-
ity programmes, the intervention was significantly more expensive
than control (DPP 2002; EDIPS 2009; HELP PD 2011; IDPP
2006). However, the diet plus physical activity intervention pro-
grammeswere estimated to be cost-effective due to the reductionof
T2DM with these programmes (DPP 2002). On the other hand,
the interventions in the included trials would be challenging and
costly to implement in daily life. In general, the adherence to diet
and lifestyle advice was low in the included trials, and might even
be lower in a non-trial setting. A more cost-effective and long-
lasting solution could be to enable people to undertake physical
activity as part of their everyday life, and regulation of food costs.
Not only people with intermediate hyperglycaemia but also peo-
ple with manifest T2DM are recommended to increase physical
45Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
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activity and lower calorie intake (ADA 2017). However, the only
long-term RCT assessing the effects of diet plus physical activity
in people with T2DM was stopped early due to futility after a
median follow-up of 9.6 years (Look AHEAD 2013). In addition,
long-term follow-up data for DPP 2002 have not shown any sub-
stantial effect on mortality or diabetes-related complications after
15 years of follow-up, even though the incidence of T2DM was
reduced with the diet plus physical activity intervention.
Quality of the evidence
For all trials, we contacted one or more trial authors to obtain
supplemental information on baseline data, bias domains and out-
comes. In addition, we asked investigators to confirmour extracted
outcomes. Unfortunately only four investigators (33%) of the in-
cluded trials either just confirmed a question or provided addi-
tional data that could be implemented for the ’Risk of bias’ assess-
ment or the meta-analyses of outcomes (EDIPS 2009; Hellgren
2016; IDPP 2006; PODOSA 2014).
We included trials with an intervention duration of two years or
more. Trials with shorter duration could have been included, but
as we were focusing on patient-important outcomes we did not
include such short-term studies (D-CLIP; DH!AAN; Hesselink
2013; Huang 2007; J-DOIT; Kawahara 2008; Kinmonth 2008;
Lindahl 1999; Marrero 2016; Page 1992; Ramachandran 2013;
Sathish 2017; Savoye2007;Thompson 2008;Villareal 2006; Yates
2011).
None of the 11 included trials in our reviewwas classified as having
low risk of bias in all ’Risk of bias’ domains. The description
of randomisation and allocation was insufficient in 33% of the
included trials (Da Qing 1997; IDPP 2006; Kosaka 2005; SLIM
2003). Only one trial was classified as having low risk of bias for
selective outcome reporting (Hellgren 2016). The remaining trials
had insufficient reporting of one or more outcomes of relevance
to our review. However, we were able to assess one or more of our
predefined outcomes in all of the included trials.
For the comparisons ’diet only versus comparator’ and ’physical
activity only versus comparator’, we judged the quality of evidence
to be very low because of sparse data and various risks of bias.
For the comparison ’diet plus physical activity’ more data were
available. However, again most outcome measures were associated
with low- or very low-quality evidence.
Potential biases in the review process
We were unable to draw funnel plots to assess small-study bias
due to lack of data for most outcomes. However, for one of our
primary outcomes - the incidence of T2DM -wewere able to draw
a funnel plot, which did not indicate publication bias. If more
data had been available on the patient-important outcomes of our
review, we would have performed more meta-analyses. Many of
the included trials were not designed or powered to detect our
predefined patient-important outcomes. For the performed meta-
analyseswe investigated heterogeneity and the potential reasons for
it through subgroup and sensitivity analyses. We were dealing with
a substantially heterogeneous group of trials. Our meta-analyses
were limited by the inability to use individual participant data to
assess whether distinct clinical characteristics may have influenced
the effect estimates of the interventions. To reduce the risk of
random errors, we conducted TSA on all predefined outcomes and
calculated prediction intervals, whenever possible. We contacted
all trial authors for clarification if one of the bias domains was not
adequately reported. Several trials were published in more than
one publication, which for some trials made it difficult to separate
the primary publication from companion papers. We excluded
trials including participants with IGT due to other conditions
(e.g. cystic fibrosis or glucocorticoid treatment).We included trials
with a minimum duration of two years in order to detect clinically
relevant differences for the predefined outcomes. Even though we
focused on long-term trials, the reporting of clinical outcomes in
the included trials was poor. Two review authors carried out data
extraction. However, the review authors extracting the data were
not blinded as to which trial they were extracting data from.
Agreements and disagreements with other
studies or reviews
We conducted an extensive search for trials, including publications
in all languages and tried to obtain additional data on all trials. In-
vestigators of three trials provided additional information (EDIPS
2009; Hellgren 2016; PODOSA 2014). We looked for additional
trials and cross-checked our data with other meta-analyses and
Cochrane Reviews of relevance (Aguiar 2014; Ali 2012; Ashra
2015; Balk 2015; Cardona-Morrell 2010; Dunkley 2014; Gillett
2012; Gillies 2007; Glechner 2015; Gong 2015; Hopper 2011;
ICER 2016; Merlotti 2014a; Merlotti 2014b; Modesti 2016;
Norris 2005; Santaguida 2005; Schellenberg 2013; Selph 2015;
Stevens 2015; Yamaoka 2005; Yates 2007; Yoon 2013; Yuen 2010;
Zhang 2017; Zheng 2016). However, several publications defined
the increased risk of T2DM development to be associated with ad-
ditional covariates, with intermediate hyperglycaemia being only
one risk factor (e.g. obesity, metabolic risk factors, family history
of diabetes - Ali 2012; Ashra 2015; Balk 2015; Cardona-Morrell
2010; Dunkley 2014; Merlotti 2014a; Merlotti 2014b; Modesti
2016; Schellenberg 2013; Zhang 2017). Furthermore, these sys-
tematic reviews excluded trials with the same intensity in diet and
physical activity, where the only difference between the interven-
tion arms was the approach on how to motivate the participants.
We excluded these trials (e.g. evaluating mobile text messages ver-
sus individual sessions, or one visit a year versus four visits a year)
because this setting addresses another research question, and it
is important to clarify whether the interventions work as such.
Also, our review is the first focusing on patient-important out-
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comes. Therefore, we only included trials with an intervention
duration of two years or more. Even though we focused on longer-
term trials, the reporting on patient-important outcomes was still
lacking. Observational data of trials with extended follow-up pe-
riods could also not prove long-term beneficial effects regarding
patient-important outcomes (DPP 2002; DPS 2001). The only
trial reporting long-term benefits was Da Qing 1997, however,
few participants were included in the analyses. In addition, these
observational extension periods of interventional trials need to be
interpreted with caution because the long-term cohort may not
be comparable with the originally randomised participants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is moderate-quality evidence that diet plus physical activ-
ity reduces or delays the risk of type 2 diabetes mellitus in peo-
ple with impaired glucose tolerance. Whether there is the same
intervention effect in people with increased risk defined by other
glycaemic variables, such as impaired fasting glucose or elevated
glycosylated haemoglobin A1c (HbA1c) levels, needs to be clari-
fied. There is no clear evidence whether diet alone or physical ac-
tivity alone influences the risk of type 2 diabetes mellitus. Data on
patient-important outcomes such as mortality, macrovascular and
microvascular diabetic complications and health-related quality of
life are sparse.
Implications for research
It remains to be clarified whether the reduction in the incidence of
type 2 diabetes mellitus with diet plus physical activity in people
with impaired glucose tolerance could decrease the long-term risk
of complications associated with type 2 diabetes mellitus. Future
trials should also investigate the effect of diet plus physical activity
in people with impaired fasting glucose or moderately elevated
HbA1c and focus on patient-important outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Da Qing 1997
Methods Cluster-randomised, controlled, clinical trial, randomisation ratio 1:1:1:1
Participants Inclusion criteria: IGT (WHO 1985)
Exclusion criteria: -
Diagnostic criteria: 2-h plasma glucose after an OGTT ≥ 7.8 mmol/L and < 11.1
mmol/L (WHO 1985).
No explicit mention of FPGmeasurements, but FPG should be < 7.8 mmol/L according
to the criteria suggested by the trial authors
Interventions Number of study centres: 33 healthcare clinics
Treatment before study: none
Run-in period: none
Extension period: yes, extended follow-up 17 years after the end of intervention
Outcomes Composite outcome measures reported: yes (Quote from publication: “CVD events
were defined as the first nonfatal or fatal cardiovascular events including myocardial
infarction, sudden death, stroke, or amputation”)
Study details Trial terminated early: no
Publication details Language of publication: English and Chinese
Funding: non-commercial funding
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “The trial was designed as a controlled clinical trial in which
subjects were randomized by clinic to investigate the incidence of diabetes in people with
IGT”
Notes Each clinic, rather than each participant, was randomised to carry out the intervention
on each of the eligible subjects attending that clinic according to one of the 4 specified
intervention protocols
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from publication: “subjects were
randomised by clinic”
Comment: insufficient information about
the allocation concealment
Allocation concealment (selection bias) Unclear risk Comment: no information. Physical activ-
ity (expressed in units/d) was significantly
higher at baseline in the DPPA group than
61Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Da Qing 1997 (Continued)
in the control group
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Comment:no blinding but judged that the
outcome was not likely to be influenced by
lack of blinding, investigator-assessed out-
come measurement
Blinding of participants and personnel
(performance bias)
amputation, blindness/severe vision loss,
end-stage renal disease
Low risk Quote from publication: “Investigators
who assessed the outcomes at follow-up
were masked to treatment allocation. Pa-
tients and other investigators were not
masked.”
Comment: sufficient blinding of outcome
assessment, investigator-assessed outcome
measurement. Not assessed during the in-
tervention period
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote from publication: “Investigators
who assessed the outcomes at follow-up
were masked to treatment allocation. Pa-
tients and other investigators were not
masked.”
Comment: sufficient blinding of outcome
assessment after the end of intervention.
Assume investigators were not blinded dur-
ing the trial due to the design of the
study. Investigator-assessed outcome mea-
surement
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measurement. Assume investigators were
not blinded during the trial due to the de-
sign of the trial. Outcome unlikely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
non-serious adverse events
High risk Comment: investigator-assessed and self-
reported outcome measurement. Assume
participants and investigators were not
blinded during the trial due to the design
of the study. The outcome could be influ-
enced by lack of blinding
Blinding of participants and personnel
(performance bias)
serious adverse events
Low risk Comment: investigator-assessed outcome
measurement. Assume investigators were
not blinded during the trial due to the de-
sign of the study. Outcome unlikely to be
influenced by lack of blinding
62Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Da Qing 1997 (Continued)
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “Investigators
who assessed the outcomes at follow-up
were masked to treatment allocation. Pa-
tients and other investigators were not
masked.” and: “From a review of this infor-
mation, two physicians, blinded to the par-
ticipant’s intervention, independently de-
termined and assigned the underlying cause
of death. A third physician (also blinded
to the intervention) settled any disagree-
ments.Only a general classificationof cause
of death was used (stroke, heart disease or
any other CVD, cancer, injuries, diabetes
or renal, and other).”
Comment: sufficient blinding of outcome
assessment after the end of intervention.
Assume investigators were not blinded dur-
ing the trial due to the design of the
study. Investigator-assessed outcome mea-
surement
Blinding of outcome assessment (detection
bias)
amputation, blindness/severe vision loss,
end-stage renal disease
Low risk Quote from publication: “Investigators
who assessed the outcomes at follow-up
were masked to treatment allocation. Pa-
tients and other investigators were not
masked.”
Comment: sufficient blinding of outcome
assessment, investigator-assessed outcome
measurement. Not assessed during the in-
tervention period
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Comment: Investigator-assessed outcome
measurement. Assume investigators were
not blinded during the trial due to the de-
sign of the study. Outcome unlikely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
non-serious adverse events
Unclear risk Comment: Investigator-assessed and self-
reported outcome measurement. Assume
participants and investigators were not
blinded during the trial due to the design
of the study. The outcome could be influ-
enced by lack of blinding
Blinding of outcome assessment (detection
bias)
serious adverse events
Unclear risk Comment: Investigator-assessed outcome
measurement. Assume investigators were
not blinded during the trial due to the de-
sign of the study. Outcome unlikely to be
influenced by lack of blinding
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Da Qing 1997 (Continued)
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Unclear risk Quote from publication (extended fol-
low-up period): “We tried to follow up
all the original study participants to estab-
lish their vital status. For deceased partici-
pants, we collected date and cause of death
from death certificates, reviews of medical
records, and interviews with proxy infor-
mants. We asked proxy informants about
the date, place, and circumstances of death
along with information about hospitals or
physicians from whom the participant had
received care around the time of death. We
obtained medical records and death certifi-
cates and, together with the informant in-
terviews, they were reviewed and adjudi-
cated independently by two doctors (JW
and YA) to establish the underlying cause
of death.”
Quote from main publication: “Of the
577 subjects with IGT who were random-
ized, 530 completed the study. Of the re-
mainder, 7 people refused follow-up, 29 left
Da Qing in 1988 (mostly because of the
establishment of a new oil field elsewhere),
and 11 died during the course of the study.
”
Comment: not stated if they did the same
to establish mortality status at the end of
intervention period. Not reported to which
group the 29 participants who left the trial
were randomised
Incomplete outcome data (attrition bias)
incidence of T2DM
Unclear risk Quote frompublication: “Of the 577 sub-
jects with IGT who were randomized, 530
completed the study. Of the remainder, 7
people refused follow-up,
29 left Da Qing in 1988 (mostly because
of the establishment of a new oil field else-
where), and 11 died during the course of
the study.”
Comment: not reported to which group
the 29 participants who left the trial were
randomised
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Quote frompublication: “Of the 577 sub-
jects with IGT who were randomized, 530
completed the study. Of the remainder, 7
people refused follow-up,
29 left Da Qing in 1988 (mostly because
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Da Qing 1997 (Continued)
of the establishment of a new oil field else-
where), and 11 died during the course of
the study.”
Comment: not reported to which group
the 29 participants who left the trial were
randomised
Incomplete outcome data (attrition bias)
non-serious adverse events
Unclear risk Quote frompublication: “Of the 577 sub-
jects with IGT who were randomized, 530
completed the study. Of the remainder, 7
people refused follow-up,
29 left Da Qing in 1988 (mostly because
of the establishment of a new oil field else-
where), and 11 died during the course of
the study.”
Comment: not reported to which group
the 29 participants who left the trial were
randomised
Incomplete outcome data (attrition bias)
serious adverse events
Unclear risk Quote frompublication: “Of the 577 sub-
jects with IGT who were randomized, 530
completed the study. Of the remainder, 7
people refused follow-up,
29 left Da Qing in 1988 (mostly because
of the establishment of a new oil field else-
where), and 11 died during the course of
the study.”
Comment: not reported to which group
the 29 participants who left the trial were
randomised
Selective reporting (reporting bias) High risk Comment: It is apparent from an abstract
of the trial that cardiovascular outcomes
were collected, but they were not reported
in a format suitable for meta-analyses. One
of the articles reported that HRQoL and
use of health care was evaluated, but there
were no data
Other bias High risk Comment: the study was cluster-ran-
domised, and no ICC was reported. There-
fore, all data in the meta-analyses are based
on an assumed intra-cluster coefficient
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DPP 2002
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: ≥ 25 years, BMI ≥ 24 kg/m2 in Asians BMI ≥ 22 kg/m2, FPG 95-
125 mg/dl (5.3-6.9 mmol/L) and 2 hour plasma glucose after an OGTT 140-199 mg/
dL (7.8-11.0 mmol/L). Because of the relative higher rate of progression from impaired
glucose tolerance to diabetes in Native Americans and the small size of the population,
the glucose requirement for eligibility in the Southwest American Indian Center will be
fasting glucose < 126 mg/dL (7.0 mmol/L) and 2 hour plasma glucose after an OGTT
140-199 mg/dL (7.8-11.0 mmol/L)
Exclusion criteria: T2DM, participants taking medicines known to alter glucose toler-
ance, ever used glucose-lowering drugs during pregnancy, illnesses that could seriously
reduce their life expectancy or their ability to participate in the trial, cardiovascular dis-
ease (hospitalisation for treatment of heart disease in past 6 months; NYHA class > 2;
left bundle branch block or third degree atrioventricular block; aortic stenosis; SBP >
180 mmHg or DBP > 105 mmHg); cancer requiring treatment in the past five years
(unless prognosis is considered good); renal disease; gastrointestinal disease; anaemia
(hematocrit < 36.0% in men or < 33.0% in women); electrolyte abnormality (serum
potassium < 3.2 or > 5.5 mmol/L)
Diagnostic criteria: impaired glucose tolerance (2 hour plasma glucose after an OGTT
140-199 mg/dl (7.8-11.0 mmol/L)) and elevated fasting glucose (FPG 95-125 mg/dl
(5.3-6.9 mmol/L)) (ADA 1997).
Interventions Number of study centres: 27
Treatment before study: none
Run-in period: 3 weeks; during the run-in period the participants had to fill out a daily
dairy and placebo pills according to a schedule
Extension period: yes, an additional follow-up with a median of 5.7 years (IQR 5.5-5.
8) after end of the intervention period
Outcomes Composite outcome measures reported: yes (Quote from publication: ”.....a com-
posite microvascular-neuropathic outcome for diabetic retinopathy, nephropathy, or re-
duced light touch sensation in the feet. Secondary outcomes include the individual com-
ponents of the composite primary outcome, cardiovascular disease, further development
of diabetes, measures of glycaemia, insulin secretion, insulin sensitivity, cardiovascular
disease risk factors, physical activity, nutrition, bodyweight, health-related quality of life,
and economic assessments.“)
Study details Trial terminated early: yes, the trial was stopped one year earlier than originally planned
due to larger intervention effect of diet and physical activity than anticipated
Publication details Language of publication: English
Funding: commercial funding (Lipha (Merck-Sante) provided medicines, and LifeScan
donated materials)/non-commercial funding (the National Institute of Diabetes and Di-
gestive and Kidney Diseases (NIDDK), National Institute of Child Health and Human
Development, the National Institute on Aging, the National Eye Institute, the National
Heart Lung and Blood Institute, the Office of Women’s Health, the National Center for
Minority Health and Human Disease, the Centers for Disease Control and Prevention,
and the American Diabetes Association)
Publication status: peer-reviewed journal
66Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DPP 2002 (Continued)
Stated aim of study Quote from publication: ”The principal objective of the DPP is to prevent or delay the
development of NIDDM in those persons who are at high risk for its development by
virtue of having impaired glucose tolerance“
Notes Individuals who meet only one of the glucose inclusion criteria was re-screened after 6
months
Because of the relative higher rate of progression from impaired glucose tolerance to
T2DMinNative Americans and the small size of the population, the glucose requirement
for eligibility in the Southwest American Indian Center differed (see above)
The trial included initially four intervention groups. The metformin group is not in-
cluded in this review. The troglitazone group was discontinued in 1998 because of po-
tential liver toxicity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: ”A sequence of
randomization numbers within a clinical
center will be constructed of the form
XXYZZZ, where XX is the clinical center
number, Y is a number that indicates as-
signment to either the intensive lifestyle in-
tervention or pharmacological treatment,
and ZZZ is a three digit sequence number
within each XXY combination. The DPP
Coordinating Center will prepare the mas-
ter randomization list with assignments to
the three treatment groups within a clinical
center using the standard urn design.
The sequence of pharmacological ran-
domization numbers within a clinical
center with the specific pharmacological
treatment assignment (i.e., metformin or
placebo) will be forwarded, in confidence,
to the drug distribution center for drug la-
belling and distribution. Pharmacological
treatment assignment to the sequence of
pharmacological randomization numbers
will be known only by the staff of the DPP
Coordinating Center and the drug distri-
bution center.“
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: ”A sequence of
randomization numbers within a clinical
center will be constructed of the form
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DPP 2002 (Continued)
XXYZZZ, where XX is the clinical center
number, Y is a number that indicates as-
signment to either the intensive lifestyle in-
tervention or pharmacological treatment,
and ZZZ is a three digit sequence number
within each XXY combination. The DPP
Coordinating Center will prepare the mas-
ter randomization list with assignments to
the three treatment groups within a clinical
center using the standard urn design.
The sequence of pharmacological ran-
domization numbers within a clinical
center with the specific pharmacological
treatment assignment (i.e., metformin or
placebo) will be forwarded, in confidence,
to the drug distribution center for drug la-
belling and distribution. Pharmacological
treatment assignment to the sequence of
pharmacological randomization numbers
will be known only by the staff of the DPP
Coordinating Center and the drug distri-
bution center.“
Comment: adequate allocation conceal-
ment ensured
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Quote frompublication: ”Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.“
Comment:no blinding but judged that the
outcome is not likely to be influenced by
lack of blinding, investigator-assessed out-
come measurement
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote frompublication: ”Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.“ and ”Primary
outcome data (OGTT and FPG results)
measured centrally will remain masked to
the investigators and to the participants un-
til confirmed progression from IGT to di-
abetes“
Comment: assessed centrally unblinded,
the outcome is not likely to be influenced
by lack of blinding. Participants and in-
vestigators blinded to until progression to
T2DM
68Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DPP 2002 (Continued)
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Quote frompublication: ”Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.“ and ”Primary
outcome data (OGTT and FPG results)
measured centrally will remain masked to
the investigators and to the participants un-
til confirmed progression from IGT to di-
abetes“ and Plasma lipid levels and HbA1c
measured
centrally will remain masked to the inves-
tigators and to the participants during the
study.”
Comment: assessed centrally unblinded,
the outcome is not likely to be influenced
by lack of blinding. Participants and in-
vestigators blinded to until progression to
T2DM
Blinding of participants and personnel
(performance bias)
socioeconomic effects
Low risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.”
Comment:no blinding but judged that the
outcome is not likely to be influenced by
lack of blinding, investigator-assessed out-
come measurement
Blinding of participants and personnel
(performance bias)
Health related quality of life
High risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.”
Comment: no blinding and the outcome is
likely to be influenced by lack of blinding,
self-reported outcome measurement
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.”
Comment:no blinding but judged that the
outcome is not likely to be influenced by
lack of blinding, investigator-assessed out-
come measurement
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.” and “Primary
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outcome data (OGTT and FPG results)
measured centrally will remain masked to
the investigators and to the participants un-
til confirmed progression from IGT to di-
abetes”
Comment: assessed centrally unblinded,
the outcome is not likely to be influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.” and “Primary
outcome data (OGTT and FPG results)
measured centrally will remain masked to
the investigators and to the participants un-
til confirmed progression from IGT to dia-
betes” and “Plasma lipid levels and HbA1c
measured
centrally will remain masked to the inves-
tigators and to the participants during the
study.”
Comment: assessed centrally unblinded,
the outcome is not likely to be influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
socioeconomic effects
Low risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.”
Comment:no blinding but judged that the
outcome is not likely to be influenced by
lack of blinding, investigator-assessed out-
come measurement
Blinding of outcome assessment (detection
bias)
Health related quality of life
High risk Quote frompublication: “Masking inten-
sive lifestyle intervention assignment to the
participants is not possible andmasking the
investigators is not practical.”
Comment: no blinding and the outcome is
likely to be influenced by lack of blinding,
self-reported outcome measurement
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “At the close of
the study, 99.6 percent of the participants
were alive, of whom 92.5 percent had at-
tended a scheduled visit within the previ-
ous five months”
Comment: not stated how many partici-
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pants who had known vital status in each
intervention group at the end of follow-up
for the DPP trial. However, at inception of
the number with unknownmortality status
are relatively low. At inception of the DP-
POS the number between the intervention
groups we balanced
Incomplete outcome data (attrition bias)
incidence of T2DM
Low risk Quote from publication: “At the close of
the study, 99.6 percent of the participants
were alive, of whom 92.5 percent had at-
tended a scheduled visit within the previ-
ous five months”
Comment: not stated how many partici-
pants who had known vital status at the end
of follow-up for the DPP trial. However,
at inception of the DPPOS a relatively low
and balanced number of participants in the
intervention groups could not be included
Incomplete outcome data (attrition bias)
measures of blood glucose control
Low risk Comment: not stated how many partici-
pants who had known vital status at the end
of follow-up for the DPP trial. However,
at inception of the DPPOS a relatively low
and balanced number between the inter-
vention groups could not be included
Incomplete outcome data (attrition bias)
time to progression to T2DM
Low risk Comment: “At the close of the study, 99.
6 percent of the participants were alive, of
whom 92.5 percent had attended a sched-
uled visit within the previous five months”
Incomplete outcome data (attrition bias)
socioeconomic effects
Low risk Comment:not clearly describedhowmany
participants included in the costs analyses,
but as the study have a high follow-up rate,
we assume that nearly all participants are
included
Incomplete outcome data (attrition bias)
Health related quality of life
Low risk Quote from publication: The current re-
port and analyses includes 3,234 partici-
pants seen at baseline, who were randomly
assigned to one of the three treatment arms
investigated
Comment: article reporting health related
quality of life do not report the number of
participants with available data at follow-
up
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Selective reporting (reporting bias) High risk Comment: several outcome are likely to be
measured and analysed, but not reported,
e.g. hypoglycaemia, non-serious adverse
events. outcomes published in many dif-
ferent publications. Many outcomes are re-
ported incompletely so that they cannot be
entered in a meta-analysis
Other bias High risk Comment: trial terminated early for bene-
fit
Comment: received funding from a phar-
maceutical company
DPS 2001
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: BMI ≥ 25 kg/m2; IGT (2-h plasma glucose after an OGTT 140-
200 mg/dL (7.8-11.0 mmol/L)) and FPG < 140 mg/dL (7.8 mmol/L) (WHO 1985),
40-65 years
Exclusion criteria: diagnosis of diabetes mellitus, involvement of people with regu-
larly vigorous physical activity, chronic disease, diseases likely to interfere with glucose
metabolism (e.g. liver disease), psychological or physical disabilities deemed likely to
interfere with participation in the study
Diagnostic criteria: IGT (2-h plasma glucose after an OGTT 140-200 mg/dL (7.8-11.
0 mmol/L)) and FPG < 140 mg/dL (7.8 mmol/L) (WHO 1985)
Interventions Number of study centres: 5
Treatment before study: none
Titration period: none
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: yes (the trial was prematurely terminated in March 2000 by an
independent end point committee, since the incidence of diabetes in the intervention
group was highly significantly lower than in the control group)
Publication details Language of publication: English
Funding: commercial funding (Novo Nordisk Foundation)/non-commercial funding
(Finnish Academy, Ministry of Education, Yrjö Jahnsson Foundation, and the Finnish
Diabetes Research
Foundation)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “The aim of the Diabetes Prevention Study is to assess the
efficacy of an intensive diet-exercise programme in preventing or delaying Type II (non-
insulin-dependent) diabetes mellitus in subjects with impaired glucose tolerance, to
evaluate the effects of the intervention programme on cardiovascular risk factors and to
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assess the determinants for the progression to diabetes in persons with impaired glucose
tolerance.”
Notes After the first screening OGTT, a repeat OGTT was carried out in participants with
IGT and the mean value of the two 2-h glucose concentrations was used as the criterion
for inclusion in the study
The inclusion criteria were developed during the recruitment period but before the final
criteria based on the two OGTTs were decided
After randomisation, study visits were scheduled for 1-2 weeks, 5-6 weeks, 3, 4 and 6
months from the beginning of the study and thereafter every 3 months. Every 3 months,
3-d food records were completed throughout the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Subjects who
enrolled in the study were randomly as-
signed to the intervention group or the
control group by the study physician, with
the use of a randomization list...” and “For
the DPS and EDIPS-Newcastle (but not
SLIM) the randomisation lists were gener-
ated and supplied by the coordinating cen-
tre in Helsinki and staff who made base-
linemeasurements had no access to the ran-
domisation lists.”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: “Subjects who
enrolled in the study were randomly as-
signed to the intervention group or the
control group by the study physician, with
the use of a randomization list,..” and “For
the DPS and EDIPS-Newcastle (but not
SLIM) the randomisation lists were gener-
ated and supplied by the coordinating cen-
tre in Helsinki and staff who made base-
linemeasurements had no access to the ran-
domisation lists.”
Comment: adequate allocation conceal-
ment ensured
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
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signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
“The independent end-points committee
confirmed all newly diagnosed cases of di-
abetes”
Comment: outcome evaluated by an
independent outcome committee. Not
described whether this committee was
blinded.We assume that the outcome com-
mittee was blinded, however the outcome
was not likely to be influenced by lack of
blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
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Blinding of participants and personnel
(performance bias)
time to progression to T2DM
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
“The independent end-points committee
confirmed all newly diagnosed cases of di-
abetes”
Comment: outcome evaluated by an
independent outcome committee. Not
described whether this committee was
blinded.We assume that the outcome com-
mittee was blinded, however the outcome
was not likely to be influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
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“The independent end-points committee
confirmed all newly diagnosed cases of di-
abetes”
Comment: outcome evaluated by an
independent outcome committee. Not
described whether this committee was
blinded.We assume that the outcome com-
mittee was blinded, and the outcome was
not likely to be influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
time to progression to T2DM
Low risk Quote from publication: “The nurses
who scheduled the study visits did not have
access to the randomization list. However,
the staff members involved in the inter-
vention had to be aware of the group as-
signment; thus, the study was only partly
blinded. Laboratory staff did not know the
subjects’ group assignments, and the sub-
jects were not informed of their plasma glu-
cose concentrations during follow-up un-
less diabetes was diagnosed.”
“The independent end-points committee
confirmed all newly diagnosed cases of di-
abetes”
Comment: outcome evaluated by an
independent outcome committee. Not
described whether this committee was
blinded.We assume that the outcome com-
mittee was blinded, and the outcome was
not likely to be influenced by lack of blind-
ing
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Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
High risk Quote from publication: “During the
post-intervention follow-up, 36 additional
participants withdrew and ten died with-
out a verified diabetes diagnosis”
Comment: participants diagnosed with
T2DM not included in the mortality anal-
yses
Incomplete outcome data (attrition bias)
incidence of T2DM
Unclear risk Quote from publication: “During the
study, 40 subjects (8 percent) withdrew -
23 in the intervention group and 17 in the
control group. Of these subjects, 9 could
not be contacted, 3 withdrew due to se-
vere illness, 1 died, and 27 withdrew for
personal reasons.” “Subjects who withdrew
from the study were considered to be at risk
for diabetes until their last oral glucose tol-
erance test, at which point data were cen-
sored.” 9 yrs publication: “The last-obser-
vation carried-forward method was applied
to all measurements for those participants
who developed diabetes or who were lost
to follow-up”
Quote from 9 years publication: “Alto-
gether, 86 participants were lost to follow
up without a diabetes diagnosis: 49 in the
intervention group and 37 in the control
group. The baseline characteristics of the
dropouts were similar between the groups.
”
Comment: inappropriate method of im-
putation
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Comment: not explicitly stated how many
participants were included in the analyses
Incomplete outcome data (attrition bias)
time to progression to T2DM
Unclear risk Quote from publication: “During the
study, 40 subjects (8 percent) withdrew -
23 in the intervention group and 17 in the
control group. Of these subjects, 9 could
not be contacted, 3 withdrew due to se-
vere illness, 1 died, and 27 withdrew for
personal reasons.” “Subjects who withdrew
from the study were considered to be at risk
for diabetes until their last oral glucose tol-
erance test, at which point data were cen-
sored.” 9 yrs publication: “The last-obser-
vation carried-forward method was applied
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to all measurements for those participants
who developed diabetes or who were lost
to follow-up”. and
Quote from 9 years publication: “Alto-
gether, 86 participants were lost to follow
up without a diabetes diagnosis: 49 in the
intervention group and 37 in the control
group. The baseline characteristics of the
dropouts were similar between the groups.
”
Comment: inappropriate method of im-
putation
Selective reporting (reporting bias) High risk Comment:morbidity was described as be-
ing reported in design article, but no data
available
Other bias High risk Comment: trial terminated early for bene-
fit
Comment: received funding from the
Novo Nordisk Foundation
EDIPS 2009
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: IGT (mean 2-h plasma glucose > 7.8 and < 11.1 mmol/L (WHO
1999) from 2 OGTTs, the 2nd conducted 1-12 weeks after the 1st); aged 40-74 years;
BMI > 25 kg/m2
Exclusion criteria: previous diagnosis of T2DM according to WHO 1999 criteria;
previous intensive treatment for IGT; previous participation in a programme of vigorous
physical activity
Diagnostic criteria: IGT (mean 2-h plasma glucose after OGTTs > 7.8 and < 11.1
mmol/L) (WHO 1999)
No explicit mention of FPG measurements but FPG should be < 7.0 mmol/L according
to the criteria suggested by the trial authors
Interventions Number of study centres: 1
Run-in period: none
Extension period: no
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial funding (Wellcome Trust)
Publication status: peer-reviewed journal
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Stated aim of study Quote from publication: “The EDIPS in Newcastle upon Tyne, UK (EDIPS-New-
castle) was designed to contribute to the evidence for diabetes prevention by lifestyle
modification in people with IGT.”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Eligible par-
ticipants (with IGT) were randomly allo-
cated to the Intervention (I) or Control (C)
group using randomisation lists, prepared
independently by the EDIPS co-ordinating
centre in Helsinki.”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: “Eligible par-
ticipants (with IGT) were randomly allo-
cated to the Intervention (I) or Control (C)
group using randomisation lists, prepared
independently by the EDIPS co-ordinating
centre in Helsinki.”
Comment: adequate allocation conceal-
ment ensured
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Quote from publication: “Blinding of
participants and intervention staff was not
possible. Data collection staff were blinded
to the extent that this was possible given
participants’ knowledge of their allocation.
”
Comment: investigator-assessed outcome
measurement. The outcome was not likely
to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
amputation, blindness/severe vision loss,
end-stage renal disease
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
hypoglycaemia
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
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Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote from publication: “Blinding of
participants and intervention staff was not
possible. Data collection staff were blinded
to the extent that this was possible given
participants’ knowledge of their allocation.
”
Comment: investigator-assessed outcome
measurement. The outcome was not likely
to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
non-fatal myocardial infarction/stroke,
congestive heart failure
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
serious adverse events
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
time to progression to T2DM
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “Blinding of
participants and intervention staff was not
possible. Data collection staff were blinded
to the extent that this was possible given
participants’ knowledge of their allocation.
”
Comment: investigator-assessed outcome
measurement. The outcome was not likely
to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Quote from publication: “Blinding of
participants and intervention staff was not
possible. Data collection staff were blinded
to the extent that this was possible given
participants’ knowledge of their allocation.
”
Comment: investigator-assessed outcome
measurement. The outcome was not likely
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to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
non-fatal myocardial infarction/stroke,
congestive heart failure
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Low risk Comment: 2 in the control group and 4
in the intervention group had unknown
mortality status; missing outcome data
balanced in numbers across intervention
groups, with similar reasons for missing
data across groups; the proportion of miss-
ing outcomes was not enough to have a
clinically relevant impact on the interven-
tion effect estimate
Incomplete outcome data (attrition bias)
amputation, blindness/severe vision loss,
end-stage renal disease
Low risk Comment: information provided by the
trial authors. All participants were included
in the analysis
Incomplete outcome data (attrition bias)
hypoglycaemia
Low risk Comment: information provided by the
trial authors. All participants were included
in the analysis
Incomplete outcome data (attrition bias)
incidence of T2DM
Low risk Quote from publication: “If participants
who left the trial and were later reported
to have developed T2D by their physician
were included in the analysis as having de-
veloped diabetes (rather than having left)
, then the number of cases of diabetes be-
comes 20 (I =7,C=13) and the relative risk
of diabetes incidence becomes 0.54 (95%
CI:0.2 to 1.2).”
Comment: the investigators performed
analyses including all participants and the
participants who left the trial. The statis-
tical significance of the effect estimate did
not differ
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Comment: information provided by the
trial authors. Unknown reason for missing-
ness and how missing data were handled
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Incomplete outcome data (attrition bias)
non-fatal myocardial infarction/stroke,
congestive heart failure
Low risk Comment: information provided by the
trial authors. Investigator-assessed out-
come measurement. The outcome was not
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
serious adverse events
Low risk Comment: information provided by the
trial authors. All randomised participants
were included in the analysis
Incomplete outcome data (attrition bias)
time to progression to T2DM
Unclear risk Comment: information provided by the
trial authors. Unknown reason for missing-
ness and how missing data were handled
Selective reporting (reporting bias) High risk Comment: more outcomes of relevance to
this review defined but not published (e.g.
glycaemic measures). However, these data
were provided by the investigators on re-
quest, except for HRQoL, which was listed
as an outcome, but no additional data were
provided
Other bias Low risk Comment: no other sources of bias identi-
fied
Hellgren 2016
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1:1
Participants Inclusion criteria: 35-75 years; IGT and/or IFG
Exclusion criteria: T2DM
Diagnostic criteria: IFG was defined as FPG > 6.0 < 7.0 mmol/L with a 2-h glucose
< 8.9 mmol/L, while IGT was defined as 2-h glucose 8.8 mmol/L and < 12.2 mmol/L,
and an FPG < 7.0 mmol/L
Interventions Number of study centres: 1
Run-in period: none
Extension period: no
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial funding (Swedish Research Council)
Publication status: peer-reviewed journal
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Stated aim of study Quote from publication: “We hypothesised that the expected increase in insulin resis-
tance over three years’ time in individuals with impaired glucose tolerance (IGT) and/or
impaired fasting glucose could be attenuated by an intervention with focus on physical
activity in ordinary primary care”
Notes Data from the two intervention groupswere initially analysed separately. As the outcomes
proved to be essentially the same in both groups, the two groups were then analysed
together and thereafter designated as the combined intervention group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “All eligible par-
ticipants were randomised to one of two
different interventions, or to ‘care as usual’,
using a specially designed computer system.
”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: “All eligible par-
ticipants were randomised to one of two
different interventions, or to ‘care as usual’,
using a specially designed computer system.
”
Comment: adequate generation of alloca-
tion concealment ensured
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of participants and personnel
(performance bias)
amputation, blindness/severe vision loss,
end-stage renal disease
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of participants and personnel
(performance bias)
hypoglycaemia
Unclear risk Comment: could be investigator-assessed
or self-reported outcome measure depend-
ing on the severity. No blinding described
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
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Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of participants and personnel
(performance bias)
non-fatal myocardial infarction/stroke,
congestive heart failure
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of participants and personnel
(performance bias)
serious adverse events
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of participants and personnel
(performance bias)
Health related quality of life
High risk Comment: self-reported outcome mea-
sure. No blinding. The outcome was likely
to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
amputation, blindness/severe vision loss,
end-stage renal disease
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
hypoglycaemia
Unclear risk Comment: could be investigator-assessed
or self-reported outcome measure depend-
ing on the severity. No blinding described
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
non-fatal myocardial infarction/stroke,
congestive heart failure
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
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Blinding of outcome assessment (detection
bias)
serious adverse events
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
Health related quality of life
High risk Comment: self-reported outcome mea-
sure. No blinding. The outcome was likely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Low risk Comment: reply from the investigators
that mortality status was known on all ran-
domised participants
Incomplete outcome data (attrition bias)
incidence of T2DM
Low risk Quote from publication: “Four people
died during the first year from reasons not
associated with the study, and 10 of the
participants developed Type 2 diabetes and
refrained from the final examination. An-
other 13 participants dropped out of the
study for various reasons (e.g. worsening
general health, difficulties attending the
group sessions and other social reasons).
Most of the dropouts were in the interven-
tion group (N = 5 in the IIG and N = 6 in
the BIG).”
Comment: a total of 13 participants
dropped out, but were contacted and asked
at the end of the trial and asked if they had
developed T2DM. 11 of these were from
the intervention group; 2 of these from the
standard group. The reason for dropout
was not explained. The proportion of miss-
ing outcomes was enough to induce clini-
cally relevant bias in intervention effect es-
timate
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Comment: data provided by the investiga-
tors. Only about 70% of the randomised
participants were included in the analyses.
Unclear how missing data were handled
Incomplete outcome data (attrition bias)
non-fatal myocardial infarction/stroke,
congestive heart failure
Unclear risk Comment: data provided by the investiga-
tors. Only about 80% were included in the
analyses. Not clear how missing data were
handled
Incomplete outcome data (attrition bias)
serious adverse events
Unclear risk Comment: information on number pro-
vided by the trial authors. Participants lost
to follow-up not included in the analysis
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Incomplete outcome data (attrition bias)
Health related quality of life
High risk Comment: data provided by the investiga-
tors. Only about 60% of the randomised
participants were included in the analyses.
Not clear how missing data were handled
Selective reporting (reporting bias) Low risk Comment: trial protocol provided by the
investigator. The trial assessed several out-
comes of interest to the review but these
were either not reported in publications or
reported in a format that made them un-
suitable for meta-analysis. However, the in-
vestigators provided the additional infor-
mation
Other bias Low risk Comment: no other sources of bias identi-
fied
HELP PD 2011
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: able to read/understand English at or above a level sufficient to
comprehend recruitment and intervention materials; BMI ≥ 25 kg/m2 but < 40 kg/m
2; fasting blood glucose 95-125 mg/dL (inclusive); ≥ 21 years
Exclusion criteria: currently involved in a supervised programme for weight loss; history
of DM, or newly diagnosed DM at screening; history of CVD occurring within the past
6 months, including myocardial infarction, angina, coronary revascularisation, stroke,
transient ischaemic attack, carotid revascularisation, peripheral arterial disease, and con-
gestive heart failure; uncontrolled high blood pressure (> 160/100 mmHg); pregnancy,
breast feeding, or planning pregnancy within 2 years; other chronic disease likely to
limit lifespan to < 2-3 years, including any cancer requiring treatment in past 5 years
except non-melanoma skin cancer; chronic use of medicine known to significantly affect
glucose metabolism, e.g. corticosteroids; conditions/criteria likely to interfere with par-
ticipation and acceptance of randomised assignment, including the following: inability/
unwillingness to give informed consent, another household member already randomised
to HELP PD, major psychiatric or cognitive problems (schizophrenia, dementia, self-
reported active illegal substance or alcohol abuse), and participation in another research
study that would interfere with HELP PD
Diagnostic criteria: fasting blood glucose 95-125 mg/dL (5.3-6.9 mmol/L) (inclusive)
Interventions Number of study centres: 1
Run-in period: none
Extension period: according to clinicaltrial.com then an extension period is planned
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
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Publication details Language of publication: English
Funding: non-commercial funding (National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK))
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “To examine the impact of a 24-month, community-based
diabetes prevention program on fasting blood glucose, insulin, insulin resistance as well
as body weight, waist circumference, and BMI in the second year of follow-up”
Notes Some of the publications were supported by Joslin Diabetes Center and Novo Nordisk.
According to ClinicalTrials.gov an extended follow-up period up to 72 months after
randomisation was planned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Eligible par-
ticipants were randomly assigned, if equal
probability, to either the lifestyle interven-
tion or the enhanced usual care arm using
a web-based data management system that
verifies eligibility”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: “Eligible par-
ticipants were randomly assigned, if equal
probability, to either the lifestyle interven-
tion or the enhanced usual care arm using
a web-based data management system that
verifies eligibility”
Comment: adequate allocation conceal-
ment ensured
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Unclear risk Quote from publication: “Outcomes are
masked and are collected every 6 months”
“Although neither the participants nor in-
terventionists were masked to treatment
assignment, the primary outcome, fasting
blood glucose, was chosen to be highly ob-
jective.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
Low risk Quote from publication: “Outcomes are
masked and are collected every 6 months”
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incidence of T2DM “Although neither the participants nor in-
terventionists were masked to treatment
assignment, the primary outcome, fasting
blood glucose, was chosen to be highly ob-
jective.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Quote from publication: “Outcomes are
masked and are collected every 6 months”
“Although neither the participants nor in-
terventionists were masked to treatment
assignment, the primary outcome, fasting
blood glucose, was chosen to be highly ob-
jective.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
socioeconomic effects
Low risk Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “Outcomes are
masked and are collected every 6 months”
“Although neither the participants nor in-
terventionists were masked to treatment
assignment, the primary outcome, fasting
blood glucose, was chosen to be highly ob-
jective.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Quote from publication: “Outcomes are
masked and are collected every 6 months”
“Although neither the participants nor in-
terventionists were masked to treatment
assignment, the primary outcome, fasting
blood glucose, was chosen to be highly ob-
jective.”
Comment: investigator assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Quote from publication: “Outcomes are
masked and are collected every 6 months”
“Although neither the participants nor in-
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terventionists were masked to treatment
assignment, the primary outcome, fasting
blood glucose, was chosen to be highly ob-
jective.”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
socioeconomic effects
Low risk Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “An intention-
to-treat approach was used and included
all postrandomized values according to the
group they were assigned”
Comment: 1% of the randomised partic-
ipants refused or withdrew by 24 months’
assessment in the intervention group; 3%
of the randomised participants in the con-
trol group refused or withdrew by 24
months’ follow-up
Incomplete outcome data (attrition bias)
incidence of T2DM
Unclear risk Quote from publication: “An intention-
to-treat approach was used and included
all postrandomized values according to the
group they were assigned”
Comment: 84% of the randomised partic-
ipants completed 24-month assessment in
the intervention group; 89% of the ran-
domised participants in the control group
completed 24 months’ follow-up. Insuffi-
cient information to assess whethermissing
data were likely to induce bias
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Quote from publication: “An intention-
to-treat approach was used and included
all postrandomized values according to the
group they were assigned”
Comment: 84% of the randomised partic-
ipants completed 24-month assessment in
the intervention group; 89% of the ran-
domised participants in the control group
completed 24 months’ follow-up. Insuffi-
cient information to assess whethermissing
data were likely to induce bias
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Incomplete outcome data (attrition bias)
time to progression to T2DM
Unclear risk Quote from publication: “The distribu-
tion of times until the development of
DM and the metabolic syndrome (mea-
sured from the date of randomization to the
date of the clinical visit or report triggering
the diagnosis) will be described using Ka-
plan-Meier plots ..., with censoring taken
to occur at the time of the last contact with
participants”
Comment: data were censored at the last
time of contact with the participants, and
not the time of diagnosis which could ex-
aggerate a potential intervention effect
Incomplete outcome data (attrition bias)
socioeconomic effects
Unclear risk Quote from publication: “An intention-
to-treat approach was used and included
all postrandomized values according to the
group they were assigned”
Comment: 84% of the randomised partic-
ipants completed 24-month assessment in
the intervention group; 89% of the ran-
domised participants in the control group
completed 24 months’ follow-up. Insuffi-
cient information to assess whethermissing
data were likely to induce bias
Selective reporting (reporting bias) High risk Comment: several outcomes of interest for
this review weremeasured but not reported
(see table Appendix 7)
Other bias Unclear risk Comment: some of the publications were
supported by Novo Nordisk. According to
ClinicalTrials.gov an extended follow-up
period to 72 months after randomisation
was planned. Data from the extension pe-
riod are still not available
IDPP 2006
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: IGT (mean 2-h plasma glucose after OGTT 140-199 mg/dL (7.8-
11.0 mmol/L) and FPG < 126 mg/dL (7.0 mmol/L)) (WHO 1999); no major illness;
35-55 years
Exclusion criteria: diagnosis of DM during recruitment; pregnancy
Diagnostic criteria: IGT (WHO 1999)
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Interventions Number of study centres: -
Treatment before study: none
Titration period: none
Outcomes Composite outcome measures reported: yes (CVD)
Study details Trial terminated early: yes;Quote from publication: ”After a median follow-up period
of 30months, because there were significant differences in the outcomemeasure between
the control and intervention groups, the committee recommended the termination of
the study in December 2004“
Publication details Language of publication: English
Funding: commercial (M/S US Vitamins)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: ”In a prospective community-based study, we tested whether
the progression to diabetes could be influenced by interventions in native Asian Indians
with IGT who were younger, leaner and more insulin resistant than the above popula-
tions“
Notes Twomore intervention groups existed thatwere not included in this review; 1 )metformin
and 2) diet plus physical activity combined with metformin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from publication: ”A randomised,
controlled clinical trial was performed in
subjects who were......“
Comment: insufficient information about
the sequence generation process
Allocation concealment (selection bias) Unclear risk Comment: no information
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Quote from publication: ”Masking:
Open Label“ and ”However, the principal
investigators were blinded to the outcome
until they were asked to close the study by
the international data monitoring commit-
tee.“
Comment: outcome evaluated by an inde-
pendent outcome committee. No blinding
Blinding of participants and personnel
(performance bias)
hypoglycaemia
High risk Quote from publication: ”Masking:
Open Label“ and ”However, the principal
investigators were blinded to the outcome
until they were asked to close the study by
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the international data monitoring commit-
tee.“
Comment: self-reported and investigator-
assessed outcome measure. No blinding.
The outcome could have been influenced
by lack of blinding. No hypoglycaemic
events in the groups of interest for this re-
view were reported
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote from publication: ”Masking:
Open Label“ ”However, the principal in-
vestigators were blinded to the outcome
until they were asked to close the study by
the international data monitoring commit-
tee.“
Comment: outcome evaluated by an inde-
pendent outcome committee and investi-
gator-assessed outcome measure
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Quote from publication: ”Masking:
Open Label“ and ”“However, the principal
investigators were blinded to the outcome
until they were asked to close the study by
the international data monitoring commit-
tee.”
Comment: investigator-assessed outcome
measure, unclear if this outcome also was
assessed by the blinded independent out-
come committee. The outcome was not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Quote from publication: “However, the
principal investigators were blinded to the
outcome until they were asked to close the
study by the international data monitoring
committee.”
Comment: outcome evaluated by an inde-
pendent outcome committee
Blinding of outcome assessment (detection
bias)
hypoglycaemia
High risk Comment: self-reported and investigator-
assessed outcome measure. No blinding.
The outcome could have been influenced
by lack of blinding. No hypoglycaemic
events in the groups of interest for this re-
view were reported
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Quote from publication: “However, the
principal investigators were blinded to the
outcome until they were asked to close the
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study by the international data monitoring
committee.”
Comment: outcome evaluated by an inde-
pendent outcome committee and investi-
gator-assessed outcome measure
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Quote from publication: “However, the
principal investigators were blinded to the
outcome until they were asked to close the
study by the international data monitoring
committee.”
Comment: investigator-assessed outcome
measure, unclear if this outcome also was
assessed by the blinded independent out-
come committee. The outcome was not
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Unclear risk Comment: unknown whether mortality
status known for participants lost to follow-
up. 7 participants in theDPPA group and 2
participants in the control group were lost
to follow-up; 5 participants in the DPPA
groupwerementioned as notwilling.How-
ever, the proportion of missing outcomes
compared with observed event risk may
have had a clinically relevant impact on the
intervention effect estimate
Incomplete outcome data (attrition bias)
hypoglycaemia
Unclear risk Comment: 7 participants in the DPPA
group and 2 participants in the control
group were lost to follow-up; 5 participants
in the DPPA group were mentioned as not
willing. The proportion of missing out-
comes compared with observed event risk
was not enough to have a clinically relevant
impact on the intervention effect estimate
Incomplete outcome data (attrition bias)
incidence of T2DM
Unclear risk Comment: 7 participants in the DPPA
group and 2 participants in the control
group were lost to follow-up; 5 participants
in the DPPA group were mentioned as not
willing. The proportion of missing out-
comes compared with observed event risk
was not enough to have had a clinically rel-
evant impact on the intervention effect es-
timate
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Comment: only 79% of the participants
randomised to the intervention group and
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91% of the participants randomised to the
control group were included in the analy-
sis of glycaemic measures. Insufficient in-
formation to assess whethermissing data in
combination with themethod used to han-
dle missing data were likely to induce bias
Selective reporting (reporting bias) High risk Quote from publication: “An internal
safety committee monitored the adverse
events and safety of study protocol. The
data and final outcome measures were
monitored by the international monitor-
ing committee who had looked at the re-
sults three times, i.e. when 500 subjects had
completed the follow-up assessments at 12,
24 and 30 months. The principal investi-
gators were blinded to the interim results.”
Comment: several outcomes with rele-
vance for this review not reported or only
reported in a format that made them
unsuitable for meta-analyses, e.g. adverse
events
Other bias High risk Comment: trial terminated early for bene-
fit
Comment: role of funding source not de-
scribed
JDPP 2013
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: aged 30-60 years; IGT based on WHO 1999 criteria (mean 2-ho
plasma glucose after OGTT 7.8-11.0 mmol/L and FPG < 7.0 mmol/L)
Exclusion criteria: previous diagnosis of DMother than gestational diabetes; a history of
gastrectomy; physical conditions such as ischaemic heart disease, heart failure, exercise-
induced asthma and orthopedic problems where physical activity was not allowed by a
doctor; liver and kidney diseases; autoimmune diseases; habit of heavy alcohol drinking,
already having vigorous physical activity
Diagnostic criteria: several diagnostic criteria for impaired glucose tolerance, therein
the WHO 1998
Interventions Number of study centres: 32
Treatment before study: -
Titration period: -
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
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Publication details Language of publication: English and Japanese
Funding: non-commercial funding (Ministry of Health, Labour and Welfare, Japan)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “A randomized control trial was performed to test whether a
lifestyle intervention program, carried out in a primary healthcare setting using existing
resources, can reduce the incidence of type 2 diabetes in Japanese with impaired glucose
tolerance (IGT).”
Notes This trial was excluded from the original Cochrane Review as it was classified as not
randomised
The sample size calculation of the trial was based on an anticipated incidence of T2DM
during 6 years of follow-up. It was described that six years follow-up was planned, but
only three years follow-up was reported
Quote from publication: “Participants with IGT, aged 30-60 years, were recruited
through health checkups conducted at each collaborative center. The recruitment started
in March 1999 and was completed in December 2002. A two-step strategy was adopted
for identifying participants with IGT as described previously. The definition of IGT
using 75 g oral glucose tolerance test (OGTT) was based on the WHO’s criteria”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Participants
were randomly allocated (allocation ratio
1:1) to the ILG or the UCG, using a com-
puter-generated randomization. The Taves
method of minimization13 was used to en-
sure that the groups were balanced for pub-
lic health centers, gender, age groups”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: “Participants
were randomly allocated (allocation ratio
1:1) to the ILG or the UCG, using a com-
puter-generated randomization. The Taves
method of minimization13 was used to en-
sure that the groups were balanced for pub-
lic health centers, gender, age groups”
Comment: adequate allocation conceal-
ment ensured
Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Quote from publication: “The result of
the randomization was unmasked to the
participants, those administering the inter-
ventions, and those assessing the data”
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Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote from publication: “The result of
the randomization was unmasked to the
participants, those administering the inter-
ventions, and those assessing the data”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Quote from publication: “The result of
the randomization was unmasked to the
participants, those administering the inter-
ventions, and those assessing the data”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Unclear risk Quote from publication: “We randomly
assigned the 304 subjects with IGT to two
groups and analyzed the data for 296 indi-
viduals (150 in the control group and 146
in the intervention group) (Figure 1). A
total of 83 subjects (28%) withdrew from
the study before the 3-year mark (40 in the
control group and 43 in the intervention
group). The withdrawals were due to per-
sonal reasons (moving etc) in 18 cases,med-
ical reasons in 5, and loss of contact in 40.
Twenty subjects were not able to continue
the study for reasons related to the collab-
orative centers themselves, such as the clo-
sure of a center. The rate of withdrawal was
higher amongmen thanwomen (36.9%vs.
19.0%, p < 0.01).”
Comment: reason for loss to follow-up in
intervention group: personal reasons (N =
11);medical reasons (N =3); loss of contact
(N = 21); closure of centres (N = 8); rea-
son for loss to follow-up in the comparator
group: personal reasons (N = 7); medical
reasons (N = 2); loss of contact (N = 19);
closure of centres (N = 12)
A relatively large number of participants
did not complete the trial. However, the
number and reasons for missingness were
balanced between the intervention groups
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Incomplete outcome data (attrition bias)
incidence of T2DM
Unclear risk Quote from publication: “We randomly
assigned the 304 subjects with IGT to two
groups and analyzed the data for 296 indi-
viduals (150 in the control group and 146
in the intervention group) (Figure 1). A
total of 83 subjects (28%) withdrew from
the study before the 3-year mark (40 in the
control group and 43 in the intervention
group). The withdrawals were due to per-
sonal reasons (moving etc) in 18 cases,med-
ical reasons in 5, and loss of contact in 40.
Twenty subjects were not able to continue
the study for reasons related to the collab-
orative centres themselves, such as the clo-
sure of a center. The rate of withdrawal was
higher amongmen thanwomen (36.9%vs.
19.0%, p < 0.01).”
Comment: reason for loss to follow-up in
intervention group: personal reasons (N =
11);medical reasons (N =3); loss of contact
(N = 21); closure of centres (N = 8); reason
for loss to follow-up in comparator group:
personal reasons (N = 7); medical reasons
(N = 2); loss of contact (N = 19); closure
of centres (N = 12)
A relatively large number of participants
did not complete the trial. However, the
number and reasons for missingness were
balanced between the intervention groups
Incomplete outcome data (attrition bias)
measures of blood glucose control
Unclear risk Quote from publication: “We randomly
assigned the 304 subjects with IGT to two
groups and analyzed the data for 296 indi-
viduals (150 in the control group and 146
in the intervention group) (Figure 1). A
total of 83 subjects (28%) withdrew from
the study before the 3-year mark (40 in the
control group and 43 in the intervention
group). The withdrawals were due to per-
sonal reasons (moving etc) in 18 cases,med-
ical reasons in 5, and loss of contact in 40.
Twenty subjects were not able to continue
the study for reasons related to the collab-
orative centers themselves, such as the clo-
sure of a center. The rate of withdrawal was
higher amongmen thanwomen (36.9%vs.
19.0%, p < 0.01).”
Comment: reason for loss to follow-up in
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intervention group: personal reasons (N =
11);medical reasons (N =3); loss of contact
(N = 21); closure of centres (N = 8); reason
for loss to follow-up in comparator group:
personal reasons (N = 7); medical reasons
(N = 2); loss of contact (N = 19); closure
of centres (N = 12)
A relatively large number of participants
did not complete the trial. However, the
number and reasons for missingness were
balanced between the intervention groups
Selective reporting (reporting bias) High risk Comment: it is clear from publication that
adverse events were collected and HbA1c
analysed, but data could not be entered in
the meta-analysis
Other bias Low risk Comment: no other sources of bias identi-
fied
Kosaka 2005
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:4
Participants Inclusion criteria: impaired glucose tolerance (FPG < 140 mg/dL (7.8 mmol/L) and a
2-h plasma glucose value between 160-239 mg/dL (8.9-13.3 mmol/L) on 100 gOGTTs;
which roughly corresponds to 140-199 mg/dL on 75 g OGTT); men
Exclusion criteria: known DM, diagnosed or suspected malignant neoplasm, diagnosed
or suspected disease of the liver, pancreas, endocrine organs, or kidney; ischaemic heart
disease or cerebrovascular disease or a history of such disease
Diagnostic criteria: IGT roughly according to the WHO 1980 criteria (WHO 1980)
Interventions Number of study centres: -
Treatment before study: -
Titration period: none
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: NR
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “In this paper, we report that the development of diabetes can
be significantly prevented by intervention in lifestyle designed to achieve and maintain
the ideal body weight of each individual during an observation period of 4 years in
subjects with IGT.”
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Notes Only men were included as trial authors expected a higher dropout rate among women
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from publication: “One of every
five subjects was randomly selected for al-
location the intensive intervention group,
and the others were assigned to the stan-
dard intervention (control) group.”
Comment: insufficient information about
the sequence generation process
Allocation concealment (selection bias) Unclear risk Comment: no information
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants de-
scribed. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Unclear risk Comment: investigator-assessed outcome
measure. No blinding of outcome assessors
described. The outcome was not likely to
be influenced by lack of blinding
Incomplete outcome data (attrition bias)
incidence of T2DM
High risk Comment: 88.8% of the originally ran-
domised participants in the intervention
group and 86.2% of the originally ran-
domised participants in the control group
had complete data for the diabetes out-
come. Method of handling missing data
as well as explanation of dropouts was not
stated in the paper
Selective reporting (reporting bias) High risk Comment: no trial protocol available. Gly-
caemic measures analysed but no data re-
ported
Other bias Unclear risk Comment: no funding source provided
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Oldroyd 2005
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: IGT (2-h plasma glucose after an OGTT 140-200 mg/dL (7.8-11.
0 mmol/L)) (WHO 1985); 24-75 years; European origin
Exclusion criteria: pregnant individuals, on therapeutic diets or whose medical condi-
tion prevented them from undertaking moderate physical activity
Diagnostic criteria: IGT (2-h plasma glucose after an OGTT 140-200 mg/dL (7.8-11.
0 mmol/L)) (WHO 1985)
Interventions Number of study centres: 1
Treatment before study: none
Titration period: none
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial funding (British Heart Foundation, Northern & Yorkshire
NHS Research and Development and the Royal College of General Practitioners)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “To evaluate the effectiveness of lifestyle interventions in
people with impaired glucose tolerance (IGT).”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “...using a ran-
dom number table to the intervention or
control group at the first appointment.”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from
publication: “Researchers performing the
randomisation were blinded to the group
allocation.” “There were fewer women (10/
32 (32%)) than men (22/32 (69%)) in the
control group compared with the interven-
tion group...”
Comment: adequate allocation conceal-
ment ensured
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Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants de-
scribed. The outcome was not likely to be
influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants. The
outcome was not likely to be influenced by
lack of blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants de-
scribed. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measure. No blinding described. The out-
comewas not likely to be influenced by lack
of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
High risk Quote from publication: “Fourteen par-
ticipants (five intervention, nine control)
withdrew from the study over 24 months
follow-up. Reasons for withdrawing were
family problems, work commitments or ill
health.” and “Nine participants (three in-
tervention, six control) failed to attend as-
sessments over 24months follow-up. In ad-
dition, one intervention participant died
after a stroke between 12 and 24 months.
Complete results are presented here for 69
participants after 6months, 62 participants
after 12 months and 54 participants after
24 months follow-up (Fig. 1).”
Comment:missing outcome data balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups. Detailed flow chart provided in
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publication.However, only 69%of the par-
ticipants completed the study. This propor-
tion of missing outcomes could have in-
duced clinically relevant bias in interven-
tion effect estimate
Incomplete outcome data (attrition bias)
incidence of T2DM
High risk Quote from publication: “Fourteen par-
ticipants (five intervention, nine control)
withdrew from the study over 24 months
follow-up. Reasons for withdrawing were
family problems, work commitments or ill
health.” and “Nine participants (three in-
tervention, six control) failed to attend as-
sessments over 24months follow-up. In ad-
dition, one intervention participant died
after a stroke between 12 and 24 months.
Complete results are presented here for 69
participants after 6months, 62 participants
after 12 months and 54 participants after
24 months follow-up (Fig. 1).”
Comment:missing outcome data balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups. Detailed flow chart provided in
publication.However, only 69%of the par-
ticipants completed the study. This propor-
tion of missing outcomes could have in-
duced clinically relevant bias in interven-
tion effect estimate
Incomplete outcome data (attrition bias)
measures of blood glucose control
High risk Quote from publication: “Fourteen par-
ticipants (five intervention, nine control)
withdrew from the study over 24 months
follow-up. Reasons for withdrawing were
family problems, work commitments or ill
health.” and “Nine participants (three in-
tervention, six control) failed to attend as-
sessments over 24months follow-up. In ad-
dition, one intervention participant died
after a stroke between 12 and 24 months.
Complete results are presented here for 69
participants after 6months, 62 participants
after 12 months and 54 participants after
24 months follow-up (Fig. 1).”
Comment:missing outcome data balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups. Detailed flow chart provided in
publication.However, only 69%of the par-
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ticipants completed the study. This propor-
tion of missing outcomes could have in-
duced clinically relevant bias in interven-
tion effect estimate
Selective reporting (reporting bias) Unclear risk Comment: no study protocol available
Other bias Low risk Comment: no other sources of bias identi-
fied
PODOSA 2014
Methods Cluster-randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: Indian and Pakistani origin; normal place of residence is in Greater
Glasgow & Clyde or Lothian Health Board areas; given informed consent; IGT on
OGTT at least once or IFG; age ≥ 35 years; waist size of > 90 cm (men) or > 80 cm
(women); no confirmed medical history of diabetes (other than gestational diabetes)
Exclusion criteria: unwilling to give consent to co-operate; T2DMon theOGTTduring
the screening phase of the study; other disease where adherence to the intervention is
contraindicated or improbable e.g. terminal illness or psychological or physical illnesses;
alcohol dependency; planned or actual pregnancy; use of prescribed drugs that affect the
primary outcome; expectation, reported by participants or the general practitioner, that
the person will be emigrating or dying before the conclusion of the trial; failure to make
a commitment to stay in the study until, at least, the 3-year follow-up examination
Diagnostic criteria: IGT (mean 2-h post prandial plasma glucose 7.8-11.0 mmol/L and
FPG < 7.0 mmol/L or IFG (FPG 6.1-6.9 mmol/L)) (WHO 1999)
Interventions Number of study centres: -
Treatment before study: none
Titration period: none
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial (National Prevention Research Initiative)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “To evaluate whether a 3-year family based programme com-
bining weight loss and physical activity can reduce the incidence of type 2 diabetes in
South Asians with impaired glucose tolerance.”
Notes Cluster-randomised trial: family clusters (78 families with 85 participants were allocated
to the intervention group and 78 families with 86 participants were allocated to the
control group. Adult relatives (known as family volunteers) to support participants in
behaviour change. Eligible family volunteers were aged≥ 18 years and reported interact-
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ing with participants at least weekly. 53% of the families in the intervention group had
family volunteers and 56% of the families in the control group. Investigators confirmed
data and provided information on which outcomes were not assessed in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Families were
randomised (using a random number gen-
erator program, with permuted blocks of
random size, stratified by location [Edin-
burgh orGlasgow], ethnic group [Indian or
Pakistani], and number of participants in
the family [one vs more than one]) to inter-
vention or control. Participants in the same
family were not randomised separately”
Comment: adequate generationof random
sequence ensured
Allocation concealment (selection bias) Low risk Quote from publication: “Families were
randomised (using a random number gen-
erator program, with permuted blocks of
random size, stratified by location [Edin-
burgh orGlasgow], ethnic group [Indian or
Pakistani], and number of participants in
the family [one vs more than one]) to inter-
vention or control. Participants in the same
family were not randomised separately”
Comment: adequate allocation conceal-
ment ensured
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
search nurses”
Comment: investigator-assessed outcome
measure. No blinding of participants or in-
vestigators. The outcome was not likely to
be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
104Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PODOSA 2014 (Continued)
waist size, and hip size by independent re-
search nurses”
Comment: investigator-assessed outcome
measure. No blinding of participants or in-
vestigators. The outcome was not likely to
be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
non-serious adverse events
High risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
search nurses”
Comment: self-reported and investigator-
assessed outcome measure. No blinding
of participants or investigators. The out-
come could have been influenced by lack
of blinding
Blinding of participants and personnel
(performance bias)
socioeconomic effects
Low risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
search nurses”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
search nurses”
Comment: investigator-assessed outcome
measure. No blinding. The outcome was
not likely to be influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
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search nurses”
Comment: investigator-assessed outcome
measure. No blinding. The outcome was
not likely to be influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
non-serious adverse events
High risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
search nurses”
Comment: investigator-assessed outcome
measure. No blinding. The outcome could
have been influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
socioeconomic effects
Low risk Quote from publication: “We did this
non-blinded trial in two National Health
Service (NHS) regions in Scotland (UK).”
and “There was no masking of group sta-
tus except for the 3-year measure of weight,
waist size, and hip size by independent re-
search nurses”
Comment: investigator-assessed outcome
measure. The outcome was not likely to be
influenced by lack of blinding
Incomplete outcome data (attrition bias)
incidence of T2DM
Low risk Quote from publication: “Analyses were
by modified intention to treat, excluding
participants who died or were lost to fol-
low-up”
Comment: 95% of the participants in
each intervention group had complete gly-
caemic data after 3 years of intervention.
Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups.
The proportion of missing outcomes was
not enough to have had a clinically relevant
impact on the intervention effect estimate
Incomplete outcome data (attrition bias)
measures of blood glucose control
Low risk Quote from publication: “Analyses were
by modified intention to treat, excluding
participants who died or were lost to fol-
low-up”
Comment: 95% of the participants in
each intervention group had complete gly-
caemic data after 3 years of intervention.
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Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups.
The proportion of missing outcomes was
not enough to have had a clinically relevant
impact on the intervention effect estimate
Incomplete outcome data (attrition bias)
non-serious adverse events
Low risk Quote from publication: “Analyses were
by modified intention to treat, excluding
participants who died or were lost to fol-
low-up”
Comment:missing outcome data balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups. The proportion of missing out-
comes was not enough to have had a clin-
ically relevant impact on the intervention
effect estimate
Incomplete outcome data (attrition bias)
socioeconomic effects
Low risk Quote from publication: “Analyses were
by modified intention to treat, excluding
participants who died or were lost to fol-
low-up”
Comment:missing outcome data balanced
in numbers across intervention groups,
with similar reasons for missing data across
groups. The proportion of missing out-
comes was not enough to have had a clin-
ically relevant impact on the intervention
effect estimate
Selective reporting (reporting bias) Unclear risk Quote from publication: “The primary
outcome of the trial was, therefore, altered
on June 29, 2009, to change in weight at 3
years to ensure sufficient statistical power,
in agreement with the Trial Steering Com-
mittee, Data Monitoring and Ethics Com-
mittee, and funders. Weight change at 3
years was included in the original protocol
as a secondary outcome.”
Comment: the investigator replied that
none of the outcomes that had relevance
to this reviewwere unpublished.Outcomes
that were not published had not been col-
lected (e.g. mortality)
Other bias Low risk Comment: no other sources of bias identi-
fied. The ICC was negative
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SLIM 2003
Methods Parallel, randomised, controlled, clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: mean 2-h blood glucose ≥ 7.8 and ≤ 12.5 mmol/L; mean fasting
blood glucose ≤ 7.8 mmol/L; white; age 40-70 years
Exclusion criteria: known DM; mean 2-hour blood glucose > 12.5 mmol/L; mean
fasting blood glucose > 7.8 mmol/L; any chronic illness that made 5 years’ survival
improbable, or that interfered with glucose tolerance, or that made participation in a
lifestyle-intervention impossible; medication known to interfere with glucose tolerance;
participation in a regular vigorous physical activity and/or diet programme
Diagnostic criteria: impaired glucose tolerance (mean 2-h blood glucose ≥ 7.8 and ≤
12.5 mmol/L; mean fasting blood glucose ≤ 7.8 mmol/L)
Interventions Number of study centres: -
Treatment before study: none
Titration period: none
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial funding (Netherlands Organisation for Scientific Research
(ZonMW: 940-35-034) and the Dutch Diabetes Research Foundation (DFN: 98.901)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: “The high prevalence of disturbances in glucose homeostasis
observed in the preliminary screening underscore the importance of early (lifestyle)
interventions in those at risk for developing diabetes. SLIM will address this topic in the
Dutch population.”
Notes Glycacemic measures in the inclusion criteria are expressed as venous blood glucose and
not as plasma glucose
Originally, the trial follow-up was planned to have a duration of the intervention for
3 years, but was extended to 6 years during the study. In 2002, a 2nd screening was
performed and additional 33 participants were included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from publication: “Randomisa-
tion was carried out with stratification for
sex and mean 2 h-plasma glucose concen-
tration.”
Comment: insufficient information about
the sequence generation process
Allocation concealment (selection bias) Unclear risk Comment: no information
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Blinding of participants and personnel
(performance bias)
all-cause mortality/cardiovascular mortal-
ity
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants or in-
vestigators described. The outcomewas not
likely to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants or in-
vestigators described. The outcomewas not
likely to be influenced by lack of blinding
Blinding of participants and personnel
(performance bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measure. No blinding of participants or in-
vestigators described. The outcomewas not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
all-cause/cardiovascular mortality
Low risk Comment: investigator-assessed outcome
measure. No blinding of investigators de-
scribed. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
incidence of T2DM
Low risk Comment: investigator-assessed outcome
measure. No blinding of investigators de-
scribed. The outcome was not likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
measures of blood glucose control
Low risk Comment: investigator-assessed outcome
measure. No blinding of investigators de-
scribed. The outcome was not likely to be
influenced by lack of blinding
Incomplete outcome data (attrition bias)
all-cause/cardiovascular mortality
Low risk Comment: mortality status was unknown
in1person in each intervention group (Fig-
ure 1; Roumen et al. European Journal of
Clinical Nutrition (2011)). This propor-
tion of missing outcomes was not enough
to have had a clinically relevant impact on
the intervention effect estimate
Incomplete outcome data (attrition bias)
incidence of T2DM
High risk Comment: 47% in the intervention group
and 48% in the control group completed
6 years’ follow-up. Not described how the
missing data for this variable was handled.
The proportion of missing data was large
enough to have had a clinically relevant
impact on the intervention effect estimate.
Besides, it was clear from the publication
that the participants who dropped out were
more obese, had higher glucose values on a
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2-h OGTT and had lower economic status
at baseline
Incomplete outcome data (attrition bias)
measures of blood glucose control
High risk Quote from publication: “Changes over
time between groups were assessed using
mixedmodel analysis on intention-to-treat,
which included all available observations,
including those from later dropouts.”
Comment: 77% of the participants ini-
tially randomised to the intervention group
and 79% in the control group were in-
cluded in the analyses of glycaemic mea-
sures. This proportion of missing data was
large enough to have had a clinically rele-
vant impact on the intervention effect es-
timate. Besides, it was clear from the pub-
lication that the participants who dropped
out at baseline weremore obese, had higher
glucose values on a 2-h OGTT and had
lower economic status
Selective reporting (reporting bias) Unclear risk Comment: no study protocol available
Other bias Unclear risk Comment: not reported in the publica-
tions why the duration of the intervention
was prolonged. No data available after 6
years of intervention
Note: where the judgement is ’Unclear’ and the description is blank, the study did not report that particular outcome.
- denotes not reported
ADA:AmericanDiabetesAssociation; BMI: bodymass index;CVD: cardiovascular disease;DBP: diastolic bloodpressure;DM: diabetes
mellitus; DPP:Diabetes Prevention Program;DPPA: diet plus physical activity; DPPOS:Diabetes Prevention ProgramOutcome Study;
DPS: Diabetes Prevention Study; EDIPS: European Diabetes Prevention Study; FPG: fasting plasma glucose; HbA1c: glycosylated
haemoglobin A1c; HELP PD: Healthy Living Partnerships to Prevent Diabetes; HRQoL: health-related quality of life; ICC: intra-
cluster coefficient; IDPP: Indian Diabetes Prevention Programmes; IFG: impaired fasting glucose; IGT: impaired glucose tolerance;
JDPP: Japan Diabetes Prevention Program; NYHA: New York Heart Association; OGTT: oral glucose tolerance test; PODOSA:
Prevention of Diabetes and Obesity in South Asians; SBP: systolic blood pressure; SLIM: Study on Lifestyle-intervention and Impaired
glucose tolerance Maastricht; T2DM: type 2 diabetes mellitus; WHO: World health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
APHRODITE Included normoglycaemic people and people with intermediate hyperglycaemia. Partic-
ipants have a high FIND-RISK score, but not necessarily intermediate hyperglycaemia
Bo 2007 The trial did not have intermediate hyperglycaemia as an inclusion criterion
D-CLIP Duration of the intervention < 2 years
De la Rosa 2007 Not a randomised trial
DH!AAN Outcomes only reported after 1 year of intervention
Quote from publication: “At the time of registration of the trial, the intended primary
outcome was the 3-year incidence of type 2 diabetes. However, as the initial response
rate was lower than expected, the recruitment period had to be extended to 2 years. Due
to a fixed end date of the study (grant restrictions), the follow-up time was reduced to
2 years. As this period was too short to properly investigate differences in incidence of
type 2 diabetes between the control and intervention group, we changed the primary
outcome to the more proximal outcomes, namely changes in weight and other weight-
related measurements (body mass index, waist circumference, and fat mass) after 1 year.
Secondary outcomes were changes in glucose metabolism, blood pressure, and lipid
profile after 1 year.”
E-LITE Included participants with metabolic syndrome or intermediate hyperglycaemia
Eriksson 1991 Inadequate randomisation, the control group was not randomised
Eriksson 2006 Included participants with T2DM
Grey 2004 Both experimental and control groups received the same nutritional education and
physical activity training
Hesselink 2013 Duration of the intervention < 2 years
Huang 2007 Duration of the intervention < 2 years
J-DOIT Duration of the intervention < 2 years
Jarrett 1979 Not comparing intervention of interest (carbohydrate 120 g/day + placebo versus ’limit
sucrose (i.e. table sugar) intake’ + placebo)
Kawahara 2008 Duration of the intervention < 2 years
Kinmonth 2008 Included participants being overweight and having a parental history of diabetes - the
number of participants with intermediate hyperglycaemia was not available. Duration
of the intervention < 2 years
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Let’s Prevent Same intensity of diet and physical activity was applied in the intervention and com-
parator group
Liao 2002 Not comparing intervention of interest (diet plus endurance physical activity versus diet
plus stretching)
Lindahl 1999 Duration of the intervention < 2 years (intervention performed after 1 year was a tele-
phone call at 24 months)
Marrero 2016 Duration of the intervention < 2 years
Nanditha 2014 Same intensity of diet and physical activity was applied in the intervention and com-
parator group
NCT02250066 Did not compare interventions of interest (mono-saturated fat versus high carbohydrate
diet)
NCT02374788 Included participants with T2DM
Page 1992 Duration of the intervention < 2 years
PULSE Same intensity of diet and physical activity in the intervention arms
Ramachandran 2013 Duration of the intervention < 2 years
Rosas 2016 Included participants with metabolic syndrome
Saito 2011 Same intensity of diet and physical activity was applied in the intervention and com-
parator group
Sartor 1980 No description of the diet-only group
Sathish 2017 Duration of the intervention < 2 years
Savoye 2007 Duration of the intervention < 2 years
Schmidt 2016 Included participants with gestational diabetes
SHINE Included participants with metabolic syndrome
Tao 2004 Inadequate randomisation: quasi-randomised participants
The Fasting Hyperglycaemia Study 1997a Not possible to get separate data on the participants with impaired glucose tolerance
(RuryHolmanwas askedwhen request wasmade in another review (Hemmingsen 2016)
). This article describes 37% of participants with normal glucose tolerance, 26% with
T2DM and 37% with impaired glucose tolerance
112Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Thompson 2008 Duration of the intervention < 2 years
Villareal 2006 Duration of the intervention < 2 years
Wein 1999 Same intensity of diet and physical activity was applied in the intervention and com-
parator group
Wing 1998 Included participants being overweight and a parental history of diabetes - the number
of participants with intermediate hyperglycaemia was not available
Wong 2013 Same intensity of diet and physical activity was applied in the intervention and com-
parator group
Yates 2011 Duration of the intervention < 2 years
Yates 2012 Intermediate hyperglycaemia was not an inclusion criterion
APHRODITE: Active Prevention in High Risk individuals OfDIabetes Type 2 in Eindhoven; D-CLIP: Diabetes Community Lifestyle
Improvement Program; FIND-RISK: Finish Diabetes RIsk Score; J-DOIT1: Japan Diabetes Outcome Intervention Trial-1; T2DM:
type 2 diabetes mellitus
Characteristics of studies awaiting assessment [ordered by study ID]
130750-201504-HR-020
Methods Parallel, randomised, controlled, clinical trial (RCT)
Randomisation ratio: 1:1:1
Participants Condition: IFG (5.6-6.9 mmol/L) or moderately elevated HbA1c (5.7%-6.4%)
Enrollment: 1200
Inclusion criteria: IFG or moderately elevated HbA1c, 30-70 years
Interventions Intervention 1: concealing of lifestyle modification aimed at reducing weight, total intake of carbohydrate, fat and
saturated fat, increasing intake of fibre and physical activity level
Intervention 2: periodic health examination during a 3-month period for monitoring fasting blood glucose and
HbA1c
Comparator: periodic health examination during a 1-year period for checking health status about T2DM
Duration of the intervention: not clearly described
Outcomes Primary outcome(s): HbA1c
Secondary outcome(s): fasting blood glucose
Other outcome(s): -
Notes Study protocol for an ongoing trial. Not possible to estimate the duration of the intervention from the study protocol.
Investigators were asked, but no reply
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ChiCTR-PRC-13003267
Methods Parallel, randomised, controlled, clinical trial (RCT)
Randomisation ratio: 1:1
Participants Condition: IGT and/or IFG
Enrollment: not reported
Inclusion criteria: Chinese, 40-69 years, IGT and/or IFG and < 150 min/week of moderate/vigorous physical
activity
Interventions Intervention: individualised physical activity plan
Comparator: not specified
Duration of the intervention: not clearly described
Outcomes Primary outcome(s): -
Secondary outcome(s): -
Other outcome(s): physical activity level and blood glucose level
Notes Study protocol for an ongoing trial. Not possible to estimate the duration of the intervention from the study protocol.
Priority of outcomes not described in protocol. Investigators were asked, but no reply
iHealth-T2D
Methods Parallel, randomised, controlled, clinical trial (RCT)
Randomisation ratio: 1:1
Participants Condition: waist circumference ≥ 100 cm or HbA1c ≥ 6.0%
Enrollment: 3600
Inclusion criteria: waist circumference ≥ 100 cm or HbA1c ≥ 6.0%; South Asian, 40-70 years
Interventions Intervention: intensive lifestyle modification
Comparator: usual care
Duration of the intervention: assume 1 year
Outcomes Primary outcome(s): incidence of T2DM and > 7% reduction in weight
Secondary outcome(s): reduction of ≥ 5 cm waist circumference and health gains in family members
Other outcome(s): identifying social, demographic and environmental factors influencing primary and secondary
outcomes
Notes Protocol for an ongoing trial. Unknown if data would be presented for the participants included based on moderately
elevated HbA1c. Duration of the intervention might be too short for inclusion in this review
NDPS
Methods Parallel, randomised, controlled, clinical trial (RCT)
Randomisation ratio: 1:1
Participants Condition: HbA1c ≥ 6.0 to < 6.5% and a normal fasting plasma glucose (< 5.6 mmol/L)
Enrollment: -
Inclusion criteria: HbA1c ≥ 6.0 to < 6.5%
114Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NDPS (Continued)
Interventions Intervention: intensive diet plus physical activity advice
Comparator: standard control
Duration of the intervention: 40 months
Outcomes Primary outcome(s): HbA1c
Secondary outcome(s): homeostasis model assessment, physical activity levels, dietary intake, weight, body fat mass,
visceral fat, BMI and waist circumference and health status
Other outcome(s): -
Notes A fraction of participants in an ongoing randomised clinical trial
Zong 2015
Methods Parallel, randomised, controlled, clinical trial (RCT)
Randomisation ratio: 1:1
Participants Condition: IFG (6.1-6.9 mmol/L) and/or IGT (2-h OGTT 7.8-11.0 mmol/L)
Enrollment: 214
Inclusion criteria: IFG and/or IGT
Interventions Intervention: not described
Comparator: not described
Duration of the intervention: 2 years
Outcomes Primary outcome(s): HbA1c
Secondary outcome(s): homeostasis model assessment, physical activity levels, dietary intake, weight, body fat mass,
visceral fat, BMI and waist circumference and health status
Other outcome(s): -
Notes We are currently searching for Chinese authors to help clarify the intervention
HbA1c: glycosylated haemoglobin A1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; OGTT: oral glucose tolerance
test; PDPP: Pakistan Diabetes Prevention Program; T2DM: type 2 diabetes mellitus
Characteristics of ongoing studies [ordered by study ID]
NCT01530165
Trial name or title Acronym: PDPP
Methods Type of study: efficacy study
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
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NCT01530165 (Continued)
Participants Condition: impaired glucose tolerance (WHO)
Enrollment: 20,000
Inclusion criteria: IGT; 30-64 yrs
Exclusion criteria: T1DM; T2DM; pregnancy; presence of chronic disease rendering survival for 3 years
unlikely; any psychological or physical disability to interfere with participation in the trial; ischaemic heart
disease
Interventions Intervention(s): aggressive lifestyle intervention consisting of nutritional and physical activity advice
Comparator(s): standard advice
Duration of the intervention: 2 years
Outcomes Primary outcome(s): incidence of T2DM
Secondary outcome(s): cost effectiveness; components of the metabolic syndrome; the impact of city
planning on prevalence of obesity and T2DM
Other outcome(s): -
Starting date Study start date: 2011
Study completion date: June 2017
Contact information Responsible party/principal investigator: Asma Ahmed, Aga Khan University
Study identifier NCT number: NCT01530165
Official title Pakistan Diabetes Prevention Program
Stated purpose of study Quote from publication: “The Karachi-based Pakistan Diabetes Prevention Study aims to address key
issues in the prevention of type 2 diabetes ”
Notes The study completion date is provided by the principal investigator. Conducted in Pakistan
PREVIEW
Trial name or title Acronym: PREVIEW
Methods Type of study: efficacy study
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
Participants Condition: IFG or IGT (IFG: fasting venous plasma glucose concentration 5.6-6.9 mmol/L or IGT:
venous plasma glucose concentration of 7.8-11.0 mmol/L at 2-h after oral administration of 75 g glucose
with fasting plasma glucose less than 7.0 mmol/L)
Enrollment: 2500
Inclusion criteria: age 25-70 years; overweight or obesity (BMI > 25 kg/m2); IFG or IGT; informed
consent required; provided participants have not recently (within 1 month) changed habits; motivation
and willingness to be randomised to any of the groups and to do his/her best to follow the given protocol
Exclusion criteria: diabetes mellitus (other than gestational diabetes mellitus); significant cardiovascular
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PREVIEW (Continued)
disease including current angina; myocardial infarction or stroke within the past 6 months; heart failure;
symptomatic peripheral vascular disease; systolic blood pressure above 160 mmHg and/or diastolic blood
pressure above 100 mmHg whether on or off treatment for hypertension. If being treated, no change
in drug treatment within last 3 months; advanced chronic renal impairment; significant liver disease e.g.
cirrhosis (fatty liver disease allowed); malignancy which is currently active or in remission for < 5 years
after last treatment (local basal and squamous cell skin cancer allowed); active inflammatory bowel disease,
celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption; previous bariatric
surgery; chronic respiratory, neurological, musculoskeletal or other disorders where, in the judgement of
the investigator, participants would have unacceptable risk or difficulty in complying with the protocol
(e.g. physical activity programme); a recent surgical procedure until after full convalescence (investigators
judgement); transmissible blood-borne diseases; psychiatric illness (e.g. major depression, bipolar disorder)
; use currently or within the previous 3months of prescription medication that has the potential of affecting
body weight or glucose metabolism such as glucocorticoids (but excluding inhaled and topical steroids;
bronchodilators are allowed); psychoactive medication, epileptic medication, or weight loss medications
(either prescription, over the counter or herbal). Low-dose antidepressants are allowed if they, in the
judgement of the investigator, do not affect weight or participation to the study protocol. Levothyroxine
for treatment of hypothyroidism is allowed if the participant has been on a stable dose for at least 3 months;
engagement in competitive sports; self-reported weight change of > 5% (increase or decrease) within 2
months prior to screening; special dietswithin 2months prior to study start; severe food intolerance expected
to interfere with the study; regularly drinking > 21 alcoholic units/week (men), or > 14 alcoholic units/
week (women); use of drugs of abuse within the previous 12 months; blood donation or transfusion within
the past 1 month before baseline; self-reported eating disorders; pregnancy or lactation, including plans to
become pregnant within the next 36 months; no access to either phone or Internet (this is necessary when
being contacted by the instructors during the maintenance phase); adequate understanding of national
language; psychological or behavioural problems which, in the judgement of the investigator, would lead
to difficulty in complying with the protocol; haemoglobin concentration below local laboratory reference
values (i.e. anaemia); creatinine > 1.5 times Upper Limit of Normal (local laboratory reference values);
alanine transaminase and/or aspartate transaminase > 3 times the Upper Limit of Normal (local laboratory
reference values) or any other significant abnormality on these tests which in the investigators opinion may
be clinically significant and require further assessment; electrocardiography. Any abnormality which in the
opinion of the investigator might indicate undiagnosed cardiac disease requiring further assessment (e.g.
significant conduction disorder, arrhythmia, pathological Q waves). This is done in adults 55-70 years of
age
Interventions Intervention(1): high protein/high-intensity physical activity
Intervention(2): high protein/moderate-intensity physical activity
Intervention(3): moderate protein/high-intensity physical activity
Intervention(4): moderate protein/moderate-intensity physical activity
Comparator(s): participants follow a moderate protein diet and moderate-intensity physical activity in-
tervention
Duration of the intervention: 3 years
Outcomes Primary outcome(s): incidence of T2DM
Secondary outcome(s): HbA1c; change in body weight and waist, hip and thigh circumference; change in
body fat mass (kg, proportion of body weight); proportion of participants maintaining at least 0%, 5% or
10% weight loss (relative to initial body weight); insulin sensitivity; risk factors for cardiovascular disease,
with at least the following measures: blood pressure, lipids (triglycerides, total, low-density lipoprotein and
high-density lipoprotein cholesterol), C-reactive protein, and liver enzymes; changes in perceived quality
of life and work ability, habitual well-being, sleep and chronic stress, subjective appetite sensations, and
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PREVIEW (Continued)
habitual physical activity; the effects of stature (height; proportion leg-length/height) in adults and changes
in stature in children and adolescents, on the changes in relationship between reduction in body weight,
body fat and insulin sensitivity
Other outcome(s): -
Starting date Study start date: June 2013
Study completion date: December 2018
Contact information Responsible party/principal investigator: Anne Birgitte Raben, Professor, University of Copenhagen
Study identifier NCT number: NCT01777893
Official title PREVention of Diabetes Through Lifestyle Intervention and Population Studies in Europe and Around
the World
Stated purpose of study Quote: “Our hypothesis is that a high-protein, low-GI diet will be superior in preventing type-2 diabetes,
compared with a moderate protein, moderate GI diet, and that high-intensity physical activity will be
superior compared to moderate-intensity physical activity”
Notes -
PROPELS
Trial name or title Acronym: PROPELS
Methods Type of study: efficacy study
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
Participants Condition: intermediate hyperglycaemia
Enrollment: 1308
Inclusion criteria: 40-74 years old for white European, or aged 25-74 years old for South Asian; previously
recorded plasma glucose or HbA1c value in the prediabetes range within the last
5 years; have access to a mobile phone, and willing to use it as part of the study
Exclusion criteria: due to the nature of the intervention those unable to undertake ambulatory-based
activity will be excluded; T2DM; screen-detected diabetes at baseline; pregnancy; normoglycaemia with
no previous record of intermediate hyperglycaemia in the previous 5 years
Interventions Intervention(s): diet as the comparator group, but additional physical activity provided
Comparator(s): receive a booklet detailing information on risk factors for T2DM and cardiovascular
disease and how physical activity can be used to prevent T2DM and cardiovascular disease
Duration of the intervention: 48 months
Outcomes Primary outcome(s): change in ambulatory activity
Secondary outcome(s): time spent in sedentary, light, moderate and vigorous intensity physical activity
assessed by accelerometer and self report; website use and text messages sent/received (intervention group
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PROPELS (Continued)
3 only); fasting and 2-h post-challenge glucose and HbA1c; fasting lipid profile, fasting insulin, highly
sensitive C-reactive protein, key adipokines (interleukin 6 and tumour necrosis factor alpha), urea and
electrolytes (sodium, potassium, urea, creatinine) and liver function tests; markers of chronic inflammation
and adipokines; vitamin C and D; genetic analysis; urine sample; height; body weight; BMI; body fat
percentage; waist circumference; arm and leg length; blood pressure; medication status; smoking status;
family history of disease; muscular/skeletal injury; illness perceptions; self efficacy; self regulation; quality
of life; depression and anxiety; diet; sleep; body composition
Other outcome(s):-
Starting date Study start date: August 2013
Study completion date: August 2018
Contact information Responsible party/principal investigator: University of Leicester, UK
Study identifier ISRCTN: 83465245
Official title The PRomotionOfPhysical activity through structuredEducationwith differingLevels of ongoing Support
for those with pre-diabetes
Stated purpose of study Quote: “Can an intervention to support physical activity behaviour change lead to sustained increases in
physical activity over four years in those with a high risk of type 2 diabetes.”
Notes -
BMI: bodymass index;HbA1c: glycosylated haemoglobinA1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; T1DM:
type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus
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D A T A A N D A N A L Y S E S
Comparison 1. Physical activity versus comparator
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Incidence of type 2 diabetes 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Serious adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Fasting plasma glucose 2 Mean Difference (IV, Random, 95% CI) Subtotals only
5 2 hour glucose values 2 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 2. Diet plus physical activity versus comparator
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
2 All-cause mortality: duration of
intervention
10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
2.1 ≥ 4 years 3 817 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.33, 5.28]
2.2 < 4 years 7 3282 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.38, 2.77]
3 All-cause mortality: diagnostic
criteria
10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
3.1 IGT 9 3798 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
3.2 Other criteria 1 301 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 All-cause mortality: age 10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
4.1 Age ≥ 50 years 8 3682 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.39, 2.66]
4.2 Age < 50 years 2 417 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.32, 6.16]
5 All-cause mortality: sex 10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
6 All-cause mortality: ethnicity 10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
6.1 Asian 4 797 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.37, 4.39]
6.2 (Predominantly)White 6 3302 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.36, 2.94]
7 All-cause mortality: obesity 10 4099 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.50, 2.50]
7.1 BMI ≥ 30 6 3322 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.36, 2.94]
7.2 BMI < 30 4 777 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.37, 4.39]
8 Incidence of type 2 diabetes 11 4511 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
9 Incidence of type 2 diabetes:
duration of the intervention
11 4511 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
9.1 Long duration (≥ 4 years) 4 1249 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.41, 0.74]
9.2 Short duration (< 4 years) 7 3262 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.48, 0.67]
10 Incidence of type 2 diabetes:
diagnostic criteria
11 4511 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
10.1 IGT 10 4210 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.66]
10.2 Other criteria 1 301 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.12, 1.11]
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11 Incidence of type 2 diabetes:
age
11 4511 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
11.1 age ≥ 50 years 9 4110 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.44, 0.58]
11.2 age < 50 years 2 401 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.57, 0.85]
12 Incidence of type 2 diabetes:
ethnicity
11 4511 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
12.1 Asian 5 1235 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.56, 0.81]
12.2 (Predominantly)White 6 3276 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.43, 0.58]
13 Incidence of type 2 diabetes:
obesity
11 4511 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
13.1 BMI ≥ 30 kg/m2 6 3318 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.43, 0.58]
13.2 BMI < 30 kg/m2 5 1193 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.55, 0.80]
14 Cardiovascular mortality 7 3263 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.24, 3.65]
15 Non-fatal stroke 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16 Non-serious adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17 Amputation of lower extremity 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18 Fasting plasma glucose 10 3530 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.06]
19 Fasting plasma glucose:
duration of intervention
10 3530 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.06]
19.1 Long duration (≥ 4
years)
3 697 Mean Difference (IV, Random, 95% CI) -0.12 [-0.24, 0.01]
19.2 Short duration (< 4
years)
7 2833 Mean Difference (IV, Random, 95% CI) -0.17 [-0.30, -0.03]
20 Fasting plasma glucose:
diagnostic criteria
10 3530 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.06]
20.1 IGT 9 3269 Mean Difference (IV, Random, 95% CI) -0.14 [-0.26, -0.01]
20.2 Other criteria 1 261 Mean Difference (IV, Random, 95% CI) -0.30 [-0.46, -0.14]
21 Fasting plasma glucose: age 10 3530 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.06]
21.1 Age ≥ 50 years 8 3150 Mean Difference (IV, Random, 95% CI) -0.14 [-0.26, -0.03]
21.2 Age < 50 years 2 380 Mean Difference (IV, Random, 95% CI) -0.41 [-0.78, -0.04]
22 Fasting plasma glucose:
ethnicity
10 3530 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.06]
22.1 Asian 4 760 Mean Difference (IV, Random, 95% CI) -0.13 [-0.30, 0.05]
22.2 (Predominantly) White 6 2770 Mean Difference (IV, Random, 95% CI) -0.17 [-0.30, -0.04]
23 Fasting plasma glucose: obesity 10 3530 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.06]
23.1 BMI ≥ 30 kg/m2 6 2822 Mean Difference (IV, Random, 95% CI) -0.16 [-0.30, -0.03]
23.2 < 30 kg/m2 4 708 Mean Difference (IV, Random, 95% CI) -0.15 [-0.34, 0.05]
24 2h plasma glucose 9 3261 Mean Difference (IV, Random, 95% CI) -0.46 [-0.79, -0.12]
25 2 hour plasma glucose: duration
of the intervention
9 3261 Mean Difference (IV, Random, 95% CI) -0.46 [-0.79, -0.12]
25.1 Long duration (≥ 4
years)
3 697 Mean Difference (IV, Random, 95% CI) -0.91 [-1.77, -0.05]
25.2 Short duration (< 4
years)
6 2564 Mean Difference (IV, Random, 95% CI) -0.31 [-0.70, 0.08]
26 2 hour plasma glucose: age 9 3261 Mean Difference (IV, Random, 95% CI) -0.46 [-0.79, -0.12]
26.1 Age ≥ 50 years 7 2881 Mean Difference (IV, Random, 95% CI) -0.27 [-0.49, -0.05]
26.2 Age < 50 years 2 380 Mean Difference (IV, Random, 95% CI) -1.62 [-2.49, -0.76]
27 2 hour plasma glucose:
ethnicity
9 3261 Mean Difference (IV, Random, 95% CI) -0.46 [-0.79, -0.12]
27.1 Asian 4 760 Mean Difference (IV, Random, 95% CI) -0.93 [-1.72, -0.14]
27.2 (Predominantly) White 5 2501 Mean Difference (IV, Random, 95% CI) -0.26 [-0.55, 0.03]
28 2 hour plasma glucose: obesity 9 3261 Mean Difference (IV, Random, 95% CI) -0.46 [-0.79, -0.12]
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28.1 BMI ≥ 30 kg/m2 5 2553 Mean Difference (IV, Random, 95% CI) -0.26 [-0.55, 0.02]
28.2 BMI < 30 kg/m2 4 708 Mean Difference (IV, Random, 95% CI) -0.95 [-1.77, -0.13]
29 Serious adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
30 Hypoglycaemia 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
31 HbA1c 4 2453 Mean Difference (IV, Random, 95% CI) -0.11 [-0.23, 0.02]
32 Non-fatal myocardial infarction 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
33 End-stage renal disease 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
34 HbA1c: duration of the
intervention
4 2453 Mean Difference (IV, Random, 95% CI) -0.11 [-0.23, 0.02]
34.1 ≥ 4 years 2 549 Mean Difference (IV, Random, 95% CI) -0.08 [-0.37, 0.21]
34.2 < 4 years 2 1904 Mean Difference (IV, Random, 95% CI) -0.07 [-0.36, 0.22]
35 HbA1c: obesity 4 2453 Mean Difference (IV, Random, 95% CI) -0.11 [-0.23, 0.02]
35.1 BMI ≥ 30 kg/m2 3 2338 Mean Difference (IV, Random, 95% CI) -0.15 [-0.27, -0.04]
35.2 BMI < 30 kg/m2 1 115 Mean Difference (IV, Random, 95% CI) 0.10 [-0.17, 0.37]
Analysis 1.1. Comparison 1 Physical activity versus comparator, Outcome 1 All-cause mortality.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 1 Physical activity versus comparator
Outcome: 1 All-cause mortality
Study or subgroup
Favours
physical
activity Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 0/81 2/76 0.19 [ 0.01, 3.85 ]
Hellgren 2016 (2) 3/84 1/39 1.39 [ 0.15, 12.97 ]
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours physical activity Favours control
(1) After 6 yrs of intervention; corrected with design effect of 1.75
(2) Data provided by the investigators
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Analysis 1.2. Comparison 1 Physical activity versus comparator, Outcome 2 Incidence of type 2 diabetes.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 1 Physical activity versus comparator
Outcome: 2 Incidence of type 2 diabetes
Study or subgroup Physical activity Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 58/141 90/133 0.61 [ 0.48, 0.76 ]
Hellgren 2016 (2) 10/84 7/39 0.66 [ 0.27, 1.61 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours physical activity Favours control
(1) After 6 yrs of intervention; corrected with design effect of 1.75
(2) After 3 years of intervention
Analysis 1.3. Comparison 1 Physical activity versus comparator, Outcome 3 Serious adverse events.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 1 Physical activity versus comparator
Outcome: 3 Serious adverse events
Study or subgroup Physical activity Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 0/81 0/76 Not estimable
Hellgren 2016 3/66 1/31 1.41 [ 0.15, 13.01 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours physical activity Favours control
(1) After 6 yrs of intervention
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Analysis 1.4. Comparison 1 Physical activity versus comparator, Outcome 4 Fasting plasma glucose.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 1 Physical activity versus comparator
Outcome: 4 Fasting plasma glucose
Study or subgroup Physical activity Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
Da Qing 1997 (1) 81 6.8 (2.2) 76 7.6 (2.6) -0.80 [ -1.56, -0.04 ]
Hellgren 2016 (2) 66 -0.4 (0.7) 31 -0.2 (0.6) -0.20 [ -0.47, 0.07 ]
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours physical activity Favours control
(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Data provided by investigators
Analysis 1.5. Comparison 1 Physical activity versus comparator, Outcome 5 2 hour glucose values.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 1 Physical activity versus comparator
Outcome: 5 2 hour glucose values
Study or subgroup Physical activity Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
Da Qing 1997 (1) 81 10.5 (3.9) 76 12.4 (4.2) -1.90 [ -3.17, -0.63 ]
Hellgren 2016 64 -0.2 (1.7) 30 -0.1 (1.9) -0.10 [ -0.90, 0.70 ]
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours physical activity Favours control
(1) End of FU values after 6 yrs of intervention; adjusted for clustering
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Analysis 2.1. Comparison 2 Diet plus physical activity versus comparator, Outcome 1 All-cause mortality.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 1 All-cause mortality
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
DPP 2002 (2) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
EDIPS 2009 (3) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
HELP PD 2011 0/151 0/150 Not estimable
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Diet + physical activity Comparator
(1) Adjusted for clustering
(2) Estimated cumulative mortality at three years
(3) Data provided by authors
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Analysis 2.2. Comparison 2 Diet plus physical activity versus comparator, Outcome 2 All-cause mortality:
duration of intervention.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 2 All-cause mortality: duration of intervention
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 4 years
Da Qing 1997 (1) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Subtotal (95% CI) 411 406 33.6 % 1.32 [ 0.33, 5.28 ]
Total events: 4 (Diet + physical activity), 3 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 < 4 years
DPP 2002 (2) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
EDIPS 2009 (3) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
HELP PD 2011 0/151 0/150 Not estimable
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
Subtotal (95% CI) 1638 1644 66.4 % 1.03 [ 0.38, 2.77 ]
Total events: 8 (Diet + physical activity), 7 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.93, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
0.005 0.1 1 10 200
Diet + physical activity Comparator
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(1) adjusted for clustering
(2) Estimated cumulative mortality at three years
(3) Data provided by authors
Analysis 2.3. Comparison 2 Diet plus physical activity versus comparator, Outcome 3 All-cause mortality:
diagnostic criteria.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 3 All-cause mortality: diagnostic criteria
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IGT
Da Qing 1997 (1) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
DPP 2002 (2) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
EDIPS 2009 (3) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Subtotal (95% CI) 1898 1900 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Other criteria
HELP PD 2011 0/151 0/150 Not estimable
Subtotal (95% CI) 151 150 Not estimable
Total events: 0 (Diet + physical activity), 0 (Comparator)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.005 0.1 1 10 200
Diet + physical activity Comparator
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(. . . Continued)
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Diet + physical activity Comparator
(1) adjusted for clustering
(2) Estimated cumulative mortality at three years
(3) Data provided by authors
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Analysis 2.4. Comparison 2 Diet plus physical activity versus comparator, Outcome 4 All-cause mortality:
age.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 4 All-cause mortality: age
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Age≥ 50 years
DPP 2002 (1) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
EDIPS 2009 (2) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
HELP PD 2011 0/151 0/150 Not estimable
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Subtotal (95% CI) 1844 1838 70.7 % 1.02 [ 0.39, 2.66 ]
Total events: 8 (Diet + physical activity), 7 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.82, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Age < 50 years
Da Qing 1997 (3) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
Subtotal (95% CI) 205 212 29.3 % 1.40 [ 0.32, 6.16 ]
Total events: 4 (Diet + physical activity), 3 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
0.005 0.1 1 10 200
Diet + physical activity Comparator
(1) Estimated cumulative mortality at three years
(2) Data provided by authors
(3) adjusted for clustering
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Analysis 2.5. Comparison 2 Diet plus physical activity versus comparator, Outcome 5 All-cause mortality:
sex.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 5 All-cause mortality: sex
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
DPP 2002 (2) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
EDIPS 2009 (3) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
HELP PD 2011 0/151 0/150 Not estimable
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Diet + physical activity Comparator
(1) adjusted for clustering
(2) Estimated cumulative mortality at three years
(3) Data provided by authors
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Analysis 2.6. Comparison 2 Diet plus physical activity versus comparator, Outcome 6 All-cause mortality:
ethnicity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 6 All-cause mortality: ethnicity
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Asian
Da Qing 1997 (1) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
Subtotal (95% CI) 392 405 42.1 % 1.27 [ 0.37, 4.39 ]
Total events: 5 (Diet + physical activity), 4 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.10, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 (Predominantly)White
DPP 2002 (2) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
EDIPS 2009 (3) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
HELP PD 2011 0/151 0/150 Not estimable
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Subtotal (95% CI) 1657 1645 57.9 % 1.02 [ 0.36, 2.94 ]
Total events: 7 (Diet + physical activity), 6 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.005 0.1 1 10 200
Diet + physical activity Comparator
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(1) adjusted for clustering
(2) Estimated cumulative mortality at three years
(3) Data provided by authors
Analysis 2.7. Comparison 2 Diet plus physical activity versus comparator, Outcome 7 All-cause mortality:
obesity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 7 All-cause mortality: obesity
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMI≥ 30
DPP 2002 (1) 3/1079 5/1082 31.7 % 0.60 [ 0.14, 2.51 ]
DPS 2001 1/265 0/257 6.3 % 2.91 [ 0.12, 71.10 ]
EDIPS 2009 (2) 2/51 0/51 7.1 % 5.00 [ 0.25, 101.63 ]
HELP PD 2011 0/151 0/150 Not estimable
Oldroyd 2005 1/37 0/32 6.4 % 2.61 [ 0.11, 61.80 ]
PODOSA 2014 0/84 1/83 6.4 % 0.33 [ 0.01, 7.97 ]
Subtotal (95% CI) 1667 1655 57.9 % 1.02 [ 0.36, 2.94 ]
Total events: 7 (Diet + physical activity), 6 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 BMI < 30
Da Qing 1997 (3) 3/72 2/76 20.9 % 1.58 [ 0.27, 9.20 ]
IDPP 2006 1/133 1/136 8.5 % 1.02 [ 0.06, 16.18 ]
JDPP 2013 1/103 0/110 6.4 % 3.20 [ 0.13, 77.72 ]
SLIM 2003 0/74 1/73 6.4 % 0.33 [ 0.01, 7.94 ]
Subtotal (95% CI) 382 395 42.1 % 1.27 [ 0.37, 4.39 ]
Total events: 5 (Diet + physical activity), 4 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.10, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
0.005 0.1 1 10 200
Diet + physical activity Comparator
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(. . . Continued)
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 2049 2050 100.0 % 1.12 [ 0.50, 2.50 ]
Total events: 12 (Diet + physical activity), 10 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.00, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.005 0.1 1 10 200
Diet + physical activity Comparator
(1) Estimated cumulative mortality at three years
(2) Data provided by authors
(3) adjusted for clustering
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Analysis 2.8. Comparison 2 Diet plus physical activity versus comparator, Outcome 8 Incidence of type 2
diabetes.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 8 Incidence of type 2 diabetes
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 33/72 51/76 16.4 % 0.68 [ 0.51, 0.92 ]
DPP 2002 (2) 155/1079 313/1082 39.0 % 0.50 [ 0.42, 0.59 ]
DPS 2001 (3) 27/265 59/257 8.6 % 0.44 [ 0.29, 0.68 ]
EDIPS 2009 (4) 7/51 13/51 2.3 % 0.54 [ 0.23, 1.24 ]
HELP PD 2011 (5) 4/151 11/150 1.3 % 0.36 [ 0.12, 1.11 ]
IDPP 2006 (6) 47/120 73/133 19.1 % 0.71 [ 0.54, 0.94 ]
JDPP 2013 (7) 9/103 18/110 2.8 % 0.53 [ 0.25, 1.13 ]
Kosaka 2005 (8) 3/102 32/356 1.2 % 0.33 [ 0.10, 1.05 ]
Oldroyd 2005 (9) 7/37 8/32 2.0 % 0.76 [ 0.31, 1.86 ]
PODOSA 2014 (10) 12/81 17/82 3.5 % 0.71 [ 0.36, 1.40 ]
SLIM 2003 (11) 11/61 19/60 3.7 % 0.57 [ 0.30, 1.09 ]
Total (95% CI) 2122 2389 100.0 % 0.57 [ 0.50, 0.64 ]
Total events: 315 (Diet + physical activity), 614 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.65, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Estimated cumulative incidence of type 2 diabetes at three years
(3) After 3.2 yrs of intervention
(4) After 3.11 years of follow-up
(5) After 3 years of intervention
(6) After 3 years of intervention
(7) End of follow-up values after 3 years of intervention
(8) After 4 years of follow-up
(9) After 24 months of intervention
(10) After 3 yrs of intervention
(11) After 3 years of intervention
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Analysis 2.9. Comparison 2 Diet plus physical activity versus comparator, Outcome 9 Incidence of type 2
diabetes: duration of the intervention.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 9 Incidence of type 2 diabetes: duration of the intervention
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Long duration (≥ 4 years)
Da Qing 1997 (1) 33/72 51/76 16.4 % 0.68 [ 0.51, 0.92 ]
DPS 2001 (2) 27/265 59/257 8.6 % 0.44 [ 0.29, 0.68 ]
Kosaka 2005 (3) 3/102 32/356 1.2 % 0.33 [ 0.10, 1.05 ]
SLIM 2003 (4) 11/61 19/60 3.7 % 0.57 [ 0.30, 1.09 ]
Subtotal (95% CI) 500 749 29.9 % 0.55 [ 0.41, 0.74 ]
Total events: 74 (Diet + physical activity), 161 (Comparator)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.15, df = 3 (P = 0.25); I2 =28%
Test for overall effect: Z = 3.94 (P = 0.000082)
2 Short duration (< 4 years)
DPP 2002 (5) 155/1079 313/1082 39.0 % 0.50 [ 0.42, 0.59 ]
EDIPS 2009 (6) 7/51 13/51 2.3 % 0.54 [ 0.23, 1.24 ]
HELP PD 2011 (7) 4/151 11/150 1.3 % 0.36 [ 0.12, 1.11 ]
IDPP 2006 (8) 47/120 73/133 19.1 % 0.71 [ 0.54, 0.94 ]
JDPP 2013 (9) 9/103 18/110 2.8 % 0.53 [ 0.25, 1.13 ]
Oldroyd 2005 (10) 7/37 8/32 2.0 % 0.76 [ 0.31, 1.86 ]
PODOSA 2014 (11) 12/81 17/82 3.5 % 0.71 [ 0.36, 1.40 ]
Subtotal (95% CI) 1622 1640 70.1 % 0.57 [ 0.48, 0.67 ]
Total events: 241 (Diet + physical activity), 453 (Comparator)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.61, df = 6 (P = 0.36); I2 =9%
Test for overall effect: Z = 6.80 (P < 0.00001)
Total (95% CI) 2122 2389 100.0 % 0.57 [ 0.50, 0.64 ]
Total events: 315 (Diet + physical activity), 614 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.65, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) After 3.2 yrs of intervention
(3) After 4 years of follow-up
(4) After 3 years of intervention
(5) Estimated cumulative incidence of type 2 diabetes at three years
(6) After 3.11 years of follow-up
(7) After 3 years of intervention
(8) After 3 years of intervention
(9) End of follow-up values after 3 years of intervention
(10) After 24 months of intervention
(11) After 3 yrs of intervention
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Analysis 2.10. Comparison 2 Diet plus physical activity versus comparator, Outcome 10 Incidence of type 2
diabetes: diagnostic criteria.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 10 Incidence of type 2 diabetes: diagnostic criteria
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IGT
Da Qing 1997 (1) 33/72 51/76 16.4 % 0.68 [ 0.51, 0.92 ]
DPP 2002 (2) 155/1079 313/1082 39.0 % 0.50 [ 0.42, 0.59 ]
DPS 2001 (3) 27/265 59/257 8.6 % 0.44 [ 0.29, 0.68 ]
EDIPS 2009 (4) 7/51 13/51 2.3 % 0.54 [ 0.23, 1.24 ]
IDPP 2006 (5) 47/120 73/133 19.1 % 0.71 [ 0.54, 0.94 ]
JDPP 2013 (6) 9/103 18/110 2.8 % 0.53 [ 0.25, 1.13 ]
Kosaka 2005 (7) 3/102 32/356 1.2 % 0.33 [ 0.10, 1.05 ]
Oldroyd 2005 (8) 7/37 8/32 2.0 % 0.76 [ 0.31, 1.86 ]
PODOSA 2014 (9) 12/81 17/82 3.5 % 0.71 [ 0.36, 1.40 ]
SLIM 2003 (10) 11/61 19/60 3.7 % 0.57 [ 0.30, 1.09 ]
Subtotal (95% CI) 1971 2239 98.7 % 0.57 [ 0.50, 0.66 ]
Total events: 311 (Diet + physical activity), 603 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.01, df = 9 (P = 0.35); I2 =10%
Test for overall effect: Z = 8.12 (P < 0.00001)
2 Other criteria
HELP PD 2011 (11) 4/151 11/150 1.3 % 0.36 [ 0.12, 1.11 ]
Subtotal (95% CI) 151 150 1.3 % 0.36 [ 0.12, 1.11 ]
Total events: 4 (Diet + physical activity), 11 (Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Total (95% CI) 2122 2389 100.0 % 0.57 [ 0.50, 0.64 ]
Total events: 315 (Diet + physical activity), 614 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.65, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
0.01 0.1 1 10 100
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Estimated cumulative incidence of type 2 diabetes at three years
(3) After 3.2 yrs of intervention
(4) After 3.11 years of follow-up
(5) After 3 years of intervention
(6) End of follow-up values after 3 years of intervention
(7) After 4 years of follow-up
(8) After 24 months of intervention
(9) After 3 yrs of intervention
(10) After 3 years of intervention
(11) After 3 years of intervention
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Analysis 2.11. Comparison 2 Diet plus physical activity versus comparator, Outcome 11 Incidence of type 2
diabetes: age.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 11 Incidence of type 2 diabetes: age
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 age≥ 50 years
DPP 2002 (1) 155/1079 313/1082 39.0 % 0.50 [ 0.42, 0.59 ]
DPS 2001 (2) 27/265 59/257 8.6 % 0.44 [ 0.29, 0.68 ]
EDIPS 2009 (3) 7/51 13/51 2.3 % 0.54 [ 0.23, 1.24 ]
HELP PD 2011 (4) 4/151 11/150 1.3 % 0.36 [ 0.12, 1.11 ]
JDPP 2013 (5) 9/103 18/110 2.8 % 0.53 [ 0.25, 1.13 ]
Kosaka 2005 (6) 3/102 32/356 1.2 % 0.33 [ 0.10, 1.05 ]
Oldroyd 2005 (7) 7/37 8/32 2.0 % 0.76 [ 0.31, 1.86 ]
PODOSA 2014 (8) 12/81 17/82 3.5 % 0.71 [ 0.36, 1.40 ]
SLIM 2003 (9) 11/61 19/60 3.7 % 0.57 [ 0.30, 1.09 ]
Subtotal (95% CI) 1930 2180 64.5 % 0.50 [ 0.44, 0.58 ]
Total events: 235 (Diet + physical activity), 490 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.27, df = 8 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 9.46 (P < 0.00001)
2 age < 50 years
Da Qing 1997 (10) 33/72 51/76 16.4 % 0.68 [ 0.51, 0.92 ]
IDPP 2006 (11) 47/120 73/133 19.1 % 0.71 [ 0.54, 0.94 ]
Subtotal (95% CI) 192 209 35.5 % 0.70 [ 0.57, 0.85 ]
Total events: 80 (Diet + physical activity), 124 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.50 (P = 0.00046)
Total (95% CI) 2122 2389 100.0 % 0.57 [ 0.50, 0.64 ]
Total events: 315 (Diet + physical activity), 614 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.65, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.88, df = 1 (P = 0.01), I2 =85%
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(1) Estimated cumulative incidence of type 2 diabetes at three years
(2) After 3.2 yrs of intervention
(3) After 3.11 years of follow-up
(4) After 3 years of intervention
(5) End of follow-up values after 3 years of intervention
(6) After 4 years of follow-up
(7) After 24 months of intervention
(8) After 3 yrs of intervention
(9) After 3 years of intervention
(10) End of FU values after 6 yrs of intervention; adjusted for clustering
(11) After 3 years of intervention
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Analysis 2.12. Comparison 2 Diet plus physical activity versus comparator, Outcome 12 Incidence of type 2
diabetes: ethnicity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 12 Incidence of type 2 diabetes: ethnicity
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Asian
Da Qing 1997 (1) 33/72 51/76 16.4 % 0.68 [ 0.51, 0.92 ]
IDPP 2006 (2) 47/120 73/133 19.1 % 0.71 [ 0.54, 0.94 ]
JDPP 2013 (3) 9/103 18/110 2.8 % 0.53 [ 0.25, 1.13 ]
Kosaka 2005 (4) 3/102 32/356 1.2 % 0.33 [ 0.10, 1.05 ]
PODOSA 2014 (5) 12/81 17/82 3.5 % 0.71 [ 0.36, 1.40 ]
Subtotal (95% CI) 478 757 43.0 % 0.68 [ 0.56, 0.81 ]
Total events: 104 (Diet + physical activity), 191 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.20, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.17 (P = 0.000030)
2 (Predominantly)White
DPP 2002 (6) 155/1079 313/1082 39.0 % 0.50 [ 0.42, 0.59 ]
DPS 2001 (7) 27/265 59/257 8.6 % 0.44 [ 0.29, 0.68 ]
EDIPS 2009 (8) 7/51 13/51 2.3 % 0.54 [ 0.23, 1.24 ]
HELP PD 2011 (9) 4/151 11/150 1.3 % 0.36 [ 0.12, 1.11 ]
Oldroyd 2005 (10) 7/37 8/32 2.0 % 0.76 [ 0.31, 1.86 ]
SLIM 2003 (11) 11/61 19/60 3.7 % 0.57 [ 0.30, 1.09 ]
Subtotal (95% CI) 1644 1632 57.0 % 0.50 [ 0.43, 0.58 ]
Total events: 211 (Diet + physical activity), 423 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 9.16 (P < 0.00001)
Total (95% CI) 2122 2389 100.0 % 0.57 [ 0.50, 0.64 ]
Total events: 315 (Diet + physical activity), 614 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.65, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.49, df = 1 (P = 0.01), I2 =85%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) After 3 years of intervention
(3) End of follow-up values after 3 years of intervention
(4) After 4 years of follow-up
(5) After 3 yrs of intervention
(6) Estimated cumulative incidence of type 2 diabetes at three years
(7) After 3.2 yrs of intervention
(8) After 3.11 years of follow-up
(9) After 3 years of intervention
(10) After 24 months of intervention
(11) After 3 years of intervention
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Analysis 2.13. Comparison 2 Diet plus physical activity versus comparator, Outcome 13 Incidence of type 2
diabetes: obesity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 13 Incidence of type 2 diabetes: obesity
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BMI≥ 30 kg/m2
DPP 2002 (1) 155/1079 313/1082 39.0 % 0.50 [ 0.42, 0.59 ]
DPS 2001 (2) 27/265 59/257 8.6 % 0.44 [ 0.29, 0.68 ]
EDIPS 2009 (3) 7/51 13/51 2.3 % 0.54 [ 0.23, 1.24 ]
HELP PD 2011 (4) 4/151 11/150 1.3 % 0.36 [ 0.12, 1.11 ]
Oldroyd 2005 (5) 7/37 8/32 2.0 % 0.76 [ 0.31, 1.86 ]
PODOSA 2014 (6) 12/81 17/82 3.5 % 0.71 [ 0.36, 1.40 ]
Subtotal (95% CI) 1664 1654 56.7 % 0.50 [ 0.43, 0.58 ]
Total events: 212 (Diet + physical activity), 421 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 5 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 9.01 (P < 0.00001)
2 BMI < 30 kg/m
2
Da Qing 1997 (7) 33/72 51/76 16.4 % 0.68 [ 0.51, 0.92 ]
IDPP 2006 (8) 47/120 73/133 19.1 % 0.71 [ 0.54, 0.94 ]
JDPP 2013 (9) 9/103 18/110 2.8 % 0.53 [ 0.25, 1.13 ]
Kosaka 2005 (10) 3/102 32/356 1.2 % 0.33 [ 0.10, 1.05 ]
SLIM 2003 (11) 11/61 19/60 3.7 % 0.57 [ 0.30, 1.09 ]
Subtotal (95% CI) 458 735 43.3 % 0.66 [ 0.55, 0.80 ]
Total events: 103 (Diet + physical activity), 193 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.46, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.37 (P = 0.000012)
Total (95% CI) 2122 2389 100.0 % 0.57 [ 0.50, 0.64 ]
Total events: 315 (Diet + physical activity), 614 (Comparator)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.65, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.36, df = 1 (P = 0.02), I2 =81%
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(1) Estimated cumulative incidence of type 2 diabetes at three years
(2) After 3.2 yrs of intervention
(3) After 3.11 years of follow-up
(4) After 3 years of intervention
(5) After 24 months of intervention
(6) After 3 yrs of intervention
(7) End of FU values after 6 yrs of intervention; adjusted for clustering
(8) After 3 years of intervention
(9) End of follow-up values after 3 years of intervention
(10) After 4 years of follow-up
(11) After 3 years of intervention
Analysis 2.14. Comparison 2 Diet plus physical activity versus comparator, Outcome 14 Cardiovascular
mortality.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 14 Cardiovascular mortality
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 1/72 0/76 18.1 % 3.16 [ 0.13, 76.44 ]
DPP 2002 (2) 2/1079 4/1082 63.7 % 0.50 [ 0.09, 2.73 ]
Oldroyd 2005 1/37 0/32 18.3 % 2.61 [ 0.11, 61.80 ]
IDPP 2006 0/133 0/136 Not estimable
EDIPS 2009 0/51 0/51 Not estimable
HELP PD 2011 0/151 0/150 Not estimable
JDPP 2013 0/103 0/110 Not estimable
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(. . . Continued)
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 1626 1637 100.0 % 0.94 [ 0.24, 3.65 ]
Total events: 4 (Diet + physical activity), 4 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Diet + physical activity Comparator
(1) After 6 yrs of intervention; adjusted for clustering
(2) From the publication: Impact of Intensive Lifestyle andMetformin Therapy on CardiovascularDisease Risk Factors in the
Analysis 2.15. Comparison 2 Diet plus physical activity versus comparator, Outcome 15 Non-fatal stroke.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 15 Non-fatal stroke
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EDIPS 2009 (1) 0/51 0/51 Not estimable
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Diet plus physical activity versus comparator, Outcome 16 Non-serious
adverse events.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 16 Non-serious adverse events
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 0/126 0/133 Not estimable
PODOSA 2014 3/84 4/83 0.74 [ 0.17, 3.21 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Diet + physical activity Comparator
(1) after 6 yrs of intervention
Analysis 2.17. Comparison 2 Diet plus physical activity versus comparator, Outcome 17 Amputation of
lower extremity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 17 Amputation of lower extremity
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EDIPS 2009 (1) 0/51 0/51 Not estimable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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(1) Data provided by authors
Analysis 2.18. Comparison 2 Diet plus physical activity versus comparator, Outcome 18 Fasting plasma
glucose.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 18 Fasting plasma glucose
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
Da Qing 1997 (1) 72 7.15 (2.72) 76 7.59 (2.59) 1.5 % -0.44 [ -1.30, 0.42 ]
DPP 2002 (2) 915 5.9 (0.8) 935 6.2 (1.1) 21.3 % -0.30 [ -0.39, -0.21 ]
DPS 2001 (3) 231 0 (0.7) 203 0.1 (0.7) 18.1 % -0.10 [ -0.23, 0.03 ]
EDIPS 2009 (4) 28 5.6 (0.7) 28 5.4 (0.8) 5.7 % 0.20 [ -0.19, 0.59 ]
HELP PD 2011 (5) 127 5.7 (0.6) 134 6 (0.7) 16.2 % -0.30 [ -0.46, -0.14 ]
IDPP 2006 (6) 108 6.1 (1.4) 124 6.5 (1.8) 5.4 % -0.40 [ -0.81, 0.01 ]
JDPP 2013 (7) 103 6 (0.8) 110 6 (0.9) 11.7 % 0.0 [ -0.23, 0.23 ]
Oldroyd 2005 30 0.25 (0.77) 24 0.12 (1) 4.1 % 0.13 [ -0.36, 0.62 ]
PODOSA 2014 (8) 84 5.85 (0.77) 83 5.98 (1.04) 9.4 % -0.13 [ -0.41, 0.15 ]
SLIM 2003 (9) 57 6.3 (1.07) 58 6.48 (0.86) 6.7 % -0.18 [ -0.54, 0.18 ]
Total (95% CI) 1755 1775 100.0 % -0.17 [ -0.27, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.70, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Not applicable
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(3) Change after 3 yrs of intervention
(4) After 4 years. Data provided by authors
(5) End of follow-up values after 2 years of intervention
(6) End of follow-up values after 3 years of intervention
(7) End of follow-up values after 3 years of intervention
(8) End of follow-up values after 3 years of intervention
(9) End of follow-up values after 4.1 years of intervention
Analysis 2.19. Comparison 2 Diet plus physical activity versus comparator, Outcome 19 Fasting plasma
glucose: duration of intervention.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 19 Fasting plasma glucose: duration of intervention
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 Long duration (≥ 4 years)
Da Qing 1997 (1) 72 7.15 (2.72) 76 7.59 (2.59) 1.5 % -0.44 [ -1.30, 0.42 ]
DPS 2001 (2) 231 0 (0.7) 203 0.1 (0.7) 18.1 % -0.10 [ -0.23, 0.03 ]
SLIM 2003 (3) 57 6.3 (1.07) 58 6.48 (0.86) 6.7 % -0.18 [ -0.54, 0.18 ]
Subtotal (95% CI) 360 337 26.3 % -0.12 [ -0.24, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.062)
2 Short duration (< 4 years)
DPP 2002 (4) 915 5.9 (0.8) 935 6.2 (1.1) 21.3 % -0.30 [ -0.39, -0.21 ]
EDIPS 2009 (5) 28 5.6 (0.7) 28 5.4 (0.8) 5.7 % 0.20 [ -0.19, 0.59 ]
HELP PD 2011 (6) 127 5.7 (0.6) 134 6 (0.7) 16.2 % -0.30 [ -0.46, -0.14 ]
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(. . . Continued)
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
IDPP 2006 (7) 108 6.1 (1.4) 124 6.5 (1.8) 5.4 % -0.40 [ -0.81, 0.01 ]
JDPP 2013 (8) 103 6 (0.8) 110 6 (0.9) 11.7 % 0.0 [ -0.23, 0.23 ]
Oldroyd 2005 30 0.25 (0.77) 24 0.12 (1) 4.1 % 0.13 [ -0.36, 0.62 ]
PODOSA 2014 (9) 84 5.85 (0.77) 83 5.98 (1.04) 9.4 % -0.13 [ -0.41, 0.15 ]
Subtotal (95% CI) 1395 1438 73.7 % -0.17 [ -0.30, -0.03 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 14.80, df = 6 (P = 0.02); I2 =59%
Test for overall effect: Z = 2.33 (P = 0.020)
Total (95% CI) 1755 1775 100.0 % -0.17 [ -0.27, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.70, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Change after 3 yrs of intervention
(3) End of follow-up values after 4.1 years of intervention
(4) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(5) After 4 years. Data provided by authors
(6) End of follow-up values after 2 years of intervention
(7) End of follow-up values after 3 years of intervention
(8) End of follow-up values after 3 years of intervention
(9) End of follow-up values after 3 years of intervention
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Analysis 2.20. Comparison 2 Diet plus physical activity versus comparator, Outcome 20 Fasting plasma
glucose: diagnostic criteria.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 20 Fasting plasma glucose: diagnostic criteria
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 IGT
Da Qing 1997 (1) 72 7.15 (2.72) 76 7.59 (2.59) 1.5 % -0.44 [ -1.30, 0.42 ]
DPP 2002 (2) 915 5.9 (0.8) 935 6.2 (1.1) 21.3 % -0.30 [ -0.39, -0.21 ]
DPS 2001 (3) 231 0 (0.7) 203 0.1 (0.7) 18.1 % -0.10 [ -0.23, 0.03 ]
EDIPS 2009 (4) 28 5.6 (0.7) 28 5.4 (0.8) 5.7 % 0.20 [ -0.19, 0.59 ]
IDPP 2006 (5) 108 6.1 (1.4) 124 6.5 (1.8) 5.4 % -0.40 [ -0.81, 0.01 ]
JDPP 2013 (6) 103 6 (0.8) 110 6 (0.9) 11.7 % 0.0 [ -0.23, 0.23 ]
Oldroyd 2005 30 0.25 (0.77) 24 0.12 (1) 4.1 % 0.13 [ -0.36, 0.62 ]
PODOSA 2014 (7) 84 5.85 (0.77) 83 5.98 (1.04) 9.4 % -0.13 [ -0.41, 0.15 ]
SLIM 2003 (8) 57 6.3 (1.07) 58 6.48 (0.86) 6.7 % -0.18 [ -0.54, 0.18 ]
Subtotal (95% CI) 1628 1641 83.8 % -0.14 [ -0.26, -0.01 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 17.37, df = 8 (P = 0.03); I2 =54%
Test for overall effect: Z = 2.14 (P = 0.032)
2 Other criteria
HELP PD 2011 (9) 127 5.7 (0.6) 134 6 (0.7) 16.2 % -0.30 [ -0.46, -0.14 ]
Subtotal (95% CI) 127 134 16.2 % -0.30 [ -0.46, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.00020)
Total (95% CI) 1755 1775 100.0 % -0.17 [ -0.27, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.70, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Chi2 = 2.53, df = 1 (P = 0.11), I2 =60%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(3) Change after 3 yrs of intervention
(4) After 4 years. Data provided by authors
(5) End of follow-up values after 3 years of intervention
(6) End of follow-up values after 3 years of intervention
(7) End of follow-up values after 3 years of intervention
(8) End of follow-up values after 4.1 years of intervention
(9) End of follow-up values after 2 years of intervention
Analysis 2.21. Comparison 2 Diet plus physical activity versus comparator, Outcome 21 Fasting plasma
glucose: age.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 21 Fasting plasma glucose: age
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 Age≥ 50 years
DPP 2002 (1) 915 5.9 (0.8) 935 6.2 (1.1) 21.3 % -0.30 [ -0.39, -0.21 ]
DPS 2001 (2) 231 0 (0.7) 203 0.1 (0.7) 18.1 % -0.10 [ -0.23, 0.03 ]
EDIPS 2009 (3) 28 5.6 (0.7) 28 5.4 (0.8) 5.7 % 0.20 [ -0.19, 0.59 ]
HELP PD 2011 (4) 127 5.7 (0.6) 134 6 (0.7) 16.2 % -0.30 [ -0.46, -0.14 ]
JDPP 2013 (5) 103 6 (0.8) 110 6 (0.9) 11.7 % 0.0 [ -0.23, 0.23 ]
Oldroyd 2005 30 0.25 (0.77) 24 0.12 (1) 4.1 % 0.13 [ -0.36, 0.62 ]
PODOSA 2014 (6) 84 5.85 (0.77) 83 5.98 (1.04) 9.4 % -0.13 [ -0.41, 0.15 ]
SLIM 2003 (7) 57 6.3 (1.07) 58 6.48 (0.86) 6.7 % -0.18 [ -0.54, 0.18 ]
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Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 1575 1575 93.2 % -0.14 [ -0.26, -0.03 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.62, df = 7 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.44 (P = 0.015)
2 Age < 50 years
Da Qing 1997 (8) 72 7.15 (2.72) 76 7.59 (2.59) 1.5 % -0.44 [ -1.30, 0.42 ]
IDPP 2006 (9) 108 6.1 (1.4) 124 6.5 (1.8) 5.4 % -0.40 [ -0.81, 0.01 ]
Subtotal (95% CI) 180 200 6.8 % -0.41 [ -0.78, -0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
Total (95% CI) 1755 1775 100.0 % -0.17 [ -0.27, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.70, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Chi2 = 1.75, df = 1 (P = 0.19), I2 =43%
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(1) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(2) Change after 3 yrs of intervention
(3) After 4 years. Data provided by authors
(4) End of follow-up values after 2 years of intervention
(5) End of follow-up values after 3 years of intervention
(6) End of follow-up values after 3 years of intervention
(7) End of follow-up values after 4.1 years of intervention
(8) End of FU values after 6 yrs of intervention; adjusted for clustering
(9) End of follow-up values after 3 years of intervention
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Analysis 2.22. Comparison 2 Diet plus physical activity versus comparator, Outcome 22 Fasting plasma
glucose: ethnicity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 22 Fasting plasma glucose: ethnicity
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 Asian
Da Qing 1997 (1) 72 7.15 (2.72) 76 7.59 (2.59) 1.5 % -0.44 [ -1.30, 0.42 ]
IDPP 2006 (2) 108 6.1 (1.4) 124 6.5 (1.8) 5.4 % -0.40 [ -0.81, 0.01 ]
JDPP 2013 (3) 103 6 (0.8) 110 6 (0.9) 11.7 % 0.0 [ -0.23, 0.23 ]
PODOSA 2014 (4) 84 5.85 (0.77) 83 5.98 (1.04) 9.4 % -0.13 [ -0.41, 0.15 ]
Subtotal (95% CI) 367 393 27.9 % -0.13 [ -0.30, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.37, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.43 (P = 0.15)
2 (Predominantly) White
DPP 2002 (5) 915 5.9 (0.8) 935 6.2 (1.1) 21.3 % -0.30 [ -0.39, -0.21 ]
DPS 2001 (6) 231 0 (0.7) 203 0.1 (0.7) 18.1 % -0.10 [ -0.23, 0.03 ]
EDIPS 2009 (7) 28 5.6 (0.7) 28 5.4 (0.8) 5.7 % 0.20 [ -0.19, 0.59 ]
HELP PD 2011 (8) 127 5.7 (0.6) 134 6 (0.7) 16.2 % -0.30 [ -0.46, -0.14 ]
Oldroyd 2005 30 0.25 (0.77) 24 0.12 (1) 4.1 % 0.13 [ -0.36, 0.62 ]
SLIM 2003 (9) 57 6.3 (1.07) 58 6.48 (0.86) 6.7 % -0.18 [ -0.54, 0.18 ]
Subtotal (95% CI) 1388 1382 72.1 % -0.17 [ -0.30, -0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.71, df = 5 (P = 0.02); I2 =64%
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 1755 1775 100.0 % -0.17 [ -0.27, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.70, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) End of follow-up values after 3 years of intervention
(3) End of follow-up values after 3 years of intervention
(4) End of follow-up values after 3 years of intervention
(5) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(6) Change after 3 yrs of intervention
(7) After 4 years. Data provided by authors
(8) End of follow-up values after 2 years of intervention
(9) End of follow-up values after 4.1 years of intervention
Analysis 2.23. Comparison 2 Diet plus physical activity versus comparator, Outcome 23 Fasting plasma
glucose: obesity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 23 Fasting plasma glucose: obesity
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 BMI≥ 30 kg/m2
DPP 2002 (1) 915 5.9 (0.8) 935 6.2 (1.1) 21.3 % -0.30 [ -0.39, -0.21 ]
DPS 2001 (2) 231 0 (0.7) 203 0.1 (0.7) 18.1 % -0.10 [ -0.23, 0.03 ]
EDIPS 2009 (3) 28 5.6 (0.7) 28 5.4 (0.8) 5.7 % 0.20 [ -0.19, 0.59 ]
HELP PD 2011 (4) 127 5.7 (0.6) 134 6 (0.7) 16.2 % -0.30 [ -0.46, -0.14 ]
Oldroyd 2005 30 0.25 (0.77) 24 0.12 (1) 4.1 % 0.13 [ -0.36, 0.62 ]
PODOSA 2014 (5) 84 5.85 (0.77) 83 5.98 (1.04) 9.4 % -0.13 [ -0.41, 0.15 ]
Subtotal (95% CI) 1415 1407 74.7 % -0.16 [ -0.30, -0.03 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 14.11, df = 5 (P = 0.01); I2 =65%
Test for overall effect: Z = 2.43 (P = 0.015)
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Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
2 < 30 kg/m
2
Da Qing 1997 (6) 72 7.15 (2.72) 76 7.59 (2.59) 1.5 % -0.44 [ -1.30, 0.42 ]
IDPP 2006 (7) 108 6.1 (1.4) 124 6.5 (1.8) 5.4 % -0.40 [ -0.81, 0.01 ]
JDPP 2013 (8) 103 6 (0.8) 110 6 (0.9) 11.7 % 0.0 [ -0.23, 0.23 ]
SLIM 2003 (9) 57 6.3 (1.07) 58 6.48 (0.86) 6.7 % -0.18 [ -0.54, 0.18 ]
Subtotal (95% CI) 340 368 25.3 % -0.15 [ -0.34, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.47, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 1755 1775 100.0 % -0.17 [ -0.27, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.70, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.02 (P = 0.0026)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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(1) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(2) Change after 3 yrs of intervention
(3) After 4 years. Data provided by authors
(4) End of follow-up values after 2 years of intervention
(5) End of follow-up values after 3 years of intervention
(6) End of FU values after 6 yrs of intervention; adjusted for clustering
(7) End of follow-up values after 3 years of intervention
(8) End of follow-up values after 3 years of intervention
(9) End of follow-up values after 4.1 years of intervention
156Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.24. Comparison 2 Diet plus physical activity versus comparator, Outcome 24 2h plasma glucose.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 24 2h plasma glucose
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
Da Qing 1997 (1) 72 10.76 (4.37) 76 12.99 (4.19) 4.8 % -2.23 [ -3.61, -0.85 ]
DPP 2002 (2) 910 7.98 (1.92) 932 8.2 (1.78) 21.8 % -0.22 [ -0.39, -0.05 ]
DPS 2001 (3) 231 -0.5 (2.4) 203 -0.1 (2.2) 16.8 % -0.40 [ -0.83, 0.03 ]
EDIPS 2009 (4) 28 7.8 (1.5) 28 8.3 (2) 8.4 % -0.50 [ -1.43, 0.43 ]
IDPP 2006 (5) 108 9.7 (3) 124 11 (4.3) 8.2 % -1.30 [ -2.24, -0.36 ]
JDPP 2013 (6) 103 8.4 (2.5) 110 8.5 (2.4) 12.3 % -0.10 [ -0.76, 0.56 ]
Oldroyd 2005 30 0.23 (1.6) 24 -0.52 (1.9) 8.2 % 0.75 [ -0.20, 1.70 ]
PODOSA 2014 84 7.38 (2.49) 83 8.05 (2.56) 10.6 % -0.67 [ -1.44, 0.10 ]
SLIM 2003 (7) 57 8.66 (2.38) 58 9.38 (2.45) 9.0 % -0.72 [ -1.60, 0.16 ]
Total (95% CI) 1623 1638 100.0 % -0.46 [ -0.79, -0.12 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 19.84, df = 8 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Data form 10 yrs DPPOS baseline publicatoin
(3) Change after 3 yrs of intervention
(4) After 4 years. Data provided by authors.
(5) End of follow-up values after 3 years of intervention
(6) End of follow-up values after 3 years of intervention
(7) End of follow-up values after 4.1 years of intervention
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Analysis 2.25. Comparison 2 Diet plus physical activity versus comparator, Outcome 25 2 hour plasma
glucose: duration of the intervention.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 25 2 hour plasma glucose: duration of the intervention
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 Long duration (≥ 4 years)
Da Qing 1997 (1) 72 10.76 (4.37) 76 12.99 (4.19) 4.8 % -2.23 [ -3.61, -0.85 ]
DPS 2001 (2) 231 -0.5 (2.4) 203 -0.1 (2.2) 16.8 % -0.40 [ -0.83, 0.03 ]
SLIM 2003 (3) 57 8.66 (2.38) 58 9.38 (2.45) 9.0 % -0.72 [ -1.60, 0.16 ]
Subtotal (95% CI) 360 337 30.5 % -0.91 [ -1.77, -0.05 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 6.24, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 2.07 (P = 0.039)
2 Short duration (< 4 years)
DPP 2002 (4) 910 7.98 (1.92) 932 8.2 (1.78) 21.8 % -0.22 [ -0.39, -0.05 ]
EDIPS 2009 (5) 28 7.8 (1.5) 28 8.3 (2) 8.4 % -0.50 [ -1.43, 0.43 ]
IDPP 2006 (6) 108 9.7 (3) 124 11 (4.3) 8.2 % -1.30 [ -2.24, -0.36 ]
JDPP 2013 (7) 103 8.4 (2.5) 110 8.5 (2.4) 12.3 % -0.10 [ -0.76, 0.56 ]
Oldroyd 2005 30 0.23 (1.6) 24 -0.52 (1.9) 8.2 % 0.75 [ -0.20, 1.70 ]
PODOSA 2014 84 7.38 (2.49) 83 8.05 (2.56) 10.6 % -0.67 [ -1.44, 0.10 ]
Subtotal (95% CI) 1263 1301 69.5 % -0.31 [ -0.70, 0.08 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 10.73, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 1623 1638 100.0 % -0.46 [ -0.79, -0.12 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 19.84, df = 8 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Chi2 = 1.52, df = 1 (P = 0.22), I2 =34%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) Change after 3 yrs of intervention
(3) End of follow-up values after 4.1 years of intervention
(4) Data form 10 yrs DPPOS baseline publicatoin
(5) After 4 years. Data provided by authors.
(6) End of follow-up values after 3 years of intervention
(7) End of follow-up values after 3 years of intervention
158Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.26. Comparison 2 Diet plus physical activity versus comparator, Outcome 26 2 hour plasma
glucose: age.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 26 2 hour plasma glucose: age
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 Age≥ 50 years
DPP 2002 (1) 910 7.98 (1.92) 932 8.2 (1.78) 21.8 % -0.22 [ -0.39, -0.05 ]
DPS 2001 (2) 231 -0.5 (2.4) 203 -0.1 (2.2) 16.8 % -0.40 [ -0.83, 0.03 ]
EDIPS 2009 (3) 28 7.8 (1.5) 28 8.3 (2) 8.4 % -0.50 [ -1.43, 0.43 ]
JDPP 2013 (4) 103 8.4 (2.5) 110 8.5 (2.4) 12.3 % -0.10 [ -0.76, 0.56 ]
Oldroyd 2005 30 0.23 (1.6) 24 -0.52 (1.9) 8.2 % 0.75 [ -0.20, 1.70 ]
PODOSA 2014 84 7.38 (2.49) 83 8.05 (2.56) 10.6 % -0.67 [ -1.44, 0.10 ]
SLIM 2003 (5) 57 8.66 (2.38) 58 9.38 (2.45) 9.0 % -0.72 [ -1.60, 0.16 ]
Subtotal (95% CI) 1443 1438 87.0 % -0.27 [ -0.49, -0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 7.55, df = 6 (P = 0.27); I2 =20%
Test for overall effect: Z = 2.40 (P = 0.016)
2 Age < 50 years
Da Qing 1997 (6) 72 10.76 (4.37) 76 12.99 (4.19) 4.8 % -2.23 [ -3.61, -0.85 ]
IDPP 2006 (7) 108 9.7 (3) 124 11 (4.3) 8.2 % -1.30 [ -2.24, -0.36 ]
Subtotal (95% CI) 180 200 13.0 % -1.62 [ -2.49, -0.76 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 3.67 (P = 0.00025)
Total (95% CI) 1623 1638 100.0 % -0.46 [ -0.79, -0.12 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 19.84, df = 8 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Chi2 = 8.77, df = 1 (P = 0.00), I2 =89%
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(1) Data form 10 yrs DPPOS baseline publicatoin
(2) Change after 3 yrs of intervention
(3) After 4 years. Data provided by authors.
(4) End of follow-up values after 3 years of intervention
(5) End of follow-up values after 4.1 years of intervention
(6) End of FU values after 6 yrs of intervention; adjusted for clustering
(7) End of follow-up values after 3 years of intervention
Analysis 2.27. Comparison 2 Diet plus physical activity versus comparator, Outcome 27 2 hour plasma
glucose: ethnicity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 27 2 hour plasma glucose: ethnicity
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 Asian
Da Qing 1997 (1) 72 10.76 (4.37) 76 12.99 (4.19) 4.8 % -2.23 [ -3.61, -0.85 ]
IDPP 2006 (2) 108 9.7 (3) 124 11 (4.3) 8.2 % -1.30 [ -2.24, -0.36 ]
JDPP 2013 (3) 103 8.4 (2.5) 110 8.5 (2.4) 12.3 % -0.10 [ -0.76, 0.56 ]
PODOSA 2014 84 7.38 (2.49) 83 8.05 (2.56) 10.6 % -0.67 [ -1.44, 0.10 ]
Subtotal (95% CI) 367 393 35.8 % -0.93 [ -1.72, -0.14 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 9.46, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 2.30 (P = 0.021)
2 (Predominantly) White
DPP 2002 (4) 910 7.98 (1.92) 932 8.2 (1.78) 21.8 % -0.22 [ -0.39, -0.05 ]
DPS 2001 (5) 231 -0.5 (2.4) 203 -0.1 (2.2) 16.8 % -0.40 [ -0.83, 0.03 ]
EDIPS 2009 (6) 28 7.8 (1.5) 28 8.3 (2) 8.4 % -0.50 [ -1.43, 0.43 ]
Oldroyd 2005 30 0.23 (1.6) 24 -0.52 (1.9) 8.2 % 0.75 [ -0.20, 1.70 ]
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Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
SLIM 2003 (7) 57 8.66 (2.38) 58 9.38 (2.45) 9.0 % -0.72 [ -1.60, 0.16 ]
Subtotal (95% CI) 1256 1245 64.2 % -0.26 [ -0.55, 0.03 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.17, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 1623 1638 100.0 % -0.46 [ -0.79, -0.12 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 19.84, df = 8 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Chi2 = 2.44, df = 1 (P = 0.12), I2 =59%
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(1) End of FU values after 6 yrs of intervention; adjusted for clustering
(2) End of follow-up values after 3 years of intervention
(3) End of follow-up values after 3 years of intervention
(4) Data form 10 yrs DPPOS baseline publicatoin
(5) Change after 3 yrs of intervention
(6) After 4 years. Data provided by authors.
(7) End of follow-up values after 4.1 years of intervention
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Analysis 2.28. Comparison 2 Diet plus physical activity versus comparator, Outcome 28 2 hour plasma
glucose: obesity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 28 2 hour plasma glucose: obesity
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
1 BMI≥ 30 kg/m2
DPP 2002 (1) 910 7.98 (1.92) 932 8.2 (1.78) 21.8 % -0.22 [ -0.39, -0.05 ]
DPS 2001 (2) 231 -0.5 (2.4) 203 -0.1 (2.2) 16.8 % -0.40 [ -0.83, 0.03 ]
EDIPS 2009 (3) 28 7.8 (1.5) 28 8.3 (2) 8.4 % -0.50 [ -1.43, 0.43 ]
Oldroyd 2005 30 0.23 (1.6) 24 -0.52 (1.9) 8.2 % 0.75 [ -0.20, 1.70 ]
PODOSA 2014 84 7.38 (2.49) 83 8.05 (2.56) 10.6 % -0.67 [ -1.44, 0.10 ]
Subtotal (95% CI) 1283 1270 65.8 % -0.26 [ -0.55, 0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.25, df = 4 (P = 0.18); I2 =36%
Test for overall effect: Z = 1.80 (P = 0.072)
2 BMI < 30 kg/m
2
Da Qing 1997 (4) 72 10.76 (4.37) 76 12.99 (4.19) 4.8 % -2.23 [ -3.61, -0.85 ]
IDPP 2006 (5) 108 9.7 (3) 124 11 (4.3) 8.2 % -1.30 [ -2.24, -0.36 ]
JDPP 2013 (6) 103 8.4 (2.5) 110 8.5 (2.4) 12.3 % -0.10 [ -0.76, 0.56 ]
SLIM 2003 (7) 57 8.66 (2.38) 58 9.38 (2.45) 9.0 % -0.72 [ -1.60, 0.16 ]
Subtotal (95% CI) 340 368 34.2 % -0.95 [ -1.77, -0.13 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 9.44, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 2.28 (P = 0.023)
Total (95% CI) 1623 1638 100.0 % -0.46 [ -0.79, -0.12 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 19.84, df = 8 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Chi2 = 2.43, df = 1 (P = 0.12), I2 =59%
-4 -2 0 2 4
Diet + physical activity Comparator
(1) Data form 10 yrs DPPOS baseline publicatoin
(2) Change after 3 yrs of intervention
(3) After 4 years. Data provided by authors.
(4) End of FU values after 6 yrs of intervention; adjusted for clustering
(5) End of follow-up values after 3 years of intervention
(6) End of follow-up values after 3 years of intervention
(7) End of follow-up values after 4.1 years of intervention
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Analysis 2.29. Comparison 2 Diet plus physical activity versus comparator, Outcome 29 Serious adverse
events.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 29 Serious adverse events
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Da Qing 1997 (1) 0/126 0/133 Not estimable
EDIPS 2009 (2) 1/51 0/51 3.00 [ 0.13, 71.96 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Diet + physical activity Comparator
(1) after 6 yrs of intervention; adjusted for clustering
(2) Data provided by authors
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Analysis 2.30. Comparison 2 Diet plus physical activity versus comparator, Outcome 30 Hypoglycaemia.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 30 Hypoglycaemia
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
IDPP 2006 0/133 0/136 Not estimable
EDIPS 2009 (1) 0/51 0/51 Not estimable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Diet + physical activity Comparator
(1) Data provided by authors
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Analysis 2.31. Comparison 2 Diet plus physical activity versus comparator, Outcome 31 HbA1c.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 31 HbA1c
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
DPP 2002 (1) 915 5.9 (0.5) 935 6.1 (0.7) 38.3 % -0.20 [ -0.26, -0.14 ]
DPS 2001 (2) 231 -0.2 (0.6) 203 0 (0.6) 31.1 % -0.20 [ -0.31, -0.09 ]
EDIPS 2009 (3) 26 5.8 (0.4) 28 5.7 (0.5) 16.6 % 0.10 [ -0.14, 0.34 ]
SLIM 2003 (4) 57 6.3 (0.8) 58 6.2 (0.7) 14.0 % 0.10 [ -0.17, 0.37 ]
Total (95% CI) 1229 1224 100.0 % -0.11 [ -0.23, 0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.80, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Diet + physical activity Comparator
(1) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(2) Change after 3 yrs of intervention
(3) 4 years of follow-up. Data provided by authors
(4) End of follow-up values after 4.1 years of intervention
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Analysis 2.32. Comparison 2 Diet plus physical activity versus comparator, Outcome 32 Non-fatal
myocardial infarction.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 32 Non-fatal myocardial infarction
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EDIPS 2009 (1) 0/51 0/51 Not estimable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Diet + physical activity Comparator
(1) Data provided by authors
Analysis 2.33. Comparison 2 Diet plus physical activity versus comparator, Outcome 33 End-stage renal
disease.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 33 End-stage renal disease
Study or subgroup
Diet +
physical
activity Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EDIPS 2009 (1) 0/51 0/51 Not estimable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Diet + physical activity Comparator
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(1) Data provided by authors
Analysis 2.34. Comparison 2 Diet plus physical activity versus comparator, Outcome 34 HbA1c: duration of
the intervention.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 34 HbA1c: duration of the intervention
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1≥ 4 years
DPS 2001 (1) 231 -0.2 (0.6) 203 0 (0.6) 31.1 % -0.20 [ -0.31, -0.09 ]
SLIM 2003 (2) 57 6.3 (0.8) 58 6.2 (0.7) 14.0 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 288 261 45.1 % -0.08 [ -0.37, 0.21 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.91, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.52 (P = 0.60)
2 < 4 years
DPP 2002 (3) 915 5.9 (0.5) 935 6.1 (0.7) 38.3 % -0.20 [ -0.26, -0.14 ]
EDIPS 2009 (4) 26 5.8 (0.4) 28 5.7 (0.5) 16.6 % 0.10 [ -0.14, 0.34 ]
Subtotal (95% CI) 941 963 54.9 % -0.07 [ -0.36, 0.22 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 5.67, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 1229 1224 100.0 % -0.11 [ -0.23, 0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.80, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
-1 -0.5 0 0.5 1
Diet + physical activity Comparator
(1) Change after 3 yrs of intervention
(2) End of follow-up values after 4.1 years of intervention
(3) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(4) 4 years of follow-up. Data provided by authors
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Analysis 2.35. Comparison 2 Diet plus physical activity versus comparator, Outcome 35 HbA1c: obesity.
Review: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type
2 diabetes mellitus
Comparison: 2 Diet plus physical activity versus comparator
Outcome: 35 HbA1c: obesity
Study or subgroup
Diet +
physical
activity Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BMI≥ 30 kg/m2
DPP 2002 (1) 915 5.9 (0.5) 935 6.1 (0.7) 38.3 % -0.20 [ -0.26, -0.14 ]
DPS 2001 (2) 231 -0.2 (0.6) 203 0 (0.6) 31.1 % -0.20 [ -0.31, -0.09 ]
EDIPS 2009 (3) 26 5.8 (0.4) 28 5.7 (0.5) 16.6 % 0.10 [ -0.14, 0.34 ]
Subtotal (95% CI) 1172 1166 86.0 % -0.15 [ -0.27, -0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.72, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 2.59 (P = 0.0095)
2 BMI < 30 kg/m
2
SLIM 2003 (4) 57 6.3 (0.8) 58 6.2 (0.7) 14.0 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 57 58 14.0 % 0.10 [ -0.17, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 1229 1224 100.0 % -0.11 [ -0.23, 0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.80, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Chi2 = 2.75, df = 1 (P = 0.10), I2 =64%
-0.5 -0.25 0 0.25 0.5
Diet + physical activity Comparator
(1) Data from 15yrs publication end of DPP data on the participants included in the DPPOS; HbA1c can be read from graph from main publ without SDs and no number
of analysed participants
(2) Change after 3 yrs of intervention
(3) 4 years of follow-up. Data provided by authors
(4) End of follow-up values after 4.1 years of intervention
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A D D I T I O N A L T A B L E S
Table 1. Overview of trial populations
Trial (de-
sign)
Interven-
tion(s)
and com-
parator(s)
Descrip-
tion of
power and
sample
size calcu-
lation
Screened/
eligible
(N)
Ran-
domised
(N)
ITT
(N)
Analysed
(N)
Finishing
trial
(N)
Ran-
domised
finishing
trial
(%)
Follow-up
(ex-
tended fol-
low-up)a
Da Qing
1997a
(cluster-
RCT)
Interven-
tion 1: diet
“Power
calcu-
lations
were done
for the
original 6-
year in-
tervention
trial. For
the present
study we
estimated
minimal
detectable
differ-
ences.
With an α
of 0·05, we
estimated
that there
was an
80%
chance of
detecting
a 43%
reduction
in all-cause
mortality
and a 63%
reduction
in cardio-
vascular
disease
mortality
when
comparing
the control
group
with the
combined
110,660 - 130 130 130 - 6 years (23
years)
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Table 1. Overview of trial populations (Continued)
lifestyle in-
tervention
groups”Interven-
tion
2: physical
activity
- 141 141 141 -
Inter-
vention 3:
phys-
ical activity
+ diet
- 126 126 126 -
Compara-
tor: stan-
dard treat-
ment
- 133 133 133 -
total: 577 530 530 530 91.9b
DPP 2002
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“The
principal
analyses of
primary
and sec-
ondary
outcomes
will em-
ploy the
”intent-
to-treat“
approach
... The
intent-to-
treat anal-
yses will
include all
random-
ized partic-
ipants with
all par-
ticipants
included
in their
randomly
assigned
treatment
group;
treatment
group as-
153,183 1079 1079 1079 1052 97.5 2.8 years
(15 years)
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Table 1. Overview of trial populations (Continued)
signment
will not
be altered
based on
the par-
ticipant’s
adherence
to the
assigned
treatment
regimen.
All sta-
tistical
tests will
be two-
sided. The
overall sig-
nificance
level of the
primary
outcome
will be α
= 0.05.
However,
because
interim
analyses
will be
conducted
through-
out the
DPP, the
signif-
icance
levels used
in the
interim
and final
analyses
of the
primary
outcome
will be
adjusted
to account
for the
multi-
plicity of
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Table 1. Overview of trial populations (Continued)
interim
analyses”
Compara-
tor:
placebo
+ standard
treatment
1082 1082 1082 1042 96.3
total: 2161c 2161 2161 2094 96.9
DPS 2001
d
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“The DPS
is designed
to be large
enough to
de-
tect a 35%
reduction
in diabetes
incidence
with an in-
tensive diet
and
exercise in-
tervention
with 80%
power
(beta =
20%)
at the two-
tailed
5% signifi-
cance
level (alpha
= 5%) ...”
- 265 265 265 241e 91 Median
4 years (10.
6 years)
Compara-
tor: stan-
dard treat-
ment
257 257 257 239e 93
total: 522 522 522 480e 92
EDIPS
2009
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“EDIPS-
Newcas-
tle was de-
signed to
con-
tribute to
the Euro-
pean study.
We aimed
for a sam-
ple size of
100 partic-
ipants
(50 in each
arm), con-
482 51 51 21f 21 41.2 3.11 years
(3.11 years)
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Table 1. Overview of trial populations (Continued)
tributing
to
a planned
total of
750 partic-
ipants
across Eu-
rope”
51 51 21 21 41.2
Compara-
tor: stan-
dard treat-
ment
total: 102 102 42 42 41.2
Hellgren
2016
(parallel
RCT)
Interven-
tion: phys-
ical activity
- 9734 - 66 66 66 - 3 years
- 30 30 30 -
Compara-
tor: stan-
dard treat-
ment
total: 123g 96 96 96 78
HELP PD
2011
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“Based on
a longi-
tudinal
correlation
of r = 0.
20, this
sample was
projected
to provide
94%
power to
detect a
net inter-
vention
effect of
3.5 mg/
dL (two-
sided alpha
of 0.05)
and 86%
power to
detect an
effect size
of 3 mg/
dL. These
estimates
include
allowance
for a 5%
1818 151 151 127h 127h 84.1 2 years
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Table 1. Overview of trial populations (Continued)
loss to
follow-up
rate every
6 months”
150 150 134 134 89.3
Compara-
tor: stan-
dard treat-
ment
total: 301 301 261 261 86.7
IDPP
2006
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“It was
assumed
that the
cumulative
incidence
of diabetes
in 3 years
would be
approx-
imately
30% in
the control
group and
that there
would be
a 50%
reduction
with the
interven-
tion meth-
ods. The
sample size
required
in each of
the four
subgroups
was 134
with a type
1 error of
5%, 80%
power, and
allowing
for a
dropout
rate of
10%”
10,839 133 120 120 120 91 3 years
136 133 133 133 98.5
Compara-
tor: stan-
dard treat-
ment
total: 269 253 253 253 94.1
JDPP
2013
(parallel
Interven-
tion: phys-
ical activity
“According
to prospec-
tive studies
1279 152 146 103 103 67.8 3 years
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Table 1. Overview of trial populations (Continued)
RCT) + diet on the
Japanese
popula-
tion, the
yearly
incidence
of diabetes
among
subjects
with IGT
varies
between 1
and 5% ...
Therefore,
it was
assumed
that the
6-year
cumulative
incidence
of diabetes
would be
30% in
the control
group. The
present
study was
designed
to detect
a 50%
reduction
in the
incidence
by the in-
tervention.
Thus the
sample size
required
was 313
with a type
1 error
of 5%,
with 80%
power
(beta =
20%) at
the two-
tailed 5%
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Table 1. Overview of trial populations (Continued)
signif-
icance
level, and
allowing
for a with-
drawal rate
of 30%”
Compara-
tor: stan-
dard treat-
ment
152 150 110 110 72.4
total: 304 296 213 213 70.1
Kosaka
2005
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
-
(Num-
ber of ran-
domised
partic-
ipants was
calcu-
lated based
on the fol-
lowing in-
forma-
tion: “The
rate of
drop-out
during the
1-year ob-
servation
was 5.6%
in the con-
trol group
and 4.7%
in the in-
tensive in-
terven-
tion group,
respec-
tively”)
- 107 102 102 95 88.8 4 years
376 356 356 324 86.2
Compara-
tor: stan-
dard treat-
ment
total: 483 458 458 419 86.7
Oldroyd
2005
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“We calcu-
lated that a
sample size
of 100 in-
divid-
uals (50 in
each arm)
was neces-
sary to de-
tect a 0.
498 39 39 30i 30 76.9 2 years
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Table 1. Overview of trial populations (Continued)
6 mmol/l
dif-
ference in
mean fast-
ing plasma
glucose
and a 20%
differ-
ence in the
proportion
with
glucose in-
toler-
ance, both
with 90%
power at
the 5% sig-
nificance
level”
39 39 24 24 61.5
Compara-
tor: no in-
tervention
total: 78 78 54 54 69.2
PODOSA
2014
(cluster-
RCT)
Interven-
tion: phys-
ical activity
+ diet
“When
the pro-
tocol was
amended
in 2009,
we knew
that the
number
of families
with more
than one
person
recruited
with
impaired
fasting
glucose or
impaired
glucose
tolerance
was small,
so the
new power
calculation
did not
take clus-
tering into
account. A
1319 85j 84 84 84 98.8 3 years
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Table 1. Overview of trial populations (Continued)
sample of
150 people
assessed
at 3 years
gave 86%
power
to detect
a mean
difference
in weight
of 2.5 kg
between
the two
groups,
assuming
an SD of 5
kg with a
two-sided
5% sig-
nificance
level.”
86 83 83 83 96.5
Compara-
tor: stan-
dard treat-
ment
total: 171 167 167 167 97.7
SLIM
2003
(parallel
RCT)
Interven-
tion: phys-
ical activity
+ diet
“It was cal-
culated
that, based
on the re-
sults of the
Finnish
Diabetes
Preven-
tion Study
(DPS), 50-
60 subjects
per group
would be
sufficient
to detect a
1.0 mmol/
l difference
in 2-h glu-
cose con-
centration
between
groups ...”
2820 74 74 52k 35 47.3 4.1 years
(range 3 to
6 years)
Compara-
tor: stan-
dard treat-
ment
73 73 54 35 47.9
total: 147 147 106 70 47.6
Grand to-
tal
All inter-
ventions
2136
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Table 1. Overview of trial populations (Continued)
All com-
parators
3091
All inter-
ventions
and com-
parators
5238l
“-” denotes not reported
aRandomised numbers in each group not specified.
bAfter 6 years of intervention, during the subsequent 17-year follow-up period after the intervention had stopped 6 participants were
lost to follow-up.
cOf the 1082 participants assigned to placebo, 1052 were available for the DPPOS (see DPP 2002); of these 935 were enrolled in the
DPPOS. Of the 1079 assigned to the behaviour changing intervention 1042 were available for the DPPOS; of these 915 were enrolled
in the DPPOS.
dTrial authors state that ITT analysis was performed but data are presented as a per-protocol analysis.
eData for the end of intervention. Participants included in the extension period were 200 in the intervention group and 166 in the
control group.
fNumber of analysed participants varied during the trial (intervention group: 39 at 1 year; 35 at 2 years; 27 at 3 years; 28 at 4 years;
21 at 5 years; control group: 43 at 1 year; 37 at 2 years; 33 at 3 years; 28 at 4 years; 21 at 5 years).
g123 participants were eligible for the trial, 4 died and 10 developed T2DM and did not complete the final examination. One received
a gastric bypass; 17 refused follow-up. Not specified to which intervention groups these people were randomised.
hNumber of analysed participants varied during the trial (intervention group: 139 at 6 months, 135 at 12 months, 125 at 18 months
and 127 at 24 months; control group: 141 at 6 months, 138 at 12 months, 132 at 18 months and 134 at 24 months).
iNumber of analysed participants varied during the trial (intervention group: 37 at 6 months, 32 at 12 months and 30 at 24 months;
control group: 32 at 6 months, 30 at 12 months and 24 at 24 months).
j78 families with 85 participants and 55 family volunteers were allocated to the intervention, 78 families with 86 participants and 69
family volunteers were allocated to the control.
kNumber of analysed participants varied during the trial (intervention group: 52 at 3 years, 51 at 4 years, 34 at 5 years and 35 (one
that was missing at 6 years attended 6-year follow-up) at 6 years; control group: 54 at 3 years, 43 at 4 years, 29 at 5 years and 35 (6
that were missing at five years attended 6-year follow-up) at 6 years.
l2 trials did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately.
DPP: Diabetes Prevention Program; DPPOS: Diabetes Prevention Program Outcome Study; EDIPS: European Diabetes Prevention
Study; HELP PD: Healthy Living Partnerships to Prevent Diabetes; IDPP: Indian Diabetes Prevention Programmes; ITT: intention-
to-treat; JDPP: Japan Diabetes Prevention Program; PODOSA: Prevention of Diabetes and Obesity in South Asians; RCT: randomised
controlled trial; SLIM: Study on Lifestyle-intervention and Impaired glucose tolerance Maastricht
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A P P E N D I C E S
Appendix 1. Search strategies
Search strategy overview
1. Population block (prediabetes, diabetes risk, diagnostic criteria (IFG, IGT, HbA1c))
AND
2. Intervention (exercise, diet, lifestyle)
AND
3. Outcomes (diabetes complications, micro/macro vascular, mortality, diabetes incidence)
AND
4. RCTs (in MEDLINE additionally filter for systematic reviews and meta-analyses)
Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Register of Studies Online)
1. MESH DESCRIPTOR Prediabetic state
2. MESH DESCRIPTOR Glucose Intolerance
3. (prediabet* or pre diabet*):TI,AB,KY
4. (intermediate hyperglyc?emi*):TI,AB,KY
5. ((impaired fasting ADJ2 glucose) or IFG or impaired FPG):TI,AB,KY
6. glucose intolerance:TI,AB,KY
7. ((impaired glucose ADJ (tolerance or metabolism)) or IGT):TI,AB,KY
8. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) ADJ h?emoglobin)):TI,AB,KY
9. (risk ADJ3 (“type 2” or “type II” or diabetes or T2D* or NIDDM)):TI,AB,KY
10. MESH DESCRIPTOR Diabetes mellitus WITH QUALIFIERS PC
11. MESH DESCRIPTOR Diabetes mellitus, Type 2 WITH QUALIFIERS PC
12. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
13. MESH DESCRIPTOR Life Style
14. MESH DESCRIPTOR Exercise EXPLODE ALL TREES
15. MESH DESCRIPTOR Exercise Therapy EXPLODE ALL TREES
16. MESH DESCRIPTOR Diet EXPLODE ALL TREES
17. MESH DESCRIPTOR Diet Therapy EXPLODE ALL TREES
18. ((lifestyle or life style) ADJ3 (intervention? or change* or modif* or program or programme)):TI,AB,KY
19. diet*:TI,AB,KY
20. (nutrition* ADJ3 (intervention? or change* or modif* or program or programme)):TI,AB,KY
21. exercis*:TI,AB,KY
22. physical activit*:TI,AB,KY
23. resistance training:TI,AB,KY
24. #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23
25. #12 AND #24
26. (diabetes prevention ADJ (program* or stud* or trial?)):TI,AB,KY
27. #25 OR #26
28. complication?:TI,AB,KY
29. mortality:TI,AB,KY
30. (CHD or CVD):TI,AB,KY
31. (coronary ADJ2 disease):TI,AB,KY
32. (coronar* ADJ (event? or syndrome?)):TI,AB,KY
33. (heart ADJ (failure or disease? or attack? or infarct*)):TI,AB,KY
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34. (myocardial ADJ (infarct* or isch?emi*)):TI,AB,KY
35. cardiac failure:TI,AB,KY
36. angina:TI,AB,KY
37. revasculari*:TI,AB,KY
38. (stroke or strokes):TI,AB,KY
39. cerebrovascular:TI,AB,KY
40. ((brain* or cerebr*) ADJ (infarct* or isch?emi*)):TI,AB,KY
41. apoplexy:TI,AB,KY
42. ((vascular or peripheral arter*) ADJ disease?):TI,AB,KY
43. cardiovascular:TI,AB,KY
44. (neuropath* or polyneuropath*):TI,AB,KY
45. (retinopath* or maculopath*):TI,AB,KY
46. (nephropath* or nephrotic or proteinuri* or albuminuri*):TI,AB,KY
47. ((kidney or renal) ADJ (disease? or failure or transplant*)):TI,AB,KY
48. ((chronic or endstage or end stage) ADJ (renal or kidney)):TI,AB,KY
49. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF):TI,AB,KY
50. (microvascular or macrovascular or ((micro or macro) ADJ vascular)):TI,AB,KY
51. (cancer or carcino* or neoplas* or tumo?r?):TI,AB,KY
52. (amputation? or ulcer* or foot or feet or wound*):TI,AB,KY
53. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) ADJ4 (diabetes or T2D* or NIDDM or “type 2”
or “type II”)):TI,AB,KY
54. #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42
OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53
55. #27 AND #54
56. (2014 OR 2015 OR 2016 OR 2017):PD
57. #55 AND #56
MEDLINE (Ovid SP)
1. Prediabetic state/
2. Glucose Intolerance/
3. (prediabet* or pre diabet*).tw.
4. intermediate hyperglyc?emi*.tw.
5. ((impaired fasting adj2 glucose) or IFG or impaired FPG).tw
6. glucose intolerance.tw.
7. ((impaired glucose adj (tolerance or metabolism)) or IGT).tw
8. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw
9. (risk adj3 (“type 2” or “type II” or diabetes or T2D* or NIDDM)).tw
10. *Diabetes mellitus/pc
11. *Diabetes mellitus, Type 2/pc
12. or/1-11
13. Life Style/
14. exp Exercise/
15. exp Exercise Therapy/
16. exp Diet/
17. exp Diet Therapy/
18. ((lifestyle or life style) adj3 (intervention? or change* or modif* or program or programme)).tw
19. diet*.tw.
20. (nutrition* adj3 (intervention? or change* or modif* or program or programme)).tw
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21. exercis*.tw.
22. physical activit*.tw.
23. resistance training.tw.
24. or/13-23
25. 12 and 24
26. (diabetes prevention adj (program* or stud* or trial?)).tw
27. 25 or 26
28. complication?.tw.
29. mortality.tw.
30. (CHD or CVD).tw.
31. (coronary adj2 disease).tw.
32. (coronar* adj (event? or syndrome?)).tw.
33. (heart adj (failure or disease? or attack? or infarct*)).tw
34. (myocardial adj (infarct* or isch?emi*)).tw.
35. cardiac failure.tw.
36. angina.tw.
37. revasculari*.tw.
38. (stroke or strokes).tw.
39. cerebrovascular.tw.
40. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw.
41. apoplexy.tw.
42. ((vascular or peripheral arter*) adj disease?).tw.
43. cardiovascular.tw.
44. (neuropath* or polyneuropath*).tw.
45. (retinopath* or maculopath*).tw.
46. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw
47. ((kidney or renal) adj (disease? or failure or transplant*)).tw
48. ((chronic or endstage or end stage) adj (renal or kidney)).tw
49. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw
50. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw
51. (cancer or carcino* or neoplas* or tumo?r?).tw.
52. (amputation? or ulcer* or foot or feet or wound*).tw.
53. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) adj4 (diabetes or T2D* or NIDDM or “type 2”
or “type II”)).tw
54. or/28-53
55. 27 and 54
[56-65: Cochrane Handbook 2008 RCT filter - sens/prec version]
56. randomized controlled trial.pt.
57. controlled clinical trial.pt.
58. randomi?ed.ab.
59. placebo.ab.
60. clinical trials as topic/
61. randomly.ab.
62. trial.ti.
63. or/56-62
64. exp animals/ not humans/
65. 63 not 64
66. 55 and 65
[67: Wong 2006a - systematic reviews filter - spec version]
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67. cochrane database of systematic reviews.jn. or search*.tw. or meta analysis.pt. or medline.tw. or systematic review.tw
68. 55 and 67
69. 66 or 68
70. (2014* or 2015* or 2016* or 2017*).dc.
71. 69 and 70
72. remove duplicates from 71
Embase (Ovid SP)
1. (prediabet* or pre diabet*).tw.
2. intermediate hyperglyc?emi*.tw.
3. ((impaired fasting adj2 glucose) or IFG or impaired FPG).tw
4. glucose intolerance.tw.
5. ((impaired glucose adj (tolerance or metabolism)) or IGT).tw
6. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw
7. (risk adj3 (“type 2” or “type II” or diabetes or T2D* or NIDDM)).tw
8. or/1-7
9. ((lifestyle or life style) adj3 (intervention? or change* or modif* or program or programme)).tw
10. diet*.tw.
11. (nutrition* adj3 (intervention? or change* or modif* or program or programme)).tw
12. exercis*.tw.
13. physical activit*.tw.
14. resistance training.tw.
15. or/9-14
16. 8 and 15
17. (diabetes prevention adj (program* or stud* or trial?)).tw
18. 16 or 17
19. complication?.tw.
20. mortality.tw.
21. (CHD or CVD).tw.
22. (coronary adj2 disease).tw.
23. (coronar* adj (event? or syndrome?)).tw.
24. (heart adj (failure or disease? or attack? or infarct*)).tw
25. (myocardial adj (infarct* or isch?emi*)).tw.
26. cardiac failure.tw.
27. angina.tw.
28. revasculari*.tw.
29. (stroke or strokes).tw.
30. cerebrovascular.tw.
31. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw.
32. apoplexy.tw.
33. ((vascular or peripheral arter*) adj disease?).tw.
34. cardiovascular.tw.
35. (neuropath* or polyneuropath*).tw.
36. (retinopath* or maculopath*).tw.
37. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw
38. ((kidney or renal) adj (disease? or failure or transplant*)).tw
39. ((chronic or endstage or end stage) adj (renal or kidney)).tw
40. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw
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41. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw
42. (cancer or carcino* or neoplas* or tumo?r?).tw.
43. (amputation? or ulcer* or foot or feet or wound*).tw.
44. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) adj4 (diabetes or T2D* or NIDDM or “type 2”
or “type II”)).tw
45. or/19-44
46. 18 and 45
[47: Wong 2006b “sound treatment studies” filter - SDSSGS version]
47. random*.tw. or clinical trial*.mp. or exp treatment outcome/
48. 46 and 47
[49-52: TSC portal filter for exclusion of animal references]
49. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
50. human/ or normal human/ or human cell/
51. 49 and 50
52. 49 not 51
53. 48 not 52
54. conference.pt.
55. 53 not 54
56. limit 55 to embase
57. remove duplicates from 56
58. (2014* or 2015* or 2016* or 2017*).dc.
59. 57 and 58
ICTRP Search Portal (Standard search)
prediabet* AND lifestyle OR
prediabet* AND style OR
prediabet* AND exercis* OR prediabet* AND activity OR
prediabet* AND diet* OR
diabet* AND prevent* AND lifestyle OR
diabet* AND prevent* AND style OR
diabet* AND prevent* AND exercis* OR
diabet* AND prevent* AND activity OR
diabet* AND prevent* AND diet* OR
diabet* AND incidence AND lifestyle OR
diabet* AND incidence AND style OR
diabet* AND incidence AND exercis* OR
diabet* AND incidence AND activity OR
diabet* AND incidence AND diet*
ClinicalTrials.gov (Expert search)
EXACT “Interventional” [STUDY-TYPES] AND ( prediabetes OR prediabetic OR “pre diabetes” OR “pre diabetic” OR hyper-
glycemia ORhyperglycaemia ORhyperglycemicOR hyperglycaemicOR “impaired glucose tolerance” OR “impaired fasting glucose”
OR “glucose intolerance” OR IGT OR IFG OR “HbA(1c)” OR HbA1 OR HbA1c OR “HbA 1c” or glycosylated hemoglobin OR
glycosylated haemoglobin OR glycated hemoglobin OR glycated haemoglobin OR “risk for diabetes” OR “risk of diabetes” OR “risk
for type 2” OR “risk for type II” OR “risk of type 2” OR “risk of type II” ) [DISEASE] AND ( exercise OR exercises OR training
OR lifestyle OR “life style” OR activity OR activities OR physical OR diet OR dietary OR diets OR nutrition OR nutritional OR
“diabetes prevention” OR “diabetes mellitus prevention” OR “type 2 prevention” OR “type II prevention” ) [TREATMENT] AND
( complication OR complications OR mortality OR coronary OR heart OR myocardial OR infarct OR infarction OR infarcts OR
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infarctions OR ischemia OR ischemic OR ischaemia OR ischaemic OR failure OR angina OR revascularization OR revascularisation
OR revascularizations OR revascularisations OR stroke OR strokes OR cerebrovascular OR apoplexy OR vascular or peripheral OR
cardiovascular OR neuropathy OR neuropathies OR polyneuropathy OR polyneuropathies OR retinopathy OR retinopathies OR
maculopathy ORmaculopathies OR nephropathyOR nephropathiesOR nephrotic OR proteinuria OR proteinuric OR albuminuria
OR kidney OR renal OR microvascular OR macrovascular OR “micro vascular” OR “macro vascular” OR cancer OR carcinoma
OR neoplasm OR neoplasms OR tumor OR tumors OR tumour OR tumours OR amputation OR amputations OR ulcer OR foot
OR feet OR wounds OR ((diabetes OR “type 2” OR “type II” OR T2D OR T2DM) AND (risk OR progress OR progression
OR progressed OR incident OR incidence OR conversion OR developed OR development OR develop OR delay OR delayed OR
prevention OR prevent OR prevented)) ) [OUTCOME]
Appendix 2. Description of interventions
Trial ID Intervention(s) Intervention(s)
appropriate as applied in
a clinical practice setting
a
(description)
Comparator(s) Comparator(s)
appropriate as applied in
a clinical practice setting
a
(description)
Da Qing 1997 I1: diet: participants with
BMI < 25 kg/m2 were
prescribed a diet contain-
ing 25-30 kcal/kg body
wt (105-126 kj/kg), 55%-
65% carbohydrate, 10%-
15% protein, and 25%-
30% fat. These partici-
pants were encouraged to
consume more vegetables,
control their intake of al-
cohol, and reduce their in-
take of simple sugars.
Participants with BMI >
25kg/m2 were encouraged
to reduce their calorie in-
take so as to gradually lose
weight at a rate of 0.5-1.
0 kg per month until they
achieved a BMI of 23 kg/
m2
Group/individual: both
Medium: group
Facilitator: physician
Frequency: weekly for one
month, monthly for three
months, and then once ev-
Intensified diet and/or
physical activity is an ap-
propriate comparator
Standard recom-
mendation: received gen-
eral information about di-
abetes and impaired glu-
cose tolerance. Were pro-
vided brochures with gen-
eral instructions for diet
and physical activities
Group/individual: no for-
mal group or individ-
ual counselling were per-
formed
Medium: group
Facilitator: not specified
Frequency: no formal ses-
sions arranged
Extended FU period: no
intervention provided. Ex-
amination after 20 years
and 23 years of follow-up
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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ery third month for the re-
minder of the six years’ in-
tervention period (30 vis-
its)
Extended FU period: no
intervention provided. Ex-
amination after 20 years
and 23 years of follow-up
I2: physical activity: par-
ticipants in clinics as-
signed to the physical ac-
tivity group were taught
and encouraged to in-
crease the amount of
their leisure physical ac-
tivity by at least 1 unit/
day (mild-moderate-stren-
uous and very strenuous)
and by 2 units/day if pos-
sible for those < 50 years
of age with no evidence
of cardiovascular disease or
arthritis
Group/individual: both
Medium: group
Facilitator: not specified
Frequency: weekly for one
month, monthly for three
months, and then once ev-
ery third month for the re-
minder of the six years’ in-
tervention period (30 vis-
its)
Extended FU period: no
intervention provided. Ex-
amination after 20 years
and 23 years of follow-up
I3: diet plus physical ac-
tivity: diet as described for
the diet group (I1) com-
bined with physical activ-
ity (I2)
Group/individual: both
Medium: group
Facilitator: physician
Frequency: weekly for one
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month, monthly for three
months, and then once ev-
ery third month for the re-
minder of the six years’ in-
tervention period (30 vis-
its)
Extended FU period: no
intervention provided. Ex-
amination after 20 years
and 23 years of follow-up
DPP 2002 Diet plus physical activ-
ity
Dietary interven-
tion: healthy, low-calorie,
low-fat diet
Physical activity inter-
vention: moderate inten-
sity for at least 150 min-
utes per week
The aim was to achieve
and maintain a weight re-
duction of at least 7%
of initial body weight
through physical activ-
ity and diet. A 16-lesson
programme covering diet,
physical activity, and be-
haviour modification was
applied during the first
24 weeks after enrolment
was flexible and individ-
ualised. Subsequent in-
dividual sessions (usually
monthly) were designed to
reinforce the behavioural
changes
Group/individual: both
Medium: in person
Facilitator: case manager
(“lifestyle coach”), usually
a dietitian
Frequency: 40 (16 lessons
in first 24 weeks, then
monthly)
Extended FU
period: lifestyle sessions
were offered to all par-
ticipants every 3rd month
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Placebo + standard rec-
ommendation
Standard diet interven-
tion: culturally sensitive
materials andmotivational
strategies
Standard physical activ-
ity intervention: partici-
pants were encouraged to
increase their activity grad-
ually and to try to reach the
goal of at least 30 minutes
of physical activity (such
as walking or biking) on 5
days each week
Written information and
annual 30 min individ-
ual session on healthy
lifestyles. Changes in di-
etary and physical activity
recommended for weight
loss for overweight and
obese participants
Group/individual: both
(At the first visit, the staff
will spend approximately
20 - 30 minutes with each
participant individually)
Medium: in person
Facilitator: staff (not de-
scribed further)
Frequency: annually
(three times)
Extended FU
period: lifestyle sessions
were offered to all par-
ticipants every 3rd month
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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with educational material
and reinforcement of orig-
inal weight loss and phys-
ical activity goals. DPP
lifestyle participants were
also offered two group
classes compromising four
sessions every year in order
to reinvigorate their self-
management behaviours
for weight loss. Yearly vis-
its
with educational material
and reinforcement of orig-
inal weight loss and phys-
ical activity goals. Yearly
visits
DPS 2001 Diet plus physical activ-
ity
Di-
etary intervention: base-
line three-day food record
was completed before first
appointment. The partici-
pants were advised to con-
sume a diet with more
than 50% of daily calories
from carbohydrates; less
than 10% from saturated
fat and 20% from mono-
and polyunsaturated fat,
or up to 25% if the surplus
is
from monounsat-
urated fat; cholesterol less
than 300 mg/day; and ap-
proximately 1.0 g protein
per kg ideal body weight
per day.The increase in the
intake of dietary fibre to 15
g per 1000 kcal or more
was encouraged
It was aimed to reduce the
intake of saturated fat and
participants are encour-
aged to use low-fat milk
and milk products, low-fat
meat and meat products,
soft margarines and veg-
etable oil rich in monoun-
saturated fatty acids (pri-
marily rapeseed oil)
If weight loss was not
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
Standard diet interven-
tion: adjust total energy
intake in order to reduce
BMI below 25 kg/m2 and
to keep to a diet with less
than 30% of daily energy
from fat. Advised to reduce
alcohol intake and to stop
smoking as appropriate.
The dietary advice is pro-
vided by verbal and writ-
ten information
Standard physical ac-
tivity intervention: ver-
bal general information
about the health effects of
recreational physical activ-
ity was provided but no
specific individual propo-
sitions and programmes
were given
Group/individual: both
Medium: in person
Facilitator: nutritionist
Frequency: advice given
initially and in annual fol-
low-up visits
No of contacts: four
Extended FU period:
yearly visit by a nurse, no
specific diet or physical ac-
tivity counselling was pro-
vided
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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achieved during the first 6-
12 months and the BMI
was over 30 kg/m2, a very
low-calorie diet was con-
sidered.
Physical activity inter-
vention: guided to in-
crease their physical activ-
ity. Exercise programmes
differed among study cen-
tres according to local sit-
uation and facilities. En-
durance exercise (walking,
jogging, swimming, aero-
bic ball games, skiing) was
recommended to increase
aerobic capacity and car-
diorespiratory fitness. Su-
pervised, progressive, in-
dividually tailored circuit-
type resistance training
sessions were organised,
if possible, twice a week.
The moderate intensity
and medium- to high-
volume programmes were
designed to improve the
functional capacity and
strength of the large mus-
cle groups of the upper and
lower body
The aim was a BMI of
less than 25 kg/m2 but, in
practice, a weight loss of 5
to 10 kg depending on de-
gree of obesity was the tar-
get for many study partic-
ipants
Group/individual:
both (the person primar-
ily in charge of preparing
meals in the family, if dif-
ferent from the study par-
ticipant, was also informed
about the study aims and
invited to join in the ses-
sions with the nutritionist
or the group meetings)
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Medium: in person
Facilitator: nutritionist,
physician
Frequency: seven sessions
with a clinical nutritionist
during the first year of the
study and then one
session every 3 months.
No of contacts: 15
Extended FU period:
yearly visit by a nurse, no
specific diet or physical ac-
tivity counselling was pro-
vided
EDIPS 2009 Diet plus physical activ-
ity
both intervention and
control groups were of-
fered standard health pro-
motion advice including
widely available contem-
porary written leaflets on
healthy eating and physi-
cal activity. Received quar-
terly newsletter
Dietary intervention: ad-
vice and counselling to de-
velop an individual plan
for behaviour change, with
the aim of achieving: >
50% total dietary energy
intake from carbohydrate,
reduced total and satu-
rated fat intake with <
30% total dietary energy
from fat, increasedfibre in-
take, and weight loss to
achieve BMI < 25 kg/m2;
invited to cook and eat ses-
sions.
Analysis of participants’
three-day food diaries, col-
lected quarterly, and regu-
lar weight and waist mea-
surementswere used to tai-
lor individual dietary ad-
vice
Physical activity inter-
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
both intervention and
control groups were of-
fered standard health pro-
motion advice including
widely available contem-
porary written leaflets on
healthy eating and physi-
cal activity. Control group
participants were other-
wise offered ’usual care’ by
their primary care physi-
cian
Group/individual:
individual
Medium: in person
Facilitator: no personal in-
volved in the trial (advised
to contact primary care
physician)
Frequency: none
No. of contacts: none
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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vention: encourage partic-
ipation in increased phys-
ical activity equivalent to
accumulating 30 minutes
of moderate aerobic phys-
ical activity per day. Anal-
ysis of participants’ three-
day activity diaries, col-
lected quarterly, was used
in motivational feedback
and to tailor goals for in-
creasing physical activity,
which were negotiated at
each visit
In addition to individual
and group activities, par-
ticipants received an in-
formation pack detailing
facilities and opportuni-
ties for physical activity
in Newcastle upon Tyne,
a City Card (a discount
scheme run by Newcas-
tle Leisure Services offer-
ing up to 80% discount on
access to physical activity
facilities) and the opportu-
nity to meet with a trainer
at a local leisure centre and
take part in an induction
session
Group/individual: both
Medium: in person
Facilitator: dietician and
physiotherapist trained in
motivational interviewing
Frequency: immedi-
ately following randomisa-
tion and two weeks later,
then monthly for the first
three months and every
threemonths thereafter up
to five years
No. of contacts: 17
Hellgren 2016 I1: physical activity (ba-
sic intervention)
In-
formation and brochures
were distributed. In addi-
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
Informa-
tion about the metabolic
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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tion the participants were:
1. offered the possibility
of cost-free blood glucose
assessments at the health
care unit;
2. provided with a tele-
phone number to a per-
sonal nurse for support
(available 8:00 a.m. to 5:
00
p.m., daily);
3. given a prescription for
physical activity. The pre-
scription was used as a re-
ferral to a physiotherapist,
who gave individualised
advice about physical ac-
tivity. This routine was the
same as in ordinary prac-
tice;
4. given a step-counter.
After two years, the par-
ticipants received a letter
with questions concerning
physical activity and an of-
fer of
a renewal of the prescrip-
tion for physical activity.
Group/individual:
individual
Medium: in person
Facilitator: physiothera-
pist, personal nurse
Frequency: NS
No. of contacts: NS
I2: physical activity (in-
tensive intervention)
In-
formation and brochures
were distributed. In addi-
tion the participants were:
1. offered the possibility
of cost-free blood glucose
assessments at the health
care unit;
2. provided with a tele-
phone number to a per-
sonal nurse for support
condition (IGT or IFG, or
both) was given orally and
in writing. Brochures with
information about recom-
mended diet and physical
activity were distributed.
Group/individual: NS
Medium: in person
Facilitator: NS
Frequency: baseline, then
yearly
No. of contacts: 3
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(available 8:00 a.m. to 5:
00
p.m., daily);
3. given a prescription for
physical activity. The pre-
scription was used as a re-
ferral to a physiotherapist,
who gave individualised
advice about physical ac-
tivity. This routine was the
same as in ordinary prac-
tice;
4. given a step-counter.
5. invitation to participate
in eight group sessions fo-
cusing on physical activity
After two years, the par-
ticipants received a letter
with questions concerning
physical activity and an of-
fer of a renewal of the pre-
scription for physical ac-
tivity
Group/individual: both
Medium: in person
Facilitator: lifestyle coach
(nurse), a nutritionist and
a physiotherapist
Frequency:
six sessions were held dur-
ing the first six months
and another two sessions
during the following six
months. During the sec-
ond year, the participants
were invited for two ad-
ditional group sessions, at
six-month intervals. Dur-
ing the third year, the par-
ticipants received a tele-
phone call every
third month, with a focus
on general well-being, a re-
minder to be physically ac-
tive and an offer of a
new prescription for phys-
ical activity.
No. of contacts: 14
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HELP PD 2011 Diet plus physical activ-
ity
The goal was weight loss
5% to 7%
The intervention was di-
vided into two phases
First phase dietary inter-
vention (month 1-6): re-
duction of intake by 500-
1000 kcal per day; reduc-
tion in total fats to 25%-
30%, saturated fats to 7%,
and protein to 15% of in-
take; increase in fruit and
vegetable consumption to
5
servings per day; intake of
≥ 3 whole grain servings
per day
The first phase physi-
cal activity intervention
(month 1-6): gradual pro-
gression to 180 minutes of
moderate intensity physi-
cal activity per week (e.g.
30 min/day of walking, 6
days/week)
Second phase dietary in-
tervention (month 7-24)
: isocaloric intake tailored
to maintenance of lost
weight; maintenance of
25%-30% energy intake
from total fats, 7% from
saturated fat, and 15%
from protein; continued
daily intake of 5 fruits and
vegetables and ≥ 3 whole
grain servings
The second phase phys-
ical activity intervention
(month 7-24): mainte-
nance of 180 min of mod-
erate intensity physical ac-
tivity per week; coping
with injuries and other
barriers to the mainte-
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
Information about healthy
eating and activity to sup-
port weight loss, and dis-
cuss existing community
resources that may fit the
in-
dividual needs of compar-
ison participants as they
pursue dietary change, in-
creased physical activity
and weight loss
Group/individual:
individual
Medium: in person
Facilitator: dietician
Frequency: two individual
sessions with a nutritionist
during the first 3 months,
In addition, comparison
participants receive a quar-
terly newsletterwith topics
related to healthy lifestyle
No. of contacts: 6
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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nance of physical activity
Group/individual: both
Medium: in person
Facilitator: community
health workers, dietician
Frequency: in the first in-
tervention phase then 1
group sessionperweek (for
6 months). In addition, all
participants receive three
personalised consultations
with a dietician. During
phase 2 (months 7-24),
participants had 2 sched-
uled contacts with the
community health worker
each month, one group
session and one phone
contact
No. of contacts: 46
IDPP 2006 Diet plus physical activ-
ity
Dietary
intervention: diet modi-
fication with reduction in
total calories, refined car-
bohydrates and fats, avoid-
ance of sugar and inclusion
of fibre-rich food
Physical activity inter-
vention: participants who
were involved in physical
labour or who had to walk
or cycle for > 30 min/day
or were performing physi-
cal activities regularly were
asked to continue their
routine activities. Partici-
pants engaged in sedentary
or light physical activity
were advised and regularly
motivated to walk briskly
for at least 30min each day
The intervention was ex-
plained
individually at the time of
randomisation, then again
by phone or letter after 2
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
standard health care advice
Group/individual: both
Medium: in person
Facilitator: physician di-
etician and social worker
Frequency: once a year
No. of contacts: 3
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
195Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
weeks; thereafter monthly
telephonic contacts were
maintained for continued
motivation. Personal ses-
sions were conducted at 6-
monthly intervals
Group/individual: both
Medium: in person
Facilitator: physician di-
etician and social worker
Frequency: every 6
months
No. of contacts: 6
JDPP 2013 Diet plus physical activ-
ity
The goals of intervention
were: 1) to reduce ini-
tial body weight by 5%
in overweight and obese
participants, and 2) to in-
crease energy expenditure
due to leisure time physi-
cal activity by 700 kcal per
week
The interventions were
carried out by the study
nurse in each collabora-
tive centre in the form
of both group and indi-
vidual sessions, using the
guideline, curriculum, and
educational materials pro-
vided by the committee
of the study group. When
needed, the study nurse
could ask a part-time dieti-
cian for diet counselling.
A 27-page booklet titled
“Change Your Lifestyle
to Prevent Diabetes” was
given to each participant as
a guide
Data on dietary intake and
physical activities were as-
sessed by the study group
and the results were sent
back to study nurses at
each collaborative center
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
general verbal and written
information on a healthy
lifestyle and diabetes in
one group session
Group/individual: group
Medium: in person
Facilitator: public health
nurses or dietician
Frequency: one time
No. of contacts: 1
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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Dietary
intervention: participants
were advised to take the
proper amount of calories,
decrease the mean percent
of energy derived from di-
etary fat to less than 25%,
and restrict daily alcohol
consumption to less than
160 kcal. They were also
advised to eat three meals
a day and avoid eating late
at night
Physical activ-
ity intervention: person-
alised goals, such as amini-
mum of 20 minutes’ mod-
erate walking each day,
were set
Group/individual: both
Medium: in person
Facilitator: public health
nurses or dietician
Frequency: during the ini-
tial six months, four group
sessions were conducted.
The individual sessions
were conducted biannu-
ally during the three years
with each session lasting
20-40 minutes. To rein-
force the intervention, be-
tween-visit contact by fax
was also made monthly
during the initial twelve
months.
No. of contacts: 10 (ex-
cluding fax contact)
Kosaka 2005 Diet plus physical activ-
ity
Participants with a BMI
≥ 22 kg/m2 were advised
to lose weight. participants
with BMI less than 22 kg/
m2 were advised to main-
tain their present weight.
Family members were par-
ticipating in the education
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
Standard diet interven-
tion: participants with a
BMI ≥ 24 kg/m2 were
advised to take 5%-10%
smaller meals than they
had been taking, and to in-
crease their physical activ-
ity. They were encouraged
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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of the participants
Dietary intervention:
eating smaller meals (re-
duce amount about 10%)
, consume large amount
of vegetables, reduce con-
sumption of fat-rich foods
Physical activity inter-
vention: physical activity:
walking 30-40 min/day;
besides advice on how to
increase physical activity
during the day (e.g. taking
staircase instead of an es-
calator etc.)
Frequency: every 3-4
months
No. of contacts: 16
Group/individual:
individual
Medium: in person
Facilitator: -
to lose weight
Participants with a BMI
< 24 kg/m2 were told to
avoid gaining weight by
dieting and physical activ-
ity
Standard physical activ-
ity intervention: partici-
pants with a BMI ≥ 24
kg/m2 were advised to
increase physical activity.
They were encouraged to
lose weight
Participants with a BMI
< 24 kg/m2 were told to
avoid gaining weight by
dieting and physical activ-
ity
Frequency: every 6
months
No. of contacts: 8
Group/individual:
individual
Medium: in person
Facilitator: -
Oldroyd 2005 Diet plus physical activ-
ity
Dietary inter-
vention: participants were
encouraged to eat regular
meals, eat more fruit and
vegetables, reduce the fat
content of foods, reduce
sugar intake and eat ad-
equate dietary fibre. The
goal was to reduce BMI to
< 25 kg/m2 in those who
were overweight or obese,
to achieve a dietary fat in-
take of 30% of total en-
ergy intake, a polyunsatu-
rated to saturated fat ra-
tio of 1.0, 50% of energy
from carbohydrate and a
dietary fibre intake of 20
g per 4.2 MJ. All partic-
ipants in the intervention
group were given written
Intensified diet and physi-
cal activity is an appropri-
ate comparator
No intervention
Participants in the control
group were offered no di-
etary or physical activity
advice for the duration of
the study
Frequency: none
No. of contacts: none
Group/Individual: NA
Medium: NA
Facilitator: none
No intervention is an ap-
propriate comparator
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nutrition education mate-
rial
Physical activity inter-
vention: a graded phys-
ical activity plan, tai-
lored to the participant’s
lifestyle and designed to
enable them to achieve
20-30 min of aerobic ac-
tivity at least once a
week. The type of phys-
ical activity was tailored
to the participant’s inter-
ests, lifestyle and physical
abilities. physical activities
such as walking, cycling,
swimming, dancing and
playing golf were encour-
aged. Information leaflets
about physical activity fa-
cilities available in New-
castle were provided as ap-
propriate. A CiTY CARD
(a scheme offering up to
80% discount on use of all
public leisure facilities in
the city) was offered to all
participants
Frequency: first 6 months
3 appointments at 2-
weekly intervals, followed
by 3 at monthly intervals.
One after 9 months and 5
at 2-monthly intervals be-
tween 12 and 24 months
No. of contacts: 12
Group/Individual:
individual
Medium: in person
Facilitator: dietitian and
physiotherapist
PODOSA 2014 Diet plus physical activ-
ity
Weight loss goal of 2.5 kg
more in the intervention
than control group
Dietary intervention:
weight loss through a calo-
Intensified diet and physi-
cal activity is an appropri-
ate comparator
Standard recommenda-
tion
Standard dietary inter-
vention: standard writ-
ten and verbal advice on
healthy eating
Standard physical inter-
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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rie-deficit diet (not specific
innutritions) using cultur-
ally adapted and translated
resources
Physical activity
intervention: weight loss
through physical activity
of at least 30 min daily
brisk walking, using cul-
turally adapted and trans-
lated resources
Frequency:
baseline, monthly for the
first 3 months, then every
3 months
No. of contacts: 15
Group/Individual: both
Medium: family
Facilitator: dietician. In
both the intervention and
control groups family vol-
unteers were asked to fol-
low the advice given and
to help the participants to
follow it
vention: standard written
and verbal advice on pro-
motion of physical activity
Frequency: baseline, then
annually
No. of contacts: 4
Group/Individual: both
Medium: family
Facilitator: dietician. In
both the intervention and
control groups family vol-
unteers were asked to fol-
low the advice given and
to help the participants to
follow it
SLIM 2003 I: Diet plus physical ac-
tivity
Dietary intervention: di-
etary recom-
mendations were based on
the Dutch guidelines for
a healthy diet (about 55%
energy from carbohydrates
(maximum 15%-25% en-
ergy mono- and disaccha-
rides); 30%-35% of en-
ergy from fat (≤ 10% en-
ergy saturated fatty acids;
< 33 mg/MJ cholesterol,
maximal 300 mg a day);
10%-15% of energy from
protein; Fibre more than 3
g/MJ a day
A bodyweight loss of 5%-
7% was the objective. If
participants did not lose
weight on this regimen
during the first year, mild
Intensified diet and physi-
cal activity is an appropri-
ate comparator
C: Standard recommen-
dation
Participants in the control
group were given, oral and
written information,
about the beneficial effects
of
a healthy diet, weight loss
and increased physical
activity, whereas no in-
dividual advice or pro-
grammes
were provided. No addi-
tional appointments were
scheduled apart from an-
nual follow-up visits
Frequency: one (at base-
line - thereafter annual fol-
low-up visits with mea-
surement of outcome vari-
ables, but no advice on
diet or physical activity
was given)
Standard diet and physi-
cal activity recommenda-
tion is an appropriate com-
parator
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energy restriction was pre-
scribed during the second
year. No very-low calo-
rie diet or dietary prod-
ucts were used to encour-
age weight loss
Physical activity inter-
vention: participants were
encouraged to increase
their level of physical ac-
tivity to at least 30 min
of moderate physical ac-
tivity a day for at least
5 days a week. Indi-
vidual advice was given
on how to increase daily
physical activity (walking,
cycling, swimming), and
goals were set. Further-
more, participants
were encouraged to partic-
ipate in a physical activity
programme, especially de-
signed for the trial, includ-
ing
components of aerobic
training and components
of resistance training. Par-
ticipants had free access to
these training sessions, and
were stimulated to partic-
ipate for at least 1 hour
a week. Participation in
the physical activity ses-
sions was recorded
Frequency: The partici-
pants were seen at a base-
line visit, after 4-6 weeks
and thereafter every third
month.
No. of contacts: 14 vis-
its during the planned
three years of interven-
tion. However, the du-
ration of the trial was
extended, so there have
probably been more vis-
its even though not stated.
No. of contacts: one
Group/Individual:
individual
Medium: in person
Facilitator: not reported
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After three months the
participants were seen ev-
ery third month.
Group/Individual: both
Medium: in person
Facilitator: dietician
aThe term ’clinical practice setting’ refers to the specification of the intervention/comparator as used in the course of a standard
medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications and other important features)
BMI: body mass index; C: comparator; FU: follow-up; I: intervention; N/CPS: no specification of clinical practice setting possible
Appendix 3. Baseline characteristics (I)
Trial ID Interven-
tion(s) and
comparator
(s)
Duration
of interven-
tion
(dura-
tion of fol-
low-up)
Descrip-
tion of par-
ticipants
Trial period
(year to
year)
Country Setting Ethnic
groups
(%)
Duration of
being at risk
for T2DM
(mean years
(SD))
Da Qing
1997
I1: diet 6 years (6
years)
Impaired
glucose tol-
erance,
Asian
1986-
1992: inter-
vention pe-
riod
Chinese
community
Outpatient Asian: 100 -
I2: physical
activity
Asian: 100
I3: diet plus
physical ac-
tivity
Asian: 100
C: stan-
dard recom-
mendation
Asian: 100
DPP 2002 I: diet plus
physical ac-
tivity
Mean 2.8
years (mean
15 years)
Impaired
glucose tol-
er-
ance and ele-
vated fasting
glucose
Being over-
weight or
obese
1996-1999
(recruit-
ment
period)
July 2001
(end
of treatment
period)
followed up
in the DPP
Outcomes
Study (DP-
USA Outpatient White: 54
African
American:
19
Hispanic: 17
American
Indian: 6
Asian: 5
-
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POS 2002,
to 2014)
C: placebo +
standard
treatment
White: 54
African
American:
20
Hispanic: 16
American
Indian: 6
Asian: 5
DPS 2001 I: diet plus
physical ac-
tivity
Mean
3.2 years (3.
2 years)
Impaired
glucose tol-
erance
Being over-
weight
1993
to 1998 (re-
cruitment
period)
The
intervention
period lasted
until end of
2001
Finland Outpatient - -
C: standard
treatment
EDIPS
2009
I: diet plus
physical ac-
tivity
Mean 3.11
years (3.11
years)
Impaired
glucose tol-
erance
Being over-
weight
2000
to 2003 (re-
cruitment
period)
UK Outpatient - -
C: standard
treatment
Hellgren
2016
I: physical
activity
3 years (3
years)
Impaired
fasting
glucose and/
or impaired
glucose tol-
erance
- Sweden Outpatient NR, assume
nearly 100%
were white
-
C: standard
treatment
HELP PD
2011
I: diet plus
physical ac-
tivity
2 years (2
years)
Im-
pared fasting
glucose
Being over-
weight
Recruit-
ment from
2007 to
2009.
Data collec-
tion
during 2007
to 2011.
Analyses
performed
in 2011 to
2012
USA Outpatient African
American:
25.8
White: 73.5
Other: 0.7
-
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C: standard
treatment
African
American:
23.3
White: 74.0
Other: 2.7
IDPP 2006 I: diet plus
physical ac-
tivity
3 years (3
years)
Impaired
glucose tol-
erance.
Asian Indian
- India Outpatient Asian
Indian: 100
-
C: standard
treatment
Asian
Indian: 100
JDPP 2013 I: diet plus
physical ac-
tivity
3 years (6
years)
Impaired
glucose tol-
erance
Recruit-
ment started
in
March 1999
and was
completed
in Decem-
ber 2002
Follow-
up of partic-
ipants
started 1999
and the last
completed 3
years’
follow-up in
2008
Japan Outpatient Asian
Japanese:
100
-
C: standard
treatment
Asian
Japanese:
100
Kosaka
2005
I: diet plus
physical ac-
tivity
4 years (4
years)
Impaired
glucose tol-
erance
- Japan Outpatient Asian
Japanese:
100
-
C: stan-
dard recom-
mendation
Asian
Japanese:
100
Oldroyd
2005
I: diet plus
physical ac-
tivity
24 months
(24 months)
Impaired
glucose tol-
erance
1994 to
1998
UK Outpatient White: 100 -
C: no inter-
vention
White: 100
PODOSA
2014
I: diet plus
physical ac-
tivity
3 years (3
years)
Impaired
glucose tol-
erance
Recruit-
ment 2006
to 2011
UK Outpatient Indian: 34
Pakistani: 66
-
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or impaired
fasting glu-
cose
C: standard
treatment
Indian: 33
Pakistani: 67
SLIM 2003 I: diet plus
physical ac-
tivity
4.1 years (4.
1 years)
Impaired
glucose tol-
erance
Recruit-
ment from
1999
to 2000. In
2002 a sec-
ond screen-
ing period
was made
Trial was
completed
2006
The Nether-
lands
Outpatient White:100 -
C: standard
treatment
White:100
- denotes not reported
C: comparator; I: intervention; SD: standard deviation
Appendix 4. Baseline characteristics (II)
Trial ID Intervention(s)
and comparator
(s)
Indicator of in-
creased risk:
IFG
(mean mmol/L
(SD))
Indicator of in-
creased risk:
2h-PPG
(mean mmol/L
(SD))
Indicator of in-
creased risk:
elevated HbA1c
(mean % (SD))
Comorbidities Comedica-
tions/Co-
interventions
Da Qing 1997 I1: diet 5.56 (0.81) 9.03 (0.94) - - -
I2: physical ac-
tivity
5.56 (0.83) 8.83 (0.79) - - -
I3: diet plus
physical activity
5.67 (0.80) 9.11 (0.93) - - -
C: standard
treatment
5.52 (0.82) 9.03 (0.89) - - -
DPP 2002 I: diet plus phys-
ical activity
5.90 (0.45) 9.13 (0.93) 5.91 (0.51) 16% of the
women in both
group had previ-
ously had gesta-
17% in all treat-
ment groups had
antihyperten-
sive treatment at
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tional diabetes
Overall
29.6% had a his-
tory of hyperten-
sion. 34% had a
history of stroke.
16% had a his-
tory of revascu-
larisation.
32% had a his-
tory of myocar-
dial infarction
baseline
5.2% of partic-
ipants reported
taking phar-
macologic ther-
apy for dyslipi-
daemia at entry
to the trial
C: placebo
+ standard treat-
ment
5.92 (0.47) 9.13 (0.95) 5.91 (0.50)
DPS 2001 I: diet plus phys-
ical activity
6.05 (0.78) 8.82 (1.50) 5.7 (0.6) Cardiovascular
disease: 8.2%
Lipid-lower-
ing intervention:
4.3%
Antihyper-
tensive interven-
tion: 27.7%
29% had antihy-
pertensive treat-
ment at baseline
5%
had lipid-lower-
ing treatment at
baseline
C: standard
treatment
6.11 (0.72) 8.83 (1.44) 5.6 (0.6) Cardiovascular
disease: 8.1%
Lipid-lowering
intervention: 6.1
Antihyper-
tensive interven-
tion: 31.5
31% had antihy-
pertensive treat-
ment at baseline
7%
had lipid-lower-
ing treatment at
baseline
EDIPS 2009 I: diet plus phys-
ical activity
5.7 (0.6) 8.7 (1.1) - - -
C: standard
treatment
5.8 (0.5) 8.9 (1.3) - - -
Hellgren 2016 I: physical activ-
ity
-a - - Only re-
ported for all in-
tervention
groups together:
16% were diag-
nosed with car-
diovascular dis-
ease; 26% with
hyperlipidaemia;
49% with hyper-
tension
-
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C: standard
treatment
- - - -
HELP PD 2011 I: diet plus phys-
ical activity
5.8 (0.7) - - - -
C: standard
treatment
5.9 (0.6) - - - -
IDPP 2006 I: diet plus phys-
ical activity
5.4 (0.7) 8.5 (0.7) 6.1 (0.5) 31.6
% had hyperten-
sion at baseline
-
C: standard
treatment
5.5 (0.8) 8.6 (0.7) 6.2 (0.5) 32.4% had hy-
pertension at
baseline
-
JDPP 2013 I: diet plus phys-
ical activity
5.9 (0.5)b 9.2 (0.9) 5.7 (0.4)c - -
C: standard
treatment
6.1 (0.5) 9.0 (0.9) 5,8 (0,4) - -
Kosaka 2005 I: diet plus phys-
ical activity
6.27 (0.42) - - - -
C: standard
treatment
6.22 (0.47) - -
Oldroyd 2005 I: diet plus phys-
ical activity
6.05 (0.89) 9.15 (0.89) 5.8 (0.7) - -
C: no interven-
tion
6.16 (0.89) 9.22 (0.92) 5.9 (0.5)
PODOSA 2014 I: diet plus phys-
ical activity
5.8 (0.6) 8.2 (1.6) - - Cholesterol-
lowering: 16%
Antihyperten-
sive: 25%
C: standard
treatment
5.8 (0.6) 8.3 (1.5) - - Cholesterol-
lowering: 29%
Antihyperten-
sive: 31%
SLIM 2003 I: diet plus phys-
ical activity
6.0 (0.87) 8.59 (1.55) 5.6 (0.5) - 21% of the par-
ticipants were re-
ceiving
blood pressure-
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lowering medi-
cation at baseline
C: standard
treatment
5.9 (0.70) 8.46 (1.84) 5.8 (0.5) - 18% of the par-
ticipants were re-
ceiving
blood pressure-
lowering medi-
cation at baseline
- denotes not reported
C: comparator; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; 2h-PPG: 2-hour postprandial plasma glucose;
I: intervention; SD: standard deviation
aIn the combined intervention Hellgren 2016 had 56.1% impaired fasting glucose; 43.9% impaired glucose tolerance and 18.2%
impaired fasting glucose and impaired glucose tolerance combined; the usual-care group had 56.1% impaired fasting glucose; 63.3%
impaired glucose tolerance and 6.7% impaired fasting glucose and impaired glucose tolerance combined
bBaseline data reported for 123 participants in the intervention group and 131 participants in the control group
cBaseline data reported according to HbA1c at baseline - data were therefore calculated by combining the groups for each intervention
arm
Appendix 5. Baseline characteristics (III)
Trial ID Intervention(s)
and comparator
(s)
Sex
(female %)
Age
(mean years
(SD))
Systolic/dias-
tolic bloodpres-
sure
(mean mmHg
(SD))
BMI
(mean kg/m²
(SD))
Weight
(mean kg (SD))
Da Qing 1997 I1: diet 55 44.7 (9.4) 132 (23.5)/87.3
(14.5)
25.3 (3.8) -
I2: physical ac-
tivity
43 44.2 (8.7) 132 (23.5)/87.3
(14.5)
25.4 (3.7) -
I3: diet plus
physical activity
44 44.4 (9.2) 132 (23.5)/87.3
(14.5)
26.3 (3.9) -
C: standard
treatment
45 46.5 (9.3) 134.4 (23.4)/88.
5 (13.5)
26.2 (3.9) -
DPP 2002 I: diet plus phys-
ical activity
68 50.6 (11.3) 123.7 (14.8)/78.
6 (9.2)
33.9 (6.8) 94.1 (20.8)
C: placebo
+ standard treat-
69 50.3 (10.4) 123.5 (14.4)/78.
0 (9.2)
34.2 (6.7) 94.3 (20.2)
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ment
DPS 2001 I: diet plus phys-
ical activity
66 55 (7) 140 (18)/86 (9) 31.3 (4.6) 86.7 (14.0)
C: standard
treatment
68 55 (7) 136 (17)/86 (10) 31.0 (4.5) 85.5 (14.4)
EDIPS 2009 I: diet plus phys-
ical activity
59 56.8 (40-72)a - 34.1 (5.5) 93.4 (16.0)
C: standard
treatment
61 57.4 (38-74) - 33.5 (4.6) 90.6 (12.5)
Hellgren 2016 I: physical activ-
ity
61 63 (9) 146 (22)/83 (11) 30.1 (4.6) -
C: standard
treatment
53 63 (9) 143 (15)/83 (9) 29.7 (4.8) -
HELP PD 2011 I: diet plus phys-
ical activity
58 57.3 (10.1) - Reported for
the whole study
population: 127.
2 (14.1)/73.2 (9.
4)
32.8 (3.9) 94.4 (14.7)
C: standard
treatment
57 58.5 (9.0) - Reported for
the whole study
population: 127.
2 (14.1)/73.2 (9.
4)
32.6 (4.1) 93.0 (16.2)
IDPP 2006 I: diet plus phys-
ical activity
22 46.1 (5.7) 121.5 (14.4)/74.
4 (8.1)
25.7 (3.3) -
C: standard
treatment
24 45.2 (5.7) 124.1 (16.0)/76.
2 (8.6)
26.3 (3.7) -
JDPP 2013 I: diet plus phys-
ical activity
48b 51.1 (6.5)c - 24.8 (3.6) 64.9 (12.9)
C: standard
treatment
50 51.7 (6.1) - 24.5 (3.2)JDPP 63.9 (11.7)
Kosaka 2005 I: diet plus phys-
ical activity
0 30s: 5.2%
40s: 32.9%
50s: 53.9%
60s: 8.1%
123 (18)/78 (13) 24.0 (2.3) -
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C: standard
treatment
0 30s: 3.9%
40s: 32.3%
50s: 56.9%
60s: 6.9%
124 (17)/79 (11) 23.8 (2.1) -
Oldroyd 2005 I: diet plus phys-
ical activity
54 58.1 (52.1) 137.2 (19.9)/77.
0 (12.6)
30.4 (5.6) 85.3 (17.9)
C: no interven-
tion
31 57.5 (44.7) 132.8 (16.4)/75.
5 (9.8)
29.9 (4.9) 85.5 (14.2)
PODOSA 2014 I: diet plus phys-
ical activity
54 52.8 (10.2) 136.9 (21.8)/82.
7 (12.5)
30.6 (5.0) 79.8 (16.2)
C: standard
treatment
55 52.2 (10.3) 137.0 (19.7)/83.
5 (10.7)
30.5 (4.6) 80.7 (15.0)
SLIM 2003 I: diet plus phys-
ical activity
46 54.2 (5.8) 142 (16)/90 (9) 29.6 (3.8) 87.5 (13.7)
C: standard
treatment
44 58.4 (6.8) 145 (14)/88 (7) 29.2 (3.3) 83.0 (11.7)
- denotes not reported
BMI: body mass index; C: comparator; EDIPS: European Diabetes Prevention Study (EDIPS) - Newcastle; SD: standard deviation
aData are expressed as mean (range).
bBaseline data reported for 123 participants in the intervention group and 131 participants in the control group
cBaseline data reported according to HbA1c at baseline - data were therefore calculated by combining the groups for each intervention
arm
Appendix 6. Matrix of study endpoints (publications and trial documents)
Trial ID Endpoints quoted in
trial document(s)
(Clini-
calTrials.gov, FDA/EMA
document, man-
ufacturer’s website, pub-
lished design paper)a,c
Trial results available in
trials register
Yes/No
Endpoints quoted in
publication(s)b,c
Endpoints quoted in ab-
stract of publication(s)
b,c
Da Qing 1997 N/T Primary
outcome measure(s): in-
cidence of T2DM after 6
years
Primary
outcome measure(s): in-
cidence of T2DM after 6
years
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Secondaryoutcomemea-
sure(s): -
Secondaryoutcomemea-
sure(s): composite cardio-
vascular events after 6
years
Other outcome measure
(s): mortality, fasting glu-
cose, 2-hour glucose val-
ues, insulin resistance and
insulin secretion
Other outcome measure
(s):mortality, insulin resis-
tance and insulin secretion
DPP 2002 Source: NCT00004992;
design article and proto-
col available from website
(DPP 2002)
Primary
outcome measure(s): in-
cidence of T2DM
No Primary
outcome measure(s): in-
cidence of T2DM
Primary
outcome measure(s): in-
cidence of T2DM
Secondaryoutcomemea-
sure(s): HbA1c; insulin
and glucose; electrocardio-
gram; cardiovascu-
lar symptom assessment;
blood pressure; carotid ul-
trasound; lipopro-
teins; fibrinolysis and clot-
ting factors; albumin ex-
cretion; physical measure-
ments; physical activity;
nutrient intake; health-re-
lated quality of life; re-
source utilisation; safety
Secondaryoutcomemea-
sure(s): HbA1c; insulin
and glucose; electrocardio-
gram; cardiovascu-
lar symptom assessment;
blood pressure; lipopro-
teins; fibrinolysis and clot-
ting factors; albumin ex-
cretion; physical measure-
ments; physical activity;
nutrient intake; health-re-
lated quality of life; re-
source utilisation; safety
Secondaryoutcomemea-
sure(s): insulin; cardiovas-
cu-
lar symptom assessment;
blood pressure; lipopro-
teins; fibrinolysis and clot-
ting factors; albumin ex-
cretion; physical measure-
ments; nutrient intake;
health-related quality of
life; resource utilization
Other outcome measure
(s): -
Other outcome measure
(s): -
Other outcome measure
(s): -
DPS 2001 Source: design article and
NCT00279240
Primary
outcome measure(s): in-
cidence of T2DM
No Primary outcome mea-
sure(s): diabetes
Primary outcome mea-
sure(s): diabetes
Secondaryoutcomemea-
sure(s): changes in plasma
glucose, insulin and
HbA1c, changes in physi-
cal activity and diet
Secondaryoutcomemea-
sure(s): changes in plasma
glucose, insulin, HbA1c,
changes in physical activ-
ity and diet
Secondaryoutcomemea-
sure(s): changes in glu-
cose, insulin, changes in
physical activity and diet
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Other outcome measure
(s): cardiovascular risk fac-
tors. Cardiovascular mor-
tality and morbidity
Other outcome measure
(s): cardiovascular risk fac-
tors, cognition
Other outcome measure
(s): cardiovascular risk fac-
tors, cognition
EDIPS 2009 Source:
ISRCTN15670600
Primary outcome mea-
sure(s): incidence of di-
abetes confirmed by two
OGTTs (between one and
12 weeks apart)
No Primary
outcome measure(s): in-
cidence of T2DM
Primary
outcome measure(s): in-
cidence of T2DM
Secondaryoutcomemea-
sure(s):
Current secondary out-
come measures as of 26/
01/2009:
Changes in: weight; phys-
ical activity; dietary fibre
intake; carbohydrate in-
take as a percentage of to-
tal dietary energy; fat in-
take as a percentage of to-
tal dietary energy
Previous secondary out-
come measures: propor-
tion of energy consumed
from fat, protein, carbohy-
drates and saturated, mo-
nounsaturated, polyunsat-
urated fatty acids, fibre
and cholesterol; physical
activity; glucose tolerance;
insulin sensitivity; cardio-
vascular risk factors; car-
diovascular morbidity and
mortality; quality of life
Secondaryoutcomemea-
sure(s): the proportion
of energy consumed from
fat, protein, carbohydrates
and saturated, monoun-
saturated, polyunsatu-
rated fatty acids, fibre and
cholesterol, body weight,
physical activity, mortality
Secondaryoutcomemea-
sure(s):
Other outcome measure
(s): -
Other outcome measure
(s): -
Other outcome measure
(s): -
Hellgren 2016 Source: study protocol
(provided by the investiga-
tors) andmain publication
Primary
outcome measure(s): in-
cidence of T2DM
No Primary
outcome measure(s): in-
cidence of T2DM
Primary
outcome measure(s): in-
cidence of T2DM
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Secondaryoutcomemea-
sure
(s): physical activity, LDL,
triglycerides, HbA1c
Secondaryoutcomemea-
sure
(s): physical activity, LDL,
triglycerides, HbA1c
Secondaryoutcomemea-
sure
(s): physical activity, LDL,
triglycerides, HbA1c
Other outcome measure
(s): insulin resistance
Other outcome measure
(s): blood pressure, inci-
dence of T2DM, weight,
waist circumference, in-
sulin resistance
Other outcome measure
(s): diastolic blood pres-
sure, incidence of T2DM,
insulin resistance
HELP PD 2011 Source: NCT00631345
and design article
Primary outcome mea-
sure(s): fasting glucose
No Primary outcome mea-
sure(s): fasting glucose
Primary outcome mea-
sure(s): fasting glucose
Secondaryoutcomemea-
sure(s): weight loss, waist
circumference, dietary in-
take, physical activity, eco-
nomic evaluation of the
program
Secondaryoutcomemea-
sure(s): weight loss, waist
circumference, dietary in-
take, physical activity, eco-
nomic evaluation of the
program
Secondaryoutcomemea-
sure(s): weight loss, waist
circumference, economic
evaluation of the program
Other outcome measure
(s): homeostasis model of
insulin resistance, triglyc-
erides, HDL-C, blood
pressure, the metabolic
syndrome, health-related
quality of life and behav-
ioral constructs, incidence
of T2DM, serious adverse
events
Other outcome measure
(s): homeostasis model
of insulin resistance, inci-
dence of T2DM
Other outcome measure
(s): homeostasis model of
insulin resistance, triglyc-
erides, HDL-C
IDPP 2006 Source: main publication
Primary
outcome measure(s): in-
cidence of T2DM
No Primary
outcome measure(s): in-
cidence of T2DM
Primary
outcome measure(s): in-
cidence of T2DM
Secondaryoutcomemea-
sure(s): -
Secondaryoutcomemea-
sure(s): -
Secondaryoutcomemea-
sure(s): -
Other outcome measure
(s): compli-
ance, weight, plasma glu-
cose, adverse events, in-
sulin secretion, waist cir-
cumference, blood pres-
sure, BMI, cholesterol lev-
Other outcome measure
(s): compli-
ance, weight, plasma glu-
cose, adverse events, in-
sulin secretion, waist cir-
cumference, blood pres-
sure, BMI, cholesterol lev-
Other outcome measure
(s): insulin secretion,
cholesterol levels
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els, glycaemic measures els, glycaemic measures
JDPP 2013 Source:
UMIN000003136
Primary outcome mea-
sure(s): incidence of dia-
betes
No Primary outcome mea-
sure(s): incidence of dia-
betes
Primary outcome mea-
sure(s): incidence of dia-
betes
Secondaryoutcomemea-
sure(s): changes of body
weight, BMI, waist cir-
cum-
ference, blood glucose, in-
sulin, HbA1c, blood pres-
sure, lipids, liver function,
and health behavior
Secondaryoutcomemea-
sure(s): changes of body
weight, BMI, waist cir-
cumference, blood glu-
cose, insulin, blood pres-
sure, lipids, liver function,
and health behavior
Secondaryoutcomemea-
sure(s): changes in body,
weight, insulin
Other outcome measure
(s): -
Other outcome measure
(s): -
Other outcome measure
(s): -
Kosaka 2005 Source: main publication
Primary outcome mea-
sure(s): development of
diabetes
No Primary outcome mea-
sure(s): development of
diabetes
Primary outcome mea-
sure(s): development of
diabetes
Secondaryoutcomemea-
sure(s): improvement of
glucose tolerance
Secondaryoutcomemea-
sure(s): improvement of
glucose tolerance
Secondaryoutcomemea-
sure(s): improvement of
glucose tolerance
Other outcome measure
(s): changes in body
weight
Other outcome measure
(s): changes in body
weight
Other outcome measure
(s): changes in body
weight
Oldroyd 2005 Source: main article
Primary outcome mea-
sure(s): -
No Primary outcome mea-
sure(s): -
Primary outcome mea-
sure(s): -
Secondaryoutcomemea-
sure(s): -
Secondaryoutcomemea-
sure(s): -
Secondaryoutcomemea-
sure(s): -
Other outcome measure
(s): described as main out-
come measures; change
from baseline nutrient in-
take, physical activity, an-
thropometry, glucose tol-
erance and insulin sensi-
tivity
Other outcome measure
(s): change in nutrient
intake, mortality, physi-
cal activity, BMI, body
weight, lipids, insulin sen-
sitivity, glycaemic mea-
sures, incidence of T2DM
Other outcome measure
(s): change in nutrient
intake, mortality, physi-
cal activity, BMI, body
weight, lipids, insulin sen-
sitivity
214Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
PODOSA 2014 Source:
ISRCTN25729565
Primary outcome mea-
sure(s): weight change
No Primary outcome mea-
sure(s): weight change
Primary outcome mea-
sure(s): weight change
Secondaryoutcomemea-
sure(s): fasting and 2-
hour glucose; progression
to T2DM; BMI; waist cir-
cumference and hip cir-
cumference; cost effective-
ness
Secondaryoutcomemea-
sure(s): fasting and 2-
hour glucose; progression
to T2DM; BMI; waist cir-
cumference and hip cir-
cumference; cost effective-
ness
Secondaryoutcomemea-
sure(s): -
Other outcome measure
(s): -
Other outcome measure
(s): blood pressure, ad-
verse events, physical ac-
tivity
Other outcome measure
(s): -
SLIM 2003 Source:Mensink et al. Di-
abetes Research and Clin-
ical Practice 2003
Primary outcome mea-
sure(s): change in glu-
cose tolerance, defined as
the 2-hour blood glucose
concentration during the
OGTT
No Primary outcome mea-
sure(s): change in glu-
cose tolerance, defined as
the 2-hour blood glucose
concentration during the
OGTT
Primary outcome mea-
sure(s): change in glu-
cose tolerance, defined as
the 2-hour blood glucose
concentration during the
OGTT
Secondaryoutcomemea-
sure(s): changes in fasting
plasma glucose concentra-
tion, changes
in plasma insulin concen-
tration, changes in insulin
resistance (as indicated by
the HOMA index) and
changes in HbA1c
Secondaryoutcomemea-
sure(s): changes in fasting
plasma glucose concentra-
tion, changes
in plasma insulin concen-
tration, changes in insulin
resistance (as indicated by
the HOMA index) and
changes in HbA1c
Secondaryoutcomemea-
sure(s): changes in fasting
plasma glucose concentra-
tion, changes
in plasma insulin concen-
tration, changes in insulin
resistance (as indicated by
the HOMA index) and
changes in HbA1c
Other outcome measure
(s): -
Other outcome measure
(s): diet intake, physical
activity, body weight, free
fatty acid, blood pressure
Other outcome measure
(s): diet intake, physical
activity, body weight, free
fatty acid, blood pressure
BMI: body mass index; EMA: European Medicines Agency; FDA: Food and Drug Administration (US); HbA1c: glycosylated A1c;
HOMA: homeostatic model assessment; N/A: not applicable; N/T: no trial document available; OGTT: oral glucose tolerance test;
T2DM: type 2 diabetes mellitus
aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g.
FDA/EMA documents, manufacturer’s websites, trial registers).
bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion
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documents or multiple reports of a primary trial).
cPrimary and secondary outcomes refer to verbatim specifications in publication/records.Other outcomemeasures refer to all outcomes
not specified as primary or secondary outcome measures
Appendix 7. High risk of outcome reporting bias according to ORBIT (Outcome Reporting Bias In
Trials) classification
Trial ID Outcome High risk of bias
(category A)a
High risk of bias
(category D)b
High risk of bias
(category E)c
High risk of bias
(category G)d
Da Qing 1997 Non-fatal myocar-
dial infarction
N/D Yes (abstract men-
tions it was assessed)
N/D N/D
Non-fatal stroke Yes (abstract men-
tions it was assessed)
Amputationof lower
extremity
Yes (abstract men-
tions it was assessed)
DPP 2002 Serious adverse
events
Yes
Non-fatal myocar-
dial infarction
N/D Yes
Non-fatal stroke Yes
Non-serious adverse
events
Yes N/D
Hypoglycaemia Yes
DPS 2001 Cardiovascular mor-
tality
Yes
Non-fatal myocar-
dial infarction
Yes
Non-fatal stroke Yes
EDIPS 2009 Health-related qual-
ity of life
Yes
Hellgren 2016 N/D
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HELP PD 2011 Serious adverse
events
N/D Yes N/D
Non-serious adverse
events
Yes
Health-related qual-
ity of life
Yes
Time to progression
to T2DM
Yes
IDPP 2006 Serious adverse
events
Yes
Non-fatal myocar-
dial infarction
Yes
Non-fatal stroke Yes
Non-serious adverse
events
N/D Yes N/D
JDPP 2013 Incidence of T2DM Yes (long-term (6
years) follow-up of
diabetes incidence)
N/D
Serious adverse
events
Yes N/D
Non-serious adverse
events
Yes
Measures of blood
glucose control
Yes
Kosaka 2005 All-cause mortality N/D Yes
Serious adverse
events
Yes
Cardiovascular mor-
tality
Yes
Non-serious adverse
events
Yes
Measures of blood
glucose control
N/D Yes N/D
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Oldroyd 2005 N/D
PODOSA 2014 N/D
SLIM 2003 N/D
N/A: not applicable; N/D: none detected
aClear that outcome was measured and analysed; trial report states that outcome was analysed but reports only that result was not
significant
(Classification ’A’, table 2, Kirkham 2010).
bClear that outcome was measured and analysed; trial report states that outcome was analysed but reports no results (Classification
’D’, table 2, Kirkham 2010).
cClear that outcome was measured but was not necessarily analysed; judgement says likely to have been analysed but not reported
because of non-significant results (Classification ’E’, table 2, Kirkham 2010).
dUnclear whether outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but
not reported on the basis of non-significant results (Classification ’G’, table 2, Kirkham 2010).
Appendix 8. Definition of endpoint measurement and assessor (I)
Trial ID All-cause
mortality
Development
of type 2 dia-
betes mellitus
Serious ad-
verse events
Cardiovascu-
lar mortality
Non-fatal
myocardial
infarction
Non-fatal
stroke
Amputation
of
lower
extremity
Da Qing
1997
IO WHO 1985
criteria (either
a
fasting plasma
glucose ≥ 140
mg/dL
(7.8 mmol/L)
or higher or a
2-hour plasma
glucose ≥ 200
mg/dL (11.1
mmol/L) after
a 75 g OGTT
and confirmed
with
a repeat test 7-
14 days after)
or from a re-
port of physi-
cian-diag-
nosed diabetes
“No adverse
events were
recorded”
SO, IO
“..cardiovas-
cular dis-
ease death (de-
fined as death
attributed to
coronary heart
disease,
stroke, or sud-
den death)”
IO
N/I N/I N/I
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with evidence
in the medical
record of high
glucose con-
centrations, or
use of glucose-
lowering
drugs
AO
DPP 2002 IO ADA criteria
(fasting
plasma
glucose level≥
126 mg/dL (7.
0 mmol/L) or
2-hour plasma
glucose ≥ 200
mg/dL (11.1
mmol/L) after
a 75 g OGTT,
and confirmed
with a
repeated test)
IO
“Serious
adverse events
have been de-
fined to in-
clude any ad-
verse
experience oc-
curring at any
dose that re-
sults in any of
the
following out-
comes: death;
a life-threaten-
ing adverse ex-
perience;
inpatient hos-
pitalisation or
prolongation
of hospitalisa-
tion; a persis-
tent or signif-
icant disabil-
ity/incapacity;
or a congen-
ital anomaly/
birth defect”
IO
“CVD-related
deaths”
IO
N/I N/I N/I
DPS 2001 IO WHO
1985 (either a
fasting plasma
glucose con-
centration of
≥ 140 mg/dL
(7.8 mmol/L)
or higher or a
2-hour plasma
glucose ≥ 200
Serious
adverse events
IO
IO N/I N/I N/I
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mg/dL (11.1
mmol/L) after
a 75 g OGTT,
and confirmed
with a repeat
test)
AO
EDIPS 2009 One patient
died
with no reason
explained; one
pa-
tient died due
to colon can-
cer; one died
due to lung
cancer
IO
WHO
1999 (either a
fasting plasma
glucose ≥ 7.0
mmol/L
(≥ 126 mg/
dL) and/or a
2-hour plasma
glucose con-
centration of
≥ 11.1 mmol/
L (≥ 200 mg/
dL), and con-
firmed with a
repeat test)
IO
N/I N/I N/I N/I N/I
Hellgren
2016
All-causemor-
tality
IO
Fasting
plasma
glucose
> 6.9 mmol/L
and/or 2-hour
plasma glu-
cose concen-
tration > 12.1
mmol/L
IO
“Serious ad-
verse events”
IO
N/I Non-fatal my-
ocardial
infarction
IO
Non-fatal
stroke
IO
amputation of
lower extrem-
ity
IO
HELP PD
2011
No partici-
pants died
IO
Fasting
glucose ≥ 126
mg/dL (ADA
2004) or using
diabetes med-
ication at the
visit
IO
“Serious ad-
verse events”
IO
No partici-
pants died
IO
N/I N/I N/I
IDPP 2006 IO WHO
1999 (either a
fasting plasma
glucose ≥ 7.0
mmol/L
IO N/I N/I N/I N/I
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(≥ 126 mg/
dL) and/or a
2-hour plasma
glucose
concentration
≥ 11.1 mmol/
L (≥ 200 mg/
dL), and con-
firmed with a
repeat test)
IO
JDPP 2013 IO WHO
1998 (either a
fasting plasma
glucose ≥ 7.0
mmol/L
(≥ 126 mg/
dL) and/or a
2-hour plasma
glucose
concentration
≥ 11.1 mmol/
L (≥ 200 mg/
dL), and con-
firmed with a
repeat test)
IO
N/I N/I N/I N/I N/I
Kosaka 2005 N/I Diabetes was
determined by
fasting plasma
glucose and it
was judged to
have de-
veloped when
fasting plasma
glucose
reached or ex-
ceeded
140 mg/dL (7.
8 mmol/L) on
two consecu-
tive tests per-
formed at an
interval of 2
weeks or less
IO
N/I N/I N/I N/I N/I
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Oldroyd
2005
IO WHO
1985 (either a
fasting plasma
glucose con-
centration ≥
140 mg/dL (7.
8 mmol/L) or
higher or a
2-hour plasma
glucose ≥ 200
mg/dL (11.1
mmol/L) after
a 75 gOGTT)
IO
N/I One partici-
pant died after
stroke
IO
N/I N/I N/I
PODOSA
2014
N/I Based on
2-hour plasma
glucose con-
centration ≥
11.1 mmol/L
(≥ 200 mg/
dL), and con-
firmed with a
repeat test at
year three, or
diagnosed by
physician
IO
Serious
adverse events
IO
N/I N/I N/I N/I
SLIM 2003 IO WHO
1999 (either a
fasting plasma
glucose ≥ 7.0
mmol/L
(≥ 126 mg/
dL) and/or a
2-hour plasma
glucose con-
centration of
≥ 11.1 mmol/
L (≥ 200 mg/
dL); single
OGTT was
performed
IO
N/I N/I N/I N/I N/I
ADA: American Diabetes Association; AO: adjudicated outcome measurement; HbA1c: glycosylated haemoglobin A1c; IO: investi-
gator-assessed outcome measurement; N/D: not defined; N/I: not investigated; OGTT: oral glucose tolerance test; SO: self-reported
outcome measurement; WHO: World Health Organization
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Appendix 9. Definition of endpoint measurement and assessor (II)
Trial ID Blindness
or severe
vision loss
End-
stage renal
disease
Nonserious
adverse
events
Hypogly-
caemic
events
Health-
related
quality
of life
Time to
progression
to T2DM
Measures of
blood
glucose
control
Socioe-
conomic ef-
fects
Da Qing
1997
N/I “Nephropa-
thy was
defined as
a history of
renal dialysis
or trans-
plantation,
death from
nephropa-
thy or end-
stage renal
disease
(ESRD),
or among
living par-
ticipants
as ACR ≥
300 mg/g
(to convert
values to
mg/mmol
multiply
by 0.113)
or serum
creatinine ≥
177 µmol/
l (2 mg/
dl). Severe
nephropa-
thy was
defined as
that which
led to renal
replacement
therapy or
death from
nephropa-
thy or
ESRD.”
IO
“No adverse
events were
recorded”
SO, IO
N/I N/I N/I 2 hour
OGTT;
FPG
IO
N/I
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DPP 2002 N/I N/I N/I N/I 36-Item
Short-
Form (SF-
36) health
survey
SO
N/I 2 hour
OGTT;
HbA1c;
FPG
IO
“The direct
costs of
medical care
received
outside the
study and
indirect
costs were
determined
annually
from patient
self-report.
Direct non-
medical
costs were
assessed
once during
DPP and
once during
DPPOS,
and costs
were annu-
alized. All
costs were
adjusted
to 2000 or
2010 U.
S. Dollars
using the
Consumer
Price Index
and the
Medical
Consumer
Price Index.
”
IO
DPS 2001 N/I N/I N/I N/I N/I N/I 2 hour
OGTT;
HbA1c;
FPG
IO
N/I
EDIPS
2009
N/I N/I N/I N/I N/I N/I N/I N/I
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Hellgren
2016
N/I End-stage
renal disease
IO
N/I Hypogly-
caemia
SO, IO
Health-
related qual-
ity of life
SO
N/I 2 hour
OGTT;
HbA1c;
FPG
IO
N/I
HELP PD
2011
N/I N/I N/I N/I 36-Item
Short-
Form (SF-
36) health
survey
SO
“The distri-
bu-
tion of times
until the de-
velopment
of T2DM
(mea-
sured from
the date
of randomi-
sation to the
date of the
clinical visit
or re-
port trigger-
ing the diag-
nosis)”
IO
FPG
IO
Cost analy-
sis, cost ef-
fective-
ness analysis
(CEA) and
cost
utility analy-
sis (CUA)
IO
IDPP 2006 N/I N/I N/I Hypogly-
caemia
SO, IO
N/I N/I 2 hour
OGTT;
FPG
IO
N/I
JDPP 2013 N/I N/I N/I N/I N/I N/I 2 hour
OGTT;
FPG
IO
N/I
Kosaka
2005
N/I N/I N/I N/I N/I N/I 2 hour
OGTT;
HbA1c;
FPG
IO
N/I
Oldroyd
2005
N/I N/I N/I N/I N/I N/I 2 hour
OGTT;
FPG
IO
N/I
PODOSA
2014
N/I N/I Mild or
mod-
erate adverse
N/I N/I N/I 2 hour
OGTT;
FPG
“The time
and costs re-
lated
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events
SO, IO
IO to dietitians,
costs related
to general
practitioner
and hospital
outpatients,
and partici-
pants’
opportunity
costs were
described
(without in-
fer-
ential statis-
tics) by year
and for the
3 years com-
bined as ap-
propriate.”
IO
SLIM 2003 N/I N/I N/I N/I N/I N/I 2 hour
OGTT;
HbA1c;
FPG
IO
N/I
AO: adjudicated outcome measurement; DPP: Diabetes Prevention Programme; DPPOS: Diabetes Prevention Program Outcomes
Study; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; IO: investigator-assessed outcome measurement; N/I:
not investigated; OGTT: oral glucose tolerance test; SO: self-reported outcome measurement
Appendix 10. Adverse events (I)
Trial ID Interven-
tion(s) and
comparator
(s)
Par-
ticipants in-
cluded in
analysis
(N)
Deaths
(N)
Deaths
(% of par-
ticipants)
Partici-
pants
with at least
one adverse
event
(N)
Partici-
pants
with at least
one adverse
event
(%)
Partic-
ipants with
at least one
severe/seri-
ous adverse
event
(N)
Partic-
ipants with
at least one
severe/seri-
ous adverse
event
(%)
Da Qing
1997
I1: diet 130 3 2.3 0 0 0 0
I2: physical
activity
131 0 0 0 0 0 0
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I3: diet plus
physical ac-
tivity
126 5 4 0 0 0 0
C: standard
treatment
133 3 2.3 0 0 0 0
DPP 2002 I: diet plus
physical ac-
tivity
1079 3 0.3 Muscu-
loskeletal
symptoms:
728
Gastroin-
testinal
symptoms:
390
Muscu-
loskeletal
symptoms:
67
Gastroin-
testinal
symptoms:
36
- -
C: placebo +
standard
treatment
1082 5 0.5 Muscu-
loskeletal
symptoms:
639
Gastroin-
testinal
symptoms:
930
Muscu-
loskeletal
symptoms:
59Gastroin-
testinal
symptoms:
86
DPS 2001 I: diet plus
physical ac-
tivity
265 1 0.4 - - - -
C: standard
treatment
257 0 0 - - - -
EDIPS
2009
I: diet plus
physical ac-
tivity
51 2 3.9 - - 1 2.0
C: standard
treatment
51 0 0 - - 0 0
Hellgren
2016
I: physical
activity
66 (mortal-
ity: 84)
3 3.6 - - 3 4.5
C: standard
treatment
31 (mortal-
ity: 39)
1 2.6 - - 1 3.2
HELP PD
2011
I: diet plus
physical ac-
tivity
151 0 0 11a 7.3 5a 3.3
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C: standard
treatment
150 0 0 15 10 5 3.3
IDPP 2006 I: diet plus
physical ac-
tivity
120 1 0.8 - - - -
C: standard
treatment
133 1 0.8 - - - -
JDPP 2013 I: diet plus
physical ac-
tivity
103 1 1.0 - - - -
C: standard
treatment
110 0 0 - - - -
Kosaka
2005
I: diet plus
physical ac-
tivity
102 - - - - - -
C: standard
treatment
356 - - - - - -
Oldroyd
2005
I: diet plus
physical ac-
tivity
37 at 6
months
32 at 12
months
30 at 24
months
1 2.7 - - - -
C: no inter-
vention
32 at 6
months
30 at 12
months
24 at 24
months
0 0 - - - -
PODOSA
2014
I: diet plus
physical ac-
tivity
84 - - 3 3.6 - -
C: standard
treatment
83 - - 4 4.8 - -
SLIM 2003 I: diet plus
physical ac-
tivity
74 at base-
line
52 at 3 years
51 at 4 years
34 at 5 years
0 0 - - - -
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35 (one that
was missing
at five years
attended 6-
year fol-
low-up) at 6
years
C: standard
treatment
73 at base-
line
54 at 3 years
43 at 4 years
29 at 5 years
35 (six that
weremissing
at five years
attended 6-
year fol-
low-up) at 6
years
1 1.4 - - - -
- denotes not reported
C: comparator; I: intervention
aData only available after one year of intervention.
Appendix 11. Adverse events (II)
Trial ID Interven-
tion(s) and
comparator
(s)
Par-
ticipants in-
cluded in
analysis
(N)
Partic-
ipants dis-
continu-
ing trial due
to an ad-
verse event
(N)
Partic-
ipants dis-
continu-
ing trial due
to an ad-
verse event
(%)
Partic-
ipants with
at least one
hospitalisa-
tion
(N)
Partic-
ipants with
at least one
hospitalisa-
tion
(%)
Partic-
ipants with
at least one
outpatient
treatment
(N)
Partic-
ipants with
at least one
outpatient
treatment
(%)
Da Qing
1997
I1: diet 130 0 0 - - - -
I2: physical
activity
131 0 0 - - - -
I3: diet plus
physical ac-
tivity
126 0 0 - - - -
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C: standard
treatment
133 0 0 - - - -
DPP 2002 I: diet plus
physical ac-
tivity
1079 - - - - - -
C: placebo +
standard
treatment
1082 - - - - - -
DPS 2001 I: diet plus
physical ac-
tivity
265 - - - - - -
C: standard
treatment
257 - - - - - -
EDIPS
2009
I: diet plus
physical ac-
tivity
51 1 2.0 - - - -
C: standard
treatment
51 0 0 - - - -
Hellgren
2016
I: physical
activity
84 1 1.1 - - - -
C: standard
treatment
39 1 2.5 - - - -
HELP PD
2011
I: diet plus
physical ac-
tivity
151 - - - - - -
C: standard
treatment
150 - - - - - -
IDPP 2006 I: diet plus
physical ac-
tivity
120 0 0 - - - -
C: standard
treatment
133 0 0 - - - -
JDPP 2013 I: diet plus
physical ac-
tivity
103 2 0 - - - -
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C: standard
treatment
110 2 0 - - - -
Kosaka
2005
I: diet plus
physical ac-
tivity
102 - - - - - -
C: standard
treatment
356 - - - - - -
Oldroyd
2005
I: diet plus
physical ac-
tivity
37 at 6
months
32 at 12
months
30 at 24
months
- - - - - -
C: no inter-
vention
32 at 6
months
30 at 12
months
24 at 24
months
- - - - - -
PODOSA
2014
I: diet plus
physical ac-
tivity
85 - - - - - -
C: standard
treatment
86 - - - - - -
SLIM 2003 I: diet plus
physical ac-
tivity
74 at base-
line
52 at 3 years
51 at 4 years
34 at 5 years
35 (one that
was missing
at five years
attended 6-
year fol-
low-up) at 6
years
- - - - - -
C: standard
treatment
73 at base-
line
54 at 3 years
43 at 4 years
29 at 5 years
- - - - - -
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35 (six that
weremissing
at five years
attended 6-
year fol-
low-up) at 6
years
- denotes not reported
C: comparator; I: intervention
Appendix 12. Adverse events (III)
Trial ID Intervention(s) and
comparator(s)
Participants in-
cluded in analysis
(N)
Participants with a
specific adverse
event
(description)
Participants with at
least one specific
adverse events
(N)
Participants with at
least one specific
adverse event
(%)
Da Qing 1997 I1: diet 130 - - -
I2: physical activity 131 - - -
I3: diet plus physical
activity
126 - - -
C: standard treat-
ment
133 - - -
DPP 2002 I: diet plus physical
activity
1079 1. Gastrointestinal
symptoms
2. Muskoskeletal
symptoms
3. Hospitalisation
1. 140
2. 259
3. 168
1. 12.9
2. 24.0
3. 15.5
C: placebo + stan-
dard treatment
1082 1. Gastrointestinal
symptoms
2. Muskoskeletal
symptoms
3. Hospitalisation
1. 331
2. 228
3. 174
1. 30.6
2. 21.1
3. 16.3
DPS 2001 I: diet plus physical
activity
265 - - -
C: standard treat-
ment
257 - - -
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EDIPS 2009 I: diet plus physical
activity
51 - - -
C: standard treat-
ment
51 - - -
Hellgren 2016 I: physical activity 66 - - -
C: standard treat-
ment
30 - - -
HELP PD 2011 I: diet plus physical
activity
151 - - -
C: standard treat-
ment
150 - - -
IDPP 2006 I: diet plus physical
activity
120 - - -
C: standard treat-
ment
133 - - -
JDPP 2013 I: diet plus physical
activity
103 - - -
C: standard treat-
ment
110 - - -
Kosaka 2005 I: diet plus physical
activity
102 - - -
C: standard treat-
ment
356 - - -
Oldroyd 2005 I: diet plus physical
activity
37 at 6 months
32 at 12 months
30 at 24 months
- - -
C: no intervention 32 at 6 months
30 at 12 months
24 at 24 months
- - -
PODOSA 2014 I: diet plus physical
activity
85 - - -
C: standard treat-
ment
86 - - -
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SLIM 2003 I: diet plus physical
activity
74 at baseline
52 at 3 years
51 at 4 years
34 at 5 years
35 (one that was
missing at five years
attended 6-year fol-
low-up) at 6 years
- - -
I2: standard treat-
ment
73 at baseline
54 at 3 years
43 at 4 years
29 at 5 years
35 (six that were
missing at five years
attended 6-year fol-
low-up) at 6 years
- - -
- denotes not reported
C: comparator; I: intervention
Appendix 13. Survey of study investigators providing information on trials
Date trial author con-
tacted
Date trial author
replied
Date trial author was
asked for additional in-
formation
(short summary)
Date trial author pro-
vided data
(short summary)
130750-201504-HR-
020
5 April 2017 No reply Asked for the duration of
the intervention
N/A
ChiCTR-PRC-
13003267
3 April 2017 No reply Asked for the duration of
the intervention
N/A
Da Qing 1997 9 March 2017 No reply Au-
thors were asked to con-
firm outcomes and asked
for additional informa-
tion, therein a study pro-
tocol
N/A
DPP 2002 9 March 2017 No reply Authors were asked to
confirm outcomes and
asked for additional in-
formation
N/A
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DPS 2001 17 March 2017 No reply Authors were asked to
confirm outcomes and
asked for additional in-
formation
N/A
EDIPS 2009 27 March 2017 20 April 2017 Authors were asked to
confirm outcomes and
asked for additional in-
formation
Provided additional in-
formation on outcomes
Hellgren 2016 29 March 2017 26 April 2017 Au-
thors were asked to con-
firm outcomes and asked
for additional informa-
tion, therein a study pro-
tocol
Provided additional in-
formation on outcomes
and a study protocol
HELP PD 2011 20 March 2017 No reply Authors were asked to
confirm outcomes and
asked for additional in-
formation
N/A
IDPP 2006 15 March 2017 19 March 2017
Did not reply to the
questions, but just con-
firmed the already-ex-
tracted data
Au-
thors were asked to con-
firm outcomes and asked
for additional informa-
tion, therein a study pro-
tocol
N/A
Kosaka 2005 16 March 2017 No reply Au-
thors were asked to con-
firm outcomes and asked
for additional informa-
tion, therein a study pro-
tocol
N/A
Oldroyd 2005 16 March 2017 No reply Au-
thors were asked to con-
firm outcomes and asked
for additional informa-
tion, therein a study pro-
tocol
N/A
NCT01530165 3 April 2017 5 April 2017 Principal investigator
asked if the trial is com-
pleted and published
The principal investiga-
tor replied that the trial
was going to be com-
pleted in June 2017
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PODOSA 2014 22 March 2017 23 March 2017
The request was for-
warded to a research fel-
low
Authors were asked to
confirm outcomes and
asked for additional in-
formation
3 April 2017
SLIM 2003 17 March 2017 No reply Au-
thors were asked to con-
firm outcomes and asked
for additional informa-
tion, therein a study pro-
tocol
N/A
N/A: not applicable
Appendix 14. Checklist to aid consistency and reproducibility of GRADE assessments: diet plus
physical activity versus standard treatment
(1) All-
cause mor-
tality
(2)
Incidence
of T2DM
(3) Seri-
ous adverse
events
(4) Cardio-
vascular
mortality
(5) Non-fa-
tal myocar-
dial infarc-
tion/stroke
(6) Health-
re-
lated qual-
ity of life
(7) Socioe-
conomic ef-
fects
Trial limita-
tions
(risk of
bias)a
Was random
sequence
genera-
tion used (i.
e. no poten-
tial for selec-
tion bias)?
Unclear Unclear Unclear Unclear Yes Yes Yes
Was allo-
cation con-
cealment
used (i.e. no
potential for
selection
bias)?
Unclear Unclear Unclear Unclear Yes Yes Yes
Was
there blind-
ing of partic-
ipants and
personnel (i.
e. no poten-
tial for per-
Yes Yes Yes Yes Yes No () Yes
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for-
mance bias)
or outcome
not likely to
be in-
fluenced by
lack of
blinding?
Was there
blinding of
outcome as-
sessment (i.
e. no poten-
tial for de-
tection bias)
or was out-
come mea-
surement
not likely to
be in-
fluenced by
lack of
blinding?
Yes Yes Yes Yes Yes No () Yes
Was an ob-
jective out-
come used?
Yes Yes Yes Yes Yes No () Yes
Were more
than 80% of
par-
ticipants en-
rolled in tri-
als included
in the anal-
ysis (i.e. no
potential re-
porting bias)
?b
Yes Yes Yes Yes Yes Yes Yes
Were data
re-
ported con-
sistently for
the outcome
of interest (i.
e. no poten-
tial selective
Yes Yes Unclear Yes N/A Unclear Yes
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reporting)?
No other bi-
ases
reported (i.
e. no poten-
tial of other
bias)?
No () No () No () No () Yes No () Yes
Did the tri-
als end up as
scheduled (i.
e.
not stopped
early)?
No () No () Yes No () Yes No () No ()
Inconsis-
tencyc
Point
estimates
did not vary
widely?
Yes Yes N/A No () N/A N/A N/A
To what ex-
tent did con-
fidence in-
tervals over-
lap (substan-
tial: all con-
fi-
dence inter-
vals overlap
at least one
of the in-
cluded stud-
ies point es-
timate;
some: confi-
dence inter-
vals overlap
but
not all over-
lap at least
one point es-
timate;
no: at least
one outlier:
where the
confi-
dence inter-
val of some
Substantial Substantial N/A Substantial N/A N/A N/A
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of the stud-
ies do not
overlap with
those
of most in-
cluded stud-
ies)?
Was the di-
rection of ef-
fect consis-
tent?
No () Yes N/A No () N/A N/A N/A
What was
the magni-
tude of sta-
tistical het-
erogeneity
(asmeasured
by I²) - low
(I² < 40%),
moderate (I²
40%-60%)
, high I² >
60%)?
Low Low N/A Low N/A N/A N/A
Was the test
for hetero-
geneity sta-
tistically sig-
nificant (P <
0.1)?
Not statisti-
cally signifi-
cant
Not statisti-
cally signifi-
cant
N/A Not statisti-
cally signifi-
cant
N/A N/A N/A
Indirect-
nessa
Were
the popula-
tions in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Were the in-
terventions
in the in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
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Was the in-
cluded out-
come not a
surrogate
outcome?
Yes Yes Yes Yes Yes Yes Yes
Was the out-
come time-
frame suffi-
cient?
Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Were the
conclusions
based on di-
rect compar-
isons?
Yes Yes Yes Yes Yes Yes Yes
Impreci-
siond
Was the con-
fidence in-
terval for the
pooled
estimate not
consistent
with benefit
and harm?
No () Yes N/A No () N/A N/A N/A
What is the
magnitude
of the me-
dian sample
size (high:
300 partici-
pants, inter-
me-
diate: 100-
300 partici-
pants, low: <
100 partici-
pants)?b
High High Intermedi-
ate
High Low () High High
What
was themag-
nitude
of the num-
ber of in-
cluded stud-
ies (large:
> 10 studies,
moderate: 5-
Moderate Large Small () Moderate Small () Small () Small ()
240Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
10 stud-
ies, small: <
5 studies)?b
Was the out-
come a com-
mon event
(e.g.
occurs more
than 1/100)
?
Yes Yes Yes Yes Yes Not applica-
ble
Not applica-
ble
Publication
biase
Was a com-
prehensive
search con-
ducted?
Yes Yes Yes Yes Yes Yes Yes
Was grey lit-
erature
searched?
Yes Yes Yes Yes Yes Yes Yes
Were no re-
strictions
applied to
study selec-
tion on the
basis of lan-
guage?
Yes Yes Yes Yes Yes Yes Yes
There was
no industry
influence on
studies
included in
the review?
No () No () Yes No () Yes No () No ()
There
was no evi-
dence of
funnel plot
asymmetry?
Yes Yes N/A Unclear N/A N/A N/A
There
was no dis-
crepancy in
findings be-
tween pub-
lished
and unpub-
lished trials?
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
241Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased
risk of developing type 2 diabetes mellitus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
(): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table(s); N/A: not applicable
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to
individual trials.
bDepends on the context of the systematic review area.
cQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity
based on I²
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the
imprecision is clinically meaningful.
eQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between
published and unpublished trials
Appendix 15. Checklist to aid consistency and reproducibility of GRADE assessments: diet versus
physical activity or standard treatment
(1) All-
cause mor-
tality
(2)
Incidence
of T2DM
(3) Seri-
ous adverse
events
(4) Cardio-
vascular
mortality
(5) Non-fa-
tal myocar-
dial infarc-
tion/stroke
(6) Health-
re-
lated qual-
ity of life
(7) Socioe-
conomic ef-
fects
Trial limita-
tions
(risk of
bias)a
Was random
sequence
genera-
tion used (i.
e. no poten-
tial for selec-
tion bias)?
Unclear Unclear Unclear Unclear N/A N/A N/A
Was allo-
cation con-
cealment
used (i.e. no
potential for
selection
bias)?
Unclear Unclear Unclear Unclear
Was
there blind-
ing of partic-
ipants and
personnel (i.
e. no poten-
tial for per-
for-
mance bias)
Yes Yes Yes Yes
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or outcome
not likely to
be in-
fluenced by
lack of
blinding?
Was there
blinding of
outcome as-
sessment (i.
e. no poten-
tial for de-
tection bias)
or was out-
come mea-
surement
not likely to
be in-
fluenced by
lack of
blinding?
Yes Yes Yes Yes
Was an ob-
jective out-
come used?
Yes Yes Yes Yes
Were more
than 80% of
par-
ticipants en-
rolled in tri-
als included
in the anal-
ysis (i.e. no
potential re-
porting bias)
?b
Yes Yes Yes Yes
Were data
re-
ported con-
sistently for
the outcome
of interest (i.
e. no poten-
tial selective
reporting)?
Yes Yes Yes Yes
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No other bi-
ases
reported (i.
e. no poten-
tial of other
bias)?
No () No () No () No ()
Did the tri-
als end up as
scheduled (i.
e.
not stopped
early)?
Yes Yes Yes Yes
Inconsis-
tencyc
Point
estimates
did not vary
widely?
N/A N/A N/A N/A
To what ex-
tent did con-
fidence in-
tervals over-
lap (substan-
tial: all con-
fi-
dence inter-
vals overlap
at least one
of the in-
cluded stud-
ies point es-
timate;
some: confi-
dence inter-
vals overlap
but
not all over-
lap at least
one point es-
timate;
no: at least
one outlier:
where the
confi-
dence inter-
val of some
of the stud-
N/A N/A N/A N/A
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ies do not
overlap with
those
of most in-
cluded stud-
ies)?
Was the di-
rection of ef-
fect consis-
tent?
N/A N/A N/A N/A
What was
the magni-
tude of sta-
tistical het-
erogeneity
(asmeasured
by I²) - low
(I² < 40%),
moderate (I²
40%-60%)
, high I² >
60%)?
N/A N/A N/A N/A
Was the test
for hetero-
geneity sta-
tistically sig-
nificant (P <
0.1)?
N/A N/A N/A N/A
Indirect-
nessa
Were
the popula-
tions in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Were the in-
terventions
in the in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
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Was the in-
cluded out-
come not a
surrogate
outcome?
Yes Yes Yes Yes
Was the out-
come time-
frame suffi-
cient?
Sufficient Sufficient Sufficient Sufficient
Were the
conclusions
based on di-
rect compar-
isons?
Yes Yes Yes Yes
Impreci-
siond
Was the con-
fidence in-
terval for the
pooled
estimate not
consistent
with benefit
and harm?
N/A N/A N/A N/A
What is the
magnitude
of the me-
dian sample
size (high:
300 partici-
pants, inter-
me-
diate: 100-
300 partici-
pants, low: <
100 partici-
pants)?b
Low () Low () Low () Low ()
What
was themag-
nitude
of the num-
ber of in-
cluded stud-
ies (large:
> 10 studies,
moderate: 5-
Small () Small () Small () Small ()
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10 stud-
ies, small: <
5 studies)?b
Was the out-
come a com-
mon event
(e.g.
occurs more
than 1/100)
?
N/A Yes N/A N/A
Publication
biase
Was a com-
prehensive
search con-
ducted?
Yes Yes Yes Yes
Was grey lit-
erature
searched?
Yes Yes Yes Yes
Were no re-
strictions
applied to
study selec-
tion on the
basis of lan-
guage?
Yes Yes Yes Yes
There was
no industry
influence on
studies
included in
the review?
Yes Yes Yes Yes
There
was no evi-
dence of
funnel plot
asymmetry?
N/A N/A N/A N/A
There
was no dis-
crepancy in
findings be-
tween pub-
lished
and unpub-
lished trials?
N/A N/A N/A N/A
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(): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table(s); N/A: not applicable
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to
individual trials.
bDepends on the context of the systematic review area.
cQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity
based on I²
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the
imprecision is clinically meaningful.
eQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between
published and unpublished trials
Appendix 16. Checklist to aid consistency and reproducibility of GRADE assessments: physical
activity versus standard treatment
(1) All-
cause mor-
tality
(2)
Incidence
of T2DM
(3) Seri-
ous adverse
events
(4) Cardio-
vascular
mortality
(5) Non-fa-
tal myocar-
dial infarc-
tion/stroke
(6) Health-
re-
lated qual-
ity of life
(7) Socioe-
conomic ef-
fects
Trial limita-
tions
(risk of
bias)a
Was random
sequence
genera-
tion used (i.
e. no poten-
tial for selec-
tion bias)?
Unclear Unclear Unclear Unclear Yes Yes N/A
Was allo-
cation con-
cealment
used (i.e. no
potential for
selection
bias)?
Unclear Unclear Unclear Unclear Yes Yes
Was
there blind-
ing of partic-
ipants and
personnel (i.
e. no poten-
tial for per-
for-
mance bias)
Yes Yes Yes Yes Yes No ()
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or outcome
not likely to
be in-
fluenced by
lack of
blinding?
Was there
blinding of
outcome as-
sessment (i.
e. no poten-
tial for de-
tection bias)
or was out-
come mea-
surement
not likely to
be in-
fluenced by
lack of
blinding?
Yes Yes Yes Yes Yes No ()
Was an ob-
jective out-
come used?
Yes Yes Yes Yes Yes No ()
Were more
than 80% of
par-
ticipants en-
rolled in tri-
als included
in the anal-
ysis (i.e. no
potential re-
porting bias)
?b
Yes Yes Yes Yes No () No ()
Were data
re-
ported con-
sistently for
the outcome
of interest (i.
e. no poten-
tial selective
reporting)?
Yes Yes No () No () No () Yes
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No other bi-
ases
reported (i.
e. no poten-
tial of other
bias)?
No () No () No () No () No () Yes
Did the tri-
als end up as
scheduled (i.
e.
not stopped
early)?
Yes Yes Yes Yes Yes Yes
Inconsis-
tencyc
Point
estimates
did not vary
widely?
N/A N/A N/A N/A N/A N/A
To what ex-
tent did con-
fidence in-
tervals over-
lap (substan-
tial: all con-
fi-
dence inter-
vals overlap
at least one
of the in-
cluded stud-
ies point es-
timate;
some: confi-
dence inter-
vals overlap
but
not all over-
lap at least
one point es-
timate;
no: at least
one outlier:
where the
confi-
dence inter-
val of some
of the stud-
N/A N/A N/A N/A N/A N/A
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ies do not
overlap with
those
of most in-
cluded stud-
ies)?
Was the di-
rection of ef-
fect consis-
tent?
N/A N/A N/A N/A N/A N/A
What was
the magni-
tude of sta-
tistical het-
erogeneity
(asmeasured
by I²) - low
(I² < 40%),
moderate (I²
40%-60%)
, high I² >
60%)?
N/A N/A N/A N/A N/A N/A
Was the test
for hetero-
geneity sta-
tistically sig-
nificant (P <
0.1)?
N/A N/A N/A N/A N/A N/A
Indirect-
nessa
Were
the popula-
tions in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Were the in-
terventions
in the in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
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Was the in-
cluded out-
come not a
surrogate
outcome?
Yes Yes Yes Yes Yes Unclear
Was the out-
come time-
frame suffi-
cient?
Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Were the
conclusions
based on di-
rect compar-
isons?
Yes Yes Yes Yes Yes Yes
Impreci-
siond
Was the con-
fidence in-
terval for the
pooled
estimate not
consistent
with benefit
and harm?
N/A N/A N/A N/A N/A N/A
What is the
magnitude
of the me-
dian sample
size (high:
300 partici-
pants, inter-
me-
diate: 100-
300 partici-
pants, low: <
100 partici-
pants)?b
Low () Low () Low () Low () Low () Low ()
What
was themag-
nitude
of the num-
ber of in-
cluded stud-
ies (large:
> 10 studies,
moderate: 5-
Small () Small () Small () Small () Small () Small ()
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10 stud-
ies, small: <
5 studies)?b
Was the out-
come a com-
mon event
(e.g.
occurs more
than 1/100)
?
Yes Yes Yes Yes Yes Not applica-
ble
Publication
biase
Was a com-
prehensive
search con-
ducted?
Yes Yes Yes Yes Yes Yes
Was grey lit-
erature
searched?
Yes Yes Yes Yes Yes Yes
Were no re-
strictions
applied to
study selec-
tion on the
basis of lan-
guage?
Yes Yes Yes Yes Yes Yes
There was
no industry
influence on
studies
included in
the review?
Yes Yes Yes Yes Yes Yes
There
was no evi-
dence of
funnel plot
asymmetry?
N/A N/A N/A N/A N/A N/A
There
was no dis-
crepancy in
findings be-
tween pub-
lished
and unpub-
lished trials?
Unclear Unclear Unclear Unclear Unclear Unclear
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(): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table(s); N/A: not applicable
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to
individual trials.
bDepends on the context of the systematic review area.
cQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity
based on I²
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the
imprecision is clinically meaningful.
eQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between
published and unpublished trials
Appendix 17. Health-related quality of life: instruments
Trial ID Instru-
ment
Dimen-
sions
(sub-
scales)
(no. of
items)
Validated
instru-
ment
Answer
options
Scores Minimum
score
Maximum
score
Weighting
of scores
Direction
of
scales
Minimal
important
difference
DPP 2002 SF-36 (G) Physical
function-
ing (10)
Role-phys-
ical (4)
Bodily
pain (2)
General
health) (5)
Vitality (4)
So-
cial func-
tioning (2)
Role-emo-
tional (3)
Mental
health (5)
Yes Likert-
scale
Scores
for dimen-
sions
Physi-
cal compo-
nent sum-
mary
(PCS)
Men-
tal compo-
nent sum-
mary
(MCS)
Minimum
scores: 0
Maximum
scores:100
No Higher
values
mean bet-
ter assess-
ment
Mini-
mal impor-
tant differ-
ence was
defined
as HRQoL
scores be-
tween
groups dif-
fered by at
least 3 %;
In
other pub-
lication
(Marrero
et al) mini-
mal impor-
tant differ-
ence is de-
fined as
two points
on
either PCS
or MCS
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HELP PD
2011
SF-36 (G) Physical
function-
ing (10)
Role-phys-
ical (4)
Bodily
pain (2)
General
health (5)
Vitality (4)
So-
cial func-
tioning (2)
Role-emo-
tional (3)
Mental
health (5)
Yes Likert-
scale
Scores
for dimen-
sions
Physi-
cal compo-
nent sum-
mary
(PCS)
Men-
tal compo-
nent sum-
mary
(MCS)
Minimum
scores: 0
Maximum
scores:100
No Higher
values
mean bet-
ter assess-
ment
NR
G: generic; S: specific; SF: short-form health survey
Appendix 18. Subgroup analyses: diet plus physical activity versus control
Outcome Trials with
long
duration (≥ 4
years) versus
trials with
short
duration (< 4
years)
(P value for
test of inter-
action
Impaired
glucose toler-
ance versus
other
diagnostic
criteria
(P value for
test of inter-
action)
Younger ver-
sus
older partici-
pants
(see text)
(P value for
test of inter-
action)
Female versus
male (see
text)
(P value for
test of inter-
action)
Ethnicity (see
text)
(P value for
test of inter-
action)
Comorbidity
(see text)
(P value for
test of inter-
action)
Par-
ticipants with
previous ges-
tational dia-
betes mellitus
All-cause
mortality
0.78 Not possible
due to lack of
data
0.73 Not possible
due to lack of
data
0.79 0.79 Not possible
due to lack of
data
Incidence of
type 2 dia-
betes mellitus
0.88 0.42 0.009 Not possible
due to lack of
data
0.01 0.02 Not possible
due to lack of
data
Fasting
plasma
glucose
0.60 0.11 0.19 Not possible
due to lack of
data
0.71 0.88 Not possible
due to lack of
data
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2-
hour plasma
glucose
0.22 Not possible
due to lack of
data
0.003 Not possible
due to lack of
data
0.12 0.12 Not possible
due to lack of
data
HbA1c 0.99 Not possible
due to lack of
data
Not possible
due to lack of
data
Not possible
due to lack of
data
Not possible
due to lack of
data
0.10 Not possible
due to lack of
data
Appendix 19. Reported subgroup analyses of diabetes incidence in trials
Trial ID Reported subgroup Publication of study
(secondary reference of primary refer-
ence)
Da Qing 1997 BMI < 25 kg/m2 versus 25 kg/m2 or
more
The relative decrease in the rate of devel-
opment of T2DM in the physical activity
compared with control was similar in over-
weight and lean at the end of intervention
Pan 1997
DPP 2002 Age (N not provided for each subgroup in
the intervention and control group of age)
25-44 years; incidence (cases/100 person
years); I: 6.2 ; C: 11.6; reduction in inci-
dence diet plus physical activity versus con-
trol 48 (95% CI 27 to 63)
45-59 years; incidence (cases/100 person
years); I: 4.7; C: 10.8; reduction in inci-
dence diet plus physical activity versus con-
trol 59 (95% CI 44 to 70)
≥ 60 years; incidence (cases/100 person
years); I: 3.1; C: 10.8; reduction in inci-
dence diet plus physical activity versus con-
trol 71 (95% CI 51 to 83)
Sex
Male; incidence (cases/100 person years);
I: 4.6 (N = 345); C: 12.5 (N = 335); reduc-
tion in incidence diet plus physical versus
control 65 (95% CI 49 to 76)
Female; incidence (cases/100 person years)
; I: 5.0 (N = 734); C: 10.3 (N = 747); re-
duction in incidence diet plus physical ac-
tivity versus control 54 (95% CI 40 to 64)
Race or ethnic group
Knowler 2002
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White: incidence (cases/100 person years);
I: 5.2 (N = 580); C: 10.3 (N = 586); reduc-
tion in incidence diet plus physical activity
versus control 51 (95% CI 35 to 63)
African; incidence (cases/100 person years)
; I: 5.1 (N = 204); C: 12.4 (N = 220); re-
duction in incidence diet plus physical ac-
tivity versus control 61 (95% CI 37 to 76)
Hispanic; incidence (cases/100 person
years); I: 4.2 (N = 178); C: 11.7 (N = 168)
; reduction in incidence diet plus physical
activity versus control 66 (95% CI 41 to
80)
American Indian; incidence (cases/100
person years); I: 4.7 (N = 60); C: 12.9 (N =
59); reduction in incidence diet plus phys-
ical activity versus control 65 (95% CI 7 to
87)
Asian; incidence (cases/100 person years);
I: 3.8 (N = 57); C: 12.1 (N = 49); reduc-
tion in incidence diet plus physical activity
versus control 71 (95% CI 24 to 89)
BMI (N not provided for each subgroup
in the intervention and control group of
BMI)
22 to < 30 kg/m2 ; incidence (cases/100 per-
son years); I: 3.3; C: 9.0; reduction in inci-
dence diet plus physical activity versus con-
trol 65 (95% CI 46 to 77)
30 to < 35 kg/m2 ; incidence (cases/100 per-
son years); I: 3.7; C: 8.9; reduction in inci-
dence diet plus physical activity versus con-
trol 61 (95% CI 40 to 75)
35 kg/m2 or above; incidence (cases/100
person years); I: 7.3; C: 14.3; reduction in
incidence diet plus physical activity versus
control 51 (95% CI 34 to 63)
Fasting plasma glucose (N not provided
for each subgroup in the intervention and
control group of fasting plasma glucose)
5.3-6.0 mmol/L; incidence (cases/100 per-
son years); I: 2.9; C: 6.4; reduction in inci-
dence diet plus physical activity versus con-
trol 55 (95% CI 38 to 68)
6.1-6.9 mmol/L; incidence (cases/100 per-
son years); I: 3.7; C: 8.9; reduction in inci-
dence diet plus physical activity versus con-
trol 63 (95% CI 51 to 72)
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Plasma glucose 2 hours after an oral
glucose load (N not provided for each
subgroup in the intervention and control
group of glucose values)
7.7-8.5 mmol/L; incidence (cases/100 per-
son years); I: 1.8; C: 7.1; reduction in inci-
dence diet plus physical activity versus con-
trol 76 (95% CI 58 to 86)
8.6-9.5 mmol/L; incidence (cases/100 per-
son years); I: 4.4;C: 10.3; reduction in inci-
dence diet plus physical activity versus con-
trol 60 (95% CI 41 to 72)
9.6-11.0 mmol/L; incidence (cases/100
person years); I: 8.5; C: 16.1; reduction in
incidence diet plus physical activity versus
control 50 (95% CI 33 to 63)
P < 0.05 for the test of heterogeneity across
strata
DPP 2002
(only participants with
FPG < 7 mmol/L and
HbA1c < 6.5% at baseline)
Diabetes incidence defined by FPG≥ 7.
0 mmol/L and/or 2-hour plasma glucose
≥ 11.1 mmol/L according to ethnicity at
the end of intervention
All participants; diet plus physical activity
4.3/100 person years (N = 932); control 8.
6/100 person years (N = 922)
White participants; diet plus physical activ-
ity 4.7/100 person years (N = 539); control
8.5/100 person years (N = 534)
African American; diet plus physical activ-
ity 4.1/100 person years (N = 161); control
8.0/100 person years (N = 147)
Hispanic; diet plus physical activity 3.6/
100 person years (N = 140); control 9.1/
100 person years (N = 135)
American Indian; diet plus physical activity
3.9/100 person years (N = 50); control 7.
9/100 person years (N = 53)
Asian American; diet plus physical activity
3.7/100 person years (N = 42); control 11.
4/100 person years (N = 53)
Diabetes incidence defined by FPG≥ 7.
0 mmol/L and/or 2-hour plasma glucose
≥ 11.1 mmol/L according to ethnicity
after a follow-up period of 9.9 years
All participants; diet plus physical activity
4.9/100 person years (N = 932); control 6.
8/100 person years (N = 922)
White participants; diet plus physical activ-
Knowler 2014
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ity 4.7/100 person years (N = 539); control
6.1/100 person years (N = 534)
African American; diet plus physical activ-
ity 6.1/100 person years (N = 161); control
8.8/100 person years (N = 147)
Hispanic; diet plus physical activity 5.3/
100 person years (N = 140); control 7.0/
100 person years (N = 135)
American Indian; diet plus physical activity
4.2/100 person years (N = 50); control 6.
5/100 person years (N = 53)
Asian American; diet plus physical activity
3.8/100 person years (N = 42); control 10.
2/100 person years (N = 53)
Diabetes incidence defined by HbA1c ≥
6.5% according to ethnicity at the end
of intervention
All participants; diet plus physical activity
4.6/100 person years (N = 932); control 8.
8/100 person years (N = 922)
White participants; diet plus physical activ-
ity 3.8/100 person years (N = 539); control
6.7/100 person years (N = 534)
African American; diet plus physical activ-
ity 10.0/100 person years (N = 161); con-
trol 18.3/100 person years (N = 147)
Hispanic; diet plus physical activity 2.9/
100 person years (N = 140); control 7.2/
100 person years (N = 135)
American Indian; diet plus physical activity
6.2/100 person years (N = 50); control 11.
5/100 person years (N = 53)
Asian American; diet plus physical activity
3.3/100 person years (N = 42); control 11.
7/100 person years (N = 53)
Diabetes incidence defined by HbA1c ≥
6.5% according to ethnicity after a fol-
low-up period of 9.9 years
All participants; diet plus physical activity
3.5/100 person years (N = 932); control 5.
0/100 person years (N = 922)
White participants; diet plus physical activ-
ity 3.1/100 person years (N = 539); control
4.1/100 person years (N = 534)
African American; diet plus physical activ-
ity 5.8/100 person years (N = 161); control
9.2/100 person years (N = 147)
Hispanic; diet plus physical activity 3.0/
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100 person years (N = 140); control 4.6/
100 person years (N = 135)
American Indian; diet plus physical activity
4.6/100 person years (N = 50); control 5.
9/100 person years (N = 53)
Asian American; diet plus physical activity
3.5/100 person years (N = 42); control 6.
3/100 person years (N = 53)
Diabetes incidence defined by FPG≥ 7.
0 mmol/L and/or 2-hour plasma glucose
≥ 11.1 mmol/L according to HbA1c at
baseline at the end of intervention (read
from figure)
HbA1c < 5.5%; diet plus physical activity
3.3/100 person years (N = 182); control 5.
3/100 person years (N = 186)
HbA1c between 5.5% -5.9%; diet plus
physical activity 3.3/100 person years (N =
394); control 8/100 person years (N = 385)
HbA1c between 6.0% -6.4%; diet plus
physical activity 3.2/100 person years (N =
346); control 11.7/100 person years (N =
361)
Diabetes defined by FPG ≥ 7.0 mmol/
L and/or 2-hour plasma glucose ≥ 11.1
mmol/L according to HbA1c at baseline
after a follow-up period of 9.9 years (read
from figure)
HbA1c < 5.5%; diet plus physical activity
4.7/100 person years (N = 182); control 4.
7/100 person years (N = 186)
HbA1c between 5.5% -5.9%; diet plus
physical activity 4.0/100 person years (N
= 394); control 6.8/100 person years (N =
385)
HbA1c between 6.0%-6.4%; diet plus
physical activity 6.7/100 person years (N
= 346); control 9.0/100 person years (N =
361)
Diabetes incidence defined by HbA1c ≥
6.5% according to HbA1c at baseline at
the end of intervention (read from fig-
ure)
HbA1c < 5.5%; diet plus physical activity
0.40/100 person years (N = 182); control
0.50/100 person years (N = 186)
HbA1c between 5.5%-5.9%; diet plus
physical activity 2.3/100 person years (N
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= 394); control 4.6/100 person years (N =
385)
HbA1c between 6.0%6.4%; diet plus
physical activity 9.2/100 person years (N =
346); control 21.5/100 person years (N =
361)
T2DM incidence defined by HbA1c ≥
6.5% according to HbA1c at baseline af-
ter a follow-up period of 9.9 years (read
from figure)
HbA1c < 5.5%; diet plus physical activity
1.6/100 person years (N = 182); control 0.
8/100 person years (N = 186)
HbA1c between 5.5%-5.9%; diet plus
physical activity 2.7/100 person years (N
= 394); control 3.5/100 person years (N =
385)
HbA1c between 6.0%-6.4%; diet plus
physical activity 6.2/100 person years (N =
346); control 11.5/100 person years (N =
361)
T2DM incidence defined by FPG ≥ 7.0
mmol/L and/or 2-hour plasmaglucose≥
11.1 mmol/L according to sex and age at
baseline at the end of intervention (read
from figure)
Men<45years; diet plus physical activity 3.
0/100person years (N=unknown); control
9.5/100 person years (N = unknown)
Men 45-59 years; diet plus physical activity
3.5/100 person years (N = unknown); con-
trol 7.5/100 person years (N = unknown)
Men ≥ 60 years; diet plus physical activity
2.5/100 person years (N = unknown); con-
trol 10.0/100 person years (N = unknown)
Women < 45 years; diet plus physical ac-
tivity 5.5/100 person years (N = unknown)
; control 8.8/100 person years (N = un-
known)
Women 45-59 years; diet plus physical ac-
tivity 4.0/100 person years (N = unknown)
; control 7.5/100 person years (N = un-
known)
Women ≥ 60 years; diet plus physical ac-
tivity 2.3/100 person years (N = unknown)
; control 4.5/100 person years (N = un-
known)
T2DM incidence defined by FPG ≥ 7.
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0 mmol/L and/or 2 hour plasma glucose
≥ 11.1 mmol/L according to sex and age
at baseline after a follow-up period of 9.
9 years (read from figure)
Men<45years; diet plus physical activity 5.
3/100person years (N=unknown); control
8.0/100 person years (N = unknown)
Men 45-59 years; diet plus physical activity
5.0/100 person years (N = unknown); con-
trol 6.8/100 person years (N = unknown)
Men ≥ 60 years; diet plus physical activity
3.8/100 person years (N = unknown); con-
trol 8.0/100 person years (N = unknown)
Women < 45 years; diet plus physical ac-
tivity 6.3/100 person years (N = unknown)
; control 7.5/100 person years (N = un-
known)
Women 45-59 years; diet plus physical ac-
tivity 4.5/100 person years (N = unknown)
; control 7.0/100 person years (N = un-
known)
Women ≥ 60 years; diet plus physical ac-
tivity 2.3/100 person years (N = unknown)
; control 4.5/100 person years (N = un-
known)
T2DM incidence defined byHbA1c≥ 6.
5% according to sex and age at baseline
at the end of intervention (read from fig-
ure)
Men<45years; diet plus physical activity 3.
5/100person years (N=unknown); control
9.0/100 person years (N = unknown)
Men 45-59 years; diet plus physical activity
3.0/100 person years (N = unknown); con-
trol 8.5/100 person years (N = unknown)
Men ≥ 60 years; diet plus physical activity
1.5/100 person years (N = unknown); con-
trol 10.0/100 person years (N = unknown)
Women < 45 years; diet plus physical ac-
tivity 5.5/100 person years (N = unknown)
; control 8.0/100 person years (N = un-
known)
Women 45-59 years; diet plus physical ac-
tivity 5.0/100 person years (N = unknown)
; control 8.5/100 person years (N = un-
known)
Women ≥ 60 years; diet plus physical ac-
tivity 3.3/100 person years (N = unknown)
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; control 7.5/100 person years (N = un-
known)
T2DM incidence defined byHbA1c≥ 6.
5% according to sex and age at baseline
after a follow-up period of 9.9 years (read
from figure)
Men<45years; diet plus physical activity 4.
3/100person years (N=unknown); control
6.0/100 person years (N = unknown)
Men 45-59 years; diet plus physical activity
2.5/100 person years (N = unknown); con-
trol 5.0/100 person years (N = unknown)
Men ≥ 60 years; diet plus physical activity
1.5/100 person years (N = unknown); con-
trol 5.5/100 person years (N = unknown)
Women < 45 years; diet plus physical ac-
tivity 5.0/100 person years (N = unknown)
; control 5.0/100 person years (N = un-
known)
Women 45-59 years; diet plus physical ac-
tivity 3.3/100 person years (N = unknown)
; control 4.0/100 person years (N = un-
known)
Women ≥ 60 years; diet plus physical ac-
tivity 1.8/100 person years (N = unknown)
; control 3.5/100 person years (N = un-
known)
DPS 2001 Sex
Male (N = 172); incidence (cases/100 per-
son years); I: 3.7 (95% CI 2.2 to 6.2); C:
6.8 (95% CI 5.8 to 12.6); HR diet plus
physical activity versus control 0.43 (95%
CI 0.22 to 0.81)
Female (N = 350); incidence (cases/100
person years); I: 4.3 (95% CI 3.0 to 6.2);
C: 6.9 (95% CI 5.2 to 9.2); HR diet plus
physical activity versus control 0.61 (95%
CI 0.39 to 0.97)
P interaction 0.33
Age
< 51 years; incidence (cases/100 person
years); I: 6.0 (95% CI 3.9 to 9.2); C: 7.6
(95% CI 5.1 to 11.2); HR diet plus physi-
cal activity versus control 0.77 (95% CI 0.
44 to 1.38)
51-61 years; incidence (cases/100 person
years); I: 4.0 (95% CI 2.3 to 6.7); C: 8.0
(95%CI5.5 to 11.5);HRdiet plus physical
Lindström 2008
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activity versus control 0.49 (95% CI 0.26
to 0.93)
> 61 years; incidence (cases/100 person
years); I: 2.4 (95% CI 1.3 to 4.7); C: 6.6
(95% CI 4.2 to 10.3); HR diet plus physi-
cal activity versus control 0.36 (95% CI 0.
17 to 0.80)
P interaction 0.0130
BMI
< 28.7 kg/m2; incidence (cases/100 person
years); I: 1.7 (95% CI 0.8 to 3.7); C: 5.2
(95% CI 3.3 to 8.1); HR diet plus physical
activity versus control 0.32 (95% CI 0.13
to 0.79)
28.7-32.3 kg/m2; incidence (cases/100
person years); I: 4.8 (95% CI 3.0 to 7.7);
C: 7.9 (95% CI 5.3 to 11.9); HR diet plus
physical activity versus control 0.59 (95%
CI 0.32 to 1.10)
> 32.3 kg/m2; incidence (cases/100 person
years); I: 5.8 (95% CI 3.8 to 8.9); C: 9.6
(95%CI6.7 to 13.8);HRdiet plus physical
activity versus control 0.60 (95% CI 0.34
to 1.04)
P interaction 0.75
Fasting plasma glucose
< 5.8mmol/L; incidence (cases/100 person
years); I: 2.4 (95% CI 1.3 to 4.5); C: 3.8
(95% CI 2.2 to 6.6); HR diet plus physical
activity versus control 0.63 (95% CI 0.28
to 1.45)
5.8-6.4 mmol/L; incidence (cases/100 per-
son years); I: 2.7 (95% CI 1.4 to 5.1); C:
6.9 (95% CI 4.6 to 10.4); HR diet plus
physical activity versus control 0.37 (95%
CI 0.18 to 0.79)
> 6.4mmol/L; incidence (cases/100 person
years); I: 7.7 (95%CI 5.2 to 11.5); C: 12.2
(95%CI8.8 to 17.0);HRdiet plus physical
activity versus control 0.62 (95% CI 0.37
to 1.03)
P interaction 0.68
Plasma glucose 2 hours after an oral glu-
cose load
< 8.2mmol/L; incidence (cases/100 person
years); I: 1.3 (95% CI 0.5 to 3.0); C: 5.3
(95% CI 3.4 to 8.4); HR diet plus physical
activity versus control 0.23 (95% CI 0.09
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to 0.61)
8.2-9.3 mmol/L; incidence (cases/100 per-
son years); I: 4.2 (95% CI 2.5 to 6.9); C: 5.
8 (95% CI 3.7 to 9.1); HR diet plus physi-
cal activity versus control 0.70 (95% CI 0.
36 to 1.37)
> 9.3mmol/L; incidence (cases/100 person
years); I: 7.6 (95%CI 5.1 to 11.3); C: 12.0
(95%CI8.6 to 16.8);HRdiet plus physical
activity versus control 0.62 (95% CI 0.37
to 1.04)
P interaction 0.69
Number of participants in each tertile was
roughly 174
BMI: body mass index; FPG: fasting plasma glucose; HR: hazard ratio; HbA1c: glycosylated haemoglobin A1c; T2DM: type 2 diabetes
mellitus
WH A T ’ S N E W
Date Event Description
21 November 2017 New citation required and conclusions have changed Update: diet plus physical activity reduces the risk of
type 2 diabetes mellitus in people with impaired glu-
cose tolerance. Data are lacking for the effect of diet
plus physical activity for people with intermediate hy-
perglycaemia defined by other glycaemic variables
21 November 2017 New search has been performed This review is an update of the review published in
issue 3, 2008. Six trials of the original review were used
for our review update. Also, we found six additional
new trials and therefore established a database of 12
included trials
C O N T R I B U T I O N S O F A U T H O R S
All protocol authors read and approved the final review update draft.
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trial authors, data interpretation, GRADE assessment and writing of review drafts.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of a previous Cochrane Review (Orozco 2008). The original review included trials with other definitions of increased
risk of type 2 diabetes mellitus. The current review only defines increased risk of type 2 diabetes mellitus with glycaemic measures. The
original review included trials with a duration of one year or more. The current review includes trials with a duration of two years or
more. The original review excluded trials not reporting the primary outcome. This review includes trials irrespective of the outcomes
reported. The primary and secondary outcomes of the review have been changed, so the focus is on patient-important outcomes.
N O T E S
We have based parts of the Methods and Appendix 1 sections of this Cochrane Protocol on a standard template established by the
CMED Group.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Diet; ∗Exercise; Cause of Death; Combined Modality Therapy [methods]; Diabetes Complications [prevention & control]; Diabetes
Mellitus, Type 2 [complications; epidemiology; ∗prevention & control]; Diet, Diabetic; Fasting [blood]; Glucose Tolerance Test;
Incidence; Randomized Controlled Trials as Topic; Risk
MeSH check words
Humans
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